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Abstract  
 
An exploratory study of mobility-related outcome measures and an exercise 
intervention in people with Huntington’s Disease (HD) 
 
Objective: There is emerging evidence that exercise may modify disease progression 
and improve function in a number of neurodegenerative diseases, but this has not been 
systematically studied in Huntington‟s disease (HD). The purpose of this study was to 
evaluate feasibility, acceptability and benefits of an exercise programme in people with 
HD.  
  
Methods: Using a randomised controlled trial design, 25 participants with manifest HD 
were allocated to either intervention (home-based exercise; n=13) or control (usual care; 
n=12) groups. Participants were assessed at baseline and eight weeks later. Eleven 
participants from the exercise and 10 from the control group completed the intervention 
study. The primary outcome was gait variability (stride time coefficient of variation 
(CV)). Secondary outcomes included other measures of gait, disease-specific motor 
scale and measures of balance, muscle strength, mobility and community walking, 
functional performance in ADL and quality of life. These measures were included to 
reflect a range of physical impairments and activity limitations seen in people with HD. 
Analysis of covariance was used to compare follow-up scores across groups after 
adjustment for differences at baseline. Effect sizes were calculated for outcome 
measures based on differences in change scores between groups. Process interviews 
were conducted at the end of the study to determine acceptability of the intervention to 
participants. 
 
Cross sectional investigation of outcome measures was undertaken initially to 
investigate discriminant and concurrent validity as well as test re-test reliability and 
minimal detectable change (MDC95) along the broad spectrum of the disease. Baseline 
data from 25 participants with manifest HD (who went on to participate in the 
intervention), in addition to data from 17 individuals with pre-manifest HD and 25 
healthy controls were analysed. This data was of use in interpreting the results from the 
interventional study. In particular, the MDC95 data helped in determining of whether 
any statistical significant changes due to the intervention are clinically meaningful.   
 
Results: Measures of gait variability, some measures of balance, community walking 
and measures of functional performance in ADL were able to distinguish between 
people with manifest HD and pre-manifest HD as well as between people with pre-
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manifest HD and healthy controls suggesting good discriminant validity. All these 
outcomes had also good concurrent validity with a disease specific motor score. The test 
re-tests reliability scores for the majority of the outcomes were high and the MDC95 
scores were low, suggesting that the individual variability on these outcomes were low.   
Adherence rates to the exercise programme were high (78.8% of participants reported 
completion of at least 78% of the prescribed sessions). Participants in the intervention 
group demonstrated significant improvement in stride time CV (95% CI (-11.5, -0.6)) 
based on complete case analysis. Significant differences between groups were also 
observed in the disease-specific motor scale and in measures of balance, mobility, 
community walking and functional performance in ADL, but not muscle strength and 
health-related quality of life. Effect sizes were large (>0.8) for the majority of the 
outcomes. The magnitude of the change as a result of the exercise intervention exceeded 
the calculated MDC95 values for some of the outcomes, which suggest that most of the 
observed changes are clinically meaningful. Qualitative feedback from the participants 
who completed the exercise programme suggested high levels of acceptability with 
positive impact on general health and mobility. Participants identified barriers and 
facilitators that affected performing the exercises at home and described management 
strategies that helped adherence to the exercise programme. 
 
Conclusions: This study was the first systematic trial to demonstrate that a short-term 
structured exercise programme is acceptable and can be safely delivered in a home 
environment; achieve good adherence; and positively affect body function and activity 
in people with HD. The sensitivity of the outcomes as determined in the cross-sectional 
study, to mobility deficits the in pre-manifest HD group is important. These outcomes 
has the potential to be used in future studies of exercise interventions in the pre-
manifest stage which aim to target such deficits early in the disease life cycle, before 
they begin to impact on a person‟s ability to participate in the community. Overall the 
data presented from this study provides a platform for further investigations to extend 
these findings about the role of exercise and physical activity in people with HD. Larger 
and more detailed studies are needed to replicate findings from this study in other 
contexts and variations in dose.  
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1 Introduction 
  
1.1 Overview 
This introductory chapter will describe the general aspects of Huntington‟s disease 
(HD). The genetic and neuropathological characteristics of HD will be explained. This 
will be followed by a description of the major clinical features and the stages of the 
disease. The currently available management approaches will also be considered with a 
specific focus on the potential role of exercise interventions in the management of HD. 
This will then lead to an explanation of the aims of the thesis at the end of the chapter. 
   
1.2 Huntington’s disease: General overview 
Huntington‟s chorea was first described by George Huntington in 1872. He provided a 
clear and concise account of the commonly seen clinical features seen in HD [1]. 
Huntington‟s chorea denotes emphasis on the most obvious clinical sign (namely 
choreic movements); however, not all people affected with HD have chorea, so focusing 
on this symptom may detract from other important aspects. The term „Huntington‟s 
disease‟ seems more appropriate and is now widely accepted [1].   
 
Huntington‟s Disease is a neurodegenerative condition;  the major features of the 
disease may be considered as a triad of motor dysfunction, cognitive deficits and 
behavioural changes [2]. The disease is genetic, with an autosomal dominant 
inheritance; each child of an affected person has a 50% chance of developing the 
disease. Although the recent identification of the mutant gene has allowed for the early 
detection of gene carriers, the disease has to date no treatment that prevents, delays or 
slows the progressive neurodegeneration. Current treatments are supportive and 
symptomatic, provided by a range of healthcare professionals, at different stages of the 
disease [3].   
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1.3 Genetics   
The gene that causes HD was identified in 1993 after a major collaborative international 
research effort. The gene has been called IT15 and is located on the short arm of the 
chromosome 4 at 4p16.3 [4]. This gene directs the cell to make the Huntington‟s protein 
that contains a sequence of amino acid glutamines. These glutamines are encoded in the 
gene by the DNA trinucleotide- cytosine-adenine-guanine (CAG) that is repeated a 
number of times. In a normal gene, the CAG repeat lengths range from 6 to 39. In a 
mutant gene, this length varies from 36 to 121 [1]. The number of CAG repeat lengths 
can be easily determined from a sample of venous blood, making confirmation of the 
diagnosis reliable in the vast majority of cases [1]. It is possible for people at risk of HD 
to take a predictive test to determine whether or not they have inherited the mutant 
gene. An individual who has an unfavourable genetic test for the HD mutation, but has 
not yet developed any clinical signs of HD (such as chorea), is considered to be pre-
manifest.    
 
Studies have shown an inverse relationship between the average age at onset and the 
CAG repeat length; the more CAG repeats included in the mutant gene, the earlier the 
onset of symptoms occurs and the quicker they typically progress [5]. However, there is 
such a wide variation that it is not always possible to predict the age of onset from 
knowing only the CAG repeat length; the CAG repeats have been demonstrated to 
account only for about 60% of the age at onset and it is believed that other factors such 
as the influence of the environment and the other genes may also have an effect [6]. 
Very broad categorization is possible; CAG repeats between 36 and 39 may cause a late 
onset or even not at all; CAG repeats between 40 and 60 usually cause an adult onset; 
and CAG repeats over 60 may cause juvenile onset [5].  
 
CAG repeats at the upper end of the normal range (28-35 repeats) show instability on 
replications which leads to expansion into the pathological range in future generations 
[7]. Instability is also greater in spermatogenesis than oogenesis, in that large 
expansions of CAG repeats on replication happen exclusively in males [8, 9]. This 
explains the likelihood of paternal inheritance in children with juvenile onset symptoms. 
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1.4 Prevalence and aspects of life history 
Most studies from the UK, US, Australia and Europe quote a prevalence of about 4–10 
affected individuals per 100 000. Low prevalence has been documented in Japan where   
prevalence of the disorder is 0.5 per 100 000, about 10% of that recorded elsewhere.  
The rate is even lower in most of Asia and Africa [7, 10]. Disease prevalence appears to 
be slightly higher in women than in men [11]. The average number of new cases per 
year has been estimated at 4.7 per million per year [11].   
 
Whilst HD may be considered a rare disorder, the burden is great for patients, 
immediate carers and offspring [1], in which half of them, on average, will inherit the 
mutant HD gene and develop the disease later in life. People with Huntington‟s disease 
can develop the symptoms of the disease at any time in their life. Symptoms typically 
start to appear between the ages of 35 and 45 years. In very rare cases, symptoms 
appear before the age of 20 years. This accounts for about 7% of the HD carriers. In this 
case, symptoms differ slightly and the disease is classified as Juvenile or Westphal 
variant HD [1, 2]. Life expectancy for all people with HD ranges from 15 to 25 years 
following the onset of symptoms. Death usually does not occur as a direct result of HD, 
but rather as a result of complications that occur as a consequence of the disease‟s 
symptoms, which include pneumonia and physical injuries from a fall [12].  
  
1.5 Pathology  
1.5.1 Macroscopic changes  
Although the mutant HD gene is expressed in a wide variety of neurons, the 
pathological changes in Huntington‟s disease are strikingly selective with prominent 
cell loss and atrophy occurring in the striatum (substructures of the basal ganglia, 
namely caudate nuclei and putamen) and deeper layers of the cortex in the early stages. 
In particular the medium spiny neurons‟ loss is the most prominent within the striatum. 
In the advanced stages, other regions of the brain such as the hypothalamus, cerebellum, 
amygdala and thalamic nuclei also become affected [12, 13].  
 
The striatum receives excitatory neurons from the cortex and has efferent medium spiny 
neurons. These neurons are rich in gamma-aminobutyric acid (GABA) and project to 
the internal globus pallidus via the direct pathway and to the external globus pallidus 
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through the indirect pathway.  In part, motor signs seen in people with HD depend on 
the degree of degeneration between these two pathways (Figure 1.1). Loss of neurons 
from the indirect pathway leads to loss of inhibition of the external globus pallidus, 
which produces more inhibition of the subthalamus, less stimulation of the internal 
globus pallidus, less inhibition of the thalamus and overstimulation of the thalamo-
cortical circuit, and therefore to chorea. In contrast, loss of neurons from the direct 
pathway leads to increased inhibition of the thalamus and less activity of the thalamo-
cortical feedback, consequently resulting in bradykinesia and rigidity. Although both 
pathways degenerate, evidence suggests that the balance between them is disturbed, 
with the neurons projecting to the external globus pallidus being more involved than the 
neurons projecting to the internal globus pallidus [14]. Chorea is suggested to dominate 
early in the course of HD because of preferential involvement of the indirect pathway of 
the basal ganglia-thalamocortical circuitry [12]. 
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     Figure 1.1:  Connections of the basal ganglia, demonstrating pathways damaged in HD [14]. 
 
 
 
 
1.5.2 Cellular changes  
Since the identification of the HD gene, a number of different approaches have been 
utilised in order to provide a better understanding of how the mutant HD gene can cause 
selective neuronal loss and neurodegeneration. Work has been conducted on HD animal 
models, in particular the R6 mice models, suggesting that the mutant HD gene exerts its 
effect by gaining a new function within the cell. Inserting the mutant HD gene into mice 
causes proteins to aggregate into the cells and move to the neuclei of neurons to form 
insoluble inclusions [4, 15]. Aggregate formations are believed to be a key factor in the 
pathological process of the disease; an abundance of evidence suggests that these 
aggregates can affect several nuclear and cytoplasmic proteins within the neurons that 
regulate transcription, apoptosis, mitochondrial function, neurotransmitter release, and 
axonal transport, leading eventually to neurons‟ death [13, 16]. Although it is not clear 
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whether these aggregates are directly related to the cellular pathology or represent a 
defence mechanism within the neurons, it is apparent that neuronal cells are 
dysfunctional („sick‟) before they die, which gives the promise for developing 
interventions that would modify the natural history of the disease [12, 13]. The natural 
history of HD is discussed in detail in the following sections.  
 
1.6 Signs and Symptoms of Huntington’s disease 
1.6.1 Natural course of the disease  
When people inherit the HD gene, there will be a period of time when they are healthy 
and have no clinically detectable abnormalities. In time, the neurons become 
dysfunctional and this healthy period merges with a pre-diagnostic phase in which 
subtle changes in mood, personality and cognition may develop [12, 17]. This pre-
diagnostic phase (when an early non specific symptom indicates the start of the disease 
before specific symptoms occur) is often called the prodromal stage (Figure 1.2). The 
healthy and prodromal phases are together called the pre-manifest stage. A clinical 
diagnosis is usually not made at this stage until the onset of obvious motor disorders 
occur [13].  
 
 
Figure 1.2: The pre-manifest stage in HD [13, 18] 
 
 
This figure has been removed by the author for copyright reasons 
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As depicted in Figure 1.2, the pre-manifest stage merges eventually with a manifest 
stage which is characterised by the appearance of a triad of progressive motor deficits, 
cognitive disorders and behavioural changes that over time affect a person‟s ability to 
participate in activities of daily living, community and work. This triad of symptoms 
affects people at different rates and at different levels of severity, although most people 
with HD display components of these symptoms at some point in the disease 
progression. 
 
1.6.2 Cognitive disorders   
Cognitive deficits in HD often do not involve short term memory but are more related to 
executive functions such as planning, sequencing, organisation and prioritization [19]. 
This  is consistent with the fronto-striatal pathway disruption seen in this population 
[20]. These impairments may start from very early in the disease, even before the onset 
of the motor symptoms, and clearly progress over time [21-23]. A vast number of 
studies have described the deficits in executive functioning in people with HD. For 
example, Lawrence et al [24] investigated the ability of people with early-stage HD to 
organise and plan during performing a task. Participants were asked to rearrange balls 
as seen in a display model, in an attempt to solve the problem in a minimum number of 
moves. Participants were advised against making a move until they felt confident that 
they could execute the entire sequence; this required them to figure out the sequence 
first. Results showed that the proportion of correct solutions decreased as the problem 
difficulty increased. There was also an increase in the mean number of excess moves 
and an increment in initial thinking times with increasing problem difficulty levels. 
Participants showed deficits in all 3 endpoints: perfect solutions, initial thinking times, 
and subsequent thinking times. Authors suggest these findings to be due to deficits in 
spatial working memory. 
  
At a clinical level, the cognitive impairments described above can affect the ability to 
maintain employment and manage daily routine. Activities such as keeping a daily 
planner or completing a list of household tasks can become overwhelming in early stage 
HD. The initiation or starting of an activity, conversation or behaviour is also often 
compromised [3]. As the disease progresses, perseveration, or being fixed on a specific 
thought, becomes noticeable [19]. In addition sustained or complex types of attention 
become impaired; individuals therefore may have difficulty doing more than one task at 
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a time [23]. Deficits in spatial perception are also noticeable [25] and can cause people 
with HD to bump into walls or a table, resulting in injuries [18]. These symptoms can 
lead to loss of independence, and the ability to complete daily living tasks such as 
dressing, shopping and managing finances can be greatly affected [2], which in turn 
may have great impact on family members and caregivers by increasing the burden of 
care. At present, interventions aimed at the cognitive component of the disease are 
primarily based on assisting individuals to develop effective compensatory strategies. 
Some people with HD may find it useful to rely on a routine to initiate or continue an 
activity without guidance, or make lists which help to organize tasks needed to do an 
activity. Others may rely on family members or carers to assist with cognitive tasks 
such as managing finances [3].    
 
1.6.3 Behavioural changes 
Unlike cognitive deficits, most of the behavioural symptoms arise with some frequency 
but do not show progression with increasing severity of the disease [12]. Depression is 
typical; in a number of studies the prevalence of depression was high, ranging from 
39% to 53% [26, 27]. Suicidal ideation is also frequent in people with HD. In a cross 
sectional study [28], about 22% of people with pre-manifest HD contemplated suicide 
occasionally, perhaps as a result of being aware of the natural history of the disease. 
Other studies have reported behavioural disorders; including anxiety, irritability, 
aggression, obsessive compulsive behaviour and apathy [19, 29]. Apathy in particular is 
common in people with HD. In a cross sectional study examining the prevalence of 
neuropsychiatric symptoms in a sample of people with HD who ranged from pre-
manifest to mid stage, apathy was present in 55.8% of the participants [30]. Apathy can 
be defined as “disengagement, with passivity and loss of enthusiasm, interest, empathy 
and interpersonal involvement” [19]. Unlike all the other behavioural symptoms, apathy 
becomes more severe as the disease progresses [12]. 
 
The combination of each of these behavioural symptoms would significantly affect the 
patient‟s functional abilities and quality of life. However, some of these symptoms can 
still be managed effectively with drug therapies. Tricyclic antidepressants are used to 
address the depression-related problems and atypical neuroleptics are used to address 
aggressive and irritable behaviours [3, 31]. 
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1.6.4 Motor deficits 
Motor deficits in HD are typically characterized by the presence of both voluntary and 
involuntary movements. The most common involuntary movements are chorea and 
dystonia. Chorea is the most noticeable feature from a motor perspective and can be 
defined as “a state of excessive, spontaneous movement, irregularly timed, randomly 
distributed and abrupt” [3]. All body parts can be affected and severity can range from 
restlessness with mild intermittent exaggeration of gesture to continuous flow of 
disabling, violent movements. At the early stages, chorea can be barely perceptible but 
with the progression of the disease it becomes more obvious until it reaches a plateau. 
Although chorea is the symptom most often associated with HD, it may be one of the 
least disabling characteristics of the disease. Drug trials aimed at reducing chorea did 
not demonstrate an increase in functional abilities, including walking [32]. A number of 
cohort studies also demonstrated that with worsening functional capacity, chorea 
decreases and dystonia increases [33, 34].  
 
Dystonia can be described as “a slow sustained muscle contraction that causes a 
twisting movement of the trunk and abnormal posture of the limbs” [3]. Dystonia is a 
very prominent feature of HD. The prevalence of dystonia of any severity in a cohort 
study of 42 participants was found to be 95%. In this study, 75% of the participants had 
a dystonia of moderate severity on at least one body part and approximately 17% had 
severe and constant dystonia [35]. The most prevalent dystonic postures that were noted 
in this study included shoulder internal rotation, sustained fist clenching, excessive knee 
flexion and foot inversion during walking. Age of onset can affect the severity of 
dystonia. In adult onset HD, dystonia is less severe and more obvious in the late stage, 
while in juvenile onset it is very prominent from early stages [36]. Unlike chorea, 
dystonia usually increases with disease severity and is correlated with a decline in 
functional capacity [36]. It also has  secondary effects such as decreased flexibility and 
range of motion [35] and possibly altered postural control, which can increase the risk 
of falls.  
 
Disorders of voluntary movements in HD include oculomotor dysfunctions, dysarthria, 
impaired balance and gait deficits [37]. Gait and balance disturbances are considered 
highly correlated to activity limitations in this population [38]. Gait disturbances are the 
most prominent of the voluntary movement disorders in HD and include a combination 
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of hypokinesia, akinesia and disordered regulation of rhythmic stepping reflected by 
increased variability of speed, step length and time across the spectrum of the disease 
[39-42].  
 
Mobility deficits in gait are likely to be linked to the occurrence of falls in this 
population. Incidence of falls in HD patients is particularly important in determining the 
ability to live independently and is a major factor implicated in admission to a nursing 
home [43]. Evidence suggests that a high proportion of people with HD fall frequently 
[38, 44, 45]. Aetiology of falls in this population is likely to be multi-factorial [2], but 
observed deficits in gait and balance are considered the main contributing factors [38, 
45]. In particular gait deficits, which are well documented in HD, are likely to 
contribute to progressive functional loss and may also detract from health-related 
quality of life. A full review of the literature investigating mobility deficits in HD is 
provided in Chapter 2. 
 
1.6.5 Stages of the disease  
The Unified Huntington‟s Disease Rating Scale (UHDRS) is routinely used to quantify 
the severity of the symptoms in HD. This scale provides uniform assessment of the 
clinical features and course of HD over the 4 domains of the disease (motor, cognitive, 
function and behaviour). The scale is highly reliable and valid which means that it can 
be used for tracking symptoms in this population [46]. The motor section of the 
UHDRS includes 15 items rated on a 0-4 scale, with 4 indicating the most severe 
impairment. This scale contains measures of saccade initiation and velocity, alternating 
hand movement, finger tapping, chorea, rigidity, dystonia, bradykinesia, gait, tandem 
walking and retropulsion test. The 5 items of the cognitive component consist of a 
verbal fluency test, the symbol digit modalities test, and the 3 items Stroop test. The 
behavioural section of the test includes 28 items assessing the severity and frequency of 
a number of behavioural abnormalities. The functional component consists of a 
Functional Assessment Scale (FAS), which is a checklist of 25 yes/no questions, the 
Independence scale, which ranges from 0 to 100, and a Total Functional Capacity Scale 
(TFC). 
 
Stages of the disease in HD are usually documented using the TFC score. Scores 
derived from the TFC scale range from 0 to 13 and provide an assessment of a person‟s 
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capacity in relevant functional domains; including employability, financial tasks, 
domestic responsibilities and self care skills. The average rate of TFC decline ranges 
from 0.63 to 0.72 points per year [33, 34]. According to the TFC score, people with HD, 
once they have become symptomatic, can be differentiated into 5 stages of the disease 
progression as follows; stage I (TFC 11-13); stage II (TFC 7-10); stage III (TFC 3-6); 
stage IV (TFC 1-2); stage V (TFC 0) [47]. Stage 1 corresponds to early stage HD, stage 
II-III middle stage HD, and stages IV-V late stage HD. This classification can serve as 
an organizational tool for planning interventions; however, considering the variability of 
the disease, these stages are not definitive categories. Table 1.1 provides an overview of 
the general features for each stage as first described by Shoulson and Fahn [47].   
 
 
Table1.1: General features of HD according to the stage of condition [47] 
 
Stage of the 
disease 
General features 
TFC 
score 
Pre-manifest 
No clinically detectable symptoms: the patient has had a positive 
gene test confirming that they will develop the disease, but is still 
fully functional and independent at home and work. 
13 
Stage I 
Mild impairments: the patients maintain their independence in 
performing activities of daily living (ADL), domestic chores and 
managing finances. They may still be employed. 
11-13 
Stage II 
The patients maintain their independence in performing ADL and 
domestic chores. They may need slight assistance in managing 
finances. Capacity for normal job is reduced. 
7-10 
Stage III 
Patients need minimal assistance in performing ADL and domestic 
chores. They need major assistance in managing finances and 
capacity for normal job is obviously reduced. 
3-6 
Stage IV 
Patients need major assistance in performing ADL, domestic chores 
and managing finances. 
1-2 
Stage V 
Patients needs complete assistance with ADL, domestic chores and 
managing finances. Twenty four hour supervision at home or facility 
placement might also be required. 
0 
 
 
1.7 Management approaches and experimental treatments in HD 
Despite research advances in the past 20 years, medical treatment in HD has made little 
progress. The 2009 Cochrane review of therapies for modifying disease progression 
[48] concludes that there is no evidence that any pharmacological therapy modifies the 
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progression of HD. The 2009 Cochrane review of adequate symptomatic treatment of 
HD [49] concludes that conclusive evidence is available only for tetrabenazine that it 
can treat the symptoms of chorea. Although tetrabenazine seems to offer HD patients 
with severe chorea a respite from their constant involuntary movement, it has serious 
side effects as it can cause bradykinesia, rigidity, and depression or sedation [31].   
 
Currently, several approaches for HD are being investigated with the aim of developing 
therapies that would slow or modify the course of the disease. A few of these 
approaches have shown potential in work done in animal models. One of these 
approaches suggests reducing the toxicity produced by the mutant Huntington protein 
by silencing the expression of the mutant allele. Within this context, early studies tested 
the effects of allele- specific knockdown (i.e. silencing), in which an inhibitory 
Ribonucleic acid (iRNA) was directed against the mutant Huntington fragment in a 
transgenic model of HD [50]. Knocking down the mutant allele demonstrated positive 
effects in reducing the disease progression and improving the disease-related symptoms 
in the HD mice model [50]. This approach, however, has disadvantages; silencing both 
the normal and the mutant alleles can have serious side effects. The complete loss of 
expression of the mouse HD gene was found to cause an embryonic lethal phenotype 
[51]. To overcome this, research has been focusing on investigating alternatives to 
silencing HD gene expression by instead examining approaches that would reduce the 
amount of mutant Huntington protein. This involves examining mechanisms to reduce 
its production or enhancing its clearance (i.e. degradation) [13, 51]. Recently, 
considerable research has been advocated to develop tools to quantify and characterize 
Huntington protein and aggregates [51]. These efforts, although slow moving, are 
producing a better understanding of the underlying mechanisms of the disease which 
may lead to the identification of the specific toxic species and this in turn may help to 
select a lead compound that reduces mutant Huntington protein and in turn the 
symptoms of HD [51].  
 
Additional lines of research that are designed to yield therapies for HD are focused on 
how mutant Huntington causes its toxicity [12, 13, 51]. Prominent among the 
mechanisms identified so far are increased oxidative stress, reduction in the synthesis 
and secretion of protective growth, changes in pre- and post synaptic neurotransmitter 
induced activities and reductions in mitochondrial function [13, 51]. Development of 
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compounds that are designed to prevent or reduce these toxicities is currently under 
investigation in cell based and model organisms and this may yield useful therapeutic 
leads in the future.  
 
Whilst the approaches cited above are still investigated in cell-based and model 
organisms, other approaches which are reconstructive (i.e. surgical) have been tried in 
people with HD. In response to successes with deep brain stimulation in Parkinson‟s 
disease (PD) [52], trials of this surgical method have been conducted in HD. The 
published papers comprise individual case reports that suggest chorea and dystonia are 
reduced in the short-term [53, 54]; however, there is not enough evidence of the long-
term benefits of this approach. Other therapies such as primary-foetal neural-
transplantation, have reported success in reducing the neuronal degeneration associated 
with HD and stopping symptomatic progression for some time in subjects with HD [55, 
56]. These observations, however, were seen in only a few subjects with HD; thus larger 
clinical trials are needed to establish the safety and efficacy of this approach.   
 
It is clear that there has been striking progress made in terms of understanding the 
pathogenesis of HD and possible therapeutic approaches. However, it should be noted 
that new treatments may take many years until they become generally available, taking 
into account the process of pre-clinical assessment and then clinical assessment once a 
treatment has been identified in the laboratory. For this reason, there is a need to 
improve all modes of management approaches, including the conventional therapies. 
Within this context, there has been growing attention in terms of research towards 
understanding the environmental factors that may affect the disease. The concept is that, 
although HD is an inherited disease, environmental factors may play a role in the 
mechanisms of gene expression and subsequently may alter the symptoms of the 
disease. It is known that significant variability exists in symptoms and age of onset, 
even among people sharing the identical CAG repeat length in their HD gene and most 
surprisingly among monozygotic twins [6, 57-60]. This lends support to the idea that the 
mutant HD gene expression can be altered by environmental factors and further 
exploration into such factors is required. 
  
Recently there is also increasing understanding of the role that exercise and physical 
activity may play as an environmental modifier in a variety of animal models, including 
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the HD animal models. Laboratory studies have demonstrated improved function in 
normal rodents in response to exercise, and have indicated some of the underlying 
resulting physiological changes, such as gene expression changes in the brain [61]. 
Recent evidence has revealed that similar benefit can be achieved in animal models of 
neurodegeneration, such as the R6/1 and R6/2 mice models of HD. Housing such mice 
in enriched environments, in which there are increased opportunities for physical 
activity, results in better performance of  motor tasks compared to mice in standard 
housing [62-65]. Even minimal amounts of enrichment produced phenotypic slowing 
and, perhaps more remarkably, was associated with delayed loss of peristriatal cerebral 
volume [62, 65]. The extent to which the physical intervention has its effect through a 
general increase in activity or through activation of specific neural circuits is currently 
not known. However, a study of task-specific training following transplantation of 
developing striatal neurons into the striatum of an adult rodent model of HD suggests 
that activation of specific circuits may be useful, at least in some circumstances, and 
was important for “learning to use the graft” [66]. These observations, along with 
reports that a passive lifestyle may potentially influence symptom onset in patients with 
HD [67], have direct implications for developing therapeutic exercise interventions in 
this population and provide theoretical support for implementing strategies to encourage 
more active lifestyles in people with HD. 
 
1.8 Exercise interventions in HD and the MRC framework  
Exercise interventions for people with HD are likely to be complex. They are likely to 
involve many components that need to be considered such as; providing information, 
advice, prescribing different types of exercise and giving demonstrations. A further 
complexity is that at the same time individuals may be undergoing investigations and 
taking medication. Exercise interventions can also be modified by a number of factors 
such as severity of the disease and individual personal factors. It is therefore essential 
that the main “active ingredients” within the intervention are defined and benefits 
evaluated [68]. The Medical Research Council (MRC) Framework for design and 
evaluating complex interventions provides a methodology for evaluation of complex 
interventions [69, 70]. Four phases have been identified in this framework to be assured 
that an intervention is fully defined, developed and evaluated before long term 
implementation; these phases are demonstrated in Figure 1.3. The pre-clinical phase 
deals with exploring the underlying theory and developing hypotheses. This is followed 
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by a modelling phase to identify components of the intervention and potential outcomes 
and then an exploratory trial to evaluate feasibility and pilot methods.   
 
 
Figure 1.3:  Phases of developing randomised controlled trials of complex interventions. The 
figure shows the different stages of the MRC for developing and evaluating complex 
interventions [69]. 
 
 
This figure has been removed by the author for copyright reasons 
 
 
As discussed earlier, mobility deficits are an important component of HD 
symptomology which may impact on safe, independent ambulation and detrimentally 
affect quality of life. As currently there is no disease-modifying treatment available for 
this condition and very little in the way of symptomatic treatment, it is important to 
improve all modes of possible management approaches, including conventional 
therapies [71]. Within this context, exercise interventions to improve mobility may offer 
a means to enrich the lives of people with HD and their carers by improving health, 
helping to maintain independence, and subsequently reducing health and care costs. 
This suggestion, along with available evidence that exercise may alter symptoms and 
disease progression in animal models of HD, provides theoretical support for the need 
to consider exercise interventions as a management approach in people with HD.    
 
Whilst exercise has been shown to be of benefit in improving the mobility status of 
people with other neurodegenerative disease such as Parkinson‟s disease and 
Alzheimer‟s disease [72-75], it is not known if or how exercise affects people with HD. 
Two recent reviews [37, 71] highlighted the scarcity of available literature in which 
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only 5 papers addressed exercise type interventions for people with HD. To date, only 5 
additional studies have been identified [2, 76-79]. External cueing techniques and 
balance training, as well as a combination of muscle strengthening, stretching and 
cardiovascular exercise, were used as strategies for helping people with HD to enhance 
their walking ability and functional status in these studies. However, the vast majority 
of these studies were either observational or non experimental in design and were 
limited by the lack of randomisation, lack of blinding, the lack of the use of objective 
outcome measures and poorly-defined intervention content. It is clear that there has 
been little recent progress in the field of exercise interventions for people with HD.  
 
Efficacy of exercise interventions should be confirmed with controlled clinical trials; 
however, the implementation of such trials is still limited by the lack of knowledge 
about specific components of appropriate interventions. A series of interviews and 
surveys with physiotherapists working in the field [80, 81] has given some insight into 
potential exercise intervention and evaluation strategies. This work indicated that 
although exercise interventions are crucial in managing mobility deficits in this 
population, sustained interventions may not be the most feasible for life-long disease 
management and it is therefore critical for physical therapists to find ways to facilitate 
early engagement and participation in independent exercise programmes. People with 
HD involved in this preliminary work were interested in exercise programmes, but 
found it difficult to engage in independent exercise programmes in the community 
mainly because of their limited ability to travel to a formal exercise setting such as the 
gym. A home-based exercise may therefore be an appropriate tool for many people with 
HD to engage independently in an exercise programme.  
 
Although an independent home-based exercise programme may be optimal for people 
with HD,  there are a number of factors that may influence the ability of people with 
HD to engage in such programmes, which include cognitive and motivational issues 
[80]. Exercise adherence is suggested to decrease after professional supervision stops in 
this population, when patients no longer receive external support or feedback about their 
progress [80, 81]. There is clearly a need to develop methods that facilitate patients‟ 
engagement and adherence to an independent exercise programme. The technology 
capabilities of DVD/ videotape (such as the use of sub-titles, music and rhythm, 
demonstration and structuring of content) make it a useful format to facilitate 
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engagement in such programmes, particularly for people who have motivational and 
cognitive problems, as is common in people with HD. Such audiovisual methods have 
been used in different clinical settings and disciplines with a positive outcome [82-84] 
and better adherence [85, 86].  
 
An exercise videotape has also been used to successfully support a person with mid-
stage HD to follow a home exercise programme [2]. This single case study is the first to 
use a videotape to support an independent exercise programme in the HD population. 
Using this case study as a basis, the Cardiff physiotherapy group developed an exercise 
DVD for people as part of the modelling work of the MRC framework to develop 
exercise interventions for people with HD. The DVD was developed for use as a home-
based exercise resource. Consultation in the form of focus groups with physiotherapists 
(n=8) working in the field, and interviews with people with HD (n=5) was undertaken in 
order to determine the content and structural requirements of the DVD. The final DVD 
included exercises specifically designed to target the specific physical problems seen in 
this population. The DVD had subsections, which means that it can be individualized. 
Feedback from people with HD involved in the development stage suggested that 
people would use the DVD as a support mechanism to develop their home-based 
exercise routines. Although the developed DVD seemed to have the potential to provide 
sustainable training in this population with ultimate contribution to an integrated 
physiotherapy service for people with HD, further evaluation was required. 
 
In line with the MRC framework, an exploratory trial was needed for evaluating the use 
of the exercise DVD before undertaking a definitive phase III randomized controlled 
trial (Figure 1.3). An exploratory study would provide an opportunity to determine the 
safety of an intervention as well as feasibility of recruitment, method of randomisation, 
content of the comparative arm (the control group) and factors that may impact on 
delivering the intervention and how these factors can be managed in future studies. An 
exploratory study would also provide an opportunity to determine the acceptability of 
the intervention to the users and their carers. 
 
1.9 Aims of the thesis    
This thesis focuses on the exploratory phase (phase II) of evaluating a home-based 
exercise programme for people with HD (using the aforementioned exercise DVD as a 
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basis for the exercise intervention). The primary aim was to evaluate feasibility, 
acceptability and benefits of a home-based exercise programme that was designed to 
specifically target physical factors which are typically impaired and are potentially 
modifiable in people with early to mid stage HD. Potential benefits were evaluated in: 
a) deficits in gait, muscle strength balance; b) functional mobility and c) health-related 
quality of life.  
 
As this was a stage II (exploratory) study, piloting of the battery of outcome measures 
that could be used to evaluate benefits in future definitive phase III randomized 
controlled trials was also necessary. Choosing appropriate outcome measures that are 
valid and reliable is crucial in developing clinical trials. The battery of clinical outcome 
measures that were used in this study (see Chapter 3) has been shown to have utility in 
people with HD and other neurological diseases. However, to date, the reliability of the 
vast majority of these outcome measures has not been evaluated in people with HD.  
 
Although this study aimed primarily to evaluate the feasibility, acceptability and 
benefits of an exercise programme in people with manifest HD, the ultimate goal is to 
develop exercise interventions that may potentially modify the disease process. The 
optimum point at which to introduce such interventions is likely to be the pre-manifest 
stage, before the onset of rapid neuronal degeneration and the emergence of clinical 
symptoms. Exercise in general is known to promote synaptic plasticity, stimulate brain 
perfusion and improve neurovascular integrity, promoting the development of new 
neural architecture [61, 87]. These potential changes may have a neuroprotective effect 
in the pre-manifest stage by keeping the neuronal cells fit for longer; thus delaying the 
onset of the disease. Overall, to test potential interventions, outcome measures that are 
sensitive to motor changes and reliable in individuals with pre-manifest HD must be 
identified. Therefore, validity and reliability of the outcome measures was also 
examined in a group with pre-manifest HD.  
 
In developing the research presented here, a review of the available literature was 
conducted to determine criteria for delivering the intervention and to highlight potential 
outcome measures that could be used to evaluate potential benefits (Chapter 2). Details 
of methods that were applied to this study are provided in Chapter 3. Validity and 
reliability of the outcome measures across the continuum of the disease were examined 
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(Chapter 4). A repeated measure design was used to evaluate benefits of the home-
based exercise programme. The benefits to: a) deficits in gait, balance and strength; b) 
functional mobility and c) health-related quality of life were examined (Chapter 5). 
Acceptability of this exercise programme to user and carers was also determined using a 
process evaluation (Chapter 6).  Outcomes of this study are required to provide a sound 
basis for determining methodological designs for Phase III randomised controlled trials.    
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2 Literature Review 
  
2.1 Overview 
In developing the research presented here, a review of the available literature was 
conducted to review the evidence for physical interventions in the management of 
mobility deficits in people with HD; determine criteria for delivering the intervention 
and to highlight potential outcome measures that could be used to evaluate potential 
benefits.  In terms of outcomes, it was relevant to examine literature related to outcome 
measures used in the assessment of factors related to deficits in gait, balance, muscle 
strength and health-related quality of life in this population.  
 
Because of the very limited evidence available that is specific to exercise in HD, it was 
necessary to make inferences from evidence in other neurodegenerative diseases; 
searches therefore also included evidence related to exercise in Parkinson‟s disease 
(PD) and Alzheimer disease (AD). The main aim of this expanded search of literature 
was to develop the protocol of the delivered exercise programme in terms of 
determining key elements that needed to be incorporated into the intervention to ensure 
its acceptability and benefits. 
 
This Chapter is divided into 5 sections. The first section will focus on methods of the 
search strategy; the other 4 sections will address the results and the discussion of the 
literature reviewed and the fifth section will address the study specific objectives and 
hypothesis.  
 
2.2 Search strategy 
2.2.1 Introduction  
In total, 4 main literature searches were conducted:  
Search 1 aimed to review evidence for physical factors related to mobility deficits in 
people with HD.  
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Search 2 aimed to review evidence in the exercise type interventions in managing 
mobility deficits in people with HD.  
Search 3 aimed to review evidence in the home-based exercise interventions in 
managing mobility deficits in PD and AD.  
Search 4 aimed to review evidence in the home use of exercise DVDs or videos in 
influencing adherence rate and physical outcomes in different populations. 
 
The literature search for all the 4 searches was limited to English language journals. 
Comprehensive searches were conducted using the following electronic databases; 
PubMed (1966- February 2012), Medline (1969- February 2012), EMBASE (1980- 
February 2012), AMED (1985- February 2012). Bibliographies of all relevant studies 
and systematic reviews were searched by hand. The results were managed using End 
Note Version X3. 
 
Key words for all 4 searches were structured using a population, intervention, 
comparison and outcome (PICO) approach [88]. Table 2.1 shows the search strategy 
used in Medline, AMED and EMBASE databases. 
 
2.2.2 Search strategy for search 1 
Population key words for search 1 included „Huntington‟s disease‟, „Huntington‟s‟ and 
„chorea‟. Because only observational studies were searched, intervention key words 
were not specified for this search. Outcome key words included, „dystonia‟, „daily 
living‟, „mobility‟, „posture‟, „balance‟, „postural control‟, „falls‟, „functional status‟, 
„gait‟, „muscle strength‟, „quality of life‟. Both prospective and retrospective 
observational studies were included if the paper identified factors in a sample of people 
with pre-manifest or manifest HD related to the following key words: physical activity, 
physical mobility, range of motion, posture, balance, postural control, muscle strength, 
gait and quality of life. The paper was excluded if all members of the population were 
aged <18 years and if the diagnosis of HD was not evident by a positive genetic test or a 
family history of HD.  
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2.2.3 Search strategy for search 2 
Population key words for search 2 included „Huntington‟ and „chorea‟. Intervention 
keywords included „physical therapy‟, „physiotherapy‟, „rehabilitation‟, „exercise 
therapy‟, „exercise‟, „stretching‟, „strengthening‟. Outcomes were searched using the 
following key terms: „daily living‟, „mobility‟, „postural control‟, „balance‟, „posture‟, 
„falls‟, „functional status‟, „gait‟, „muscle strength‟, „quality of life‟. Studies were 
included if they investigated changes in mobility status following an exercise based 
intervention. Due to the limited amount of published papers, all publication types were 
considered; including review papers, conference proceedings, experimental trials, quasi 
experimental trials, observational trials and experts‟ opinion. Studies were excluded if 
all members of the population were aged <18 years and diagnosis of HD was not 
confirmed by a positive genetic test or a family history of HD with signs of chorea or if 
the intervention did not influence mobility status or function. 
 
2.2.4 Search strategy for search 3 
Population key words for search 3 included „Parkinson‟s disease‟, „multiple sclerosis‟ 
and „Alzheimer disease‟. Intervention keywords included „physiotherapy‟, „physical 
therapy‟, „exercise‟, „home exercise‟ and outcome keywords included „balance‟, 
„postural control‟, „falls‟, „functional status‟, „mobility‟, „gait‟, „muscle strength‟, 
„quality of life‟. Full text randomised controlled trials and experimental studies which 
investigated changes in mobility status and function following a home based exercise 
programme in PD or AD were included. Exclusion criteria were if all members of the 
population were aged <18 years, the intervention was not fully or partly home-based, 
the intervention did not influence mobility status or function, or only one subject was 
studied. 
  
2.2.5 Search strategy for search 4   
There were no limits placed on the types of patient population. Keywords for 
intervention included: „video‟, „recording‟, „DVD‟, „home exercise‟. Outcomes key 
words were „compliance‟, „adherence‟, „physical‟. Full text randomised controlled trials 
and experimental studies which investigated the influence of a home use of an exercise 
DVD or videotape on adherence rate and health outcomes were included. The study was 
excluded if the use of a DVD or videotape was not considered as part of the home-based 
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exercise programme and if compliance or adherence was not recorded or considered as 
an outcome measure.  
 
 
                                    Table 2.1: Summary of search strategy and records of findings 
 
 Search 1 Search 2 Search 3 Search 4 
Search strategy  
 
1= Huntington* 
2= Chorea 
3= 1 OR 2 
4= Dystonia 
5= Daily living 
6= Posture 
7= Balance 
8= Mobility 
9= Postural control 
10=Muscle strength 
11= Gait 
12= Functional 
13= Falls 
14= quality of life 
15= 4 OR 5 OR 6 
OR 7 OR 8 OR 9 
OR 10 OR11 OR 
12 OR 13 OR 14 
16= 3 AND 15 
 
1= Huntington* 
2= Chorea 
3= 1 OR 2 
4= Physical therapy 
5= Physiotherapy 
6= Rehabilitation 
7= Exercise therapy 
8= Exercise 
9= Stretching  
10= Strengthening  
11= 4 OR 5 OR 6 OR 7 
OR 8 OR 9 OR 10 
12= Daily living 
13= Posture 
14= Balance 
15= Postural control 
16= Muscle strength 
17= Gait 
18= Function 
19= Falls 
20= quality of life 
21=12 OR 13 OR 14 
OR 15 OR 16 OR 17 
OR 18 OR 19 OR 20 
22= 3 AND 11 AND 
21  
 
1= Parkinson* 
3= Alzheimer* 
4= 1 OR 2 OR 3 
5= Physiotherapy 
6=Physical Therapy 
7= Exercise 
8= Home  
9= 5 OR 6 OR 7 
OR 8  
10= Daily living 
11= Posture 
12= Balance 
13=Postural control 
14=Muscle strength 
15= Gait 
16= Function 
17= Falls 
18= quality of life 
19= 10 OR 11 OR 
12 OR 13 OR 14 
OR 15 OR 16 OR 
17 OR 18 
20= 4 AND 9 AND 
19 
 
 
1= Video* 
2= Recording 
3= DVD* 
4= Exercise 
5= Adherence  
6=Compliance  
7= 1 OR 2 OR 
3 
8= 5 OR 6  
9= 4 AND 7 
AND 8  
 
Records 
retrieved 
9,974 557 2,994 1,357 
Records 
excluded by title 
or abstract 
9,948 542 2,982 1,346 
Records 
excluded by full 
text 
5 4 6 4 
Records  
included 
21 11 6 7 
Records 
identified by 
hand search 
7 3 3 2 
Total included 28 14 9 9 
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2.2.6 Search outcome 
One reviewer (the PhD student) identified and reviewed all titles and abstracts followed 
by the full text of each paper. In total 14,882 papers were retrieved from the 4 
conducted searches; 14,818 studies were excluded by the title, abstract or method and 
19 studies were excluded by full text. Fifteen papers were identified by hand searching. 
Twenty eight of the included papers were related to mobility deficits in HD. Research 
conducted to investigate the benefits of exercise interventions in HD was very limited 
with only 10 studies identified. Two qualitative studies and 2 reviews were also 
included. Exercise interventions in PD appeared to be much more widely researched in 
areas relating to mobility deficits and therefore this search focused mainly on the studies 
related to home-based exercise interventions in which 7 papers were reviewed. An 
additional 2 papers related to home-based exercise interventions in AD were also 
included. Nine papers related to impact of the home use of an exercise videotape on 
adherence and health outcomes in different populations were included.  
 
Details of study design, sample size, methods of assessment and/or intervention and the 
key findings were extracted and summarized in tables. Using the Critical Appraisal 
Skills Programme (CASP) appraisal tool [89], each of the included papers from search 1 
and search 2 were critically appraised by one reviewer (the PhD student). The CASP 
tool is comprised of 3 appraisal sections: an assessment of study validity, an evaluation 
of methodological quality and presentation of results, and an assessment of external 
validity. The level of evidence from each paper included in the review for search 2 was 
classified according to Sackett‟s rules [90]. According to Sackett, there are 5 main 
levels of evidence for clinical interventions. At the highest level (Level 1) are 
interventions that have been validated with RCTs with low false-positive (alpha) rates 
and high power. Level 2 is where the intervention is supported by RCTs with high false-
positive rates and low power. Level 3 applies when nonrandomized comparisons 
between concurrent, matched groups have been used. Alternatively, a group may be 
compared with their own performance at another point in time. Level 4 applies to 
nonrandomized group comparisons which includes experimentally controlled single-
case time-series designs. Level 5 refers to case series without controls, where 
information is provided only on the outcome of patients without evidence of 
experimental design. Single case studies can be classified under this heading. Due to 
heterogeneity of populations, interventions and outcome measures, on each search, it 
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was not possible to carry out a meta-analysis. A narrative review of all included studies 
was therefore undertaken. 
 
2.3 Mobility-related deficits in HD  
2.3.1 Mobility-related deficits in HD and the International Classification of 
Functioning, Disability and Health (ICF) model  
To allow for the integration of several perspectives regarding mobility deficits in this 
population, the International Classification of Functioning, Disability and Health (ICF) 
model of the World Health organisation (WHO) [91], which is commonly used in 
assessing mobility in neurological conditions, was applied in this review. The advantage 
of using the ICF is that it provides specific terminology that can be used to refer to a 
specific health condition which can be used by all health care professionals. Thus it 
provides a common international language for communication and research.  
 
The ICF framework describes aspects of a person‟s health and health-related wellbeing 
at 3 levels; the individual body parts and functions, the individual as a whole (activity) 
and the individual in a social context (participation) [91]. Within the ICF framework, 
each of these 3 levels encompasses different domains. The ICF provides specific 
descriptions that can be used to refer to a specific domain. These descriptions provided 
by the ICF framework were used in this review to guide categorization of the mobility-
related deficits in HD according to their relevant domains (Figure 2.1). Detailed 
discussion regarding the categorization of mobility-related deficits in HD in line with 
the ICF model is provided in the sections below.  
 
In the context of the ICF, body structures can be defined as the anatomical parts of the 
body, whereas body functions are defined as the physiologic functions of body systems. 
A problem in body function or structure such as a significant deviation or loss is 
interpreted as impairment. As per the ICF, muscle strength can be seen as a function of 
the musculoskeletal system, whilst balance is an integrated function of the vestibular, 
visual, somatosensory as well as the musculoskeletal systems. In the health condition of 
HD, deficits in balance and muscle strength which are reported in the literature in HD 
[38, 44, 45, 92-98] represent main impairments in body functions in this population. 
Both muscle strength and balance are linked with the ability to move independently. 
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Balance and muscle strength form the foundation to undertake a wide range of mobility 
activities that constitute normal daily life, including walking, and therefore impairments 
in muscle strength and balance are known to have negative effects on mobility activities 
[99]. In people with HD, there is growing evidence to suggest that impairments in 
balance and muscle strength may restrict mobility [38, 45, 96]. Impairments in balance, 
predominantly, may place individuals with HD at increased risk of falls [38, 45]. 
Therefore this review focused on muscle strength and balance as two categories of 
physical impairments in people with HD.  
 
Activity forms the intermediate level of the ICF model. As per the ICF, activity is the 
component of function which involves execution of a task or action by an individual 
[91]. Among the most important and common day-to-day activities are tasks that 
involve mobility components. WHO defines mobility as the “individual‟s ability to 
move about effectively in his/her surroundings” [100]. This definition however, informs 
only aspects of ambulant mobility. In a more general and comprehensive sense mobility 
can be defined as the process of moving oneself and of changing body position or 
location [101].  
 
According to the ICF, a number of activities can be listed under the mobility domain 
and this review focused on evaluating the aspects of mobility that are believed to be 
limited in people with HD. This included aspects of mobility that incorporates walking, 
sit to stand, turning and stepping [91]. Walking in particular represents a common and 
an integral activity of daily life. It serves as an individual‟s basic need to move from one 
place to another. In people with HD, accurate data regarding limitations in walking are 
important, because loss of independence in ambulation is the greatest predictor of 
nursing home placement in this population [43]. For these reasons, aspects of 
limitations in walking and other forms of mobility activities in HD were addressed in 
this review.    
 
Participation forms the third and the last level of the ICF. As per the ICF, participation 
can be viewed as the involvement in a life situation and participation restrictions as 
problems individuals may experience in involvement in life situations [91]. 
Participation may be best presented by health-related quality of life measures [102]. 
Quality of life can be defined as the physical, social and psychological functioning of an 
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individual as being influenced by a disease or therapy [103]. It refers to the subject‟s 
appraisals of their current level of health and functioning as well as satisfaction 
compared to what they perceive to be ideal. In people with HD, the progressive loss of 
mobility may put people at risk of falls and lead to functional dependence; the aspects 
that may detract from health-related quality of life [104]. For this reason aspects of 
quality of life related to mobility deficits in this population were also addressed in this 
review.   
 
The ICF takes into account both the personal and environmental contexts that may 
impact on the functional performance of an activity. In people with HD, personal factors 
such as cognitive impairments and behavioural disturbances such as apathy [2, 38] as 
well as environmental factors such as the physical environment including  the level of 
the supervision [80] and cueing strategies [105, 106] may have an impact on the 
mobility tasks that are performed. Figure 2.1 below shows how the different domains of 
the ICF in people with HD can be influenced by both individuals and environmental 
factors. The following sections will provide a detailed review of papers related to 
mobility deficits in HD across the 3 domains of the ICF model through the spectrum of 
the disease. Both personal and environmental factors and their influential impact on 
activity performance in HD will be discussed in detail in later sections in the context of 
exercise interventions in this population.  
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 Figure 2.1: Physical impairments, activity limitations and participation restrictions related to 
mobility deficits in HD, structured according to the International Classification of Functioning, 
Disability and Health (ICF) model 
 
 
 
 
2.3.2 Review of available studies related to mobility deficits in people with HD in 
line with the ICF model 
In total 28 papers related to mobility deficits in HD were reviewed; of these, 7 studies 
were related to balance, 3 studies to muscle strength, 13 studies to gait deficits and 6 
studies to deficits in other mobility activities such as sit to stand, stepping and turning. 
Furthermore, 4 papers related to health-related quality of life in people with HD were 
also reviewed. The vast majority of these studies were conducted with good 
methodological quality (according to the CASP critical appraisal tool). Summaries of 
these studies are provided in Tables 2.2; 2.3; 2.4 and a summary of their critical 
appraisal is provided in Table 2.5 below.  
Disease or Disorder
HD (Basal ganglia degeneration)
(Physical Impairments)
Muscle weakness
Impaired balance
(Activity Limitations)
Walking difficulties 
Decreased mobility and 
functional status  
(Environmental Factors)
•Tasks 
•Cueing 
•Physical environment
(Personal Factors)
•Apathy
•Cognitive impairments
(Participation Restriction)
Decreased health-related 
quality of life  
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Table 2.2: Summary of papers included for body function, ICF categories: balance and muscle strength 
Papers related 
to balance 
impairments 
in HD 
Authors/time Subjects Mean age (SD) Main methods/outcome measures Key findings 
Kloos et al, 2011 [44] MHD=94 MHD=50.8 (10.7) 
Fall history in the previous 6 months / Tenitti 
mobility test (TMT) of balance 
The TMT scores significantly predicted the risk of fall in HD 
Salomonczyk et al, 2010 
[92] 
MHD=11 
PHD=22 
HC=17 
MHD=46.3 (3.2) 
PHD=42.4 (10.5) 
HC=39.2 (2.8) 
Force platform/ 6 conditions of standing in 
which visual information was degraded   
MHD had significantly greater postural sway on all conditions compared to 
PHD and HC  
PHD close to onset had significantly greater postural sway on conditions 
when visual information was degraded compared to PHD far to predict 
years of onset and HC 
Rao et al, 2009a [93] MHD=30  MHD=53.2 (11.2) Functional reach test (FRT) 
FRT scores were worse in stage II compared to stage I and  had worsened 
further worse in stage III compared to stage II 
FRT scores correlates with TFC, gait speed, CV step length 
Rao et al, 2009b [94] 
PHD=15 
HC= 15 
PHD=38.9 (10.5) 
HC=39.5 (9.1) 
Functional reach test (FRT) No significant differences between PHD and HC in the FRT 
Busse et al, 2009 [45] MHD=24 MHD=56.6 (11.7) 
Fall history in the previous 12 months / Berg 
balance scale (BBS) 
The BBS scores significantly predicted the risk of fall in HD 
Grimbergen et al, 2008 
[38] 
MHD=45 
HC=27 
MHD=51.1 (10.1) 
HC=52.2 (8.5) 
Fall history in the previous 6 months and 
prospective falls monitoring for 3 months / 
BBS 
BBS scores are significantly higher in fallers compared to non-fallers  
Tian et al, 1992 [95] 
MHD=20 
HC=20 
MHD=53.1 (10.4) 
HC=51.2 (9.5) 
Force platform / 6 conditions of standing in 
which visual, proprioceptive and vestibular 
cues were attenuated  
Sway: for all tests the AP sway was significantly higher in MHD compared 
to HC 
Response to external protrusion: the latency to the initiation of the 
corrective response to sudden translation of the force platform, was 
prolonged in MHD compared to HC 
Papers related 
to muscle 
weakness in 
HD 
Busse et al, 2008 [96] 
MHD=20 
HC=20 
MHD=51.7 (7.6) 
HC=48.9 (7.3) 
Hand held dynamometer /6 muscle groups of 
hip, knee and ankle 
MHD had on average about half the strength of HC 
Muscle strength indices in MHD correlated with TFC, the UHDRS motor 
score, functional assessment scale and independence scale 
Kosinski et al, 2007 [97] PHD=1 PHD=37 Muscle biopsies/analysis of fibroblast culture 
Deficits in mitochondrial function including deficiency in the complex IV 
cytochrome oxidase enzyme activity 
Saft et al,  2005 [98] 
MHD=15 
PHD=15 
HC=37 
MHD=43.7 (8.8) 
PHD=37.1 (9.6) 
HC=39.8 (8.1) 
P magnetic resonance spectroscopy 
Mitochondrial ATP synthesis and oxidative function were significantly 
lower in MHD and PHD compared to HC 
MHD, manifest HD; PHD, pre-manifest HD; HC, healthy controls; CV, coefficient of variation; TFC, Total Functional Capacity scale; UHDRS, Unified Huntington‟s Disease Rating scale  
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                          Table 2.3: Summary of papers included for activity, ICF categories: gait, stepping, turning and sit to stand transitions 
Papers related 
to gait 
deficits in HD 
Authors/time Subjects Mean age (SD) Main methods/outcome measures Key findings 
Rao et al, 2011 [39] PHD=10 PHD=38.6 (7.9) 
Automated walkway / spatiotemporal gait 
parameters/ assessment at baseline, 1 year and 5 
years later 
Gait velocity significantly decreased and variability of stride length and 
swing time significantly increased over five years 
Delval et al, 2011 [107] 
PHD=17 
HC=25 
PHD=36.5 (6.4) 
HC=36.0 (7.3) 
Force platform and 3D camera system / gait 
parameters of the first 4 to 5 steps under self 
triggered condition 
1st and 2nd step speed and length significantly decreased in PHD 
compared to HC 
Tabrizi et al, 2009 [108] 
MHD=123 
PHD=120 
HC=123 
MHD=48.8 (9.9) 
PHD=40.8 (8.9) 
HC=46.1 (10.2) 
Automated walkway/spatiotemporal gait 
parameters at self selected speed 
CV% stride length was significantly higher in both MHD and PHD when 
compared with HC 
Busse et al, 2009 [45] MHD=24 MHD=56.6 (11.7) 
Fall history in the previous 12 months / walking 
speed (10 m walk test) 
Gait speed was significantly lower in fallers compared to non-fallers 
Rao et al, 2008 [40] 
MHD=30 
PHD=15 
HC=20 
MHD=50.2 (9.2) 
PHD=36.9 (2.1) 
HC=44.3 (9.1) 
Automated walkway / spatiotemporal gait 
parameters at self selected speed 
Gait speed, stride length, double support time, % of stance time,  CV stride 
length, CV step time decreased in MHD and PHD when compared with HC 
Delavl et al, 2008 [109] 
MHD=15 
HC=15 
MHD=43.9 (9.8) 
HC=40.5 (10.5) 
Video motion system/spatiotemporal gait 
parameters/ walking under 3 conditions; free 
gait, walking with dual motor task, walking with 
dual cognitive task  
Significant differences between MHD and HC in all conditions in cadence, 
stride length, gait speed and CV of all these parameters 
Grimbergen et al, 2008 
[38] 
MHD=45 
HC=27 
MHD=51.1 (10.1) 
HC=52.2 (8.5) 
Fall history in the previous 6 months and 
prospective falls monitoring for 3 months /  
automated walkway (spatiotemporal gait 
parameters) 
MHD people had a decreased gait velocity and decreased stride length and 
stride length CV compared to HC 
MHD-fallers had significantly greater stride length CV compared to MHD 
non-fallers 
Delval et al, 2007 [41] 
MHD=15 
HC=15 
MHD=47.3 (10.2) 
HC=40.5 (10.5) 
Force platform and 3D camera system/ gait 
parameters of the first 4 to 5 steps under self 
triggered condition 
1st and 2nd step speed and length decreased and step duration increased for 
MHD compared to HC 
Bilney et al, 2005 [110] 
MHD=30 
HC=30 
MHD=51.2 (10.6) 
HC=50.9 (11.6) 
Clinical stride analyzer / spatiotemporal gait 
parameters/walking at self selected slow, 
preferred and fast speeds 
Slow, preferred and fast walking: cadence, stride length were significantly 
lower and CV of stride length was higher in MHD comparing to HC 
Churchyard et al, 2001 
[111] 
MHD=20 
HC=16 
MHD= 50.2 (9.2) 
HC= 52.2 (8.5) 
Clinical stride analyzer/ spatiotemporal gait 
parameters/walking at self selected slow, 
preferred and fast speeds 
Preferred gait speed: (compared to MHD): decreased velocity, stride 
length, cadence and increased variability.   
Slow and fast gait speed: (internal cue)(compared to HC): MHD group 
could modify velocity and stride length but velocity, stride length, and 
cadence remained less than for HC 
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                                Table 2.3: (continued) Summary of papers included for activity, ICF categories: gait, stepping, turning and sit to stand transitions 
 
 
Papers related 
to gait 
deficits in HD 
Authors/time Subjects Mean age (SD) Main methods/outcome measures Key findings 
Hausdorff et al, 1998 [112] 
MHD=20 
PD=15 
HC=16 
MHD=47 (11.3) 
PHD=67 (12.8) 
HC=39 (10.4) 
Force sensitive insoles / walking at self selected 
walking speed/spatiotemporal gait parameters  
All measures of gait variability were increased in PD and even 
more in MHD when compared to HC 
Hausdorff et al, 1997 [113] 
MHD=17 
HC=10 
MHD=46.8 (12.8) 
HC=34.5 (13.4) 
 
Force sensitive insoles / walking at self selected 
walking speed/ α; a measure of the degree to 
which one stride interval is correlated with the 
previous and subsequent intervals over different 
time scale was calculated 
α  was lower in MHD when compared with HC 
α was significantly correlated with disease severity (TFC) 
Koller and Trimble, 1985 
[32] 
MHD=13 
HC=10 
MHD= 57.3 (10.2) 
HC= 53.2 (11.2) 
Clinical stride analyzer / spatiotemporal gait 
parameters at self selected gait speed 
Gait speed, stride length and cadence decreased in MHD and stride 
time increased compared to HC 
Papers related 
to deficits in 
stepping, 
turning and  
sit to stand 
transitions  
Panzera et al, 2011 [114] 
MHD=11 
HC=17 
MHD=47.1 (11.0) 
HC=39.2 (2.8) 
Force platform/ COG sway and velocity in 3 tests 
1) step up and over an obstacle 2) sit to stand 3) 
step and turn. 
 
MHD developed significantly less rising force during the step up 
and over test and also during rising up from a chair compared to 
HC 
Sway velocity of COG was significantly higher for MHD when 
performing the sit-to-stand and step and turn tests  
Goldberg et al, 2010 [115] 
MHD=14 
HC=9 
MHD=46.5 (9.1) 
HC=40.8 (12.1) 
Multi- operational Apparatus for Reaction time  / 
stepping response time 
Stepping response time was significantly lower in MHD comparing 
to HC 
Khalil et al, 2010 [116] 
MHD=10 
PHD=5 
HC=6 
MHD=57.3 (10.2) 
PHD= 47.3 (10.4) 
HC=48.3 (17.1) 
Triaccelerometer/ duration, slopes and ranges of 
sit to stand transitions during the timed Up and 
Go test   
TUG duration, sit to stand duration, slope and range were 
significantly worse in MHD when compared with HC 
Sit to stand duration and slope were significantly worse in PHD 
when compared with HC 
Rao et al, 2009a [93] MHD=30 MHD=53.2 (11.2) Timed Up and Go test (TUG) 
TUG scores were significantly worse in stage II compared to stage 
I and further worse in stage III compared to stage II 
TUG scores correlate with TFC, gait speed, CV step length 
Rao et al, 2009b [94] 
PHD=15 
HC= 15 
PHD=38.9 (10.5) 
HC=39.5 (9.1) 
Timed Up and Go test (TUG) No significant differences between PHD and HC in the TUG 
Busse et al, 2009 [45] MHD=24 MHD=56.6 (11.7) 
Fall history in the previous 12 months  / Timed 
Up and Go test (TUG) 
The TUG scores significantly predicted the risk of fall in HD 
MHD, manifest HD; PHD, pre-manifest HD; HC, healthy controls; PD, Parkinson‟s disease; CV, coefficient of variation; TFC, Total Functional Capacity scale; COG, centre of gravity    
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Table 2.4: Summary of papers included for participation, ICF category: health-related quality of life 
 
 
 
 
 
 
 
 
 
 
Papers related 
to deficits in 
health- 
related 
quality of life 
in HD 
Authors/time Subjects Mean age (SD) Main methods/outcome measures Key findings 
Ho et al, 2009 [117] MHD=70 MHD=50.1 (11.9) 
QoL / SF-36/control data obtained from 
previous publication  
SF-36 scores in MHD decreased comparing to the control data 
SF-36 scores significantly correlated with UHDRS-motor, TFC  and BDI 
scores  
Ready et al, 2008 [118] 
MHD=22 
 
MHD=47.3 (13.2) 
 
QoL / study-specific developed 
questionnaire  
QoL scores significantly correlated with UHDRS-functional and cognitive 
scores 
Ho et al, 2004 [119] 
MHD=79 
CG=79 
MHD=55.2 (11.9) 
CG=54.7 (11.4) 
QoL / SF-36, SIP   
SF-36 and SIP scores is significantly lower in MHD when compared to CG 
SF-36 and SIP sub-scales correlated significantly with UHDRS-motor and 
BDI scores 
Hedler et al, 2001[120] 
MHD=77 
HC=74 
 
MHD=51.4 (11.4) 
HC=52.3 (8.2) 
QoL; SIP 
SIP scores were significantly lower in MHD when compared to HC 
SIP scores significantly correlated with UHDRS-motor scores, disease 
duration and MMS scores   
UHDRS-motor was the only disease specific variable to significantly predict 
SIP score 
MHD, manifest HD; HC, Healthy controls; CG, care-giver;  QoL, Quality of life; SF-36, Short form 36; SIP, Sickness impact profile; UHDRS, Unified Huntington‟s disease rating scale; TFC, Total functional 
capacity scale;  BDI, Beck Depression Inventory scale; MMS, Mini Mental status score 
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Table 2.5: Summary of the critical appraisal of papers related to mobility deficits in HD 
 
 
 
Authors/time 
Focused 
question 
Appropriate 
method 
Acceptability 
of cases 
recruitment 
Acceptability 
of control 
selection 
Appropriate 
outcome 
measures 
Accounting 
for 
confounding 
factors 
Appropriate 
data analysis 
Appropriate 
results 
Can the 
results be 
applied to 
local 
population 
Fitness of 
results with  
other 
available 
evidence 
Rao et al, 2011[39] Yes Yes Yes NA Yes Yes Yes Yes Yes Yes 
Delval et al, 2011[107] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Panzera et al, 2011[114] Yes Yes Yes Yes Yes No Yes Yes NC Yes 
Kloos et al, 2011 [44] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Salomonczyk et al, 2010 [92] Yes Yes Yes Yes Yes No Yes NC NC Yes 
Goldberg et al, 2010 [115] Yes Yes Yes NC Yes Yes Yes Yes Yes Yes 
Khalil et al, 2010 [116] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Tabrizi et al, 2009 [108] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Rao et al, 2009a [93] Yes Yes Yes NA Yes Yes Yes Yes Yes Yes 
Rao et al, 2009b [94] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Busse et al, 2009 [45] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Ho et al, 2009 [117] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Rao et al, 2008 [40] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Delavl et al, 2008 [109] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Busse et al, 2008 [96] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Grimbergen et al, 2008 [38] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Ready et al, 2008 [118] Yes Yes Yes NC Yes Yes Yes Yes Yes Yes 
Delval et al, 2007 [41] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Kosinski et al, 2007 [97] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Bilney et al, 2005 [110] Yes Yes Yes No Yes Yes Yes Yes Yes Yes 
Saft et al, 2005 [98] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Ho et al, 2004 [119] Yes Yes Yes NC Yes Yes Yes Yes Yes Yes 
*Items of critical appraisal are derived from the Critical Appraisal Skills Programme (CASP) appraisal tool [89]; NA, Not applicable; NC, Not clear   
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Table 2.5: (continued) Summary of the critical appraisal of papers related to mobility deficits in HD 
 
 
 
 
 
 
 
Authors/time 
Focused 
question 
Appropriate 
method 
Acceptability 
of cases 
recruitment 
Acceptability 
of control 
selection 
Appropriate 
outcome 
measures 
Accounting for 
confounding 
factors 
Appropriate 
data analysis 
Appropriate 
results 
Can the 
results be 
applied to 
local 
population 
Fitness of results 
with  other 
available 
evidence 
Churchyard et al, 2001 [111] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Hedler et al, 2001 [120] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Hausdorff et al, 1998 [112] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Hausdorff et al, 1997 [113] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Tian et al, 1992 [95] Yes Yes NC NC Yes No No NC NC Yes 
Koller and Trimble 1985 
[32] 
Yes Yes NC NC Yes No Yes Yes NC Yes 
*Items of critical appraisal are derived from the Critical Appraisal Skills Programme (CASP) appraisal tool [89]; NA, Not applicable; NC, Not clear   
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2.3.2.1 Physical impairments in body structure and function  
2.3.2.1.1 Balance  
In people with HD, impairments in balance are well characterized particularly at the 
mid stage of the disease [38, 44, 45, 92-95]. Two studies [92, 95] investigated aspects of 
static balance whilst standing on a stationary platform in people with manifest HD and 
demonstrated increased antero-posterior sway when compared to controls (Table 2.2). 
The postural sway increased when visual feedback was not available [92, 95]. On 
imposing an external perturbation by unexpected movement of the support platform, 
corrective postural responses were of similar magnitude compared to control groups, 
but they were significantly delayed in people with HD [95]. Thus it appears that greater 
postural sway may be related to deficits in using sensory cues rather than being a 
primary postural impairment. 
 
In addition to static balance, aspects of impairments in dynamic balance and internal 
protrusion were documented in people with manifest HD using clinical tools. In one 
study, 2 clinical balance tools (Functional Reach Test (FRT) and the Berg Balance 
Scale (BBS)), were used to assess balance in a sample of 30 subjects with manifest HD 
[93]. The FRT evaluates response to internal perturbation and the BBS includes a 
number of items that test static and dynamic balance as well as response to internal 
perturbations. The study demonstrated significant differences in balance as scored using 
these 2 tests between subjects with manifest HD and healthy controls and between 
subjects with manifest HD at different stages of the disease. The latter finding suggests 
that balance impairments in this population continue to progress with the progression of 
the disease. In fact there are some indications that impairments in both static and 
dynamic balance may start well in the pre-manifest stage, before the onset of clinical 
symptoms, and continue to worsen in the manifest stage in this population. Individuals 
with pre-manifest HD who were close to their predicted age of onset (≤ 5 years) 
demonstrated greater postural sway compared to healthy controls in standing on a 
stationary force platform, when the visual and proprioceptive information was degraded 
and only vestibular information was available [92]. Although this study was limited by 
the small sample size and the failure to report clear information about how the control 
group was recruited and how factors such as age and height were controlled, it was one 
of the first to report on balance impairments in the pre-manifest stage. Findings from 
this study were consistent with data from another study in which participants with pre-
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manifest HD demonstrated  an increased base of support whilst walking (an indication 
of impaired dynamic balance) when compared with healthy controls [40].  
 
The findings from the above 2 mentioned studies about the existence of balance 
impairments in the pre-manifest stage contradicts reports from a single study by Rao et 
al [94], where the authors report no significant differences in balance between 
individuals with pre-manifest HD and healthy controls as measured using the Functional 
Reach Test (FRT) [94]. The small sample size of this study (n=15 pre-manifest HD and 
15 healthy controls) may explain the lack of sensitivity of the FRT test to detect balance 
changes in the individuals with pre-manifest HD. More importantly, there is a 
possibility that the sample in this study was far to the predicted age of onset; an aspect 
that was not clearly reported by the authors. The other possibility is that this test may be 
inappropriate to measure balance in individuals with pre-manifest HD as the other 
studies that demonstrated impaired balance at this stage were based on biomechanical 
quantitative measures that can be sensitive to subtle changes. There is a potential that 
other clinical assessment tools which incorporate more complex patterns of movement 
may be able to capture subtle changes in balance at this very early stage of the disease. 
Therefore validation of such measurement tools in future studies is clearly required.  
 
Assessment of balance in this population may be an important component, as there is a 
growing evidence to suggest that balance impairments may restrict mobility in people 
with HD. Three of the 4 studies that screened falls in HD demonstrated that 
impairments in balance predominantly may place people with HD at increased risk of 
falls. In a study by Grimberg et al [38] that included 45 participants at early to mid stage 
HD, recurrent fallers (participants who had at least 2 falls in the last 12 months) had 
significantly lower performance on the Berg Balance Scale (BBS) when compared with 
non-fallers. Similarly, in a study by Kloos et al [44], recurrent fallers had significantly 
lower balance scores on the Tinetti Mobility Test. Furthermore, in a study by Busse et al 
[45] which was conducted in 24 participants at mid stage HD, balance as measured 
using the BBS was a significant predictor for the risk of falls in this population. Taking 
into account these observations and the fact that the risk of falls is the number one 
predictor for loss of functional independence in HD [43], assessment of balance in 
people with HD is clearly important and needs to be targeted in therapeutic trials in this 
population.     
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2.3.2.1.2 Muscle strength   
Only one study was identified in this review that assessed the muscle strength of the 
lower limbs in people with HD (Table 2.2). In this study, Busse et al [96] measured the 
isometric muscle strength of 6 lower limb muscle groups (hip extension, hip abduction, 
knee flexion, knee extension, ankle plantarflexion, ankle dorsiflexion) using a hand held 
dynamometer in 20 subjects with manifest HD and 20 healthy age-matched controls. A 
maximal muscle strength index was calculated in which contribution from all muscle 
groups was combined into a single index. People with HD were significantly weaker 
relative to an age matched healthy control group. This was reflected both in the 
individual muscle groups as well as by the maximal strength index. Although this study 
is limited by the use of the hand held dynamometer which is known to have greater 
error in assessing muscle strength in neurological populations [121, 122], it is the first 
one to report muscle strength reduction of the lower limbs in people with HD. It should 
be noted however, that the muscle strength reduction in people with HD has also been 
implied in other studies that focused on evaluating muscle strength of the upper limbs 
[123, 124]. This lends support to the existence of muscle strength reduction in this 
population. For example, grip force reduction and the increase of its variability was 
reported in people with early to mid stage HD [123]. Furthermore, the effects of 
creatine supplementation in people with HD were studied over a period of 1 year [124]. 
In this study, a 5 - 10% reduction in muscle strength of elbow flexors over time was 
recorded in people with HD.  
 
The assessment of muscle strength of the lower limbs in HD may be important as it is 
known that muscle strength reduction in other populations is inter-linked with a decline 
in functional performance [125]. In fact, the study by Busse et al [96] reported 
significant correlations between functional and motor scores (TFC, the UHDRS-motor, 
functional assessment and independence scales) (r>0. 45, p<0.05) and strength indices, 
suggesting that muscle weakness may contribute to functional decline in people with 
HD. Further in-depth analysis is still required to interpret the influence of the muscle 
strength reductions on functional performance of mobility activities of daily living in 
people with HD. However, it should be noted that some insights can be drawn from 
available literature on other neurodegenerative disease such as PD. In people with PD, 
reduction of muscle strength of the lower limbs correlates well with reduced ability to 
perform mobility activities such as navigating stairs, rising from a chair and walking 
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[125, 126]. In the realm of walking, strength of the ankle, knee and trunk was found to 
be positively correlated with gait speed in individuals with PD, and knee strength 
explained about 15% of the variance in the gait speed while individuals with PD were 
on medication [126]. These relations between muscle strength and the functional 
performance of mobility activities, such as walking in people with PD, are important 
and provide insights into exercise interventions. Exercise interventions that aim to 
improve muscle strength may also have a positive impact on mobility activities such as 
walking.   
 
The origin of muscle strength reduction in the HD population is unknown; however it 
can be as a result of multiple components. For example, the alteration of muscle tone 
seen in HD secondary to dystonia [35] may impair the ability to produce a maximum 
voluntary muscle contraction effectively, leading to a reduction in the muscle strength. 
Furthermore, biological changes in skeletal muscle tissue such as mitochondrial 
dysfunction and morphological changes of neuromuscular junctions which have been 
observed in individuals with HD [97, 98] may potentially impact on muscle strength in 
this population. Deficits in mitochondrial function have even been identified in 
individuals with pre- manifest HD [97], which suggests that skeletal muscle changes 
may start to develop years before the onset of clinical diagnosis, although this has not 
been empirically studied.  
    
In addition to the above mentioned factors, loss of muscle strength in HD can be 
secondary to physical inactivity. Although an in-depth activity monitoring has not been 
carried out yet in people with HD, there are some reports to suggest that people in this 
population tend to be physically less active with the progression of the disease [127]. 
This is in agreement with the evidence available from other neurological diseases of a 
relationship between decreased physical activity and worsening of the voluntary motor 
symptoms [128, 129]. Physical inactivity induces further plastic changes to the 
muscular tissues such as fibre-type transformations and protein loss [130]. In such 
cases, the reduction of muscle strength would be generalised to all the inactive muscle 
groups. The findings reported by Busse et al [96] of a non-specific pattern of muscle 
strength reduction (muscle weakness was not restricted to a particular muscle group of 
the lower limbs) lends the support of physical inactivity as one contributing factor of 
muscle weakness in this population. Taking into account that muscle weakness in HD 
                                                                                                                          2. Literature review 
 
39 
 
may be secondary to physical inactivity along with the other factors provides further 
support for the need to consider exercise interventions in this population. Muscle 
strength reductions as a result of physical inactivity have the potential to be ameliorated 
by exercise interventions [125]. Improvements of muscle strength in other 
neurodegenerative disease and in the elderly with sedentary life styles, as a result of 
exercise interventions are well documented [125].   
 
In conclusion, reduction in muscle strength, although it is an under reported clinical 
feature across the spectrum of the disease in HD, may be an important component. The 
suggestion that impairments in muscle strength can contribute to mobility deficits in this 
population and that these impairments can be amenable to exercise interventions, 
emphasizes the need for assessing muscle strength in future exercise trials in HD.  
   
2.3.2.2 Activity 
2.3.2.2.1 Walking  
Walking represents a common and an integral activity of daily life. It serves as an 
individual‟s basic need to move from one place to another. In people with HD, deficits 
in walking are the most prominent of mobility limitations. Accurate data regarding 
limitations in walking are important, because loss of independence in ambulation is the 
greatest predictor of nursing home placement in this population [43]. In particular, 
knowledge about specific deficits in gait in this population may be crucial as gait 
deficits such as decreased walking speed and increased stride to stride variability were 
associated with a higher risk of falls in people with HD [38, 44, 45]. 
 
Thirteen studies have examined the characteristics of gait in this population [32, 38, 40, 
41, 45, 106-113]. The vast majority of these studies have focused on the spatiotemporal 
aspects (time and distance) of the foot pattern. Most of these studies have been carried 
out in gait laboratories or hospital ward settings. Most studies have demonstrated that 
bradykinesia, hypometria, akinesia, and greater variability of movement are the main 
features of gait in HD (Table 2.3). In terms of temporal measures, a number of studies 
have shown that people with manifest HD walk more slowly than usual, typically in the 
range 0.76-1.09 m/s, rather than 1.02-1.4 m/s which is typical for age-matched 
controlled subjects [32, 40, 41, 110-112]. These studies also demonstrated that people 
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with HD had lower cadence, stride time, and higher double support time than control 
subjects. With respect to spatial measures of gait, subjects with HD showed shorter 
stride length at fast, slow and preferred walking speeds compared to control subjects. 
The stride length at the preferred walking speed in manifest HD ranged from 0.74-1.2 m 
rather than 1.3-1.5 m as would be expected from age matched controls in these studies. 
Reduced step length, step time and gait speed in manifest HD tend to become more 
accentuated while performing a secondary cognitive or motor task such as counting 
backwards [109, 111] or carrying a tray [109], suggesting that the automaticity of 
executing motor tasks in HD is primarily impaired. Thus performing dual motor or 
cognitive tasks may place greater attentional demands on people with manifest HD than 
they do in healthy controls. Other abnormalities of walking in HD have been observed 
during gait initiation, in which people with HD demonstrated lower first step speed and 
length compared to controls [41] suggesting that akinesia is an important component of  
locomotion disorders in HD. 
   
One of the prominent features of gait deficits in this population that has been reported in 
a number of studies and has been demonstrated even at a very early stage of the disease 
is increasing variability of gait. Individuals with manifest HD have been found to have 
greater variability in gait speed from trial to trial [111]. Greater variability in HD has 
also been noted in stride time, stride length, swing time and double support time 
compared to controls [40, 110-112]. Quantitative evaluation indicates that variability in 
stride intervals in manifest HD tends to be more random when compared to age 
matched healthy controls [113]. This means that the correlation of one stride with 
nearby strides is reduced; suggesting that individuals with HD may have difficulty in 
using sensory feedback to alter their walking in an ongoing manner, which may 
influence the quality and adaptability of their walking. 
 
Gait deficits present throughout the course of the disease and there is a growing 
evidence to suggest that these deficits may start from the pre-manifest stage [40, 107, 
108]. People with pre-manifest HD have been found to have decreased gait speed and 
stride length, increased step time, double support time and percentage of time in stance 
[40] and increased stride length [40, 107, 108] and step time variability [40, 107] when 
walking along a computerized walkway that recorded the spatiotemporal parameters of 
gait and their variability. Furthermore,  individuals with pre-manifest HD have been 
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found to have deficits in gait initiation under self triggered and externally triggered 
conditions in which the first step speed, duration and length was reduced and variability 
of stride length and time increased compared to gene negative, age matched controls, as 
measured using a video motion system connected to two force platforms [107]. 
Longitudinal analysis demonstrated that these deficits in gait worsen over time in the 
pre-manifest stage. A study that examined gait in ten subjects with pre-manifest HD 
over a period of five years demonstrated significant decrease in gait speed and increase 
in gait variability as measured using the stride length and swing time coefficient of 
variations [39].   
 
The origin of increased gait deficits in HD is still not clearly understood. In people with 
neurodegenerative disease such as HD, deficits in the central nervous system‟s ability to 
regulate motor output could be a contributing factor, but many physical associated 
changes that have been reported in HD can also contribute to this process, including 
muscle weakness and impaired balance. As mentioned earlier, gait deficits are likely to 
place people with HD at increased risk of falls [38]. These deficits may also contribute 
to self-imposed mobility restrictions and detract from quality of life [104]. It is not 
surprising that many people with HD may report that physical activities in general and 
levels of mobility in the community in particular are significantly affected, although 
monitoring of mobility activities has not yet been empirically studied in this population. 
It can be suggested that because of the walking difficulties observed in this population, 
people with HD find it difficult maintaining their balance over uneven surfaces and 
successfully monitoring changes in the surrounding environment, which may affect 
their levels of mobility in the community. Overall, it must be noted that gait deficits 
may be an important component of activity limitations in HD and  as such may be 
amenable to exercise interventions [104] and therefore they need to be considered in 
future trials.  
 
2.3.2.2.2 Other mobility activities 
In addition to walking; sit to stand, turning and stepping are other activities that are 
limited in people with HD [114, 116]. In general, these activities are essential to change 
body position, negotiate obstacles and monitor changes in the surrounding environment. 
In particular in the realm of sit to stand, rising from a seated to a standing position is 
one of the most common activities of daily living, it is a prerequisite for walking, and is 
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particularly important to maintain physical independence [131], which makes this an 
important activity to be evaluated in people with mobility deficits such as people with 
HD. 
 
Six studies were identified in this review that examined aspects related to these mobility 
activities (sit to stand, turning and stepping) in people with HD [45, 93, 94, 114-116] 
(Table 2.3). In one study, deficits, particularly in stepping in manifest HD, were 
examined [115]. The study demonstrated that people with HD had a significantly and 
markedly reduced stepping response time when compared to healthy controls. In a more 
recent study [114], the performance of 3 mobility activities (step up and over an 
obstacle, sit to stand transition and step up and turn) in individuals with manifest HD 
was examined using kinetic and kinematic data. The study demonstrated that the HD 
group were significantly slower when moving from a seated to standing position, when 
stepping and turning and when stepping onto and over an obstacle, confirming clinical 
observations that bradykinesia is a marker of HD when completing mobility activities. 
In addition, the HD group in this study developed less rising force during the sit to stand 
test and experienced greater velocity in centre of gravity (COG) sway during the sit to 
stand as well as step and turn tests. This gives further insights into how postural deficits 
in this population may affect the performance of functional activities. The production of 
less rising force during the sit to stand test, which indicates that the performance of such 
activity is challenging for individuals with HD, is consistent with the previous reports of 
reduced muscle strength of the lower limbs of individuals with HD [96]. Furthermore, 
the greater COG sway velocity indicates that control of posture, which may be related to 
the balance impairments seen in this population, significantly challenged the 
performance of such activities, even though the individuals with HD tend to move with 
slower movement time than the controls.  
  
The combination of sit to stand and turning was further assessed in another study [94] 
using a clinical assessment tool (the Timed UP and Go (TUG) test). The performance of 
the TUG test times a task that requires walking, turning and transfer from sit to stand. 
The study demonstrated that people with HD were slower in completing this test when 
compared with healthy controls. In a study by Busse et al [45] which was conducted in  
participants at mid stage HD, mobility status as measured using the TUG was a 
significant predictor for the risk of falls in this population. In a follow-up study [116], 
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the performance of the TUG test was assessed along the spectrum of the disease using a 
kinetic sensor. The total TUG duration as well as slopes, range and durations of sit to 
stand transitions were extracted from the sensor. Results obtained from this study 
demonstrated that the sensor derived measures detected decreased TUG duration, 
decreased slopes, range and duration of sit to stand transitions of the test in the 
individuals with manifest HD when compared with healthy controls. More importantly, 
findings from this study demonstrated that the sensor derived measures detected 
decreased slopes and durations of the sit to stand transitions of the test in individuals 
with pre-manifest HD when compared to healthy controls. The findings from this study 
are important and suggest that subtle changes in the performance of such mobility 
activities may start to develop from the pre-manifest stage.  
    
Although data of sit to stand, turning and stepping activities are limited in the HD 
literature, particularly along the broad spectrum of the disease, assessing HD in the 
context of these tasks is important. The inability to successfully complete these “every 
day” activities can negatively impact life style and affect health-related quality of life 
[132]. As exercise interventions that target impairments such as muscle strength and 
balance have the potential to simultaneously improve performance in such activities 
[125, 132], assessing these activities in  future exercise interventions in HD is required.       
 
2.3.2.3 Participation  
As indicated earlier, participation may be best presented by health-related quality of 
life. In medical care, health-related quality of life has become firmly established as an 
important endpoint [133]. This is especially true of chronic disease for which a cure is 
unlikely [134] and HD is a classical example of such a long-term condition. Therefore, 
the evaluation of health- related quality of life in this population is important.  
 
Four studies were identified in this review that evaluated health-related quality of life in 
people with HD [117-120] (Table 2.4). In all of these studies, findings suggest that HD 
has an effect on individuals‟ health-related quality of life. Using generic health-related 
quality of life measures such as the Short Form- 36 (SF-36) and the Sickness Impact 
profile (SIP), individuals with mild to moderate HD reported a lower quality of life than 
population norms. 
                                                                                                                          2. Literature review 
 
44 
 
In individuals with HD, factors such as the depressive mood, cognitive and motor 
impairments, as well as functional dependence, may contribute to a reduced quality of 
life [117-120]. Of these factors, motor impairments and functional independence appear 
to have the most detrimental effect on health-related quality of life in this population. In 
3 studies motor impairments, as measured using the UHDRS-motor scale, were found to 
significantly correlate with the measures of health-related quality of life [117, 119, 120]. 
In one of these studies which examined the effects of cognitive and motor impairments 
as well as disease duration on health-related quality of life, motor impairments were the 
only disease-specific factor which significantly predicted health-related quality of life 
[120]. In 2 other studies, functional abilities as measured by the Unified Huntington‟s 
Disease Rating Scale (UHDRS)-functional score [118] and the Total Functional 
Capacity (TFC) scale [117] were also found to significantly correlate with measures of 
health-related quality of life. These data are consistent with findings that motor 
impairments and a decline in functional performance tend to be robust predictors of 
quality of life in other populations with mobility disorders [135]. In HD, motor 
impairments are common and very obvious. As described earlier, these impairments 
may contribute to the mobility deficits seen in this population such as difficulties in 
walking. The suggestion that motor impairments and decline in functional performance 
are related to quality of life in this population is important and has clear implications for 
clinical trials of exercise interventions. Exercise interventions that target motor 
impairments and functional limitations in people with HD show promise in 
simultaneously improving health-related quality of life [136]. For these reasons, 
assessing health-related quality of life in clinical trials of exercise interventions is 
clearly required.      
  
2.3.3 Summary of literature review of mobility-related deficits in HD and the 
need to validate outcome measures in line with ICF model 
In developing appropriate trials of exercise interventions to improve mobility in HD, it 
is important to consider ways in which clinical improvements can be measured. The 
UHDRS is a disease specific scale that is routinely used to quantify the severity of the 
disease in HD. Although the scale is highly reliable in people with HD, it may not be 
specific to measure changes in the functional abilities as a result of exercise 
interventions in this population.  For example, such a scale may lack the sensitivity to 
identify clinically related changes at the early stages of the disease due to ceiling 
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effects. In a multisite, observational study of 786 research participants at the pre-
manifest and early stages of HD, over 88% of the participants were scored at ceiling as 
having the maximum score on both the Total Functional Capacity (TFC) scale and the 
Functional Assessment Scale (FAS) [137]. Similarly in two studies, 95% to 100% of the 
individuals at pre-manifest stage scored at the ceiling on gait, tandem walk and 
retropulsion items of the motor section of the UHDRS. The fact that the UHDRS is an 
ordinal type of measure may have influenced its sensitivity to detect early changes in 
this population. Ratio or interval measures based on timing certain tasks instead, as 
suggested based on observations from other neurological populations, can to be more 
sensitive to a wide spectrum of severity of impairments and functional losses [138]. 
Such measures need to be considered when evaluating mobility deficits in people with 
HD and in response to exercise interventions.  
 
Taking into account the wide range of physical impairments, activity limitations and 
participation restrictions seen in this population (Figure 2.1), the choice of outcomes to 
evaluate mobility deficits in HD may be best considered in the light of the ICF model. 
As depicted in Figure 2.1, at the impairments level, physical factors that are believed to 
be impaired in this population and are potentially modifiable by exercise interventions 
need to be considered. This includes balance and muscle strength. At the participation 
level, aspects that are believed to be restricted by mobility deficits such as health-related 
quality of life which can be positively influenced by exercise interventions need to be 
taken into account. At the activity levels, although tasks such as sit to stand and 
stepping and turning need to be considered, activity limitations may be best presented 
by walking difficulties in this population. In particular, deficits in gait parameters need 
to be taken into account. As described earlier, deficits in gait are well characterized in 
HD. Increased gait variability  in particular is known to exist early in the life cycle of 
HD and progress over time [39, 40, 107, 108]. Furthermore, increased gait variability 
relates to functional status in this population [38], and the amelioration of this 
component of gait has the potential to translate into functional improvement [104]. This 
makes gait variability one potential primary outcome measure in exercise interventions 
in this population.  
 
In the realm of walking, it must be noted that the ICF framework results in an increased 
emphasis on the need to consider both the performance and capacity measures of an 
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activity in assessing people with mobility deficits [91] as is the case in people with HD. 
Capacity can be defined as the highest probable level of functioning that a person may 
reach in a given domain at a given moment, whilst performance represents what an 
individual does in his/her environment. Gait parameters such as gait variability that can 
be derived from directly observed tests administered in standardized laboratory settings 
are thus more likely to evaluate capacity of walking. The assessment of an individual‟s 
walking performance (what they actually do) may include measures of the number of 
paces over a representative time period in the community. These measures that provide 
indications of individuals‟ performance need to be taken into account along with those 
measures that provide indications of capacity in assessing walking of people with HD in 
therapeutic trials. 
 
In clinical trials, the used outcome measures need to be valid and reliable. As described 
earlier, measures of gait have been extensively validated using quantitative laboratory 
assessment tools in this population. However, to date only a few studies have examined 
the validity of a range of measures of balance [38, 45, 94], muscle strength [96], health-
related quality of life [117, 119, 120] and measures of other mobility activities [45, 93] 
with no validation for any measures of levels of mobility carried out in the community. 
There is clearly a need to further validate clinical measures of the range of physical 
impairments, activity limitations and participation restrictions which are related to 
mobility deficits seen in this population. The validation of these outcomes may be best 
considered in the context of the proposed model of the ICF of the mobility deficits in 
HD (Figure 2.1). As indicated earlier, gait variability at the activity level is a primary 
component of gait deficits in HD that can be linked with measures at the impairments 
level (muscle strength and balance) and it may have an impact on measures at the same 
level (functional performance of ADL and community mobility) as well as measures at 
the participation level (health-related quality of life). Validation of mobility outcomes in 
HD, therefore, may require primarily exploring these inter-relations between measures 
of balance, muscle strength, health-related quality of life as well as levels of mobility 
carried out in the community with the primary component of gait deficits (gait 
variability).  
 
As noted before, valid outcome measures in neurological diseases need to be sensitive 
to the spectrum of impairments and functional losses seen in a population [138]. In 
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people with HD, there is clearly a need for outcome measures that are sensitive to the 
very early changes seen in the pre-manifest stage. The ultimate goal of therapeutic trials 
in HD is to develop treatments that prevent, slow down or modify the disease process 
[139] which are targeted to be applied at the pre-manifest stage, before the onset of 
rapid neuronal degeneration and the emergence of clinical symptoms. Thus clinical 
tools that are sensitive to change in pre-manifest HD are needed for such trials. To date, 
and apart from the gait measures, there are very limited data on validation measures of 
balance, muscle strength, other tasks of mobility and community walking as well as 
health-related quality of life in individuals with pre-manifest stage. Only 2 studies 
investigated the sensitivity of balance outcomes in pre-manifest HD [92, 94], 1 study 
investigated the sensitivity of measures of the sit to stand activities [116], with no report 
of evaluation of clinical measures of muscle strength, community mobility and health-
related quality of life. As future interventions may be best applied in the pre-manifest 
stage, there is clearly a need for further evaluations of outcome measures that are 
sensitive to early changes in the pre-manifest stage.     
     
In addition to the need for further validation of outcomes along the spectrum of the 
disease, the reliability of mobility outcomes in HD has yet to be established. The 
mobility outcome measures cited above in this review have been shown to have utility 
in people with HD. However, to date and apart from gait measures evaluated using an 
automated walkway [140], there has been no evaluation of the reliability of any of these 
outcomes in people with HD. Choosing appropriate outcome measures that are reliable 
is crucial in clinical trials. Documentation of any change of mobility as a result of an 
intervention should incorporate knowledge of reliability of the included measures and 
take associated variability into account [141]. Any measured difference may include 
some variability that could be due to the normal biological variability of the participants 
or to error in the measurement system or both. Therefore, knowledge of the reliability 
and associated variability of the used measures is important to be able to judge whether 
true change exists as a result of an intervention. This knowledge is also important to 
optimize our choices of outcomes that can be used to measure change in clinical trials. 
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2.4 Exercise interventions directed towards improving mobility in people with 
HD  
2.4.1 General overview  
As discussed in the previous section, gait deficits are an important component of HD 
symptomology, which may decrease independence in activities of daily living. Exercise 
may potentially play a role in reducing gait deficits and therefore in enhancing walking 
ability and functional status in HD. Despite this potential, the evidence base in support 
of exercise interventions in HD is still lacking. To date, only 10 papers [2, 76-79, 142-
147] that have addressed the role of exercise interventions for people with HD have 
been identified. The vast majority of these papers were either an observational or non 
experimental design. None of these papers was of sufficient methodological quality 
(according to the CASP critical appraisal tool). The presentation and evaluation of the 
available evidence on exercise studies directed toward improving mobility for people 
with HD is provided in the later sections of this chapter. Summaries of these studies are 
provided in Table 2.6 and a summary of their critical appraisal is provided in Table 2.7 
below. Full review of these papers is provided in the later sections.  
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Table 2.6: Summary of studies related to exercise interventions directed towards improved mobility in HD 
 
Authors/ 
time 
Study 
design 
Exp/control 
(n) 
Stage of 
HD Mean age (SD) 
Type of intervention for Exp  
(setting; wks/freq/min or hr) 
Type of 
intervention for 
control 
(wks/freq/min) 
Measures/Results 
Kegelmeyer et al, 
2010 [abstract] 
[77] 
Randomised 
controlled 
trial 
Exp= 12 
Control= 8 
Not 
reported 
NR 
Video game (Dance Dance 
Revolution) (home; 6/2/45 min) 
A handheld video 
game (home; 
6/2/45 min) 
Balance; Tinetti Mobility Test-balance section, Four Square 
Step test a 
Ekwall et al, 2010 
[abstract] [76] 
Individual- 
case control 
study  
Exp= 12 
Early to 
mid 
stage 
NR 
Transitions and balance training 
(clinic; 6/2/1 hr) 
NA 
Disease specific motor score; UHDRS-motor 
Balance; the Berg Balance Scale a, a one leg stance test, a figure 
of eight test 
Mobility; the Timed Up and Go test and the falls efficacy scale 
Zinzi, 2009 [79] 
Postal 
survey   
Exp= 40 
Early to 
mid 
stage 
Exp= 49.4 
(11.0) 
Patient‟s and caregiver‟s perceptions 
of an intensive rehabilitation 
programme on survey 
NA 
Perceived improvements in mobility status by all of the 
respondents after discharge 
 
Zinzi, 2007 [78] 
Individual- 
case control 
study  
Exp=40 
Early to 
mid 
stage 
Exp=52.0 (3.3) 
Combination of occupational therapy, 
speech therapy and physiotherapy 
exercises (inpatient; 3/6/8 hr) 
NA 
Mobility and functional status; Tinetti Mobility Test-gait score 
a, Physical Performance Test a   
Quinn et al, 2002 [2]  
Single case 
study 
Exp=1 
Mid 
stage 
Exp= 49 
Exercise video; balance and muscle 
strength (home; 14/5/35 min) 
NA 
Disease specific motor score; UHDRS-motor b 
Balance; the Berg Balance Scale b 
Mobility; gait speed b and falls efficacy scale b 
Quality of life; SF-36 b 
Imbriglio and 
Peacock, 1992 [143] 
Expert 
opinion  
NA NA NA NA NA 
Exercise interventions are essential to maintain independence 
and quality of life 
Sheaf, 1990 [146] 
Single case 
study 
Exp=1 
Late 
stage 
NR Hydrotherapy (NR) NA 
No objective outcome measures were reported. Chorea 
subjectively noted to be reduced 
Peacock, 1987 [145] Case series Exp=10 NR NR 
Balance and muscle strength exercises 
(clinic & home; 12/1/45 min) 
NA No objective outcome measures were reported  
Lavers, 1981 [144] Case series  Exp=6 NR NR 
Balance and muscle strength exercises 
(inpatient; 8/1/NR) 
NA No objective outcome measures were reported 
Binswanger, 1980 
[142] 
Case series  Exp=5  NR NR Content is not defined (home; 4/2/1hr) NA No objective outcome measures were reported 
Wks, weeks; freq, frequency; Exp, experimental group; NR, Not Reported; NA, Not Applicable; a statistically significant differences; b improvements in descriptive statistics when statistical analysis is not applicable  
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Table 2.7: Summary of the critical appraisal of papers related to exercise interventions directed toward improve mobility in HD 
 
Authors/ 
date 
Study 
design 
Level of 
evidence 
Focused 
question 
Population 
defined 
Inclusion 
criteria 
defined 
Sample size 
calculation 
Allocation 
defined 
Intervention 
reproducible 
Outcome 
measure 
defined 
Assessor 
blinded 
Data 
analysis 
defined 
Inferential 
analysis 
employed 
Generalisability 
Kegelmeyer et al, 
2010 [abstract] 
[77] 
Randomised 
controlled 
trial  
Level 2 Yes  Yes NR  NR  NR No Yes NR Yes Yes No 
Ekwall et al, 2010 
[abstract] 
[76] 
Individual- 
case control 
study 
Level 4 Yes Yes NR  NR  NA No Yes NR Yes Yes No 
Zinzi, 2009 [79] Postal survey   Level 4 Yes Yes Yes NA NA NA NA NA Yes NA No 
Zinzi, 2007 [78] 
Individual- 
case control 
study 
Level 4 Yes Yes Yes No NA No Yes NA Yes Yes No 
Quinn et al, 2002 
[2] 
Single case 
study 
Level 5 Yes Yes NA NA NA Yes Yes NA Yes No No 
Imbriglio and 
Peacock, 1992 
[143] 
Expert 
opinion  
Level 5 NA NA NA NA NA NA NA NA NA NA No 
Sheaf, 1990 [146]  
Single case 
study 
Level 5 No No NA NA NA No No NA No No No 
Peacock, 1987 
[145] 
Case series Level 5 No No No No NA No No NA No No No 
Lavers, 1981[144] Case series  Level 5 No No No No NA No No NA No No No 
Binswanger, 1980 
[142] 
Case series  Level 5 No No No No NA No No NA No No No 
NR, Not Reported; NA: Not Applied; * items of critical appraisal are derived from  the Critical Appraisal Skills Programme (CASP) appraisal tool [148].  
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2.4.2 Review of available exercise studies directed towards improving mobility in 
people with HD 
Binswanger [142] evaluated the benefits of an individualized home-based exercise 
programme in 5 people with HD. The author indicated that people were included if they 
had a good mental status and were motivated to perform the exercise programme, 
although it was not clear how this was determined. Demographic data of participants 
such as their age, gender and data about cognitive scores, functional ability, disease 
severity and medication status were not provided. The exercise programme consisted of 
one hour of exercises performed twice a week for 4 weeks in the home, with the help of 
a physiotherapist. The components of the exercise programme were not specified but 
thought to include a combination of stretching, strengthening exercises and gait training. 
Outcome measures that were used to evaluate benefits were not clearly defined; the 
author stated “standard physiotherapy tests of physical and functional capacity were 
used”. Participant‟s alertness and ability/ willingness to participate in activities were 
subjectively observed. The author noted an improvement in alertness and balance that 
appeared to result in safer ambulation. The methodological quality of this study was 
low, especially considering the failure to report the use of objective outcome measures. 
The intervention, although directed towards specific areas of deficits such as balance 
and muscle weakness, was not described sufficiently to allow replication. There was no 
follow up period to assess carry over effect, which makes it difficult to draw any 
conclusion regarding the potential long term effect of the utilized exercise programme 
in this study.   
 
In a similar study, the effects of a group therapy exercise programme for 6 participants 
in a long term care psychiatric ward was described by Lavers [144]. The exercise 
programme was conducted weekly over a 12 month period and included balance, 
strengthening and coordination exercises. The exercises took the form of mat and chair 
exercises. Mat exercises focused on performing bridging, kneeling, crawling, long 
sitting and standing which are all important exercises to enhance balance and muscle 
strength. Chair exercises focused on training with weighted cuffs for upper limb 
strengthening. Despite the author stating that the aims of the exercise programme were 
to maintain mobility, balance, increase social interactions and decrease passive 
behaviours, no objective outcome measures were reported which limits the ability to 
draw firm conclusions about the effectiveness of the exercise programme in this study. 
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In another case series study, Peacock [145] evaluated the effects of an outpatient 
exercise programme for 10 participants at an early stage of HD. A 5-level disease 
severity rating scale, which was not clearly defined, was used to screen for people who 
were not severely affected by HD. Details of the study participants were not provided. 
The exercise programme included participation in a 12- week exercise class, in which 
participants met once a week. Subjects attended 3 additional booster sessions held 
monthly. The programme included 45 minutes of exercises that focused on improving 
overall flexibility as warm up exercises which were followed by a set of balance and 
muscle strengthening exercises. As indicated by the author, although exercises were 
delivered in a group setting, they were individualized for each subject. Subjects were 
given a list of exercises and were encouraged to continue their exercises at home 
independently or with the support of a family member. The benefits of the exercise 
programme were evaluated using outcome measures which were not clearly defined and 
included tests of flexibility, standing balance and balance in kneeling. The author 
reported that all participants on the completion of the 6 month exercise programme 
showed improvement on the tests of flexibility. Furthermore, most of the participants 
also improved on the tests of standing balance and muscle strength. Data to support 
these claims were not provided. Although this study indicated that exercise 
interventions may be beneficial for people at early stage HD with minimal impairments, 
the study was limited by low methodological quality for a number of reasons. The data 
of pre-and post intervention were not provided and no inferential statistical analyses 
were conducted. The details of exercises completed during the group session and at 
home were not sufficiently reported to enable replication; the content of the exercises, 
frequency, intensity and duration was not reported. Adherence to any home-based 
exercises was not monitored thus limiting conclusions about the frequency of exercise 
needed to attain therapeutic effects. 
 
Similarly, the potential benefit from hydrotherapy in minimizing the effects of the 
impairments and improving function for a patient in the late stage of HD has been 
reported in a single case study by Sheaff [146]. The included subject, as described by 
the author, who had very prominent chorea and experienced difficulties in walking. No 
other details about this subject were provided. The exercise programme was composed 
of gentle exercises conducted in water once a week. The duration of the programme was 
not stated. Outcomes of the exercise programme were not objectively quantified; 
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however, effects on chorea and ability to exercise in water were subjectively described. 
Adherence to the exercise programme in addition to the subject‟s view on the 
intervention was reported. The author indicated that the subject demonstrated good 
adherence to the exercise programme as only one session was missed due to illness and 
that the subject appeared to enjoy the sessions. Although benefits of the exercise 
programme were subjectively reported by the author, the failure to use any objective 
outcome measures precludes conclusions being drawn regarding the usefulness of the 
exercise programme utilized in this study.  
  
The potential benefits of a physiotherapy programme which included components of 
exercise interventions for people with HD at the mid stage was addressed in a paper by 
Imbriglio and Peacock [143] based on their extensive experience with people with HD. 
The authors suggested that the main aim of evaluation and intervention at the mid stage 
is to achieve the maximum independence with minimal risk. The importance of routine 
exercises that included flexibility, strengthening, balance and endurance training was 
addressed by the authors. However, the details of the specific content and aspects on 
how to deliver such training as well as the use of objective measurement tools to 
evaluate the effectiveness were not provided.  
 
A major shortcoming in all the studies described above is the lack of use of recognised 
outcome measures for the assessment of benefits of interventions. In contrast to the 
above studies, a few more recent publications considered the use of standardized 
measurement tools to evaluate the benefits of the proposed interventions, thus giving 
more support to the potential role of physiotherapy exercise programmes in the 
management of people with HD. In a single case study presented by Quinn and Rao [2], 
a 14 week home exercise programme was provided for a patient with mid stage HD. 
The basis of the intervention in this study was an exercise video that was designed to 
address elements of flexibility and balance aiming to decrease disease specific 
impairments and improve the patient‟s functional abilities and quality of life. A detailed 
description of the exercises included in the exercise video was provided by the authors. 
Outcome measures included the short form 36 (SF-36), Berg Balance Scale, number of 
falls, the Modified Efficacy Falls scale, gait speed and Unified Huntington Disease 
Rating Scale (UHDRS). Improvements as a result of the intervention after the 14 weeks 
were reported in all of the outcome measures that were used in this study. Although the 
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results from this study could not be generalized, this case study was the first to report 
improvement in the routinely used outcome measures as a result of a home exercise 
programme for a person with HD. Improvement in balance, walking speed, reduction in 
the number of falls and improvement in the overall quality of life upon completion of 
the programme were reported. The results from this case study are important as this 
study was the first to report improvements as a result of an exercise intervention in 
people with HD based on the use of objective measures.   
 
Recently 2 studies using within subject design provided results that gave further insight 
into how exercise interventions may benefit mobility in people with HD. Zinzi et al [78]  
investigated the benefits with respect to participation of people with early to mid stage 
HD in an inpatient rehabilitation programme. Forty participants with a confirmed 
diagnosis of HD were recruited to this study. The rehabilitation programme consisted of 
respiratory exercises, speech therapy, occupational therapy and a physical therapy 
exercise programme; however details of the specific content of each component of the 
rehabilitation programme was not provided. Participants were admitted for 3 week-long 
periods of intensive treatment that were repeated 3 times a year for 2 years. Data from 
the first year indicated that only 20 patients completed the 3 admissions in that year. 
Data from the second year showed that only 11 patients of the initial 40 who were 
involved in the baseline measurements completed all 6 admissions over two years. A 
standard clinical assessment was performed at the beginning and end of each admission 
using the Physical Performance Test (PPT). The PPT test is a 9 item measure of motor 
function and balance. The findings revealed that each 3-week period of treatment 
resulted in highly significant (P<0.001) improvements of motor performance. No carry 
over effects were recorded from 1 admission to the following on the PPT, however, no 
motor decline was detected over 2 years (n=11). This suggests that a multidisciplinary 
rehabilitation programme including physiotherapy positively influences the motor and 
functional performance of subjects affected with HD and results in an overall stable 
condition for at least 2 years. The lack of a control group and the high drop-out rate in 
this study, however, limits the drawing of definite conclusions from the obtained results. 
Subjects who had completed at least 1 course of the inpatient rehabilitation protocol in 
this study completed a questionnaire in a follow up study [79] that aimed to evaluate 
their perspectives on their involvement in the rehabilitation programme. All the 
respondents (n=37/40) perceived improvements after discharge. Improvements were 
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reported on gait, balance and fall reduction. The duration of benefit was estimated to 
last between 1 and 3 months by 71% of the respondents. The majority of the 
respondents (n=30/37, 81%) reported their intention to continue with the rehabilitation 
programme in the future; confirming the acceptability of the programme to subjects 
with HD and their carers. 
 
In another study, Ekwall et al [76]  evaluated the benefits of an outpatient physiotherapy 
exercise programme in 12 subjects with early to mid stage HD. The exercise 
programme focused on training of transitions and balance and was conducted twice 
weekly for a period of 6 weeks. Benefits resulting from the intervention were evaluated 
using a battery of outcome measures that included the UHDRS motor score assessment, 
the Berg Balance Scale, the Timed Up and Go test, a 1 leg stance test, a figure of 8 test 
and the falls efficacy scale. Significant improvement was observed in balance only, as 
measured by the Berg Balance Scale. The study was limited mainly by the small sample 
size and the lack of a control group.       
 
An observed improvement in balance on completion of an exercise programme was also 
reported by Kegelmeyer et al [77] in the first controlled trial of an exercise programme 
to date. In this study the efficacy of an exercise programme using a video game to 
improve dynamic balance and mobility in individuals with HD was examined in which 
20 subjects with early to mid stage HD were randomly allocated to either the 
experimental group (n=12) or the intervention group (n=8). As the reported study is 
currently in abstract format only, methods of recruitment, randomisation and data about 
characteristics of participants on each arm of the study are not available and therefore a 
full appraisal of evidence obtained from this study is not possible. The experimental 
group performed a video game of Dance Dance Revolution (DDR) for 45 minutes twice 
weekly for 6 weeks. The control group performed a handheld video game. The study 
demonstrated that participation in the DDR programme resulted in significant 
improvement in the 4 square step test (FSST) but not in the Tinetti Mobility Test (TMT) 
balance scores. The contradictory results obtained may be explained by the fact that the 
2 tests of balance (the FSST and the TMT) are based on 2 different scales of 
measurements. The FSST is a timed test of dynamic balance which is based on interval 
data, while the TMT is based on an ordinal scale of measuring balance. As indicated 
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earlier, ordinal scales may lack the sensitivity to capture functional related changes as a 
result of exercise interventions [138].     
 
2.4.3 Summary of review of available exercise studies directed towards 
improving mobility in people with HD 
To summarize, the evidence base in support of exercise interventions directed to 
improve mobility in people with HD is very limited. Five of the reported papers [2, 142, 
144-146] were conducted at an observational level; they were papers of either a single 
case or case series designs. In addition, methodological quality for the vast majority of 
the reported papers is poor. In most of the papers (n=6) [76, 77, 142, 144-146], 
participants‟ characteristics were not described in sufficient detail and factors that may 
have an impact on the effectiveness of the intervention; such as severity of the disease, 
functional ability, cognitive status and medication use were not reported or taken into 
consideration. Apart from two studies [78, 79], all studies did not clearly report 
inclusion criteria, although all included a diagnosis of HD. None of the studies reported 
power and sample size calculations. One study [77] reported the use of randomised 
controlled design, but the study as it is currently only as an abstract of conference 
proceeding, the randomization procedure is unknown and therefore selection bias 
cannot be discounted. In this study, it was also not clear if the assessor was blinded or if 
the authors took any measures to protect against assessor bias. Almost half of the 
studies (n=4) [142, 144-146] failed to report the use of valid and reliable outcome 
measures. Across all of the studies, the interventions were not described in sufficient 
detail that allows replication, and in addition they were clinically heterogeneous with 
regards to the type of exercise and to the frequency and duration of exercise being 
undertaken which makes it difficult to combine evidence for analysis.  
 
2.5 Determining criteria for conducting studies of exercise interventions in 
people with HD 
The evidence from animal studies and other neurological diseases, as well as limited 
support in studies of people with HD, suggests that exercise interventions may 
potentially play a role in facilitating independence in activities of daily living in people 
with HD by addressing impairments and limitations to functional activities. The review 
above, however, indicates that there is a critical need to establish a stronger evidence 
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base that can support the use of physical activity/exercise in clinical and community 
practice for people with HD. More rigorously designed studies are needed to examine 
the potential benefits of such interventions on key mobility outcomes in the HD 
population. Rimmer et al [138] suggested that in conducting exercise trials, researchers 
must consider developing structured exercise programmes that build on previous 
research regarding the targeted group. The type and severity of activity limitations and 
associated impairments and participation restrictions in the targeted group within the 
context of the ICF model need to be taken into account. In addition, exercise exposure 
in terms of intensity, frequency, type, mode and settings needs to be considered and 
specified. Providing such specifications will support a stronger evidence base and may 
potentially facilitate that the intervention can be replicated or translated into clinical 
practice. The following sections provide key findings from the literature that helped to 
determine specifications of the protocol of the exercise programme that was used in this 
project. 
 
2.5.1 Content of exercise programme 
The specific content of the intervention should be determined to support the conduct of 
well conducted trials of exercise interventions in HD. As indicated earlier, deficits in 
balance and muscle strength are the main impairments in HD that may relate to activity 
limitations in this population (Figure 2.1). Thus, targeting these impairments should be 
considered in exercise interventions in HD. The small amount of evidence in support of 
exercise intervention in HD (Table 2.6) suggests that exercise programmes that include 
a combination of muscle strengthening and balance exercises should be beneficial in 
managing the motor symptoms seen in this population. The beneficial role of these 
types of exercise interventions has been previously illustrated in other 
neurodegenerative diseases. For example, 2 recent systematic reviews in Parkinson‟s 
disease (PD) [72, 73] reported that exercise programmes focusing on balance and 
muscle strength can improve multiple factors, including gait and health-related quality 
of life. In a questionnaire survey and a series of interviews conducted with 
physiotherapists working routinely with HD, there was an emphasis that balance and 
strengthening exercises directed to improve mobility in HD, should be functional and 
task-specific [81]. Task-specific activities involve the practice within the context of 
functional tasks of everyday living such as walking, standing up from sitting position, 
turning and stepping [149]; aspects of activities that seem to be limited in HD [45, 93, 
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114-116]. Task-specific exercises involve using repetitions, alterations of the 
environment, and modification of the conditions of the task as a means of progressing 
task difficulty [149, 150]. For example, for balance training, task-specific exercises 
involving the progression from a wide to a narrow base of support, from static to 
dynamic activities and from a low to high centre of gravity could be included. A task-
based model for the exercise intervention is designed to enhance skill learning [151] and 
may be particularly important for people with HD. The benefits of a task-specific 
exercise as a means to improve functional abilities and task performance have not been 
empirically studied in HD but have been documented in other neurodegenerative 
diseases with basal ganglia disorders such as PD. In one study [152], a 4 week period of 
training on sit to stand performance in 19 participants with PD resulted in a reduction of 
the time taken to complete the sit to stand transition by 25% and increased both the 
horizontal and vertical velocities by 18% and 51% respectively compared to the 
conventional exercise programme. In another study by Lehman et al [153] improvement 
in gait velocity and step length in individuals with PD was demonstrated after 10 days 
of walking and specific orientations for a longer step length. Similar results were 
obtained by Morris et al [154] who conducted a similar study with a similar training 
protocol in people with PD. These results along with data from a review paper [132] 
indicate that skills in people with PD can be learned most effectively when they are 
practiced repeatedly in relation to meaningful goals. Task-specific exercises may 
therefore be equally important in people with HD and need to be considered in exercise 
interventions in this population.  
 
2.5.2 Considering influential factors 
A notable shortcoming of most of the literature investigating the benefits of exercise 
interventions in people with HD is the failure to quantify disease severity and functional 
and cognitive status. These disease specific factors may influence response to exercise 
interventions and therefore should be considered when planning exercise interventions. 
This is particularly crucial as there is an increased emphasis within the ICF model to 
consider such individual factors in assessing people with mobility deficits as it is in 
people with HD [91] (Figure 2.1).  
 
Cognitive impairments in particular can act as a barrier in delivering exercise 
interventions as they are likely to impact on the ability to learn new motor skills, 
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including the performance of new exercises [80, 81]. Studies that investigated the 
mechanisms of motor learning in HD have demonstrated that people with manifest HD 
had poor acquisition of information and use more of an explicit learning strategy, rather 
than implicit, when compared with controls [155]. Implicit learning refers to 
“reinforcement or habit learning, involving no verbalisation or meta-cognitive 
processing of the learned material” [156]. The basal ganglia are suggested to be highly 
implicated in implicit sequence learning [157]. Explicit learning, on the contrary, refers 
to “using a high degree of awareness and ability to verbalise the learning process” 
[156]. A comparative study by Pillon et al  [155] showed that HD patients performed as 
poorly as patients with Alzheimer's disease on free recall of items in a list-learning task 
(implicit learning), but significantly better with cued recall (explicit learning). Another 
study [19] used a paired associated learning task, involving unrelated word pairs (for 
example, gold-sugar; friend-train). Whereas recall improved over successive trials in 
controls, neither the HD nor the Alzheimer group demonstrated improvement. However, 
when participants were actively encouraged to form an associative link between words 
(for example, imagine a gold bar in a bowl of sugar); recall improved dramatically in 
HD but showed no change in Alzheimer Disease. The data suggest that HD patients do 
not spontaneously adopt active strategies for learning, but when external cues are 
provided, performance can improve. This specificity of learning in HD has apparent 
clinical implications on the delivery of exercise interventions in this population; 
external cues can be used to improve the performance of the delivered exercises. Cueing 
applied in clinical settings provides a reference or external trigger for movement 
generation, which usually involves the use of augmented sensory information in the 
form of external visual or auditory cueing [156]. A major aim of using the cues in 
therapeutic interventions in HD can be to teach people with HD how to effectively 
bypass the damaged basal ganglia structures, and use frontal lobe pathways to control 
movement by responding to auditory or visual input [135]. This bypassing theory is 
based on suggestions which indicate the existence of a distinctive medial and lateral 
system for movement generation [156, 158, 159]. The medial system, including the 
basal ganglia, supports the generation of movements based on self initiation. The lateral 
system, including the pre-motor cortex (frontal pathways), dominates during externally-
generated movements. 
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Despite the suggestion that cueing can be useful as a motor learning tool only a few 
studies have investigated its benefits in people with HD, with contrasting results. Thaut 
et al [105] demonstrated the modulation of gait speed in people with HD as a result of 
their ability to synchronize their gait to rhythmic cues from a metronome. However, 
Delval et al [106] demonstrated that under dual task conditions metronome cues were 
not helpful. The use of different designs in these 2 studies may explain these contrasting 
results; the potential benefits of using the sensory cues in HD may be potentially 
masked on performing tasks that require more attentional demands, which explains the 
results obtained by Delval et al [106].  
 
Whilst data are limited in HD, there is abundant evidence that cueing improves motor 
performance in PD. A number of studies [151-153, 160] have examined the effects of 
cueing on walking performance and other mobility activities such as sit to stand in un-
cued conditions after the intervention. The results from these studies demonstrated the 
positive effects of cueing on acquiring and retaining motor performance. For example, 
the effect of a 3-week period of cued gait training was examined immediately after the 
intervention period and after 6 weeks [151]. Significant changes in gait performance 
were demonstrated after the intervention, and retention at the 6-week follow up was 
maintained. In another study, the effect of cued sit to stand training versus non-cued 
was examined [152]. Results from this study demonstrated that the cued sit to stand- 
training had a greater effect than non-cued training and that this effect was maintained 
for 2 weeks after the intervention. Overall, these findings along with data from a review 
paper [156] suggest that the acquisition and retaining of motor learning in basal ganglia 
disorders can be improved when associated with external stimuli. As such, cue-
augmented modes need to be incorporated into the delivery of exercise interventions in 
HD.   
 
2.5.3 Intervention settings and the home-based exercise programmes  
Environmental factors, including the physical environment of exercise settings, need 
consideration in planning exercise interventions. This is in line with the ICF model 
which emphasizes that environmental factors along with the individuals‟ needs should 
be taken into account when delivering therapeutic interventions for people with mobility 
deficits [91]. 
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In terms of exercise settings, clinic, hospital or gym based exercise programmes involve 
travel to a health facility or specific exercise settings. These programmes may be 
inaccessible and exclude some individuals with HD [80] from being able to participate 
in exercise therapies. Home-based exercise programmes have the advantage of the 
convenience of doing the exercises when one is able and not having to travel to an 
exercise facility, potentially reducing direct cost to the patient [161]. There is additional 
support for this approach in that delivering exercise programmes in the homes of people 
with neurodegenerative disease has been shown to promote efficient transferability of 
skill acquisition [160, 162]. In one study using a within-subject controlled design, 
functional activities including walking and carrying out transfers were measured in 33 
participants with PD, at home and in the hospital before and after a 6-week baseline 
period and after 6 weeks home-based exercise programme [162]. The study revealed 
that participants had significantly higher scores on a functional activity scale after 
treatment in the home setting compared to the hospital. The results support application 
of the treatment concept and highlight that exercise interventions aimed at improving 
function in neurodegenerative disease may be best provided in the home situation. 
Whilst conclusive trials of exercise interventions in HD are lacking, there is 
accumulating evidence to suggest that home-based exercise programmes in other 
neurodegenerative diseases such as PD and AD are feasible and have a positive impact 
on various aspects of mobility measures. This review identified 7 clinical trials in PD 
[160-166] and 2 others in AD  [74, 167] that has investigated the feasibility and benefits 
of home-based exercise programmes. Methods of monitoring and delivery of the 
exercise programmes in these studies varied with supervision ranging from being 
maximal (fully supervised by a therapist on each session) to very minimal (self 
supervised exercise programme) (Table 2.8 & 2.9). A summary of these papers is 
provided in the sections below.  
 
2.5.3.1 Home-based exercise programmes in PD 
Recently, Nieuwboer et al [160] demonstrated that 3 weeks of an external cueing 
training programme conducted in people‟s own homes improved walking speed, step 
length and balance and reduced severity of  freezing gait in freezers at 6-week follow 
up. Each individual in this study was trained in a variety of situations and daily 
activities by a physiotherapist who was present at each training session. In another study 
[164], a personalised 6 week, supervised home-based exercise which focused on 
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balance and muscle strength training was compared with usual care, with participants 
being tested at baseline, and at 8-week and 6-month follow-up assessment. The study 
demonstrated a consistent but non-significant trend towards lower fall rates in the 
exercise group at both 8 weeks and 6 months. However, significantly lower rates of 
repeat near falling were evident for the exercise group at 8 weeks and 6 months. 
 
Although the above mentioned studies demonstrated feasibility of home-based exercise 
programmes that were fully supervised by a health care professional, findings from 
other studies demonstrated that people with PD can exercise safely at home using a 
pragmatic, minimally supervised exercise programme. In a recent study conducted by 
Allen et al  [163], the feasibility and benefits of a 6 month exercise programme aimed at 
reducing the risk of falls in people with PD was evaluated. Participants attended a 
monthly exercise class conducted by a therapist, and were instructed to complete 
exercises between sessions at home 3 times a week for the intervention period. No 
adverse events were documented and the reported adherence to the exercise programme 
was high with an average of 2.2 out of 3 of the weekly home sessions completed. 
Findings from the study demonstrated a greater improvement, although not statistically 
significant, in the falls risk score in the exercise group compared to the control. 
Significant improvements were observed on the freezing of gait questionnaire and timed 
sit to stand test. Furthermore, there were statistically non-significant trends toward 
greater improvements in the exercise group in the measures of walking speed and fear 
of falling.   
 
In addition to the above cited study by Allen et al, 2 other studies conducted by Nocera 
et al  [166] and Caglar et al [165] used a similar protocol and demonstrated similar 
findings. In both of these studies, participants attended a practice session and were 
instructed on the proper method and mechanics for each exercise at the beginning of the 
home exercise programme. Participants were then provided with an exercise booklet 
outlining the movements for each of the exercises and instructed to perform the 
exercises at home for the intervention period. In the study by Nocera et al [166], 
participants were also contacted by weekly phone calls to monitor their progress. In 
both of these studies, no adverse effects were reported and participation in the home 
exercise programme resulted in improvements in gait speed, step length [165] and in 
measures of static as well as dynamic balance [165, 166]. Results from these studies 
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suggest that if people with PD are taught individualized and detailed home exercises by 
a therapist, there is potentially a significant clinical improvement in their motor 
performance.  
 
Lun et al [161] in a controlled trial, examined whether benefits seen in self supervised 
home-based exercise programmes would be similar to a therapist supervised exercise 
programme. Participants in this study who were in the self-supervised home based 
group received the same set of exercises as the therapist-supervised group. They were 
familiarized with the exercise programme over 2 1-hour sessions with the same 
therapist who supervised the other group and then were instructed to continue their 
exercises at home twice a week for 8 weeks. The adherence rates were similar between 
the groups (87 and 91% for the self supervised and therapist supervised groups, 
respectively). Both programmes were found to result in statistically significant 
improvements in motor symptoms, as measured by the Unified Parkinson‟s Disease 
Rating Scale (UPDRS)-motor subsection score (the primary outcome in the study). 
These results are important and imply that people with neurodegenerative disease who 
still live in their own homes may potentially best receive exercise intervention in the 
home. 
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Table 2.8: Summary of papers related to home-based exercise interventions in PD 
Authors/ 
time 
Study design 
Exp/ 
control (n) 
Mean age (SD) 
Type of intervention for Exp 
(wks/freq/min or hr) 
Type of 
intervention for 
control 
(wks/freq/min or 
hr) 
Measures/Results 
Allen et al, 2010 
[163] 
RCT 
Exp= 24 
Control= 24 
Exp= 66 (10) 
Control= 68 (7) 
Minimally supervised programme; 
Progressive balance and muscle strength 
exercises (24/3/40-60 min) 
Only falls 
prevention advice at 
the start of the study 
Mean of adherence; 70% of prescribed sessions 
Freezing of gait (FOG); FOG questionnaire a   
Mobility; sit to stand time a, gait speed, falls efficacy scale  
QoL; PDQ39  
Nocera et al, 
2009 [166] 
Individual- 
case control 
study 
Exp= 10 
Control= 
NA 
Exp= 73.4 (8.5) 
Minimally supervised programme; Exercise 
booklet focused on balance training with 
task-specific exercises to target limitations on 
the subjects daily function (10/NR/NR) 
NA 
Mean of adherence; NR 
Balance; posturography measures on  composite score of sensory 
organization test (SOT) a 
Nieuwboer et al, 
2007 [160] 
Randomised 
cross over trial 
Exp 1= 76 
Exp 2= 77 
Exp 1=67.5 (7.0) 
Exp =69 (5.3) 
Supervised programme; Cueing training at 
variety of tasks using a prototype cueing 
device supervised by therapist (3/3/ 30 min) 
NA 
Disease-specific motor score; UPDRS- gait   and balance items a 
FOG; FOG questionnaire  a     
Balance; functional reach test, timed single leg a, timed tandem 
stance a 
Mobility; gait speed a  and step  length a, falls efficacy scale  a 
QoL; PDQ39 
Ashburn et al, 
2007 [164] 
RCT 
Exp = 70 
Control =72 
Exp= 72.7 (12.3) 
Control=71.6 
(8.0) 
Supervised programme; Individualized 
exercises; ROM, balance, and muscle 
strength training  (6/2/1 hr) 
Usual care 
Balance; Berg balance scale (8 wk,  6 months), Functional reach 
test (8 wk,  6 months a) 
Mobility; rate of falls (8 wk,  6 months ), rate of repeat fall (8 wlk a,  
6 months a) 
QoL;  Euro Quol  (8 wk,  6 months a) 
Caglar et al, 2005 
[165] 
RCT 
Exp =15 
Control =15 
Exp=64.3 (9.6) 
Control=67.4 
(5.1) 
Minimally supervised programme; Exercise 
booklet focused on ROM, balance, gait and 
functional activity training (8/7/1hr) 
Usual care 
Mean of adherence; 90%  
Mobility; gait speed a, first step length a, cadence, time to walk 
around a chair a.  
Lun et al, 2005 
[161] 
Parallel group-
controlled trial 
Exp 1= 8 
Exp 2= 11 
Exp 1=66 (8.0) 
Exp 2=67 (11.1) 
Exp1; home based unsupervised exercise 
programme  
Exp2; group supervised exercise programme 
For both groups; balance and strength 
training (8/2/1 hr). 
NA 
Mean of adherence; Exp1 (87%), Exp2 (91%) 
Disease specific scale*; UPDRS motor score a 
Balance; Berg balance scale, ABC confidence scale  
Mobility; Timed up and go test  
*Significant and equal decrease in the UPDRS-motor in both 
groups from baseline to 8wlk  
Nieuwboer et al, 
2001 [162] 
 
Within subject 
controlled trial 
Exp= 33 
Control=NA 
Exp=66.2 (7.0) 
Supervised programme; Cueing and mobility 
training with task-specific exercises (6/3/30 
min) 
NA 
Disease specific scale; UPDRS total score a 
Mobility; activity scale a, gait speed a, stride length a, cadence 
(measured at home & hospital)*. 
*Scores obtained at home setting were better than those obtained at 
hospital settings  
Wk, week; freq, frequency; Exp; Experimental group; RCT, Randomised Controlled Trial; NA, Not Applicable; NR, Not Reported; QoL, quality of life; a statistically significant differences  
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2.5.3.2 Home-based exercise programmes in AD 
The home-based exercise interventions that have been investigated to date in AD focus 
mainly on involving the carer in delivery of the home-based exercise programmes. 
Considering that cognitive impairments and depression are 2 impacting factors in 
people with AD, the carers are needed for structuring patients‟ day- to- day activities 
and providing ongoing care. Therefore they can be trained to supervise home-based 
exercise programmes [74, 167]. In a randomised controlled trial (Reducing Disability in 
Alzheimer Disease (RDAD study) [74] that involved 153 participants with AD and their 
family carers, participants were randomly allocated to either a home- based exercise 
intervention or to routine medical care. During a 12-week treatment period, carers in the 
intervention group were taught to guide the participant with AD on performance of an 
individualized exercise programme. The exercise programme included endurance 
activities (primarily walking), strength training, balance, and flexibility exercises at 
home. In addition, carers in this group were taught a problem-solving approach and 
behavioural management strategies with the aim of encouraging subjects with AD to 
exercise, and at the same time to decrease undesirable agitated or depressed behaviours 
that may affect their engagement in the exercise programme. Participants were 
evaluated at baseline, post-treatment, and 6, 12, 18, and 24-month follow-up. Patient 
health status was measured with the Short Form 36 (SF-36), the Sickness Impact Profile 
(SIP), and carers‟ reports of patients‟ restricted activity days, bed disability days, and 
falls. Study findings indicated that carers were able to direct subjects with AD to follow 
scheduled exercise activities. Significant differences between intervention and control 
groups were obtained at follow up post intervention with those in the intervention group 
having fewer restricted activity days and improved SF-36 scores. Over 24 months of 
follow-up, changes in SF-36 were maintained and improvements in SIP mobility were 
noted. These findings were consistent with the findings from Steinberg et al [167] that 
used a similar protocol of a home-based exercise intervention mediated by the carer that 
demonstrated good adherence to the exercise intervention, significant improvement in 
ADL performances and a trend in improvement in the chair sit to stand test and walking 
speed, as well as health-related quality of life. These findings are important and suggest 
that in neurodegenerative diseases where cognitive aspects are a potential issue, carers 
can be trained successfully to use effective strategies in order to encourage and facilitate 
participation in home-based exercise programmes.    
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Table 2.9: Summary of papers related to home-based exercise programmes in AD 
Authors/ 
time 
Study 
design 
Exp/control 
(n) Mean age (SD) 
Type of intervention for Exp (setting; 
wks/freq/min or hr) 
Type of intervention for 
control (wks/freq/min) Measures/Results 
Steinberg et al, 2009 
[167] 
RCT 
Exp= 14 
Control= 13 
Exp= 74 (8.1) 
Control= 76.5 (3.9) 
Home based exercise programme delivered 
by the carer; 2 home visits by PT to ensure 
correct performance of exercises; exercises 
focused on aerobic, muscle strength and 
balance training  (12/6/NR) 
Home safety assessment and 
recommendation on 
interventions (2/1/ 1hr) 
Mean of adherence; 75% of the targeted goals 
Mobility; gait speed*, time for 5 repetitions sit to 
stand*, performance of ADL test a   
QoL; Alzheimer Disease quality of life Scale*   
Trends that were not statistically significantly 
toward improvements      
Teri et al, 2003 [74] RCT 
Exp= 76 
Control= 77 
Exp= 78 (6) 
Control= 78 (8) 
Home based exercise programme delivered 
by the carer; training for the carers on 
behavioural management of participant to 
enhance adherence to the programme; 
weekly visits of therapist to effectively train 
carers; exercises focused on balance, 
flexibility, muscle strength and endurance 
activities (12/2/ 1hr) 
Usual care 
Balance; functional reach test, standing balance 
Mobility; gait speed, number of days of restricted 
activity (3 months a, 24 months) 
QoL; SF-36 (3 months a, 24 months a), Sickness 
impact profile (3 months, 24 months a) 
Wk, week; freq, frequency; Exp; Experimental group; RCT, Randomised Controlled Trial; NR, Not Reported; QoL, quality of life; a statistically significant differences 
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2.5.4 Mode of exercise delivery and the use of DVD/videotape approach 
2.5.4.1 Considering motivational aspects  
Considering the neurodegenerative nature of HD, individualised exercise instruction on 
a regular basis may be desirable in this population [80, 81]. Sustained interventions, 
however, may not be feasible or cost effective for life-long disease management. It is 
therefore critical for therapists to find ways to facilitate engagement in independent 
exercise programmes. Given that home-based exercise programmes are feasible in other 
neurodegenerative diseases, encouraging people with HD to engage and participate in 
regular physical activity, outside of scheduled therapist-supervised clinic appointments 
at their homes, may promote achievement of therapy goals in this population [80]. 
There are a number of factors, however, that may influence the ability of people with 
HD to engage in unsupervised exercise programmes which include motivational issues 
[80, 81]. Lack of motivation (apathy) is a core feature of the disease that could impact 
on the initiation of a new life routine, including an exercise programme. Considering 
that motivation is vital to adherence [168], finding strategies to improve motivation is a 
key to the success of any provided therapy programme. A number of strategies that have 
been used in other neurodegenerative disease such as PD and AD have potential for 
application in HD. The ParkFit study [169] suggests that behavioural motivation 
techniques can be used  successfully in subjects with PD to encourage them  to engage 
in a regular physical activity. Within this strategy, counselling is used to promote 
behavioural change through working closely with subjects. The strategy includes 
education about the benefits of physical activity, advice about suitable activities, setting 
goals, and recruiting social support. Similarly the RDAD (Reducing Disability in 
Alzheimer Disease) study [74] found that using a behaviour management approach is a 
key component to encourage subjects with AD to engage in an independent home-based 
exercise programme. Within this approach it was essential to involve the carer and to 
provide a personalised rationale for the programme (specific to the specific individual) 
in order to maximize motivation and enhance adherence to the programme. Such 
strategies are important and can be incorporated into the design of exercise intervention 
trials in people with HD.  
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2.5.4.2 The use of DVD/videotape approach 
Taking into account the cognitive and motivational aspects associated with HD, there is 
clearly a need to develop methods that facilitate a person‟s engagement and adherence 
to an independent exercise programme. The technological capabilities of DVD/ 
videotape (such as the use of sub-titles, rhythm, augmented visual and auditory cues 
provided through real life demonstration of exercises) make it a useful format to 
facilitate engagement in such programmes, particularly for people who have 
motivational and cognitive problems as is common in people with HD. 
  
Such audiovisual methods have been used to support the delivery of home-based 
exercise programmes in different clinical settings (Table 2.10). Nine randomised 
clinical trials [83, 85, 86, 170-175] that investigated the home use of an exercise 
DVD/videotape in different clinical conditions were identified in this review. Clinical 
conditions included Chronic Obstructive Pulmonary Disease (COPD), shoulder and 
back pain, knee and hip osteoarthritis, orthopaedic surgery for upper and lower limbs 
and balance training for elderly who were at risk of fall. Findings from these papers 
suggested positive outcomes of the home use of an exercise DVD/videotape that were 
classified into 3 main categories 1) exercise performance 2) exercise adherence 3) 
physical outcomes. A summary of these findings is provided in the sections below.  
 
2.5.4.2.1 DVD/videotape impact on exercise performance  
The effect of the mode of delivery of exercises on the quality of exercise performance 
was investigated in 4 studies [83, 85, 86, 175] with mixed results. However, the balance 
of evidence suggests that the use of a videotape approach has a better impact on the 
quality of exercise performance over the other modes of exercise delivery. Three studies 
reported positive impact of the use of the videotape approach on the quality of exercise 
performance over other modes of exercise delivery [83, 85, 86], whilst only 1 study 
reported no difference [175]. Schoo et al [175] reported that providing additional 
videotapes to facilitate correctness of exercise performance in older adults with lower 
limb osteoarthritis resulted in no further benefits than when exercise booklets were 
given together with verbal instructions. As discussed by the authors, the level of 
exercise simplicity required in this study may have influenced these findings. In another 
study by Weeks et al [86], videotape instruction was compared with still-photograph 
instruction in a group of healthy subjects on the quality of performing common simple 
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and complex exercises. Subjects were scheduled for an acquisition session and retention 
test 24 hours apart after demonstration of exercises using either videotape or still 
photograph instructions. Exercise acquisition was easier and knowledge retention was 
significantly higher in the videotape group and subjects in this group reported greater 
motivation and confidence about performing the exercises correctly. Additionally, all 
subjects in this group, when viewing the still photograph approach, indicated a 
preference for using a videotape over illustrations to learn the exercises. Similar 
conclusions were reported by 2 other studies. In one of these studies [85], a group of 
subjects following total knee replacement who viewed a videotape to reinforce learning 
had significantly higher knowledge of total knee surgery precautions and performed 
their exercises with less errors than those in the control group. Similarly, a group of 
subjects with shoulder or back pain who received home-based exercise videotapes to 
help them manage their condition were more skilled in performing exercises as 
evaluated using a standardized procedure and more motivated to continue self treatment 
based on data from qualitative interviews with subjects on completion of the study [83]. 
 
2.5.4.2.2 DVD/videotape impact on exercise adherence  
There is evidence to suggest that using a DVD or videotape to support delivery of home 
exercise programmes may lead to better adherence, although some of the reported 
findings show mixed results. Four of the included studies [85, 170, 172, 175] assessed 
whether the use of an exercise videotape would enhance the rate of adherence. Only 2 of 
these studies reported a better impact of the videotape strategy over other modes on 
adherence rates [85, 172]. The fact that the findings regarding adherence are varied can 
be attributed to a number of reasons, including the heterogeneity of the clinical settings, 
the populations included and the structural and content aspects of videotapes being used 
in these studies. Whilst Lysack et al [170] and Schoo et al [175] concluded that there 
was no statistically significant difference in adherence or satisfaction with the use of 
video instruction, compared with the use of written materials or audiotapes, Lin et al 
[85] found that subjects who received an exercise videotape, were significantly more 
compliant in prescribed exercises, when compared to a group who received written 
information about exercises. Similarly, Petty et al  [172] found a customised videotape 
to be more effective in helping people with COPD to initiate and adhere to the exercise 
programme. 
  
                                                                                                                          2. Literature review 
 
70 
 
2.5.4.2.3 DVD/videotape impact on physical outcomes  
Six studies [83, 85, 171-174] of the included papers assessed whether the adherence to 
the home use of an exercise videotape had any effect on physical outcomes such as knee 
symptoms, shoulder and back pain, disease severity, range of motion, muscle strength 
and health related quality of life. The vast majority of these papers (n=5/6) [83, 85, 171, 
172, 174] highlighted positive effects on outcomes in using a home-based exercise 
videotape in their respective fields. For example, in one study, the effects of using a 
home exercise videotape along with educational booklet in people with COPD were 
compared with the use of the educational booklet alone. The use of the exercise 
videotape in this study was demonstrated to significantly improve symptoms related to 
exercise tolerance and to breathlessness [171]. Findings from this study were consistent 
with findings from another study [172] in which the effects of using home-based 
exercise videotape were found to improve fatigue and aspects of health-related quality 
of life in people with COPD. Similarly, in one study of elderly people with balance 
disorders, the use of a home-based exercise videotape resulted in improvements in 
muscle strength, flexibility and balance [174].  Furthermore, in 2 studies of orthopaedic 
conditions (knee surgery and shoulder and low back pain) [83, 85], the use of a home-
based exercise videotape was found to improve range of motion, reduce pain [85] and 
increase physical functioning [83].  
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Table 2.10: Summary of papers related to the home use of an exercise DVD/videotape 
 
Authors/ 
time 
Study 
design Population 
Exp/ 
control (n) 
Mean age (SD) 
Type of intervention for 
Exp 
(wks/freq/min or hr) 
Type of intervention 
for control 
(wks/freq/min or hr) 
Measures/Results 
Moore et al, 2009 
[171] 
RCT COPD 
Exp= 10 
Control= 10 
Exp= 70.5 (5) 
Control= 70 (13) 
Educational booklet about 
COPD and exercise and 
home exercise videotape  
(6/4/30 min) 
Educational booklet 
only about COPD and 
exercise 
Exercise tolerance; Incremental Shuttle Walk Test a 
Breathlessness; Chronic Respiratory Questionnaire a    
Petty et al, 2006 
[172] 
RCT COPD 
Exp1= 72 
Exp2= 69 
Control= 73 
Exp1= 68.8 (9.2) 
Exp2= 68.4 (9.0) 
Control= 66.8 (9.9) 
Exp1; home-based 
customized exercise 
videotape (8/3/NR) 
Exp2; standard exercise 
videotape (8/3/NR) 
Usual care 
Adherence, conversion to and retaining exercise habits were 
significantly better in both videotape groups relative to control 
Impact of lung disease; Fatigue Impact Scale a* , Seattle 
Obstructive Lung Disease a*  Questionnaire 
QoL; SF-36  a*   
*significantly improved in customised video tape group 
compared to the other groups 
Lysack et al, 
2005 [170] 
RCT 
Total knee 
or hip 
replacement  
Exp= 18 
Control= 22 
Exp= 64.8 (11.6) 
Control= 61.8 (11) 
Home-based customized 
exercise videotape (4/6/30) 
Written and verbal 
instructions of 
exercises to perform 
at home (4/6/30) 
Adherence; study specific questionnaire  
Satisfaction; study specific questionnaire   
Miller et al, 2005 
[83] 
RCT 
Shoulder 
pain or low 
back pain  
Exp1= 134 
Exp2= 194 
Control= 222 
Exp1= 55.1 (13.9) 
Exp2=52.4 (16.2) 
Control= 52.7 (15.3) 
Exp1=  home exercise video 
(the treating PT) (4/NR/NR)  
Exp2=  home exercise video 
(anonymous PT) 
(4/NR/NR) 
 
Verbal face to face 
instructions of 
exercises to be 
performed at home 
(4/NR/NR) 
Progress of the condition; Shoulder disability index or Roland 
and Morris disability scale  
Perceptions of exercise instructions; qualitative interviews b  
Patient‟s self treatment skills; Measure of patient self treatment 
skills scale a*  
QoL; SF-36 a* 
a*Both video groups were significantly different comparing to 
controls  
b videotape motivated patients to continue self treatment 
Schoo et al, 2005 
[175] 
RCT 
OA of hip 
or knee 
Exp1= 30 
Exp2= 30 
Control= 30 
Exp1= 69.2 (6.4) 
Exp2= 70.9 (7.2) 
Control=71.1 (6.8) 
Exp1= a home exercise 
brochure with audiotape of 
instructions (8/6/NR) 
Exp2=  a home exercise 
brochure with videotape of 
exercises (8/6/NR) 
Home exercise 
brochure (8/6/NR) 
Adherence rate; exercise diary   
Correctness of exercise performance; correctness of exercise 
performance scale 
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Table 2.10: Continued for summary of papers related to the home use of an exercise DVD/videotape 
Authors/ 
time 
Study 
design Population 
Exp/ 
control (n) 
Mean age (SD) 
Type of intervention for 
Exp 
(wks/freq/min or hr) 
Type of intervention 
for control 
(wks/freq/min or hr) 
Measures/Results 
Sohng et al, 2003 
[174] 
RCT 
Elderly who 
are at risk of 
fall 
Exp= 22 
Control= 23 
Exp= 75 (7.6) 
Control= 76.4 (6.5) 
Instructions from PT and 
videotaped instructions of 
exercises to be performed at 
home (8/4/45 min) 
Usual care 
Muscle strength; isometric muscle strength of knee and ankle a 
Balance; sharpened Romberg test a 
Ankle ROM a 
Instrumental activities of daily living (IADL) 
Weeks et al 2002 
[86] 
RCT 
Healthy 
subjects 
Exp= 10 
Control= 10 
Exp= 23.1 (7.4) 
Control= 23.6 (8.1) 
Videotape instructions of 
exercises (1/2/30 min) 
Instructions of 
exercises via still 
photograph 
illustrations (1/2/30 
min) 
Acquisition of exercise performance a 
Retention test of exercise performance in 24 hours of 
acquisition a 
Motivation toward performing the exercises  a 
Roddy et al, 2002 
[173] 
RCT 
Repair of 
rotator cuff 
tear 
Exp= 54 
Control= 54 
Exp= 58.7 (10.6) 
Control= 57.2 (9.1) 
Videotape instructions of 
exercises (24/4/NR) 
Personal instructions 
of exercises from a 
physiotherapist 
(24/4/NR) 
Exercise adherence; exercise diary 
Shoulder pain and disability index; The University of 
Pennsylvania Shoulder Scale scores 
Lin et al, 1997 
[85] 
RCT 
Knee 
arthroplasty 
Exp= 31 
Control= 29 
Exp= 63.7 (11.6) 
Control= 62.4 (11) 
Instructions of  an exercise 
booklet and exercise 
videotape (6/5/30 min) 
Instructions of an 
exercise booklet but 
no video (6/5/30 min) 
Adherence rate a 
Quality of performance of exercises a 
Pain and ROM of knee flexion and extension a 
 
Wk, week; freq, frequency; Exp; Experimental group; RCT, Randomised Controlled Trial; NA, Not Applicable; NR, Not Reported; QoL, quality of life; a statistically significant differences; OA, osteoarthritis; 
COPD, Chronic Obstructive Pulmonary Disease; ROM, Range of Motion.    
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2.5.5 Summary of review related to determining criteria for conducting studies of 
exercise interventions in people with HD 
Figure 2.1 shows a model of the key elements that emerged from this literature review 
and may potentially impact on the acceptability and benefits of an exercise programme 
delivered for people with HD. This model indicates that a well defined exercise 
programme specifically tailored to target the physical impairments and activity 
limitations seen in this population and focusing mainly on balance and muscle strength 
and incorporating task-specific activities, may be able to improve functional abilities 
and health-related quality of life in people with HD. As transferability of functional 
improvement is most noticeable in the setting in which training is delivered, a person 
still living in his/her own home would be better receiving an exercise intervention in 
their own home. Considering the cognitive and motivational issues associated with the 
disease, home-based exercise interventions may potentially be best delivered with an 
exercise resource that augments the information provided by the provision of attention-
focusing verbal and visual cues such as an exercise DVD or videotape. In such settings, 
it may be important to train the carer how to guide and supervise the person‟s exercise 
programme. The success of the programme may depend largely on the carer‟s ability to 
continue to support the programme outside the actual training sessions. The success of 
the exercise programme may also depend on using motivational behavioural strategies 
that entail providing an introduction and rationale about the delivered programme and 
potential short term and long term benefits to maximize motivation and enhance 
adherence.  
 
2.6 Thesis aims, objectives and hypothesis     
2.6.1 Aims of the study  
Based on the literature reviewed here, there is evidence to suggest that exercise 
interventions can be beneficial in preserving or improving physical performance of 
people with HD. It is evident, however, that exercise interventions for people with HD 
have not been subject to rigorous research. Furthermore, it is clear that further 
investigations are required to examine reliability and validity of outcome measures that 
can be used to evaluate potential benefits of exercise interventions in this population.    
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Exercise interventions in this population are likely to be complex. The Medical 
Research Council (MRC) Framework for design and evaluation of complex 
interventions provides a methodology for evaluating complex interventions [69, 70]. It 
incorporates an exploratory phase which should be undertaken prior to the initiation of 
definitive phase III randomized controlled trials in order to determine feasibility and 
acceptability of the intervention and pilot the use of outcome measures. This research 
therefore focused on a phase II exploratory study of a home-based exercise programme 
and was conducted with 2 aims in mind. The first aim was to determine reliability and 
validity of the outcome measures that were used in the main part of the study and the 
second aim was to investigate feasibility, acceptability and the potential benefits of a 
home-based exercise programme. The study therefore, consisted of 2 main parts: the 
first part was a preliminary investigation of the reliability and validity of potential 
outcome measures across the spectrum of the disease and the second part was an 
evaluation of feasibility, acceptability and potential benefits of a home-based exercise 
programme that was designed to specifically target physical factors which are believed 
to be impaired and are potentially modifiable in people with early to mid stage HD 
(using an exercise DVD that was previously developed as the basis of the intervention 
and the criteria determined in this review). Benefits on measures of mobility and health-
related quality of life were evaluated. 
 
2.6.2 Objectives and hypothesis   
2.6.2.1 Objectives and hypothesis for part 1 
The specific objectives for the first part of the study include the following:  
1. To determine test re-test reliability of a battery of outcome measures 
representative of spatiotemporal gait, balance, muscle strength, functional status 
and health- related quality of life in people with pre-manifest HD.  
2.  To determine test re-test reliability of a battery of outcome measures 
representative of spatiotemporal gait, balance, muscle strength, functional 
mobility and health- related quality of life in people with manifest HD at early to 
mid stage.  
3. To examine the validity of the above battery of outcome measures by examining 
their sensitivity to detect deficits in gait, muscle strength, balance, functional 
mobility and health-related quality of life in both pre-manifest and manifest HD. 
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4.  To examine the validity of the measures in muscle strength, balance, functional 
status and health-related quality of life by understanding their relations with 
measures of gait variability. 
 
The specific hypotheses for the first part of the study include the following:  
H1 There are significant differences in measures of gait, muscle strength, balance, 
functional status and health-related quality of life in people with pre-manifest HD 
compared to healthy controls. 
H2 There are significant differences in measures of gait, muscle strength, balance, 
functional mobility and health-related quality of life in people with manifest HD 
compared to healthy controls. 
H3   Measures of gait in HD are significantly related to measures of: a) muscle strength; 
b) balance; c) functional mobility; and d) health-related quality of life. 
 
2.6.2.2 Objectives and hypothesis for part 2 
The specific objectives for the second part of the study include the following:  
1. To evaluate potential benefits of a home-based exercise programme on: a) 
impairments in gait, b) balance and muscle strength; c) functional mobility and 
d) health-related quality of life in people with early to mid stage HD. 
2. To evaluate if people with early to mid stage HD adhere to a home-based 
exercise programme and what factors would impact on their adherence.  
3. To evaluate the acceptability of a home-based exercise programme to the people 
with early to mid stage HD and to their carers.   
 
The specific hypotheses for the second part of the study include the following:  
H1 Individuals with early- to mid-stage HD who participate in a home-based exercise 
programme will demonstrate significantly decreased gait deficits upon completion of 
the exercise programme compared to the control group. 
H2 In relation to decreased gait deficits, individuals with early- to mid-stage HD who 
participate in a home-based exercise programme will demonstrate significantly: a) 
improved balance; b) improved muscle strength; c) improved functional mobility; and 
d) improved health-related quality of life, upon completion of the exercise programme 
compared to the control group. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three  
 
Methods 
 
                                                                                                                                        3. Methods 
 
76 
 
 
3 Methods 
 
3.1 Outline of overall study design  
This exploratory research study consisted of two parts. Part 1:  An observational study 
that aimed to investigate reliability and validity of a set of mobility related outcome 
measures across the continuum of the disease. Measures were chosen to reflect a range 
of physical impairments, activity limitations and participation restrictions which may 
relate to mobility deficits seen in people with HD [176] and were potentially modifiable 
with exercise interventions. This included biomechanical measures of gait and clinical 
measures of balance, muscle strength, physical functioning in ADL and health-related 
quality of life that have been shown previously to have utility in people with HD and 
other neurological conditions (details of the outcome measures are provided in section 
3.3.4). Evaluating the validity and reliability of the outcome measures used in this part 
of the study was helpful in interpreting the results from the exercise intervention study 
(Part 2).  
 
Part 2: Potential benefits, feasibility and acceptability of the exercise programme were 
evaluated in this part of the study. A repeated measures randomised design was used. 
Twenty five participants with early to mid-stage HD were asked to complete the home-
based exercise programme at a certain time point during the study (see study flow chart: 
Figure 3.1). Participants who completed the study were assessed 3 times by the 
researcher (the PhD student) over the study duration (at baseline; at 8 weeks and at 16 
weeks) using a battery of outcome measures whose psychometric properties were 
evaluated in the first part of the study. User opinion of the process and benefits of 
involvement in the programme were obtained after completion of the study. Details of 
inclusion and exclusion criteria and recruitment strategy are provided in section 3.2. 
Details about Part 1 are provided in section 3.3 and about Part 2 are presented in section 
3.4.  
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Figure 3.1: Flow chart of the study 
 
 
Figure 1: Study design. This figure shows the flow chart of the study. A) Evaluation of discriminative validity of the 
outcome measures was undertaken in a sample of 67 participants. The sample (n=67) included 17 participants at the pre-
manifest stage, 25 participants at the early to mid stage of the disease and 25 healthy controls. B) Eighteen participants 
((n=9 pre-manifest) and (n=9 manifest)) were tested twice with a 1 week gap between the 2 assessments to evaluate the 
reliability of the battery of outcome measures. C, D, E, F&G) The existing 25 manifest HD participated in evaluating a 
home-based exercise programme. Participants who completed the study were assessed 3 times (at baseline (point A), at 8 
weeks (first follow-up assessment; point E) and at 16 weeks (second follow-up assessment; point G)). Participants were 
asked to complete the home-based exercise programme for 8 weeks at a specific time point during the study duration 
(either between baseline and first follow-up (i.e. early intervention) or between the first and second follow-up assessment 
(i.e. delayed intervention)). Participants who received the intervention after the first follow-up assessment provided 
control data for those receiving the intervention following the baseline assessment. Second follow-up assessment was on 
the main outcome measure (gait variability) only and additionally focuses on collecting data about adherence of early 
intervention group to any kind of programme after cessation of formal exercise input.  
Manifest HD
(n=25)
Healthy (n=25)
Pre-manifest 
HD
(n=17)
Control (n=12)
No intervention 
(8 weeks)
Intervention 
(n=13)
Home- based
intervention 
(8 weeks)
First follow-up assessment
(With additional process 
evaluation)
E) First follow-up 
assessment
D) Eight-
week period
A) Baseline 
assessment
Manifest HD
(n=9)
Pre-manifest
HD (n=9)
1 week
B) Reliability 
study
1 week
Part 1
Part 2
Home –based
intervention               
(8 weeks)
First follow-up assessment
No intervention 
8 weeks
Second follow-up assessment
(With additional process 
evaluation)
Second follow-up 
assessment
G) Second follow-
up assessment
F) Eight-
week period
C) Randomization
Phase I
Phase II
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3.2 Participants 
3.2.1 Inclusion and exclusion criteria  
3.2.1.1 Inclusion and exclusion criteria for HD participants (Part 1 & 2) 
The aim was to recruit participants who were gene positive for HD. This included 
people who were pre-manifest and those who were in the early and mid stages of the 
disease. Potential participants were screened for the following inclusion criteria: 
1. A positive genetic test for HD.  
2. Total Functional Capacity (TFC) score 13 with a diagnostic confidence score of 
either 0 or 1 of the UHDRS-motor as rated by neurologist, indicating the 
presence of none-specific motor signs of HD for pre manifest participants. 
3. Presentations of motor signs and a score of 4 on the motor diagnostic confidence 
scale of the UHDRS-motor as rated by neurologist providing confirmation of 
HD diagnosis for participants with manifest HD. 
4. Ability to walk independently with or without an assistive device but without the 
aid of another person. 
5. Self-reported or physician-reported difficulties with walking and/or balance for 
participants with manifest HD. 
6. Maintaining a stable medical regime for 4 weeks prior to initiation of study. 
7. Aged above 18 years. 
8. Capacity to give informed consent. 
 
Participants were excluded if they had a history of coexisting neurological conditions 
such as stroke, or other causes of balance disorders and severe visual problems, or if 
they have any other medical condition which would prevent them from engaging in 
regular physical activity; or if they had cognitive or behavioural symptoms that would 
prevent them cooperating with the intervention.  
 
3.2.1.2 Inclusion and exclusion criteria for healthy controls (Part 1 only)  
A group of healthy controls was recruited to match the age range of the recruited pre-
manifest and manifest participants. Healthy participants were excluded if they had any 
peripheral injury or other medical condition that made them unable to walk without 
assistive device or prevented them from completing the battery of outcome measures.  
                                                                                                                                        3. Methods 
 
79 
 
3.2.2  Recruitment  
3.2.2.1 Recruitment of participants with HD (Part 1 & 2) 
Potential participants attending their routine neurology clinic appointment at University 
Hospital of Wales, Cardiff were first screened by the clinic neurologist for the inclusion 
and exclusion criteria mentioned above. If suitable, they were invited to participate in 
this study alongside the „Registry‟ study. Many subjects attending the HD clinic were 
already enrolled in the Registry study (04//WSE05/89). The registry study is a full 
clinical dataset, including the full medical and medication history. One of the optional 
components within the Registry project includes permission to be contacted between 
visits. Subjects who have consented to this component were contacted by letter and 
informed of the study.  
 
Once approached, potential participants were given an information sheet (Appendix1), 
reply slip and stamped addressed envelope. Potential participants who were given the 
information sheet had sufficient time, at least one week, to consider the information 
provided before being contacted to discuss their involvement, unless they indicated a 
positive response by post prior to this time. All participants gave their written informed 
consent before participation, in accordance with Local Research Ethics Committee 
approval (09/WSE02/24).  
 
Recruitment began in June 2009 and ended in November 2010. One hundred and six 
sequential subjects with manifest HD were screened for eligibility for this study. Fifty 
five were eligible and given information sheets. Only 25 consented and completed 
baseline assessments. In addition, 30 potential participants with pre-manifest HD were 
invited to participate in Part 1 of the study. Seventeen of them agreed to participate, 
consented and completed baseline assessments. Details of flow of recruitment for the 
study are provided in Figure 3.2.  
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Figure 3.2: Flow of recruitment of participants with HD for the study 
 
 
 
 
3.2.2.2 Recruitment of healthy controls (Part 1 only) 
Twenty five healthy controls were recruited. These people were either carers or relatives 
of people with HD who were mutation negative and introduced to us by the participant 
with HD (n=15) or were students and staff (n=10) at Cardiff University who did not 
have a family history of HD. All potential participants received an information sheet 
(Appendix 1) and were given at least 1 week to consider the information, before being 
contacted to discuss their involvement. All participants gave their written informed 
consent before participation in accordance with the Local Research Ethics Committee 
approval mentioned above. 
 
3.3 Part 1: Evaluating validity and reliability of the outcome measures across the 
continuum of HD symptoms 
3.3.1  Rationale  
Discriminant and convergent validity are both considered subcategories of construct 
validity [177] which was evaluated in this study. In terms of discriminant validity, tests 
that are required to detect differences on the same construct should discriminate in 
known groups; this is often called the known group method [178]. For example people 
Subjects with manifest HD
(Sequential subjects assessed for eligibility 
(n=106)) 
•Did not meet inclusion criteria (n=39)
•Enrolled in drug trials (n=12)
•Declined to participate (n=26)
•Did not respond (n=4)
•Consented and completed baseline 
assessments (n=25)
Subjects with pre-manifest HD
(Sequential subjects assessed for eligibility 
(n=30)) 
•Did not meet inclusion criteria (n=4)
•Declined to participate (n=3)
•Did not respond (n=6)
•Consented and completed baseline 
assessments (n=17)
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with HD are expected to demonstrate differences in balance relative to a healthy 
matched control group as they are known to be clinically different.  
 
Gait variability is a well validated measure in HD that is known to correlate with 
functional status in this population [38]. Tests that measure similar constructs should 
converge [178] which means that in the presence of higher gait variability (indicator of 
poorer functional performance), one may expect a poorer performance on measures of 
balance for example. Knowledge of the relationship between measures of gait 
variability and clinical measures of balance, muscle strength, functional performance in 
mobility activities and other activities of daily living as well as community walking and 
health-related quality of life is important and may potentially provide insight into 
outcome measures that can be used in therapeutic interventions. 
 
Validity of a test relies on its accuracy and reliability. If an outcome measure is to be 
used in interventional research, it is crucial to evaluate its test re-test reliability, to 
evaluate the ability of the test to be replicated in the same subject [141]. An instrument 
that has an adequate test re-test reliability gives consistent results if a subject is re-tested 
whilst under stable conditions. Test re-test reliability has been described as relative or 
absolute [179]. Both of these forms of reliability were examined in this study. Relative 
reliability examines the relationship between 2 or more measurements and the 
consistency of an individual‟s position within the group. Absolute reliability examines 
variability in scores in repeated measurements. Although intra-class correlation 
coefficients (ICCs) are generally considered to be more appropriate indicators of 
relative reliability than simple correlation coefficients (i.e. Pearson‟s r and Spearman‟s 
rho), their use is limited by the fact that ICC values are not related to the actual scale of 
measurement and are dependent on the range of the individuals‟ performances. In 
situations where there is a large range of scores in the sample, a high ICC may be 
obtained, despite there being large within-subject differences in the actual scores 
between repeated measurements and vice versa [141]. To overcome this, the 
complementary use of an absolute reliability, as opposed to relative reliability, is 
recommended [179]. Statistically, absolute reliability is determined by the standard 
error of measurement (SEM), or the standard deviation of the measurement errors, and a 
clinically useful mechanism for looking at absolute reliability is the minimal detectable 
change (MDC) score [141]. The MDC is defined as the minimal amount of change that 
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is not due to natural variation in measurement or due to error. Scores at or above the 
MDC are due to real change on the test rather than measurement error. Thus the MDC 
score is useful in determining whether an improvement in interventional research is 
truly a change in subjects‟ status or due to an error in measurement [178].   
 
3.3.2 Evaluating validity of outcome measures in HD  
An evaluation of the validity of a battery of outcome measures to assess mobility in HD, 
considering the disease stage, was undertaken (Figure 3.1). The sample (n=42) included 
pre-manifest mutation carriers (n=17) and manifest HD at early to mid stage of the 
disease (n=25). In addition, healthy controls (n=25) were recruited for this part of the 
study.  
 
Discriminant validity of the outcome measures was investigated by evaluating their 
responsiveness to detect differences between the 3 study groups. In particular, the 
sensitivity of the battery of outcome measures to differentiate between people with 
manifest and pre-manifest HD and between people with pre-manifest HD and healthy 
controls was examined. On the other hand, convergent validity was investigated by 
examining the relationship between measures of balance, muscle strength, functional 
performance in mobility activities and other activities of ADL, community walking and 
health-related quality of life with a measure of gait variability.  
 
3.3.3 Evaluating reliability of outcome measures in HD  
As part of this study, an evaluation of the test re-test reliability and the minimal 
detectable change of the used battery of outcome measures along the broad spectrum of 
the disease was conducted. Eighteen of the existing participants who were assessed at 
the baseline (9 pre-manifest (gene mutation carrier) and 9 manifest HD) completed a 
second assessment session, with a 1-week gap between, on the used battery of outcome 
measures. The order of assessments for each participant was randomized (between 
participants). This randomized order remained the same for repeated testing (within 
participants). 
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3.3.4 Outcome measures  
Outcome measures included here were chosen to reflect a range of physical 
impairments, activity limitations and participation restrictions related to the mobility 
deficits seen in people with HD. These outcomes were structured according to the 
International Classification of Functioning, Disability and Health (ICF) framework. As 
depicted in Table 3.1, physical impairments in body functions were represented by a 
disease-specific motor scale (the modified motor score of the UHDRS (mMS)) [180] as 
well as measures of balance and muscle strength. Balance was assessed using the Berg 
Balance Scale (BBS) [181], the Romberg (RT) and Sharpened Romberg (SRT) tests 
[182] and measures of postural sway [148]. Muscle strength was assessed using the 
Maximal Voluntary Isometric Muscle Contraction (MVIC) scores of knee flexors and 
extensors which were obtained using the Kin-com isokinetic testing chair dynamometer 
unit [183]. 
 
In the realm of mMS and BBS, both tests involve the evaluation of physical 
impairments in the contexts of assessing the performance in some tasks such as walking 
(for both mMS and BBS), stepping and turning (for the BBS) (see section 3.3.4.1 for 
more details about these tests). As these tasks are principally listed under the activity 
level within the ICF [184] (see Chapter 2 for more details about what is considered as 
an activity), categorization of the mMS and BBS as measures of body function can 
overlap with the activity level. These 2 tests seem to be multi-dimensional; however 
their constructs are predominantly based on evaluating motor impairments as a body 
function [46, 185]. Therefore it is more appropriate for these 2 tests to be listed under 
the level of body structure and function within the ICF model rather than being listed 
under the activity level. 
 
Activity was represented by a number of mobility measures as well as a measure of 
functional performance of activity of daily living (ADL). The main component of 
mobility which was assessed was walking. Walking measures included gait speed, stride 
time and gait variability as reflected by the stride time coefficient of variation. All these 
measures were quantified using the GAITRite system [140]. Measures of community 
walking over an extended period of time provided indications of performance and were 
recorded using a mobility monitor (StepWatch Activity monitor) [186]. Other 
components of mobility activities that are believed to be limited in HD such as sit to 
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stand, stepping and turning [114, 116] were assessed using other measures of mobility 
which included the Four Square Step test (FSST) [187], the Timed Up and Go (TUG) 
test [93] and the 30 seconds Chair Sit to Stand test (CSST) [188]. Functional 
performance of ADL activities that involve upper motor function was assessed using the 
Physical Performance Test (PPT) [189]. Levels of participation were represented by a 
health-related quality of life measure; the Short Form (SF-36) [119] was used to provide 
a measure of health-related quality of life in this study. 
 
 
Table 3.1: Summary of the outcome measures evaluated (structured according to the 
International Classification of Functioning (ICF) model) 
 
Domain Category Method of assessment Main variables 
Body 
structure 
and function 
Disease-specific 
motor score 
Modified motor score of the 
UHDRS section (mMS) 
Total score of the mMS 
Balance 
Berg Balance Scale (BBS) 
 
Total score of the BBS 
Romberg and Sharpened 
Romberg tests (RT & SRT) 
Total timed score to 
complete RT & SRT 
Force platform 
COP sway; rms-AP, rms-
ML, excursion-AP and 
exertion-ML 
Muscle strength 
Isokinetic dynamometry 
(Kin-com) 
MVIC of knee flexors and 
extensors 
Activity 
Walking- gait 
Automated walk-way 
(GAITRite) 
Gait speed, stride time, 
stride time CV 
Community 
walking 
Activity monitor (SAM) 
Average of daily step count, 
percentage of time spent at 
low, med and high physical 
activity and peak activity 
index 
Other measures of 
mobility activities 
Four Square Step Test 
(FSST) 
Time to complete the FSST 
Timed-Up and Go (TUG) 
test 
Time score to complete the 
TUG test 
30 sec Chair-Sit to Stand 
Test (CSST) 
Number of sit to stand 
transitions completed in 30 
seconds 
 
Functional 
performance in 
ADL 
Physical Performance Test 
(PPT) 
Total score of the PPT 
Participation 
Health-related 
quality of life 
SF-36 
 
SF-36 subscales 
UHDRS, Unified Huntington‟s disease rating scale; COP, Centre of pressure; rms, root mean 
square;  AP, anterior-posterior; ML-medio-lateral; MVIC, maximal voluntary isometric 
contraction; CV, coefficient of variation  
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3.3.4.1 Measures of physical impairments in body structures and functions 
3.3.4.1.1 A measure of disease-specific motor score  
The modified motor score of the UHDRS (mMS) [180] was recorded at baseline for all 
HD participants. The mMS includes 10 items rated on a 0 to 4 scale with 4 indicating 
the most severe impairment. This modified scale rates dysarthria, tongue protrusion, 
alternating hand movement, finger tapping, luria, rigidity, bradykinesia, gait, tandem 
walking and reactive balance.  
 
3.3.4.1.2 Measures of balance  
3.3.4.1.2.1 Berg Balance scale  
The Berg Balance Scale (BBS), a 14 item comprehensive test of static and dynamic 
balance, was used to assess balance [181]. Validity and reliability of this test has been 
established in the elderly and in people with stroke, traumatic brain injury and 
Parkinson‟s disease (PD) [181, 182, 185, 190, 191]. The scale has also been previously 
used in HD [38, 45] and validated to predict the risk of falls in this population [45].  
 
For rating using the BBS, 14 observable tasks common to everyday life measured on a 5 
point scale were completed by participants. Participants were asked to perform the 
following tasks; 1) sit unsupported 2) change position from sitting to standing 3) change 
position from standing to sitting 4) transfer 5) stand unsupported 6) stand with feet 
together 7) tandem standing 8) standing on one leg 9) standing with eyes closed 10) 
turning trunk 11) turning 360 degrees 12) retrieving object from the floor 13) stool 
stepping and 14) reaching forward while standing. The total score on all sub-tasks (out 
of a possible score of 56, with higher scores indicating better performance) was used for 
data analysis. 
 
3.3.4.1.2.2 Romberg and Sharpened Romberg tests  
The Romberg and Sharpened Romberg tests evaluate static balance and measure the 
ability to maintain steady standing in a variety of foot positions (Table 3.2). Participants 
were asked to perform 4 tasks of Romberg test; 1) standing feet apart and with eyes 
open 2) standing feet apart and with eyes closed 3) standing feet together (medial 
malleoli touching) and with eyes open and 4) standing feet together and with eyes 
                                                                                                                                        3. Methods 
 
86 
 
closed. No hierarchical order was used (i.e. participants who failed to perform the lower 
level of the test continued to be examined on the higher levels).  
 
To perform the Romberg tests, participants were asked to maintain their position in 
standing with the arms folded across the chest for a maximum of 30 seconds. In 
addition to Romberg‟s test, participants were asked to perform 2 tasks of sharpened 
Romberg which included 1) standing in tandem (heel-toe position) with eyes open and 
2) standing in tandem with eyes closed. To perform the Sharpened Romberg tests, 
participants were asked to stand in tandem with arms folded across the chest and eyes 
open and eyes closed for a maximum of 30 seconds. Participants were asked to perform 
2 trials of each task of the Romberg and Sharpened Romberg tests. The amount of time 
the participant remained in the position without moving the arms or the feet or losing 
balance was recorded for each trial. The average of the 2 trials of each task was 
calculated. The total of the average times of the 6 tasks (out of 180 seconds) was 
calculated and used for analysis. 
  
 
Table 3.2: Tasks of Romberg and Sharpened Romberg tests 
 
Test Tasks 
Maximum 
score 
Romberg tests 
Standing with feet apart and with eyes open 30 
Standing with feet apart and with eyes closed 30 
Standing with feet together and with eyes open 30 
Standing with feet together and with eyes closed 30 
Sharpened 
Romberg tests 
Tandem stand with eyes open 30 
Tandem stand with eyes closed 30 
Total  180 
 
 
3.3.4.1.2.3 Measures of postural sway 
Quantitative static force platform measurements, which are based on body sway 
assessment through the observation of the centre of pressure (COP) trajectory, were 
recorded in this study. These measures have demonstrated excellent reliability in 
healthy elderly people and in other neurological conditions (ICC>0.9) [148, 192].  
                                                                                                                                        3. Methods 
 
87 
 
Participants in this study were asked to stand on a static force platform (Kistler®) for 2 
successive trials of performing quiet standing with eyes open. Two minutes of rest were 
given between trials. Instructions were standardized, as different experimental set ups 
and protocols are known to affect platform outcomes [193-196]. Participants were 
instructed to stand on the force platform placing their feet side by side 15 to 25 cm 
apart, and looking straight ahead with their heads erect while visually fixing a black 
spot that is placed at a distance of 3 meters on a flat screen and at eye level. Participants 
were also instructed to cross over their arms with the opened palm of the hand falling on 
the opposite shoulder. Once stable, instructions were provided to the participants to 
stand as still as possible for as long as they could up to a maximum of 30 seconds.  
 
The Kistler® force platform was connected to an 8 channel amplifier. Data were 
acquired for 30 seconds for each task and sampling frequency was 1000 Hz. The signals 
from the platform were processed on a PC connected to a converter. Data were then 
analysed using a purpose written computer programme using software (MatLab 
R2007a), to calculate parameters from the COP data. The programme provided graphics 
of the mono-directional and planar displacements of the COP and of the diffusion 
stabilogram. The calculated parameters included the root mean square and excursion of 
the movement of the centre of pressure (COP) in the anterior posterior (AP) and 
mediolateral (ML) directions. Root mean square represents the variation of the 
movement of COP in a certain direction; whilst excursion represents the path taken by 
the COP over the duration of the test [148].  
 
3.3.4.1.3 Measures of muscle strength  
The maximal voluntary isometric contraction (MVIC) is the simplest and most 
commonly used method of accurately measuring the force-producing capabilities of a 
muscle group [183]. This is because isometric testing holds constant the variables of 
velocity of joint motion and muscle length [197]. Furthermore, measurement of MVIC 
using isokinetic dynamometry has become the standard method of strength 
measurement in research studies of neurological disorders [183, 197]. For the purposes 
of this study the MVIC values of quadriceps and hamstring were evaluated using the 
Kin-com isokinetic testing chair dynamometer unit. 
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A standardized procedure was used in order to ensure consistency of application of the 
technique. Participants were seated on the chair. The backrest was adjusted to 110 
degrees of posterior incline. Seat belts and pads were used to stabilize the lower leg, 
thigh and pelvis. The most inferior portion of the transducer pad was adjusted above the 
lateral malleoli. The axis of the lever arm was aligned to be at the same level of the 
inferior part of the lateral epicondyle of femur. The knee was flexed at an angle of 90 
degrees. The angle of the knee was determined by using a universal goniometer. 
Participants performed 3 trials of 3 seconds of MIVC for each of the right and left knee 
flexors and knee extensors. Sixty seconds of rest were given between trials. Subjects 
were instructed to keep their back against the backrest and to fold their arms against 
their chest during the test. Participants were given verbal coaching during the 3 seconds 
of contraction “to push or pull as hard as they can”. Three progressive sub-maximal 
warm up repetitions of both knee flexors and extensors were performed prior to testing 
in order to familiarize the participants with the testing procedure. Thirty seconds rest 
interval was given after the warm up and prior to the main testing procedure. In order to 
ensure consistency between all research assessment sessions, information relating to the 
chair position, chair height, pad position and lever arm length were documented at the 
first session to enable them to be reproduced in the following sessions. The average of 
the 3 trials for the knee flexors and extensors was used for data analysis. 
 
3.3.4.2 Measures of activity  
3.3.4.2.1 Measures of mobility 
3.3.4.2.1.1 Walking-measures of gait 
Gait speed, stride time and stride time coefficient of variation were computed for all 
participants using the GAITRite system (CIR Systems, Inc.: Havertown, PA) [140]. The 
system is designed to quantify gait parameters in an automated fashion. It consists of an 
instrumented walkway with sensors embedded within its surface. As participants walk 
on the walkway, sensors record pressure applied at each footfall as a function of time. 
The walkway is connected to a serial port of a laptop computer in which footfall data 
can be collected, processed, and spatial and temporal gait parameters can be computed. 
The GAITRite walkway used in this project was 427 cm long and 61 cm wide. This 
contains an active area of 16,149 sensors arranged in a grid pattern with a spatial 
resolution of 1.27cm and a sampling frequency of 60 Hz (Figure 3.3). The reliability of 
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the GAITRite system in quantifying gait parameters has been established with reports of 
good to excellent test re-test reliability in studies examining the walking of young and 
older normal adults, and in individuals who have arthritis, Alzheimer disease, 
Parkinson‟s disease (ICC range from 0.75 to 0.99) [198-204]. Excellent test re-test 
reliability (ICC above 0.8 for all parameters) has also been established  in a HD 
population [140].  
  
 
Figure 3.3: GAITRite walkway (CIR Systems, Inc.: Havertown, PA) which was used to 
quantify gait parameters in the study 
 
 
 
 
Each participant was asked to perform 10 trials of walking along the walkway at their 
comfortable pace. Standardized instructions at each assessment session were provided 
“walk toward the end of the walkway at a pace that is comfortable for you”. The 
participant was allowed to rest at the end of each trial if required. A self determined 
pace was used so as to minimise walking variability [205]. A 2 meters acceleration and 
deceleration distance at either end of the walkway was included so that a steady state of 
gait was captured on the walkway. Two familiarisation trials at the beginning of the 
testing session were included.  
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Data from the GAITRite was processed using GAITRite GOLD, version 3.9 software. 
The setting for light and short footsteps was used for all processing of footsteps. If a 
participant‟s first or last footstep did not fall completely within the active area of the 
walkway, those footsteps were removed from the recorded walk. The number of steps 
included in computation of gait parameters was standardized to improve the consistency 
of the measure [206]. An average of 50 steps (5 steps per trial for 10 trials) was 
therefore used to calculate the gait parameters (gait speed, stride time and stride time 
coefficient of variation) from each participant at each session. The stride time 
coefficient of variation was calculated as the (standard deviation/mean×100%). To 
calculate the stride time and stride time coefficient of variation, the pooled left and right 
strides were used. The advantage of this approach is that it allows for increased the 
number of strides to be included in the analysis; thus providing a more precise measure 
of gait variability [104]. Furthermore, this method was used in this study so as to 
facilitate comparison of data obtained in this study with data from previous studies on 
gait deficits in HD in which a similar approach of calculating gait variability was used 
[41, 42, 107]. It should be noted however, that one of the concerns  of using this method 
(i.e. averaged data from pooled right and left strides) is that the calculation of the 
coefficient of variation could be confounded by any underlying spatiotemporal 
asymmetry in the presence of disease [207]. In this study a pilot analysis was conducted 
on a sub-sample of HD individuals (n=10) which demonstrated no clear underlying 
spatiotemporal asymmetry. Furthermore previous research demonstrated that an 
asymmetrical distribution of impairments is not a clear expected feature of gait deficits 
in Huntington‟s Disease [112] (in contrast to other neurological diseases such as stroke).   
 
3.3.4.2.1.2 Community walking  
Levels of community walking were measured using the Step Watch 
TM
 (Cymatech, 
Seattle, Washington, USA), step activity monitor SAM, a sealed waterproof 2-
dimensional accelerometer. The monitor is reliable and valid for use in a range of 
neurological conditions [186, 208] and has been used in people with HD [45]. The 
monitor was attached to the right lower limb immediately above the lateral malleolus of 
the ankle with an elastic strap and recorded level of activity by counting steps taken per 
minute continuously over the monitoring period. The SAM was programmed using an 
infrared docking port (SAM Dock Programme 1.6.La) before the monitoring period 
with sensitivity settings appropriate to height, cadence and gait speed for each 
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participant. The settings were verified by visual inspection during a test trial as a light 
on the monitor is programmed to blink each time a step occurred for the first 30 steps 
taken by the participant. All participants were asked to wear the monitor for all the 
waking hours for 7 consecutive days and remove it only for bathing. Participants were 
asked to report any instances where the monitor had to be removed. Following the 
monitoring period, data were downloaded into a computer using the infrared docking 
port and the following activity indices were extracted; the average 24 hour step count 
over a week, percentage of time spent in inactivity in minutes, low activity, medium 
activity and high activity and peak activity index (Table 3.3).  
 
 
Table 3.3: Activity indices extracted from the Step Activity Monitor 
Activity index Parameters Description 
Average of step 
total 
Average of step total The average 24 hr step count over a week 
Percentage of 
time spent at 
different levels 
of activity 
Percentage of time spent in 
inactivity 
Percentage of time in which no steps were 
recorded 
Percentage of time spent in 
low activity 
Percentage of time in which the step count fell 
between and inclusive of 1 and the limit for low 
Activity (less than 15 steps per minute) 
Percentage of time spent in 
medium activity 
Percentage of time in which the step count fell 
between and inclusive of the low activity limit +1 
and the limit set in for medium activity (between 
15 and 40 steps per minute) 
Percentage of time spent in 
high activity 
Percentage of time in which the step count was 
greater than the medium activity limits (greater 
than 40 steps per minute) 
Peak activity 
index 
Best 30 minutes 
The average step rate of the highest 30 minutes of 
the included time in a day, regardless of when they 
occurred 
 
 
3.3.4.2.1.3 Other measures of mobility  
3.3.4.2.1.3.1 Four Square Step Test 
The Four Square Step Test (FSST) requires participants to rapidly change direction and 
step while stepping forward, backward, and sideways, over a low obstacle, while time to 
complete the test is measured. The test is valid and reliable in measuring balance in the 
elderly [187] and has been used previously in people with stroke, vestibular disorders 
and peripheral limb amputations [209-211].  
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To perform this test, 4 canes resting flat on the floor were used to form 4 squares. 
Participants were asked to stand in square number 1 facing square number 2 and to step 
as fast as possible into each square in the following sequence; square number 2, 3, 4, 1, 
4, 3, 2, and 1. The time taken to complete the sequence was recorded with a lower time 
indicating a better performance. Timing of the test started when the first foot contacted 
the floor in square 2 and finished when the last foot came back to touch the floor in 
square 1. The following instructions were given to participants, “Try to complete the 
sequence as fast as possible without touching the sticks, facing forward through the 
entire sequence. Make sure that both feet make contact with the floor in each square.” 
Following a demonstration, a practice trial was performed to ensure that participants 
knew the sequence. The average of 3 trials was computed for data analysis. A trial was 
repeated if the subject failed to complete the sequence successfully, lost balance, or 
made contact with a cane during the sequence. Participants who were unable to perform 
the test by being unable to face forward through the sequence and needed to turn to step 
were given a fixed score of 60 seconds that resembles a higher score relative to the 
maximum score obtained by participants who were able to complete the test 
successfully. 
 
3.3.4.2.1.3.2 Timed Up and Go test  
The Timed Up and Go (TUG) test measures the time taken to rise from a seated 
position, walk 3 meters, turn, walk back and sit down again. The test re-test reliability 
of this test has been previously established in the elderly and in people with 
Alzheimer‟s disease (AD) and PD [182, 191, 212]. The scale has also been previously 
used in HD [45, 93] and validated to predict the risk of falls in this population [45].  
 
To perform this test, participants were instructed to sit with their back against a chair 
(48cm from floor to seat with armrests), feet behind a tape marker, and arms resting on 
the armrests of the chair.  Participants were instructed to independently rise on the word 
“go”, comfortably walk a clearly marked distance of 3 meters, turn around a cone, walk 
back to the chair, and sit down with their back against the chair. Time started on the 
word “go” and ended when the participant‟s back returned to the chair. One practice 
trial and 2 timed trials were performed; the 2 timed trials were averaged for data 
analysis.  
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3.3.4.2.1.3.3 Chair Sit to Stand Test   
The 30 second Chair Sit to Stand Test (CSST) quantifies the maximum number of sit to 
stand repetitions that can be performed in 30 seconds (higher scores indicate better 
performance). The test is reliable and valid for use in the elderly and in people with 
balance disorders [213-215]. The test started with the participant seated in the middle of 
the chair, back straight, feet firmly planted on the floor approximately hip width apart 
and the back of lower legs away from the chair. Knees were bent at a 90-degree angle 
with arms crossed over the chest. At the signal "go," the participant rose to a full stand 
(body erect and straight) and then returned back to the initial seated position. 
Participants were encouraged to complete as many full stands as possible within a 30-s 
time limit. Participants were instructed to be fully seated between each stand. While 
monitoring the participant's performance to assure proper form, the completion of each 
correct stand was counted. Following a demonstration, a practice trial of 1 repetition 
was given to check proper form, followed by the 30-s test trial. Participants completed 3 
trials of the test with 2 minutes rest interval. The scores from the 3 trials were averaged 
for data analysis. 
 
3.3.4.2.1.4 Measures of functional performance in ADL  
Functional performance in ADL was assessed using the Physical Performance Test 
(PPT). The PPT is a direct observational test that assesses multiple dimensions of 
physical function (basic and complex activities of daily living [ADL]) with different 
levels of difficulty [189]. The test is valid and reliable for use in the elderly [216] and 
was previously used in people with PD [217]. Scoring of this test is by timing the 
completion of a task. This time is then related to a categorical score of 0 to 4, in which 4 
represents people in the fastest 20% at completing the task, 1 represents those in the 
slowest 20%, and 0 represents those who cannot complete the task. The test includes 
lifting a book and putting it on a shelf, putting on and removing a jacket, picking up a 
penny from the floor, turning 360 degrees and a 50-foot walk. The total score on the 7-
item PPT (out of 28 with higher scores indicating better performance) was used for data 
analysis. 
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3.3.4.3 Measures of participation  
3.3.4.3.1 Measures of health-related quality of life  
The Short Form 36 (SF-36) (version 1) was used to evaluate the perceived health-
related quality of life and level of participation [218]. This survey was previously used 
in HD [117, 119] and has also been validated in numerous populations with 
neurological disabilities [182]. Participants in this study were asked to complete the SF-
36 form on their own and with the help of their carers if required. The scores from the 
eight subscales of the SF-36 which include 1) physical functioning, 2) role limitations 
due to physical problems 3) vitality/ energy 4) bodily pain 5) social functioning 6) role 
limitations due to emotional problems 7) mental health and 8) general health 
perceptions (out of 100 for each subscale with higher scores reflecting better quality of 
life) were used for data analysis. In addition the summary of physical components and 
the summary of mental components (out of 100) were included in the analysis.  
    
3.3.5 Outcome measures and potential confounders 
To estimate the effect of the variables such as gender, age, height and weight on the 
used outcome measures, these variables were recorded at baseline. As an entry to the 
study, medical history including current medication use and living circumstances was 
also obtained from all participants at the baseline. Data of CAG repeat lengths for all 
participants with pre-manifest and manifest HD participants were obtained from 
medical notes or the Registry study.  In addition, the Total Functional Capacity Scale 
(TFC), the UHDRS- cognitive score and the modified motor score of the UHDRS 
(mMS) were recorded at baseline for all HD participants.  
 
3.3.6 Statistical considerations for part 1 
3.3.6.1 Statistical analysis 
Data from all measurements, excluding data from the process evaluation, were analysed 
using the Statistical Package for the Social Sciences (SPSS) Version 18 (SPSS, 
Chicago). Data were visually assessed for normality using histograms and Q-Q plots 
and for variance assumptions using Levene‟s test for equality of variances to allow for 
the appropriate choice of statistical test.  
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To examine the discriminative validity of the clinical outcome measures, differences 
between groups on the outcome measures used were examined using one way ANOVA, 
after checking for appropriate matching according to age, height and weight. Between 
group comparisons were considered significant if p ≤ 0.05. When significant differences 
were identified, post-hoc analyses were conducted using Tukey HSD or Dunnet T3 tests 
(based on whether Levene‟s test was significant or not). In cases where normality was 
not shown, the non parametric Kruskal-Wallis test was used to compare between groups 
(Group comparisons were considered significant if p ≤ 0.05. If significant differences 
for main effect were indicated, post hoc analysis was conducted using Mann-Whitney 
U-tests with appropriate Bonferroni correction for multiple comparisons; an adjusted 
alpha level of 0.017 as significant was applied in this case.  
 
To test convergent validity of clinical tests of mobility, balance, muscle strength, 
functional performance in ADL and health-related quality of life, their correlations with 
measures of gait variability (stride time coefficient of variation) were computed using 
Pearson‟s or Spearman correlation coefficients (dependent on the normal distribution of 
each variable). Data were checked for the presence of outliers using casewise diagnostic 
procedure [219]; cases where standardized residuals (differences between observed and 
predicted values divided by an estimate of their standard deviation) were greater than 
1.96 or lesser than -1.96 were considered to be outliers (i.e. cases where standardized 
residuals were outside 2 SD of their distribution). In addition, data were visually 
inspected with scatter plots. In cases where outliers were identified, data sources were 
firstly checked for coding errors. Additionally, analyses were run with and without the 
outlying cases so as to estimate the effects of outliers on the obtained results.   
 
To evaluate test re-test reliability, a paired t-test or Related Samples Wilcoxon Signed 
Ranks test using the test and re-test scores was used to evaluate if there were any 
systematic differences between the 2 test scores. Furthermore, Bland and Altman 
methods were used to assess the magnitude of differences between the 2 test scores (i.e. 
between-days). Calculations included the mean difference between measures, the 95% 
confidence interval (CI) for the mean differences and the standard deviations of the 
differences [220]. Additionally, differences between scores obtained from day 1 and day 
2 were plotted against the average of the 2 scores for each individual. These graphs 
were helpful to illustrate the size of each difference, the range of the differences and 
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their distributions about zero which represents no difference (i.e. perfect agreement). 
These graphs were also useful to indicate if there were any outliers and biases in the 
measurement or if the differences were related to the size of the mean (i.e. if the size of 
differences increases in cases where the mean increases or decreases). It should be noted 
however, that 95% limits of agreement were not calculated in this study. Rankin and 
Stocks [220] suggest that the sample size should be large enough, preferably larger than 
50 for the limits for agreement to be estimated well. As the sample size in this study 
was small (i.e. 9 subjects in the manifest HD group and 9 subjects in the pre-manifest 
HD group), limits of agreement are not reported here.  
   
The intra-class correlation coefficients (ICC) were calculated to assess both systematic 
and random error that may affect relative test re-test reliability. The ICC (3,k) (the 2 
way mixed model of consistency), either a type 3,1 3,2, 3,3 or type 3,10 ICC was used 
[221]. The ICC (3,1) was used for the BBS, PPT, and SF-36 because final scores on 
these tests were based on a single trial. The ICC (3,2) was used for the TUG, Romberg 
tests and measures of postural sway because final scores for these outcomes were based 
on an average of 2 trials. The ICC (3, 3) was used for the CSST and the FSST because 
the final scores for these tests were based on the average of 3 trials. The ICC (3, 10) was 
used for all gait parameters because final scores were based on the average of 10 trials.  
 
Measures of absolute reliability were expressed as the standard error of measurement 
(SEM) and the minimal detectable change (MDC) [141]. The standard error of 
measurement (SEM) was estimated from the square root of the mean error term from a 
repeated measure ANOVA [222, 223]. The MDC at the 95% confidence level (MDC95) 
was calculated.  The MDC95 was calculated as 1.96 * √2 * SEM. Thus, the MDC95 
values provide information about the confidence limits associated with measurement 
error so that, for example, it can be stated with 95% confidence that an individual‟s 
change score that exceeds the MDC represents a true change. 
 
3.3.6.2 Sample size  
An a priori sample size calculation was conducted for Part 1 of the study. A main aim of 
this part of the project is to investigate the ability of the outcome measures to 
discriminate between participants with pre-manifest HD and healthy controls and 
between participants with manifest HD and healthy controls. Changes in gait variability 
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were chosen as the primary outcome measure for the power calculation, since measures 
in gait variability were found to be the most sensitive and specific gait parameters in 
distinguishing between healthy controls and people with HD  in a previously published 
study by Rao et al [40]. In this study, authors reported results which suggest a mean 
difference for stride length coefficient of variation of 4.6 between pre-manifest HD and 
healthy controls, 4.1 between manifest HD and healthy controls and 2.3 between 
manifest and pre-manifest HD. This equated to effect size index of 0.7 based on a 
formula reported by Portney and Watkins [178] for estimating effect sizes when 
comparing between groups using the one way ANOVA. In the same study by Rao et al 
[40], the authors reported results which suggest a mean difference for step time 
coefficient of variation of 3.0 between pre-manifest HD and healthy controls, 5.1 
between manifest HD and healthy controls and 2.1 between manifest and pre-manifest 
HD. This equated to effect size index of 0.4. As this was the first study to report deficits 
in gait variability along the spectrum of the disease and there is a possibility that effect 
size of 0.7 for stride length coefficient of variation is overestimated, an effect size of 0.4 
was used in this study for sample size calculations. Using an effect size of 0.4, a sample 
of 20 participants in each group was required, using a power of 0.8 and an alpha of 0.5 
(two tailed) [178].    
 
In addition 20 participants were required to detect a Pearson‟s correlation coefficient of 
0.6 with a power of 0.8 and an alpha of 0.05 (two-tailed). A sample of 18 participants 
(tested twice) was also sufficient to be able identify an intra-class correlation coefficient 
(ICC) of 0.8 as being significantly greater than an ICC of 0.45 (moderate) which would 
be the minimally accepted value [224]. This sample size was both feasible for 
recruitment purposes in this study and sufficient to identify substantial [225] reliability 
(Appendix 6).  
 
3.4 Part 2: Evaluating feasibility, acceptability and benefits of a home-based 
exercise programme  
3.4.1 Study design  
Feasibility, acceptability and benefits of a home-based exercise programme for people 
with manifest HD at early to mid stage of the condition were evaluated at this part of the 
study which comprised 2 phases. In the first phase, the existing participants with 
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manifest HD who completed the baseline assessments (n=25) were randomly assigned 
to either early intervention group (n=13) or delayed intervention group (i.e. control) 
(n=12). The delayed intervention group (i.e. control) initially received standard care. 
This involved no specific exercise interventions. Whilst this was not a perfect control 
group (standard care can be as complex as the intervention being evaluated and may 
change with time) [69], it was the best compromise that could have been achieved at 
this stage of the project. The early intervention group received a home-based exercise 
programme for 8 weeks. During these 8 weeks, participants in the control group were 
advised not to change their routine related to performing physical activity and were 
asked to record their weekly physical activity in a diary (Appendix 2). After 8 weeks, 
both groups were assessed (first follow-up assessment). At this point, the exercise 
programme for the early intervention group was completed and the intervention was 
offered to the delayed intervention group (i.e. control) which compromised of the start 
of the second phase of this part of the study (see Figure 3.1 for the flow chart of the 
study). This design facilitated comparison of intervention with no intervention (i.e. 
control) whilst at the same time assured that each participant in the study was offered 
the intervention at a specific time point. Following the first follow-up assessment, both 
groups were reassessed after an additional 8 weeks on the main outcome measure (stride 
time coefficient of variation) (second follow-up assessment). In addition, a debriefing 
was undertaken at the second follow-up assessment as to whether the early intervention 
group continued with any of the programme after cessation of formal exercise input. 
Second follow-up assessments, therefore, provided information on any carry over (in 
the main outcome measure; gait variability) as well as adherence with home-based 
interventions for the early intervention group, who received the intervention following 
the initial baseline and then had no intervention after the first follow-up assessment. The 
second follow-up assessments also had the potential to enhance adherence and 
commitment specifically in those allocated to the delayed intervention group (i.e. 
control group) [69, 70]. Completion of the intervention was followed by a process 
evaluation that aimed to ascertain participants‟ and carers‟ opinion of the process and 
benefits of involvement in a home-based exercise programme (see section 3.4.4 for 
more information about the process evaluation).  
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3.4.2 Randomization  
Participants were randomly allocated to either early or delayed intervention  groups 
using a minimisation procedure [226] which is an accepted alternative method to 
stratified randomization [227, 228]. With minimisation, allocation of the next 
participant enrolled in the study to a particular group depends on the characteristics of 
those participants already enrolled. Minimisation has the advantage, particularly in 
small trials, that there will be only minor differences between groups in those factors 
used in the allocation process [227]. Such balance is particularly important where there 
are strong prognostic factors that would impact on the outcome.  
 
For the purposes of this project the randomization was carried out with the aid of the 
MINIM software [229] that is designed specifically to perform randomization in clinical 
trials by the method of minimisation. MINIM assigns the next participant to the study 
arm that would best minimise the imbalance between groups based on the categories 
provided. MINIM calculates the balance between the groups, using the weighting of 
each included variable using a method described by Pocock [228]. This balance is 
calculated assuming the next participant will be allocated to each of the possible 
treatment groups in turn (usually 2). It then takes into account the assignment that 
would result in minimal imbalance. In cases where the 2 groups have the same 
imbalance, the next participant will be allocated with a probability of 0.5 to each.  
However if there is a preferred allocation, the next participant will be allocated to the 
group that would best minimise imbalance with a probability of 0.7.  
 
Using the MINIM software helped to adhere to the randomization protocol as the study 
progressed. Two prognostic factors were considered to potentially impact on the 
outcome of this study and needed to be balanced between the 2 study groups at the 
baseline. These factors were age and severity of the functional impairment as based on 
Total Functional Capacity (TFC) scores. These 2 factors were treated equally (i.e. both 
age and disease severity were given the same weighting during the minimisation 
procedure. Using MINIM software, age was classified into 6 categories as follows: 1) 
less than 30, 2) between 30 and 39, 3) between 40 and 49, 4) between 50 and 59, 5) 
between 60 and 69, 6) more than 69. Similarly, the TFC was classified into 4 categories; 
1) TFC scores correspond to stage I (11-13), 2) TFC scores correspond to stage II (7-
10), 3) TFC scores correspond to stage III (3-6), 4) TFC scores correspond to stage IV 
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(1-2). Using these categories, MINIM software helped to randomly allocate participants 
and at the same time ensure balance between the study groups in terms of age and 
disease severity as determined by the TFC score. 
 
3.4.3 Protocol of the exercise programme  
Participants were asked to perform exercises at home 3 times a week using a purpose 
developed exercise DVD. The exercise DVD was structured based on consultations 
with therapists working routinely with people with HD as well as findings from the 
exercise literature on other neurodegenerative disease. The included exercises were 
chosen to target the physical factors that are believed to be impaired in HD, such as 
balance, and focused on practicing task-specific activities that are believed to be limited 
in this population.   
 
Overall, the exercise DVD consisted of 5 sections; the first section focused on warm up 
and flexibility activities; the second, third and fourth sections focused on strength, and 
balance exercises specifically tailored for people with HD and the fifth section focused 
on cooling down and included relaxation, stretching and breathing techniques (Table 
3.4).  The balance exercises were divided into 2 sections in which the first section 
focused on practicing narrowed and altered functional base of support exercises. The 
easiest of these exercises required participants to maintain body position in standing 
whilst the medial malleoli of the feet are touching each other. To progress in difficulty, 
these movements were then performed while 1) standing with eyes closed, 2) standing 
on one leg, 3) standing, placing one foot in front of the other, with eyes open and then 
closed, 4) forward and side lunges. At the easiest level, these movements could be 
performed while holding onto a table, chair or countertop. The progression was then to 
perform these movements without holding and touching the countertop only as needed 
for balance. The second section of the balance exercises focused on performance of 
task-specific activities that required alterations of dynamic balance such as standing and 
sitting, turning and stepping up onto stairs. Each of these exercises was performed for 1 
minute and the set of exercises was repeated a number of times on completion of the 
first circuit. To progress in difficulty the number of repetitions of each of the exercises 
was increased and the number and length of rest breaks decreased. 
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Table 3.4: Sections of the exercise DVD 
 
 
All participants were provided with the exercise DVD, which was individually 
prescribed with sub-sections based on the participants‟ specific abilities; suitable 
exercises from the DVD (based on what the participant was able to do) were chosen and 
taught to participants by the researcher (PhD student). Participants were encouraged to 
progress their exercising by gradually increasing the number of repetitions whilst 
decreasing the number and length of rest breaks until they were able to perform each 
exercise in the same manner and frequency as indicated in the DVD. At this point, 
participants were encouraged to increase the difficulty of the exercise by increasing the 
level of progression.  
 
In addition to performing the exercises from the DVD, participants were instructed to 
undertake a 30 minute gradual progressive walking programme. Participants were asked 
to walk once a week on level ground around their homes and neighbourhoods.  
Section 1: Flexibility and warm up Section 2: Balance and coordination 
 Neck stretches 
 Shoulder rolls  
 Horizontal shoulder flexion 
 Arm circles 
 Hand stretches 
 Ankle circles 
 Calf muscle stretches 
 Hamstring stretch 
 Lying supine twist 
 Quadriceps  stretch 
 Prone press ups 
 Kneeling child‟s pose 
 
 Standing with feet together, eyes open  
 and then closed 
 Standing on one leg 
 Tandem standing 
 Forward lunges 
 Side lunges 
 
1.  
 
Section 3: Circuit resistance training Section 4: Strengthening 
 Sit to stand repetitions 
 Shoulder press with weights 
 Squatting 
 Shoulder abduction with weights 
 Trunk rotations & reaching with weights 
 Step Ups 
 Instructions on getting on/off floor 
 Bridging 
 Alternate Arm and Leg Raises 
 Plank 
Section 5: Cool down and relaxation  
 Cat/Camel stretch 
 Trunk Rotations 
 Breathing exercises 
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Participants were instructed to walk at their freely chosen pace and to take rest breaks 
during walking if required. Participants were encouraged to progress their walk by 
decreasing the number of breaks and increasing the amount of time they could walk 
until they reached the 30 minutes. Participants were also asked to keep a record of their 
exercise programme in an exercise diary (Appendix 2).  
 
All participants were supported by a researcher (the PhD student) who conducted an 
initial home visit to ensure correct execution of the exercises. A pre-planned schedule 
was used to ensure the comprehensiveness of the topics discussed at the home visit for 
each participant (Appendix 3). During the home visit, the potential benefits of the 
exercise programme were discussed with participants. The relevance of doing each of 
the exercises was communicated. Advice about intensity of the exercises, equipment 
required, precautions and postural instructions was also provided. In addition, 
instruction and demonstration on how to use the DVD and to perform the exercises was 
given by the researcher during this home visit. When introducing the walking as an 
exercise, the researcher spent time explaining to the participant the desired level of 
intensity. Participants were instructed to walk at normal pace. Preferably, participants 
were instructed to walk at a speed that does not cause shortness of breath. Participants 
were instructed to walk for whatever length of time they were able at first with the goal 
of increasing the time until they could walk for at least 30 minutes. All participants 
were advised on recognition of any warning signs, such as severe pain, at which to 
cease the execution of exercise and they were provided with the telephone contact 
number of the researcher to ask for any advice. All discussions and instructions during 
the home visit were performed in the presence of the carer (if applicable) who was 
asked if he/she would help the participant if needed and in such case, carer‟s 
involvement was discussed and agreed with the participant.  
 
All participants were provided with weekly phone calls by the same researcher to 
monitor their progress, encourage them to continue their exercises and discuss any 
issues which might arise. A pre-planned schedule (Appendix 3) was also used for the 
phone calls to ensure the comprehensiveness of the topics discussed with each 
participant. During the phone calls, participants were asked if they performed the 
exercises from the previous week, how often they performed the exercises, what 
exercises they performed, what exercises they would do in the following week, if they 
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had difficulties in performing any of the exercises and if they had any concerns that they 
wanted to discuss.  
 
3.4.4 Outcome measures  
Outcome measures which were described in Part 1 were evaluated at baseline and 8 
weeks post intervention in both groups. The primary outcome measure was gait 
variability due to the reported sensitivity to disease progression in HD [39, 40, 107, 
112] and the potential that it has to serve as a clinically relevant parameter in the 
evaluation of mobility and in response to therapeutic interventions [104]. The focus in 
this study was on one parameter of gait variability; the temporal variability in the gait 
cycle duration (i.e. stride time) which is represented using the stride time coefficient of 
variation. Variability in stride time reflects the walking rhythm; it has reliance on 
central and peripheral inputs and can be viewed as the final output of the locomotor 
system [104, 230]. Stride time may be an important parameter to consider, particularly 
in HD, as disorders of footstep timing are the most obvious gait deficits in this 
population. For these reasons variability in stride time was used as the primary outcome. 
Secondary outcomes included the other measures of gait (gait speed and stride time), 
measures of balance, muscle strength, community walking, other measures of mobility 
and functional performance of ADL and health-related quality of life as well as a 
disease-specific motor measure (the mMS) (detailed description of the used outcome 
measures is provided in Part 1 in section 3.3.4).  
 
3.4.5 Quality control measures 
All assessments of outcome measures were undertaken by the researcher (the PhD 
student). The researcher was not blinded to group allocation; however standard 
procedures were used (see Appendix 4 for standard operating procedures of outcome 
measures) and all tests were based on objective measures or were self-administered (i.e. 
SF-36). Tests that were potentially affected by examiner bias (i.e. BBS and mMS) were 
videotaped and rated by a blinded assessor using an established methodology [231]. The 
blinded assessor had no previous connection with the participants and acted purely as a 
video assessor. After recording, video clips were edited to remove time and date 
identifiers. Each clip was given a code in which the order of the pre and post 
intervention clips was reversed for the odd numbered participants so that the clip after 
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intervention was shown to the blinded assessor before the relevant pre-intervention clip. 
The blinded assessor was informed that the 2 clips of each participant were separated in 
time by about 8 weeks in which the participant may or may not have received the 
intervention and that the clips did not necessarily appear in chronological order. This 
was performed to avoid bias based on the order of presentation of the clips. 
 
3.4.6 Specific statistical considerations for part 2 
3.4.6.1 Statistical analysis  
Data analysis of the interventional study was carried out on complete cases; data from 
all participants who completed the first follow-up assessments were included in the 
analysis. Analysis of covariance (ANCOVA) was used to compare between groups in 
which first follow-up scores were compared across groups after adjustment for any 
observed chance differences at baseline [147]. To aid data interpretation, scatter plots of 
individual responses were produced; scores at baseline of each participant were plotted 
against the change scores, categorized by group allocation for all variables.  Effect sizes 
based on the difference in the change score from baseline to first follow-up between the 
study groups were calculated for each of the outcome measures. Data at the second 
follow-up assessment on the primary outcome measure (stride time coefficient of 
variation) were analysed only descriptively.  
  
3.4.6.2 Sample size  
A main aim of this part of the study was to investigate the benefits of a home-based 
exercise programme in reducing gait variability in people with Huntington‟s disease. 
Changes in gait variability were chosen as the main outcome measure for the power 
calculation since they serve as sensitive and clinically relevant parameters in evaluation 
of fall risk [104]. Consequently, available data in the literature for changes in gait 
variability in HD among people who are at risk of fall and people who are not at risk of 
falls, has been investigated. Grimbergen et al [38] reported results that suggest a mean 
difference of 2.3 for a measure of gait variability (stride length coefficient of variation) 
between fallers and non-fallers in HD (mean (SD) in fallers and non-fallers were of 6 
(3.5), 3.7 (1.4) respectively). This equated to an effect size of 0.9. Using the effect size 
of 0.9, the number of subjects required for this part of the study to demonstrate a 
treatment effect was 40 for 2 groups of 20 subjects. This is derived from a power 
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calculation for t-tests and is based on requiring a power of 0.8, significance level of 0.05 
and a two tailed test. 
  
Although the initial power calculations determined that 20 subjects were needed per 
group, the study was stopped prior to reaching this target because of the difficulty in 
finding participants who met the inclusion criteria and were willing to participate. The 
ratio of subjects screened to subjects enrolled and the reasons for exclusion were 
documented and provide data for feasibility of recruitment in future randomized trials. 
More details about recruitment and reasons for exclusion are provided in Chapter 5.    
 
3.4.7 Process evaluation  
Quantitative and qualitative data were combined to provide multidimensional 
information about participants‟ adherence to the exercise programme and their opinions 
of the process and benefits of involvement in the study. Self reported adherence was 
obtained using the exercise diaries and self reported motivation, in terms of involvement 
in the exercise programme, was evaluated using the Intrinsic Motivation Inventory 
questionnaire. In addition, perceived benefits and factors that could have impacted on 
the adherence to the exercise programme were explored using semi structured 
interviews that were conducted with participants and their carers (if applicable) on 
completion of the exercise programme. 
 
3.4.7.1 Adherence rate  
Average adherence rates across the study period were calculated as the number of 
exercise sessions reported as a percentage of potentially expected exercise sessions 
prescribed for the 8 weeks. For the purpose of analysis, a cut-off point for acceptable 
adherence was defined; participants were considered to have a good adherence if they 
reported performance of at least 50% of the prescribed sessions.  
 
3.4.7.2 Participants’ motivation: Intrinsic Motivation Inventory subscales 
Participants' self report about their perceptions of their involvement in the exercise 
programme was assessed using the Intrinsic Motivation Inventory (IMI) scale [232]. 
The IMI is a multidimensional measurement tool designed to assess participants' 
subjective experience related to a target activity. It consists of a multi-item 
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questionnaire assessing the subject's interest/enjoyment, perceived competence, effort, 
value/usefulness, felt pressure and tension, and perceived choice while performing a 
given activity. The interest/enjoyment subscale is considered a self-report measure of 
intrinsic motivation. The perceived choice and competence concepts are regarded as a 
positive predictor of intrinsic motivation. The pressure/tension is theorized to be a 
negative predictor of intrinsic motivation. The full version of the questionnaire includes 
45 items and 7 subscales. A shorter version of the questionnaire with only 5 subscales 
that was found to be valid and reliable in neurological patients was used in this study 
(Appendix 4) [168]. For each item of the IMI scale, a response on a scale of 7 points 
indicates how true the statement of the item is (1 indicates not true at all and 7 indicates 
very true). Lower score of the pressure/tension subscale and higher scores of all the 
other subscales indicate a positive outcome.   
 
3.4.7.3 Semi structured interviews  
Semi-structured interviews were used mainly to explore perceived results and factors 
that impacted on usability to the exercise DVD and adherence to the exercise 
programme. A schedule that included both open and closed questions (Appendix 5) was 
used to serve as a guide to the topics covered during the interview. Each interview 
focused the discussion on debriefing the rate of adherence during the course of the 
programme and exploring how people used the exercise DVD at home. The main carer 
was present at the interview in most cases (n=16); carers were invited to participate in 
the interviews and to provide clarifications where necessary. All the interviews were 
audio recorded and lasted between 30 to 45 minutes.  
 
The interviews were transcribed in full into text. This process of full transcription 
helped to strengthen the trustworthiness of the data by avoiding selective recording of 
the information [233]. Ensuring the truth value (credibility) [234] of the study, the 
accuracy of the transcripts was confirmed by an independent researcher and by 
consultation with participants. 
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3.4.7.4 Data analysis for process evaluation 
3.4.7.4.1 Quantitative analysis  
Data from the IMI scale were analysed descriptively in which average and standard 
deviations of each subscale were calculated. Correlations between adherence rate, IMI 
subscales, stride time CV and UHDRS-cognitive score were calculated using the 
Spearman correlation coefficient to determine interrelationship between these factors 
and in particular to explore if the physical and cognitive impairments as well as the 
participant‟s subjective experience on their involvement in the programme would relate 
to the adherence rate. 
 
3.4.7.4.2 Qualitative analysis  
A content analysis approach [235] was used to analyse data from the interviews. 
Responses from closed questions were analysed using a priori coding, while responses 
from open questions were analysed using an inductive approach in which codes 
emerged from the data. The qualitative data analysis package NVivo (version 8.0. 163, 
QSR International Pty Ltd) was used to aid the analysis process. A procedure of coding 
and recoding was used [234]; the transcripts were read and re-read to do further coding 
and refinement. This process was continuous and entailed comparing codes from an 
interview with the codes from a newer interview, which helped to identify prompt 
questions. After open coding for the first 8 transcripts, the remaining transcripts were 
coded using the existing codes and with adding new codes on encountering data that did 
not fit into existing codes. Following identification of codes from each transcript, the 
modeller option in NVivo [236] was used to help with ordering the codes, linking them 
together and clustering them into categories and subcategories. The transcripts with 
their codes were made available to an independent researcher (the same researcher who 
checked the accuracy of the transcripts) for review and through discussion we refined 
and defined the codes and their relationship to each other, and to the main question that 
was being investigated. Final codes were agreed within the research team and were sent 
to the participants for member checking in which participants agreed that interpretations 
of the researcher represented their ideas. Final codes were further cross checked and 
triangulated with information obtained in relevant available literature, thus confirming 
content and final conclusions [234].  
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3.5 Ethical considerations  
3.5.1 General ethical considerations  
Local Research Ethical approvals were obtained from South East Wales Research 
Ethics Committee for all aspects of this study. All participants were required to provide 
informed consent. Participants were free to withdraw at any time without giving any 
reason.  
 
The researcher (the PhD student) conformed to the University and NHS Trust lone-
worker policies during the home visits. A risk assessment of the site visit was carried 
out for each home visit. The initial contact with the research subject was made to 
arrange a suitable visit time and to explain the purpose and content of the visit and 
answer any initial queries participants may have. The means of transport to the home 
and having adequate information on safe routes to and from the destination were 
clarified along with a clear itinerary of the visits (including appointment times and the 
names, addresses and contact numbers of the subjects to be visited). Arrangements were 
put in place for communicating with the supervisor. In this case the PhD student carried 
a mobile phone at all times and contacted the supervisor on arrival and on completion of 
the home visit. The PhD student was also provided with a personal alarm system to be 
used in case of an emergency. 
 
Carers were asked if they were willing to be involved in the process evaluations. Data 
were pseudonymised and stored electronically on hard disk (and not placed on a server 
or network) in a secure location within the School of Healthcare Studies (SOHCS), 
Cardiff University. A laptop computer was used for the clinical assessment procedures; 
however data would not be permanently stored on these computers. All computers that 
were used to store data were password protected. Data were transferred to the main hard 
drive via USB data transfer device on completion of each specific clinical assessment 
procedure. Any data that was collected via the laptop computer were pseudo-
anonymised. The laptop did not hold any patient‟s identifiable data. Specifically, a 
unique code name (pseudonym) was calculated from initial personal data obtained. The 
link between the pseudo-anonymised codes and patients‟ personal details was stored 
separately in a lockable filing cabinet in a secure location as per the HD Registry study 
code.  
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All conversations that took place during the process evaluation were audio recorded for 
the purposes of analysis. Consent for audio recording was obtained beforehand. All the 
recorded tapes were destroyed once they had been transcribed.  To ensure the accuracy 
of the transcript contents, a copy of the transcript was sent back to the participants 
requesting their comments to ensure that the transcript represented their ideas. All audio 
and video records obtained were stored in locked cabinets in the School of Health Care 
Studies, Cardiff University. Audio and video information and data have not been used 
for commercial purposes. Data will be retained for a period of 15 years. This retention 
period complies with Guidelines set out by the Cardiff University Research Governance 
Framework. Data were stored electronically and in paper form in Cardiff University in 
the School of Health Care Studies. 
 
3.5.2 Specific ethical considerations  
3.5.2.1 Risk during assessment  
The clinical assessment that was conducted was considered unlikely to cause undue 
stress to participants. All participants were fully informed of testing procedures before 
participation, and made aware that they could withdraw from the study without giving 
reasons at any time. Individuals were carefully monitored during testing by the 
researcher (PhD student). The care and comfort of the participants was ensured at all 
times.  
 
Additionally, potential risks anticipated from wearing the mobility monitors were also 
considered. The StepWatch Activity Monitor (SAM) is a commercially available, 
battery operated accelerometer device. It has been used in previous long term activity 
monitoring studies [128, 208] and the device was considered to pose minimal risk to the 
research subjects. The device is constructed in a sealed case which is routinely visually 
inspected for damage.   
 
3.5.2.2 Potential risk of involvement in the exercise programme 
3.5.2.2.1 Risk of falls 
Potential side effects for those study participants involved in the exercise programme 
were considered. One of the foremost concerns of physiotherapists working with HD is 
that the person might fall whilst exercising [80]. Some studies suggest a U-shaped 
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association, in which the most inactive and the most active people might be at the same 
risk of falls [237]. A number of strategies were utilised in this study to ensure 
participant‟s safety whilst exercising. These included providing clear illustration and 
instructions of the risk factors, involving the carer (if applicable), providing appropriate 
prescription of exercises and providing a home visit at the beginning of the treatment 
programme to make sure of the ability of the participant to correctly perform the 
exercises and the weekly phone calls to monitor progress.  
 
3.5.2.2.2 Risk of muscle damage  
Another side effect which has been considered for those study participants involved in 
the exercise programme was the risk of muscle damage. In people with HD, there may 
be a risk of muscle damage due to impaired mitochondrial energy function in muscle 
cells [238] and high-intensity aerobic exercise in people with HD has been suggested to 
cause muscle damage [97, 239]. The proposed exercise programme was low intensity 
and did not involve any heavy load bearing exercise or high intensity cardiovascular 
intervention and therefore posed minimal risk to participants. All participants were 
advised on recognition of any warning signs at which to cease the execution of exercise, 
and provided with a telephone contact number of the researcher (PhD student) to ask for 
any advice. 
 
3.6 Project management (study steering group) 
The study was overseen by a Study Steering Group (SSG) which was independently 
chaired and included an independent statistician and a representative of service user. 
The steering group met 3 times during the course of the study either face to face or by 
audio conference. The SSG acted as data monitoring and ethics committee as the study 
was very small. The SSG provided overall supervision of the study and ensured that it 
was being conducted in accordance with the principles of Good Clinical Practice and 
the relevant regulations. The SSG agreed the study protocol and any protocol 
amendments and provided advice to the investigators on all aspects of the study. The 
SSG monitored the progress of the study, including the recruitment, data completeness, 
data analysis and ensured that there were no major deviations from the study protocol. 
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4 Results and discussion: Part 1 
 
4.1 Overview 
This chapter presents the results and discussions of Part 1 of the study, which aimed to 
evaluate validity and reliability of a specific battery of outcome measures in both 
manifest and pre-manifest HD groups. This psychometric data of the outcomes in the 
manifest HD group was of use in interpreting the results from the exercise 
interventional study that was conducted as part of this research (presented in Chapter 5). 
Furthermore, psychometric data for the outcomes in the pre-manifest HD group were 
useful to make inferences about the best outcomes that can be used in future trials of 
exercise intervention at this early stage of the disease.  
 
The measures were chosen to reflect a range of physical impairments, activity 
limitations and participation restrictions related to mobility deficits seen in people with 
HD. These outcomes were structured according to the International Classification of 
Functioning (ICF) [91] (Figure 4.1). Detailed discussion regarding the choice of the 
measures that were evaluated in this study and their categorization in line with the ICF 
model is provided in Chapter 2 and Chapter 3.  
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Figure 4.1: Outcome measures evaluated in this study (structured according to the International 
Classification of Functioning (ICF) model) 
 
 
 
 
As depicted in Figure 4.1, physical impairments in body functions were represented by 
a disease-specific motor scale (the modified motor score of the UHDRS (mMS)) as well 
as measures of balance and muscle strength. Balance was assessed using the Berg 
Balance Scale (BBS), the Romberg (RT) and Sharpened Romberg (SRT) tests and 
measures of postural sway. Muscle strength was assessed using the Maximal Voluntary 
Isometric Muscle Contraction (MVIC) of knee flexors and extensors which was 
evaluated using the Kin-com isokinetic testing chair dynamometer unit. 
 
Activity was represented by a number of mobility measures as well as a measure of 
functional performance of activity of daily living (ADL). The main component of 
mobility which was assessed was walking. Walking measures included gait speed and 
gait variability, which were quantified using the GAITRite system. Measures of walking 
carried out in the community by participants over an extended period were recorded 
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(Measures of participation)
Measures of health-related 
quality of life 
Short Form 36
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using a mobility monitor (StepWatch Activity monitor). Other components of mobility 
activities that are believed to be limited in HD such as sit to stand, stepping and turning 
[114-116] were assessed using other measures of mobility which included the Four 
Square Step Test (FSST), the Timed Up and Go (TUG) test and the 30 seconds Chair 
Sit to Stand test (CSST). Functional performance of ADL activities that involve fine 
upper motor function such as writing as well as “coarse” upper motor function such as 
dressing was assessed using the Physical Performance Test (PPT). Levels of 
participation were represented by a health related quality of life measure; the Short 
Form (SF-36) was used to provide a measure of health-related quality of life in this 
study. 
 
Validity and reliability data of the above listed outcomes are presented here in 3 
sections. In the first section, discriminant (known-groups) validity (i.e. sensitivity) 
which is examined by the ability of the outcomes to distinguish between the 3 study 
groups (manifest HD, pre-manifest HD and healthy controls) [177, 178] is illustrated. 
Individuals with manifest HD, pre-manifest HD and healthy controls are known to be 
clinically different. Thus outcomes in this study were considered to have good 
discriminant validity in the manifest HD if they were able to differentiate between 
individuals with manifest HD and healthy controls. Similarly outcomes were considered 
to have good discriminant validity in the pre-manifest HD if they were able to 
differentiate between individuals with pre-manifest HD and healthy controls. Group 
differences were assessed using either a one-way ANOVA (in the cases of normal 
distributions) or a Kruskal-Wallis test (where normality could not be assumed) with 
post-hoc analysis performed whenever differences between groups were identified (see 
Chapter 3 for more details about methods and the statistical analysis that was applied). 
 
In the second section of the results, concurrent-convergent validity of outcomes of 
balance, muscle strength, mobility, functional performance in ADL and health-related 
quality of life is presented. Concurrent-convergent validity of these outcomes was 
assessed by the strength of their correlations with a measure of gait variability (stride 
time coefficient of variation). Gait variability was chosen as a criterion measure because 
it is a well validated measure in HD and is known to predict functional status in this 
population [38-40, 107, 109]. Associations between the tests were statistically examined 
using Pearsons or Spearmans correlations (where normality could not be assumed).  The 
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strength of the correlations was classified according to the criteria of Landis and Koch 
[240] , which are shown in Table 4.1.  
 
 
Table 4.1: Criteria to evaluate the strength of correlations 
 
Correlation 
coefficient 
Interpretation of strength of agreement 
<0.000 Poor 
0.00-0.20 Slight 
0.21-0.40 Fair 
0.41-0.59 Moderate 
0.60-0.79 Substantial (high) 
0.80-1.00 Almost perfect (very high) 
 
 
For the interpretation of the results and according to the criteria provided in Table 4.1 
above, 2 measures are considered to correlate substantially if the correlation coefficient 
is of 0.6 or above. For this reason, a correlation coefficient of 0.6 is used as a cut-off 
point to determine if an outcome measure has a good concurrent-convergent validity. 
Outcomes of balance, muscle strength, mobility and health-related quality of life were 
considered to have a good concurrent-convergent validity if they correlated highly or 
very highly with measures of gait variability (correlation coefficient of 0.6 or above).  
 
In the third section of the results, data about relative and absolute reliability of the 
outcomes in both individuals with manifest HD and individuals with pre-manifest HD is 
presented. Relative reliability which is usually used to examine the degree of 
relationship between 2 or more measurements is illustrated in this chapter by providing 
the intraclass correlation coefficient (ICC) of each of the outcomes. According to 
Portney and Watkins [178] an ICC of at least 0.7 is sufficient for group comparisons. 
Thus an outcome can be considered to have a high relative reliability if the ICC value is 
larger than 0.7. However, it should be noted that the use of the ICC values is limited by 
the fact that they are prone to dependency on the heterogeneity of the sample; a high 
ICC may be obtained when there is a large range of scores in the sample, despite there 
being large within-subject differences in the actual scores between repeated 
measurements and vice versa [141]. For this reason, the interpretations of the ICC 
values obtained for each of the outcomes in the sections below are considered along the 
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knowledge of their absolute reliability [179]. The absolute reliability is presented using 
the standard error of measurements (SEM). The SEM provides information about how 
much within subject variability can be expected on scores on repeated measurements 
[141, 179]. To be clinically useful, an outcome must have a small SEM to be able to 
detect real difference from a specific factor [178]. Although no clear criteria are 
available for acceptable SEM scores of the outcome measures used in this study, it has 
been suggested that SEM values less than 10% of the total range of measurements in 
general are acceptable [241, 242]. Thus, for the interpretation of the results from this 
part of the study, the cut-off point of 10% of the total range of scores was used to 
determine if the amount of variability of an outcome on repeated assessments as 
determined by the SEM is acceptable.  
 
In addition to the SEM, the minimal detectable change (MDC) is presented. The MDC 
represents the minimal amount of change in a subject‟s status that is not due to natural 
variation in measurement or due to error [141, 178]. The values of the MDC of each of 
the outcomes that is presented in this chapter will be used in the following chapter 
(Chapter 5; results from the interventional study) to determine whether any statistically 
significant changes on the outcomes in the exercise intervention can be attributed to real 
changes in the outcomes or are subject to measurement error or natural variations of the 
tests. 
   
In addition to the above, data from Bland and Altman methods for evaluating test re-test 
reliability is presented in the reliability section of the results. This method is used to 
assess the magnitude of the differences between 2 scores (i.e. the agreement between 
the 2 scores); whether these differences are acceptable and whether there are any 
directional biases in the measurements. Data that are presented in this section includes 
the mean of the differences between day 1 and day 2 scores for each of the outcomes as 
well as the standard deviation and the 95% confidence interval (CI) of the differences. 
For data interpretations, an outcome measure is considered to have a better agreement if 
the mean of the differences is close to zero and the standard deviation of the differences 
is relatively small [220]. The 95% CI of the differences is used to inform if there is a 
bias in the measurements; if zero does not lie within the interval it can be concluded that 
a bias exist between the 2 scores [220]. To aid the data interpretation, scatter plots of the 
difference scores between day 1 and day 2 of each individual plotted against the average 
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of the 2 scores for each of the outcomes are presented. These graphs are used to 
illustrate the size of each difference, the range of the differences and their distributions 
around zero (i.e. perfect agreement). These graphs are also used to visually check if 
there are outliers, bias in the measurement or if the differences are related to the size of 
the mean (i.e. if the size of differences increases in cases where the mean increases or 
decreases).  
 
4.2 Results  
For each parameter the assumption of normality was assessed visually by inspection of 
histograms and Q-Q plots to allow for the appropriate choice of statistical test.  
Measures of functional performance in ADL and health-related quality of life were 
normally distributed. All the measures of gait, community walking, postural sway, the 
CSST and health related quality of life were normally distributed; measures of muscle 
strength,  the BBS and the total score of the RT and SRT tests were right skewed whilst 
the measures of muscle strength, FSST and the TUG were left skewed, hence non-
parametric tests were applied in these cases.  
 
4.2.1 Validity of outcome measures  
4.2.1.1 Participants  
Twenty five individuals with manifest HD, 17 with pre-manifest HD and 25 healthy 
controls were recruited for this part of the study (Part 1). Demographic data is presented 
in Table 4.2 below. Healthy controls were matched with the individuals with manifest 
and pre-manifest HD for gender, age, height and weight. All participants with pre-
manifest HD scored either 0 (n= 11) or 1 (n=6) on the diagnostic confidence score of 
the Unified Huntington‟s Disease Rating Scale (UHDRS); confirming no clinically 
noticeable motor symptoms [46]. The individuals with pre-manifest HD had a mean 
(SD) score for the modified motor score of the UHDRS (mMS) of 1.5 (1.6) and for the 
Total Functional Capacity (TFC) of 13 (0) which indicates that clinical examination 
detected no or minimal specific impairments and no functional limitations in these 
individuals. The manifest HD subjects had a mean (SD) score for the mMS of 23.9 
(7.9). The mean number of years since symptom onset in this group was 5.7 years, 
ranging from 1 year to 15 years. In addition, the mean TFC was 6.6, ranging from 2 to 
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11. The mMS and the TFC scales were not administered in healthy controls because 
they were not at risk of HD. 
 
 
Table 4.2: Demographic characteristics of participants 
Demographic (mean ± SD) Healthy controls Pre-manifest HD Manifest HD 
Age in years 
a
 49.3 ± 12.1 43.6 ± 12.5 52.1 ± 12.9 
Gender (Males/Females) 12/13 9/8 11/14 
Weight (kg) 
a
 74.7 ± 18.7 82.2 ± 23.5 69.2 ± 11.9 
Height (cm) 
a
 168.3 ± 11.3 169.7 ± 10.5 167.5 ± 9.1 
mMS (unit) NT 1.5 ± 1.6 23.9 ± 7.9 
TFC score (unit) NT 13 ± 0 6.6 ± 2.4 
Years since symptom onset NA NA 5.7 ± 3.5 
SD, standard deviation; mMS, modified motor score of the Unified Huntington‟s Disease Rating 
Scale; TFC, Total Functional Capacity scale; NT, Not Tested; NA, Not Applicable.  
a
 An ANOVA test did not demonstrate significant differences in average age (F=2.3; p=0.1), height 
(F=2.5; p=0.8) and weight (F=0.2; p=0.1) across the 3 groups.  
 
 
4.2.1.2 Discriminant validity 
4.2.1.2.1 Measures of physical impairments in body structures and functions  
4.2.1.2.1.1 Measures of balance  
Descriptive statistics of all measures of balance are presented in Table 4.3 below. Most 
healthy controls (16/25; 64%) and participants with pre-manifest HD (8/17; 47%) 
reached the ceiling score of 56 on the BBS. Furthermore, in the RT and SRT, all healthy 
controls and pre-manifest HD participants reached the 30 second ceiling on the tasks of 
standing with feet apart and feet together with either eyes open or closed. The ceiling 
effect was also observed on the SRT with eyes open for all healthy controls and on the 
vast majority of the participants with pre-manifest HD (16/17; 94%). A floor effect was 
seen for the SRT test with eyes closed on the group of participants with manifest HD in 
which only 4 participants out of the 25 (16%) were able to perform the test. Due to 
these observed ceiling and floor effects, between group comparisons using the 
individual Romberg tasks was not useful. The total score of the 6 subtasks of Romberg 
and Sharpened Romberg tests was therefore calculated and used to compare between 
group performances.  
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Both the BBS and the root mean square of the postural sway in healthy controls were 
significantly different from participants with manifest HD (p<0.001) but not from those 
with pre-manifest HD. These results give indications of the discriminant (known-
groups) validity of these outcomes in the manifest HD but not in the pre-manifest HD 
(i.e. their ability to differentiate between people with manifest HD and healthy controls 
but not between people with pre-manifest HD and healthy controls).  
 
Out of the 6 balance outcomes used in this analysis, significant group differences were 
found between each participant category on the total score of the RT and SR tests. The 
total score of the RT and SRT in healthy controls was significantly different from 
manifest HD participants and those with pre-manifest HD. This indicates discriminant 
(known-groups) validity of this measure in both the manifest and pre-manifest stages of 
HD.   
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Table 4.3: Measures of balance across groups 
 
Parameter (mean ± SD) Healthy controls Pre-manifest HD Manifest HD 
BBS (unit) 
b
 55.5 ± 0.9  55.0 ± 1.5  42.5 ± 9.7 
RFTEO (s) 30  ± 0 30 ± 0 23.2 ± 10.4 
RFAEO (s) 30 ± 0 30 ± 0 28.9 ± 3.4 
SREO (s) 30 ± 0 29.8 ± 0.8 6.0 ± 10.5 
RFTEC (s) 30 ± 0 30 ± 0 20.3 ± 12.1 
RFAEC (s) 30 ± 0 30 ± 0 23.3 ± 11.3 
SREC (s) 23.3 ± 8.2 14.8 ± 10.9 1.1 ± 3.8 
RT and SRT Total score (s) 
b
 173.3 ± 8.2* 164 ± 11.1  102.9 ± 39.9 
rms-AP (m) 
a
 0.006 ± 0.002  0.007 ± 0.002  0.1 ± 0.005 
rms-ML (m) 
a
 0.005 ± 0.002  0.005 ± 0.001  0.1± 0.004 
Excursion-AP (m) 
a
 12.1 ± 5.5 11.9 ± 5.9 10.6 ± 4.9 
Excursion-ML (m) 
a
 9.6 ± 5.5 9.8 ± 5.7 10.5 ± 5.2 
BBS, Berg Balance Scale; RFTEO, Romberg test with Feet Together and Eyes Open; RFAEO, 
Romberg with Feet Apart and Eyes Open; SREO, Sharpened Romberg with Eyes Open; RFTEC, 
Romberg test with Feet Together and Eyes Closed; RFAEC, Romberg with Feet Apart and Eyes 
Closed; SREC, Sharpened Romberg with Eyes Closed; RT, Romberg test; STR, Sharpened 
Romberg test; rms, root mean square of postural sway movement; AP, anterior-posterior; ML, 
medio-lateral.  
Significantly different from Manifest HD (p<0.05) 
Significantly different from Pre-manifest HD and Manifest HD (p<0.05) 
a
 Analysis based on the One way ANOVA test and post hoc tests 
b
 Analysis based on the Kruskal-Wallis test and post hoc tests 
 
 
4.2.1.2.1.2 Measures of muscle strength  
Descriptive data of measures of muscle strength are presented in Table 4.4 below. As 
depicted from Table 4.4 the MVIC measures for both knee flexors and extensors in 
healthy controls were significantly different from manifest HD participants (p<0.01) but 
not from those with pre-manifest HD. This indicates discriminant (known-groups) 
validity of the MVIC measures in the manifest HD only.  
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Table 4.4: Measures of muscle strength across groups 
 
Parameter (mean ± SD) Healthy controls Pre-manifest HD Manifest HD 
MVIC of knee extensors (N.m) 
b
 352.8 ± 162.9  373.4 ± 168.5  212.9 ± 159.8 
MVIC of knee flexors (N.m) 
b
 195.9 ± 81.6  220.9 ± 106.3  111.4 ± 85.7 
MVIC, Maximal Voluntary Isometric Contraction 
Significantly different from Manifest HD (p<0.05) 
b
 Analysis based on the Kruskal-Wallis test and post hoc tests 
 
 
4.2.1.2.2 Measures of activity  
4.2.1.2.2.1 Measures of mobility  
4.2.1.2.2.1.1 Walking- measures of gait  
Average data for the gait measures are summarized in Table 4.5. The gait speed and 
stride time in healthy controls were significantly different from manifest HD 
participants (p<0.0001) but not from those with pre-manifest HD. These results 
therefore, provide indications of the discriminant (known-groups) validity of these 
measures in the manifest HD only.  
 
Interestingly, significant group differences were found between each participant 
category for stride time coefficient of variation (CV). Stride time CV in healthy controls 
was significantly different from pre-manifest participants (p<0.05) and those with 
manifest HD (p<0.001). This provides suggestions of the discriminant (known-groups) 
validity of gait variability measures (stride time CV) in both the manifest and pre-
manifest stages of HD. 
 
Table 4.5: Measures of gait across groups 
 
Parameter (mean ± SD) Healthy controls Pre-manifest HD Manifest HD 
Gait speed (cm/s) 
a
 130.7 ± 11.2  122.2 ± 12.4  73.3 ± 32.2 
Stride time (s) 
a
 1.04 ± 0.08  1.06 ± 0.08  1.26 ± 0.41 
Stride time CV (%) 
a
 2.0 ± 0.5* 2.7 ± 0.9  14.4 ± 13.5 
Significantly different from Manifest HD (p<0.05) 
Significantly different from Pre-manifest HD and Manifest HD (p<0.05) 
a
 Analysis based on the One way ANOVA test and post hoc tests 
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4.2.1.2.2.1.2 Walking- measures of community walking 
Table 4.6 presents descriptive statistics of measures of levels of walking carried out in 
the community across each group. Significant differences were identified between 
healthy controls and participants with manifest HD across the daily step count and the 
percentages of time spent at no, moderate and high levels of physical activities 
(p<0.01). However, no significant differences were detected on these measures between 
healthy controls and participants with pre-manifest HD. This indicates discriminant 
(known-groups) validity of these measures in the manifest HD only. 
 
Interestingly, significant differences were found between each participant category on 
peak activity index. Peak activity index in healthy controls was significantly different 
from manifest participants and those with pre-manifest HD (p<0.001). This provides 
indications of the discriminant (known-groups) validity of this measure in both the 
manifest and pre-manifest stages of HD. 
  
 
Table 4.6: Measures of community walking across groups 
 
Parameter (mean ± SD) Healthy controls Pre-manifest HD Manifest HD 
Daily right step count (step 
per day) 
a
 
6928 ± 2423  5262 ± 1672  3490 ± 1903 
The percentage of daily 
time spent at no PA 
a
 
70.4 ± 8.2  74.5 ± 7.3  78.6 ± 9.4 
The percentage of daily 
time spent at low PA 
a
 
17.5 ± 6.2 17.0 ± 4.5 16.1 ± 7.5 
The percentage of daily 
time spent at moderate PA 
a
 
8.6 ± 4.4  7.2 ± 4.0  4.8 ± 3.1 
The percentage of daily 
time spent at high level of 
PA 
a
 
3.5 ± 1.9  1.3 ± 1.4  0.5 ± 0.7 
Peak activity index 
a
 49.6 ± 7.4* 42.9 ± 8.5  29.9 ± 9.1 
PA; physical activity  
Significantly different from Manifest HD (p<0.05) 
*Significantly different from Pre-manifest HD and Manifest HD 
a
 Analysis based on the One way ANOVA test and post hoc tests 
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4.2.1.2.2.1.3 Other measures of mobility  
Average data for the other measures of mobility across groups are presented in Table 
4.7 below. A floor effect was observed on the FSST in the group of participants with 
manifest HD; 5 of the participants in this group out of the 25 (20%) could not perform 
this test.  
 
The scores of TUG in healthy controls‟ time were significantly different from manifest 
HD participants (p<0.001) but not from those with pre-manifest HD. This indicates 
discriminant (known-groups) validity of this measure in the manifest HD only. In 
contrast to the TUG, the scores of the FSST and the CSST in healthy controls were 
significantly different from manifest HD participants and those with pre-manifest HD 
(p<0.01). This provides indications of the discriminant (known-groups) validity of the 
FSST and the CSST in both the manifest and pre-manifest stages of HD. 
 
 
Table 4.7: The other measures of mobility across groups 
 
Parameter (mean ± SD) Healthy controls Pre-manifest HD Manifest HD 
FSST (s) 
b
 8.5 ± 1.2* 10.4 ± 2.5  30.4 ± 19.5 
TUG (s) 
b
 7.8 ± 0.8  8.7 ± 1.5  16.2 ± 9.3 
CSST (number of repetitions) 
a
 13.5 ± 2.8* 11.0 ± 2.5  7.2 ± 3.5 
BBS, Berg Balance Scale; FSST, Four Square Step Test; TUG, Timed Up and Go test; CSST, 
Chair Sit to Stand Test. 
Significantly different from Manifest HD (p<0.05) 
Significantly different from Pre-manifest HD and Manifest HD (p<0.05) 
a
 Analysis based on the One way ANOVA test and post hoc tests 
b
 Analysis based on the Kruskal-Wallis test and post hoc tests 
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4.2.1.2.2.2 Measures of functional performance in ADL 
Descriptive data of the measure of functional performance in ADL (PPT) are presented 
in Table 4.8 below. The PPT in the healthy controls was significantly different from 
manifest HD participants and those with pre-manifest HD (p<0.002). This provides 
indications of the discriminant (known-group) validity of this measure in both the 
manifest and pre-manifest HD.   
  
 
Table 4.8: The measure of functional performance in ADL across groups 
 
Parameter (mean ± SD) Healthy controls Pre-manifest HD Manifest HD 
PPT (unit) 
a
 25.7 ± 1.4* 23.6 ± 1.9  12.3 ± 5.4 
PPT, Physical Performance Test. 
Significantly different from Manifest HD (p<0.05) 
*Significantly different from Pre-manifest HD and Manifest HD (p<0.05) 
a
 Analysis based on the One way ANOVA test and post hoc tests 
 
 
4.2.1.2.3 Measures of participation 
4.2.1.2.3.1  Measures of health-related quality of life  
In the manifest HD, floor and ceiling effects were observed on a number of the SF-36 
subscales. In each of the subscales, a floor effect refers to when a participant had a zero 
score and ceiling effect refers to when a participant had a score of 100. The floor effect 
in manifest HD was observed on  the physical function, the role physical, the social 
functioning and the role emotional subscales. In addition a ceiling effect was observed 
on the role physical, bodily pain and social functioning subscales in the manifest HD 
(Table 4.9). Similarly, a ceiling effect was observed on the physical function, role 
physical, bodily pain and role emotional in the pre-manifest HD group (Table 4.9).  
Descriptive data of all the subscales of the SF-36 are presented in Table 4.10 below.  
All the subscales of the SF-36 in healthy controls apart from the bodily pain were 
significantly different from manifest HD participants. However, none of the subscales in 
the healthy controls were significantly different from the pre-manifest HD group. This 
suggests discriminant (known-groups) validity of all the subscales of the SF-36 except 
the bodily pain subscale in the manifest HD only. 
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Table 4.9: Percentages of floor and ceiling effects on the subscales of health-related quality of 
life (SF-36-version 1) in manifest and pre-manifest HD groups  
 
 
 
 
Table 4.10: The subscales of health-related quality of life (SF-36-version 1) across groups 
 
Parameter (mean ± SD) 
Healthy 
controls 
Pre-manifest HD Manifest HD 
PF (unit) 
a
 93.3 ± 10.6  92.6 ± 17.1  36.5 ± 28.9 
RP (unit) 
a
 87.5 ± 25.7  85.3 ± 39.3  41.3 ± 47.4 
BP (unit) 
a
 82.9 ± 18.1 83.0 ± 27.5 77.3 ± 28.9 
GH (unit)
 a
  79.6 ± 19.1   76.1 ± 15.1   46.7 ± 19.9  
VT (unit) 
a
 73.5 ± 14.4    70.5 ± 13.4   48.1±16.5  
SF (unit) 
a
 81.6 ± 13.7   73.2 ± 23.2  57.9 ± 25.3  
RE (unit) 
a
 92.3 ± 23.7  96.1 ± 11.1  49.3 ± 48.1 
MH (unit) 
a
 81.5 ± 11.1   79.1 ± 9.9  66.9 ± 15.5  
PCS (unit) 
a
 84.3 ± 12.5  82.7 ± 15.7   46.8 ± 20.3 
MCS (unit)
 a
  77.9 ± 10.5  74.8 ± 10.6  56.9 ± 12.8 
Significantly different from Manifest HD (p<0.05) 
a
 Analysis based on the One way ANOVA test and post hoc tests 
 
Parameter  
Pre-manifest HD Manifest HD 
Floor effect Ceiling effect Floor effect Ceiling effect 
PF (n (%)) none 10 (58.8) 4 (16.0) none 
RP (n (%)) none 14 (82.2) 10 (40.0) 6 (24.0) 
BP (n (%)) none 8 (47.1) none 11 
GH 
 
 (n (%)) none none none none 
VT (n (%)) none none none none 
SF (n (%)) none none 2 (8.0) none 
RE (n (%)) none 12 (70.1) 11 (44.0) 9 (36.0) 
MH (n (%)) none none none none 
PCS (n (%)) none none none none 
MCS (n (%)) none none none none 
PF; Physical Functioning; RF; Role limited due to physical problems; RE; Role limited due 
to emotional problems; SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, Bodily 
Pain; GH, General Health Perception; PCS, Physical Component Summary; MCS, Mental 
Component Summary.  
On each subscale, floor effect refers to when a participant had a score of zero. 
On each subscale, ceiling effect refers to when a participant had a score of 100.    
                                                                                                    4. Results and discussion: Part 1 
 
 
125 
 
4.2.1.3 Concurrent-convergent validity 
Concurrent-convergent validity was assessed in the individuals with manifest HD 
(n=25) by comparison with measures of balance, muscle strength, mobility, levels of 
mobility carried out in the community, functional performance in ADL and health-
related quality of life with a measure of gait variability (stride time CV).   
 
Associations between the tests were examined using Pearsons or Spearmans 
correlations (where normality distribution could not be assumed; i.e. MVIC of knee 
flexors and extensors, BBS, FSST, TUG and RT and SRT). Outliers were identified in a 
number of variables (Appendix 6). Correlation coefficients including and excluding 
outliers are reported in Appendix 6. Excluding outliers in all variables apart from the 
rms-ML of postural sway did not influence conclusions obtained from results based on 
using the whole sample (Appendix 6). Hence data presented below in Table 4.11 
considered the whole set of subjects (n=25) for the calculation of the correlation 
coefficients between the stride time CV and measures of balance, muscle strength, 
function, quality of life and level of physical activity.  
 
As depicted in Table 4.11, out of the 6 measures of balance, only the BBS correlated 
significantly and substantially with the stride time CV (r=0.72). This provides an 
indication of the good concurrent-convergent validity of this measure.  
 
In term of measures of muscle strength, neither the MVIC of knee flexors nor the MVIC 
of knee extensors demonstrated concurrent-convergent validity (r<0.45). For the 
measures of community walking, only peak activity index demonstrated good 
concurrent- convergent validity; peak activity index correlated significantly and 
substantially with stride time CV (r=0.62). All the measures of mobility which included 
the FSST, TUG and CSST as well as the measure of functional performance in ADL 
(PPT) demonstrated good concurrent-convergent validity; all these measures correlated 
significantly and substantially with stride time CV (r>0.6). Out of all the subscales of 
SF-36 (i.e. measures of health related quality of life) only the physical function subscale 
and the physical component summary demonstrated good concurrent-convergent 
validity; only these measures correlated significantly and substantially with stride time 
CV (r ≥ 0.6).   
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Table 4.11: Correlations of measures of balance, muscle strength, mobility, community 
walking, functional performance in ADL and health-related quality of life with stride time CV  
 
Category 
Outcome 
measure 
Correlation 
with Stride 
time CV 
Category 
Outcome 
measure 
Correlation 
with Stride 
time CV 
Balance 
BBS -0.72** 
Community 
walking  
Percentage of 
time spent at 
low PA 
-0.06 
RT and SRT 
total score 
-0.44* 
Percentage of 
time spent at 
moderate PA 
-0.21 
rms-AP of 
postural sway 
0.50* 
Percentage of 
time spent at 
high PA 
-0.29 
rms-ML of 
postural sway 
0.51* 
Peak activity 
index 
-0.62** 
Excursion-AP 0.1 
Health- 
related 
quality of life 
PF -0.61** 
Excursion-ML 0.19 RP -0.38 
Muscle 
strength 
MVIC of knee 
extensors 
-0.14 BP -0.11 
MVIC of knee 
flexors 
-0.44 GH -0.34 
Mobility 
FSST 0.64** VT -0.33 
TUG 0.60** SF -0.16 
CSST -0.71** RE 0.15 
Functional 
performance 
of ADL 
PPT -0.66** MH -0.15 
Community 
walking 
Daily step count -0.32 PCS -0.6** 
Percentage time 
spent at no PA 
-0.13 
MCS -0.04 Percentage of 
time spent at 
low PA 
-0.06 
BBS, Berg Balance Scale; RT, Romberg test; SRT, Sharpened Romberg test; rms, root mean square of 
postural sway movement; MVIC, Maximal Voluntary Isometric Contraction; FSST, Four Square Step 
Test; TUG, Timed Up and Go test; CSST, Chair Sit to Stand Test; PA, Physical Activity; PF; Physical 
Functioning; RF; Role limited due to physical problems; RE; Role limited due to emotional problems; 
SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, Bodily Pain; GH, General Health 
Perception; PCS, Physical Component Summary; MCS, Mental Component Summary.   
*p<0.05; **p<0.001 
                                                                                                    4. Results and discussion: Part 1 
 
 
127 
 
4.2.2 Reliability of outcome measures  
4.2.2.1 Reliability of outcome measures in people with manifest HD   
Table 4.12 reports the mean and standard deviations of the demographic and main 
clinical characteristics of the study participants. Participants who were included in the 
reliability analysis (n=9) were similar to those who were not exposed to repeated 
assessments (n=16); no significant differences were found for age, weight, height and 
disease severity as measured by the TFC score. This suggests that the results of the 
reliability study could be generalized to the entire study sample. 
 
  
Table 4.12: Characteristics of participants with manifest HD who completed reliability 
assessments and those who did not 
 
Parameter (mean ± SD) 
Participants who 
completed reliability 
(n=9) 
Participants who did 
not complete 
reliability (n=16) 
p value 
 
Age in years 48.4 ± 13.3 54.2 ± 12.3 0.31 
Weight (kg) 71.5 ± 8.9 68.1 ± 15.1 0.48 
Height (cm) 169.2 ± 8.9 165.9 ± 8.1 0.49 
TFC 7.0 ± 2.3 6.2 ± 2.7 0.36 
TFC; Total Functional Capacity scale  
 
 
Table 4.13 shows the means, standard deviations of the scores from the first and second 
testing days as well as the mean, standard deviation and 95% CI of the differences 
between the scores obtained from the 2 days. Table 4.14 illustrates the ICCs, the 
standard error of measurements (SEM) and the minimal detectable change (MDC95). 
These were calculated for all measures of muscle strength, mobility, and functional 
performance in ADL and health-related quality of life. In terms of measures of balance, 
only the BBS, the total score of the RT and SRT and the root mean square of the 
postural sway were included in the reliability analysis. As the excursion measures of 
postural sway did not demonstrate any discriminant or concurrent-convergent validity in 
HD, they were excluded from the reliability analysis in this chapter and also from 
evaluating the exercise intervention in the next chapter (Chapter 5).    
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The BBS was the most reliable of the balance measures with ICC value of 0.95. The 
SEM of the BBS was clearly lower than the predefined acceptable difference of 10% of 
the total range of measurement (1.4 <10% of 19) which indicates minimal variability 
within subjects on performing repeated assessments on this test. This was consistent 
with the data obtained from bland and Altman methods; the mean and the standard 
deviation of the difference scores were relatively small (Table 4.13 and Figure 4.2a) 
which indicates good agreement. The total score of the RT and SRT and measures of 
the root mean square of postural sway had lower ICCs relative to the BBS and their 
SEM values were higher than the 10% of the corresponding total range of scores. 
Furthermore, Figure 4.2b indicates a potential bias in the total score of RT and SRT; the 
difference score (day 2 minus day 1) in had a positive value in 6 cases. This means that 
6 out of 9 participants performed better on this test on day 2 comparing to what they did 
on day 1. Overall the results presented here suggest that out of the balance tests 
evaluated in this study, the BBS may be the one balance test that has the least amount of 
variability within subjects on repeated testing in people with manifest HD with no 
indication of directional bias.   
 
The ICC values for the MIVC of both the quadriceps and hamstring muscle groups were 
high (ICC 0.94 for each). However, their SEM values were relatively large; the SEM 
values for MIVC of knee extensors and extensors were much higher than the cut-off 
point of 10% of the total range of measurements (75.1> 10% of 630 and 35.7> 10% of 
299.6). This was also reflected by observing a relatively large mean and standard 
deviation of the difference scores as well as wide 95% CIs of the differences (Table 
4.13 and Figure 4.3). This suggests that these measures are potentially prone to a higher 
degree of variability on repeated testing in individuals with manifest HD.  
 
All measures of gait including gait speed, stride time and stride time coefficient of 
variations were highly reliable (ICCs ranged from 0.83 to 0.98). For all of these 
measures, the SEM scores were lower than the 10% of the corresponding total range of 
measurements. This provided an indication of the minimal variability within subjects on 
performing repeated testing on these measures in subjects with manifest HD. These 
results were consistent with data obtained from Bland and Altman data seen in Table 
4.13; means and standard deviations of the difference scores for all these 3 variables 
(i.e. gait speed, stride time and stride time coefficient of variation) were relatively small 
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which indicate good agreement. Figure 4.4 shows that the differences were distributed 
around zero (i.e. there were no indications of directional biases) and in all but one case, 
the difference was less than 0.03 second in stride time and less than 2.5 unit in stride 
time coefficient of variation. For gait speed, in all but three cases, the difference was 
less than 7 cm/s.  
 
The CSST was the most reliable of the mobility measures with ICC values scored above 
0.9. The test seemed to be the least variable on repeated testing; the SEM score of the 
CSST was lower than the 10% of the total range of scores (0.8 <10% 10.0). This was 
consistent with data obtained from Bland and Altman methods; the mean and standard 
deviation of the difference scores were relatively very small for this measure (Table 
4.13) which indicates good agreement. Figure 4.5c shows that points were distributed 
around zero (i.e. there was no indication of directional bias) and that in all but one case, 
the difference was equal or less than 1 repetition.  
 
In both the FSST and the TUG, the SEM scores exceeded the 10% of the corresponding 
total range of measurements which suggests that these tests relative to the CSST are 
potentially prone to a higher degree of variability on repeated testing in people with 
manifest HD. Data obtained from Bland and Altman methods provided further insights 
into the reliability of the FSST and TUG. In TUG, the differences in eight cases were 
close to zero; however there was one outlier that may have inflated the degree of 
variability on this test (Figure 4.5b).  Regarding the FSST, Figure 4.5a indicates a 
potential bias as all but 2 points were below the zero line (i.e. the differences (day 2 
minus day1) had a negative value). This means that 7 subjects took less time to 
complete the FSST on day 2 than the time they took on day 1. This bias was also 
reflected in the 95% CI for the mean difference (95% CI was 0.9 to 10.2 seconds). Zero 
did not lie in the interval thus indicating a bias between the 2 testing days. Figure 4.5a 
also indicates that differences in FSST were potentially related to the size of the mean; 
the three cases in which the mean score was higher than 30 seconds showed the largest 
differences.     
 
The test re-test reliability of the PPT was excellent. The calculated ICC value was 0.96 
and the SEM score was small (i.e. less than 10% of the total range). This was consistent 
with data obtained from Bland and Altman methods; the mean and standard deviation of 
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difference scores were relatively very small (Table 4.13). Figure 4.5d shows that in 4 
points the difference was zero and in the 5 other points the difference was 3 units or 
less.  
 
 The ICC values of the subscales of the SF-36 ranged from 0.13 to 0.79. The subscales 
of bodily pain and vitality had the lowest ICC values (ICC= 0.13 and 0.21 respectively) 
and the subscales of mental health and physical component summary had the highest 
ICC values (ICC=0.75 and 0.79 respectively).  The SEM was higher than the 10% of 
the respective range of each of the subscale which suggests that in the absolute term, the 
subscales of the SF-36 may be subject to a higher degree of variability on repeated 
assessments in individuals with manifest HD. This was reflected by the wide 95% CI of 
the mean differences for all the subscales (Table 4.13).  As depicted in Figure 4.6 the 
most variable subscales were the role physical, role limited due to physical problems, 
bodily pain and role limited due to emotional problems; the ranges of the differences in 
at least 4 of the cases in these subscales were -20 to 75, -50 to 75, -77 to 33, -33 to 100 
respectively. From Figure 4.6, there were indications that in the role physical and the 
bodily pain subscales, differences may be related to the size of the mean; in the role 
physical subscale the largest differences were shown in 4 out of 5 of the cases that had a 
mean that is larger than 40. In the bodily pain subscale the largest differences were seen 
in cases where the mean is lesser than 88. As depicted from Figure 4.6, there were 
further indications of directional biases in 4 of the subscales that include general health, 
vitality, mental health and mental component summary.  In each of these subscales, data 
in 6 out of the 9 participants were below the zero line (i.e. the difference (day 2 minus 
day 1) had a negative value). This means that in these subscales most participants had a 
lower score on day 2 relative to their scores on day 1.  
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Table 4.13: Descriptive data for test re-test reliability for outcome measures in manifest HD  
 
 
 
Category 
Outcome 
measure 
Day 1 Day 2 
Difference between day 1 and 
day 2  
mean ± SD mean ± SD mean ± SD 95% CI 
Balance 
BBS (unit) 43.4 ± 6.3 43.2 ± 6.4 -0.2 ± 2.0 -1.7, 1.7 
Romberg 
test total 
score (s) 
100.4 ± 34.5 109.6 ± 27.1 9.2 ± 20.2 -8.8, 27.4 
rms-AP of 
postural 
sway (m) 
0.02 ± 0.01 0.02 ± 0.01 0.004 ± 0.003 -0.002, 0.003 
rms-ML of 
postural 
sway (m) 
0.01 ± 0.002 0.02 ± 0.007 -0.004 ±0.004 -0.004, 0.003 
Muscle 
strength 
MVIC of 
knee 
extensors 
(N.m) 
250 ± 207.6 280 ± 227.7 29.5 ± 106.2 -53.4, 130.3 
MVIC of 
knee flexors 
(N.m) 
134 ± 101.4 104.1 ± 104.2 -30.5 ± 50.5 -76.5, 13.5 
Mobility- 
measures of 
gait 
Gait speed 
(cm/s) 
72.4 ± 30.5 74.6 ± 33.1 2.28 ± 11.55 -7.7, 12.9 
Stride time 
(s) 
1.3 ± 0.2 1.2 ± 0.2 -0.04 ± 0.09 -0.13, 0.03 
Stride time 
CV (%) 
12.3 ± 7.9 11.4 ± 7.1 -1.05 ± 1.9 -2.7, 0.6 
Other 
measures of 
mobility 
FSST (s) 25.5 ± 14.8 26.6 ± 19.2 -0.5 ± 11.3 0.9, 10.2 
TUG (s) 15.0 ± 6.0 17.1 ± 12.9 2.1 ± 8.3 -4.6, 9.9 
CSST 
(number of 
repetitions) 
8.0 ± 3.4 7.4 ± 3.3 -0.5 ± 1.1 -1.3, 0.1 
Functional 
performance 
in ADL 
PPT (unit) 
 
11.6 ± 4.5 
 
12.0 ± 4.6 0.3 ± 1.3 -0.6, 1.6 
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Table 4.13: Continued for descriptive data for test re-test reliability for outcome measures in 
manifest HD  
 
 
 
 
 
 
 
 
 
 
 
Category 
Outcome 
measure 
Day 1 Day 2 
Difference between day 1 and 
day 2  
mean ± SD mean ± SD mean ± SD 95% CI 
Health- 
related 
quality of 
life 
PF 41.1 ± 28.1 41.1 ± 28.1 8.9 ± 26.5 -11.5, 29.3 
RP 41.6 ± 41.5  41.7 ± 41.5 -2.8 ± 34.1 -28.9, 23.4 
BP 77.7 ± 28.3  77.8 ± 28.4 -12.3 ± 31.6 -36.7, 11.9 
GH 45.8 ± 24.2  45.8 ± 24.2 -2.1 ± 17.1 -15.3, 11.1 
VT 46.1 ± 18.5  46.1 ± 18.5 -10.6 ± 16.9 -23.5, 2.3 
SF 54.1 ± 22.5 54.3 ± 22.5 -6.2 ± 20.1 -21.6, 9.3 
RE 59.3 ± 46.5 59.3 ± 46.5 0 ± 40.8 -31.4, 31.4 
MH 67.8 ± 16.3 60.4 ± 26.5  -10.2 ± 14.7 -21.5, 1.1 
PCS 48.2 ± 21.2  53.4 ± 20.7 0.2 ± 14.8 -9.8, 10.3 
MCS 53.4 ± 20.7  53.4 ± 20.7  -9.0 ± 14.8 -20.4, 2.4 
 rms, root mean square of postural sway movement; AP, anterior-posterior; ML, medio-
lateral;MVIC, Maximal Voluntary Isometric Contraction; FSST, Four Square Step Test; TUG, 
Timed Up and Go test; CSST, Chair Sit to Stand Test; PPT, Physical Performance Test; CV, 
coefficient of variation; PF; Physical Functioning; RF; Role limited due to physical problems; 
RE, Role limited due to emotional problems; SF; Social Functioning; MH, Mental Health; 
VT, Vitality; BP, Bodily Pain; GH, General Health Perception; PCS, Physical Component 
summary; MCS, Mental Component Summary.  
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Table 4.14: Intra Class Correlation Coefficients (ICCs) for test re-test reliability, standard error 
of measurements (SEM) and minimal detectable changes (MDC95) for outcome measures in 
manifest HD  
Category Outcome measure 
Day 1 
ICC SEM MDC95 
range 
range 
(10%) 
Balance 
BBS (unit) 19.0 1.9 0.95 1.4 3.9 
Romberg test total score (s) 101.0 10.1 0.88 14.3 39.6 
rms-AP of postural sway (m) 0.02 0.002 0.90 0.003 0.008 
rms-AP of postural sway (m) 0.01 0.001 0.81 0.002 0.005 
Muscle 
strength 
MVIC of knee extensors 
(N.m) 
630.0 63.0 0.94 75.1 155.5 
MVIC of knee flexors (N.m) 299.6 29.9 0.94 35.7 98.8 
Mobility- 
measures of 
gait 
Gait speed (cm/s) 85.0 8.5 0.97 8.1 22.5 
Stride time (s) 0.9 0.09 0.83 0.08 0.22 
Stride time 
CV (%) 
20.1 2.0 0.98 1.3 3.6 
Other 
measures of 
mobility 
FSST (s) 42.0 4.2 0.91 7.0 19.3 
TUG (s) 18.2 1.8 0.74 5.9 16.3 
CSST (number of 
repetitions) 
10.0 1.0 0.97 0.8 2.2 
Functional 
performance 
in ADL 
PPT (unit) 13.0 1.3 0.96 0.8 2.2 
Health- 
related 
quality of life 
PF 90 9.0 0.54 18.8 52.1 
RP 100 10 0.67 24.1 66.8 
BP 77 7.7 0.13 22.4 62.1 
GH 75 7.5 0.67 12.1 33.5 
VT 60 6.0 0.25 11.9 32.9 
SF 55.6 5.5 0.69 14.2 39.3 
RE 100 10 0.64 28.9 80.1 
MH 52 5.2 0.79 10.4 28.8 
PCS 64.8 6.4 0.75 9.2 25.5 
MCS 70.7 7.0 0.61 10.4 28.8 
rms, root mean square of postural sway movement; AP, anterior-posterior; ML, medio-lateral;MVIC, 
Maximal Voluntary Isometric Contraction; FSST, Four Square Step Test; TUG, Timed Up and Go 
test; CSST, Chair Sit to Stand Test; PPT, Physical Performance Test; CV, coefficient of variation; 
PF; Physical Functioning; RF; Role limited due to physical problems; RE; Role limited due to 
emotional problems; SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, Bodily Pain; 
GH, General Health Perception; PCS, Physical Component summary; MCS, Mental Component 
Summary. 
  
134 
 
 
1501251007550
50
40
30
20
10
0
-10
-20
Average score of total Romberg test (second)
D
if
fe
re
n
c
e
 s
c
o
re
 o
f 
to
ta
l 
R
o
m
b
e
rg
 t
e
s
t 
(s
e
c
o
n
d
)
0
B
5550454035
4
3
2
1
0
-1
-2
Average score of Berg Balance Scale (unit)
D
if
fe
re
n
c
e
 s
c
o
re
 o
f 
B
e
rg
 B
a
la
n
c
e
 S
c
a
le
 (
u
n
it
)
0
A
0.0400.0350.0300.0250.0200.0150.010
0.004
0.003
0.002
0.001
0.000
-0.001
-0.002
-0.003
-0.004
-0.005
Average score of rms-AP (m)
D
if
fe
re
n
c
e
 s
c
o
re
 o
f 
rm
s
-A
P
 (
u
n
it
)
0
C
0.0300.0250.0200.0150.010
0.004
0.002
0.000
-0.002
-0.004
-0.006
-0.008
-0.010
Average score of rms-ML (m)
D
if
fe
re
n
c
e
 s
c
o
re
 o
f 
rm
s
-M
L
 (
m
)
0
D
Figure 4.2: Bland and Altman plots of measures of balance in manifest HD
Figure 4.2: Distribution plots of average scores of measures of balance against difference score s(day 2minus day1).  Zero 
line indicates no difference. Positive difference (points above zero line ) in  A &B indicate better performance at day 2. 
Positive difference in C &D indicates lower performance at day 2.  
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Figure 4.3: Bland and Altman plots of measures of muscle strength in manifest HD
Figure 4.3: Distribution plots of average scores of measures of muscle strength against difference scores (day 2-day1).  Zero line 
indicates no difference. Positive difference (points above zero line ) in A & B indicates better performance at day 2. Negative 
difference (points below zero line) indicates lower performance at day 2. 
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Figure 4.4: Bland and Altman plots of measures of gait in manifest  HD
Figure 4.4: Distribution plots of average scores of measures of gait against difference scores (day 2minus day1).  Zero 
line indicates no difference. Positive difference (points above zero line ) in A  (gait speed)indicates better  performance 
at day 2. Positive difference (points above zero line ) in B &C  indicates lower performance at day 2.  
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Figure 4.5: Bland and Altman plots of measures of mobility and functional performance in ADL in manifest HD
Figure 4.5: Distribution plots of average scores of measures of mobility and function against difference scores (day 2 
minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in A & B  indicates lower 
performance at day 2. Positive difference (points above zero line ) in C & D  indicates better performance at day 2. 
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Figure 4.6: Bland and Altman plots of measures of health-related quality of life in manifest HD
Figure 4.6: Distribution plots of average scores of measures of health related quality of life against difference 
scores (day 2minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in A ,B , 
C & D indicates better performance at day 2. Negative difference (points above zero line ) indicates lower 
performance at day 2. Blue circles indicate the number of cases on these points. 
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Figure 4.6: continued Bland and Altman plots of measures of health-related quality of life in manifest HD
Figure 4.6: Distribution plots of average scores of measures of health related quality of life against difference scores 
(day 2minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in E , F, G & H 
indicates better performance at day 2. Negative difference (points above zero line ) indicates lower performance at day 
2. Blue circles indicate the number of cases on these points. 
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Figure 4.6: continued Bland and Altman plots of measures of health-related quality of life in manifest HD
Figure 4.6: Distribution plots of average scores of measures of health related quality of life against difference scores (day 2 
minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in I& J indicates better 
performance at day 2. Negative difference (points above zero line ) indicates lower performance at day 2.
        4. Results and discussion: part 1                                                                                                                                                                                                                                                  
 
 
 
141 
 
4.2.2.2 Reliability of outcome measures in people with pre-manifest HD   
Table 4.13 reports average data of the demographic and main clinical characteristics of 
those who completed reliability assessment and those who did not in the group of 
participants with pre-manifest HD. Participants who were included in the reliability 
analysis (n=9) were similar to those who have not been involved in repeated 
assessments (n=8); no significant differences were found on age, weight and height.  
 
 
Table 4.15: Characteristics of participants with pre-manifest HD who completed reliability 
assessment and those who did not 
 
Parameter (mean ± SD) 
Participants who 
completed reliability 
(n=9) 
Participants who did 
not complete 
reliability (n=8) 
p value 
 
Age in years 44.3 ± 13.3 42.8 ± 11.1 0.8 
Weight (kg) 84.3 ± 27.3 79.8 ± 18.3 0.7 
Height (cm) 170.1 ± 10.1 169.2 ± 11.6 0.9 
 
 
Table 4.16 shows the means, standard deviations from the first and second testing days 
as well as the mean, standard deviation and 95% CI of the differences between the 
scores obtained from the 2 days. Table 4.17 illustrates the ICCs, the standard error of 
measurements (SEM) and the minimal detectable change (MDC95) for measures of 
balance, muscle strength, mobility, and functional performance in ADL and health-
related quality of life.  
 
The BBS and the root mean square of postural sway were highly reliable (ICCs ranged 
from 0.98 to 0.85). The SEM scores of these measures were lower than the 10% of their 
corresponding total range of measurements that suggests the minimal variability of 
these measures on repeated testing in people with pre-manifest HD. This was also 
reflected by the data obtained from Bland and Altman methods; the mean differences 
for these measures were relatively small and the 95% CIs of the mean differences were 
very narrow. The graphs in Figure 4.7 provided further insights into this; for example in 
the BBS, the difference score in 4 cases was zero and in 4 other cases was only 1 unit.  
In contrast to the BBS and the postural sway measures, the test re-test reliability of the 
total score of the RT and SRT was lower (ICC=0.77). Furthermore, the SEM of this 
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outcome was higher than the 10% of the total range of scores which suggests that this 
test is subject to a higher degree of variability on performing repeated testing in people 
with pre-manifest HD. Figure 4.7b provided more insight into this; although the 
difference score in 6 cases was close to zero, there were 3 cases in which the difference 
score was of at least 17 seconds.     
 
For the measures of muscle strength, the test re-test reliability of the MVIC of both knee 
flexors and extensors were high (ICC values were of 0.88 and 0.97 respectively). The 
SEM values were however relatively large (SEM values were larger than the 10% of the 
total range of scores). This was also reflected by obtaining relatively large standard 
deviations and 95% CI of the difference scores (Table 4.16).  As depicted in Figure 4.8, 
the ranges of the differences were -100 to 200 N.m and -48 to 57 N.m in MVIC of knee 
extensors and knee flexors respectively. These results indicate that these measures are 
subject to some variability in repeated assessments in people with pre-manifest HD.    
 
Measures of gait speed and stride time had the highest test re-test reliability (ICC= 0.96 
for both). The small standard deviation at the test and re-test assessment of the stride 
time CV indicated that the amount of variability between participants was minimal, 
which may have potentially created smaller test re-test reliability coefficient (ICC= 
0.72). However, the SEM values for the 3 variables (gait speed, stride time, stride time 
CV) were lower than the 10% of their corresponding total range of scores. This suggests 
that the amount of absolute errors (variability) between test and re-test on these 
measures within individuals was minimal. These results were consistent with data 
obtained from Bland and Altman methods seen in Table 4.16; means and standard 
deviations of the difference scores for all these 3 variables (i.e. gait speed, stride time 
and stride time coefficient of variation) were relatively small. Figure 4.9 shows that the 
differences were distributed around zero (i.e. there were no indications of directional 
biases) and in most cases, the difference was less than 0.05 second in stride time and 
less than 5 cm/s in gait speed. For stride time coefficient of variation, the difference in 
all cases was 1 unit or less.  
 
The FSST, TUG, CSST all had good test re-test reliability coefficients; the ICCs of 
these measures ranged from 0.82 to 0.88. The PPT had a lower test re-test reliability 
coefficient (ICC=0.62) compared to the other measures. The small standard deviation at 
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the test and re-test assessment of the PPT indicated that the amount of variability 
between participants was minimal, which may have potentially created a smaller test re-
test reliability coefficient. Of these outcomes only the FSST, CSST and PPT had SEM 
values that were lower than the 10% of their corresponding total range of scores. This 
suggests that the amount of absolute errors (variability) between test and re-test on these 
measures within individuals was minimal. This was also reflected by obtaining 
relatively small mean, standard deviations and 95% CI of the difference scores for all 
these measures (Table 4.16). Figure 4.10 shows the differences were distributed around 
zero in the CSST and PPT (i.e. there were no indications of directional biases). 
However, as depicted from Figure 4.10 a potential bias is indicated in the TUG and the 
FSST; most points in the TUG (6/9) and in the FSST (8/9) were below the zero line (i.e. 
the difference (day 2 minus day 1) had a negative value). This means that in most cases, 
participants took less time in day 2 relative to the time they took in day 1 to complete 
TUG and FSST. This directional bias was also reflected in the 95% CI of the FSST for 
the difference scores (95% CI of differences ranged from -2.2 to -0.23 seconds). Zero 
did not lie in the interval which indicates a bias between the 2 testing days. 
Additionally, Figure 4.10a indicates that differences in FSST were potentially related to 
the size of the mean; there was a tendency of obtaining a larger difference with the 
increase of the size of the mean score.    
 
The calculated ICC values of the subscales of the SF-36 ranged from 0.5 to 0.91.  The 
subscales of role limited due to physical problems and role limited due to emotional 
problems had the lowest ICC values (ICC= 0.61 and 0.50 respectively) and the 
subscales of physical component summary and mental component summary had the 
highest ICC values (ICC=0.88 and 0.91 respectively). The SEM was higher than the 
10% of the respective range of each of the subscales; however the SEM of the physical 
and mental component summaries just fell short below this criterion (Table 4.16). This 
suggests that in the absolute terms, the physical and mental component summaries of 
the SF-36 may be the least susceptible to variability on repeated assessment in the pre-
manifest HD.  As depicted in Figure 4.11 points are distributed around zero in both the 
physical and mental component summaries and differences are less than 10 units in 7 
cases in the physical component summary and less than 10 units in all cases in the 
mental component summary. Although the mean difference is small in majority of the 
other subscales (Table 4.16), outliers of differences were identified in 5 of the subscales 
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(physical function, role physical, general health, social functioning and role emotional 
(Figure 4.11). These outliers may have therefore influenced the variability of these 
subscales in repeated assessments in people with pre-manifest HD.      
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Table 4.16: Descriptive data for test re-test reliability for outcome measures in pre-manifest HD  
 
Category 
Outcome 
measure 
Day 1 Day 2 
Difference between day 1 and 
day 2  
mean ± SD mean ± SD mean ± SD 95% CI 
Balance 
BBS (unit) 55.1 ± 1.2 55.4 ± 0.7 0.3 ± 0.5 0.05, 0.71 
Romberg 
test total 
score (s) 
163.6 ± 12.5 170.0 ± 10.8 6.7 ± 10.1 -1.0, 14.5 
rms-AP of 
postural 
sway (m) 
0.007± 0.002 0.006 ± 0.002 0.005 ± 0.001 -0.0007, 0.002 
rms-ML of 
postural 
sway (m) 
0.005 ±0.002 0.003 ± 0.003 0.009 ± 0.002 0.001,0.003 
Muscle 
strength 
MVIC of 
knee 
extensors 
(N.m) 
356 ± 136.8 374.7 ± 148.6 19.5 ± 101.7 -58.7, 97.7 
MVIC of 
knee flexors 
(N.m) 
221 ± 105.9 223.1± 116.5 -1.6 ± 34.1 -27.8, 24.7 
Mobility-
measures of 
gait 
Gait speed 
(cm/s) 
122.5 ± 13.4 125.6 ± 11.7 1.8 ± 5.6 -2.5, 6.1 
Stride time 
(s) 
1.1 ± 0.07 1.1 ± 0.09 -0.02 ± 0.03 -0.04,0.008 
Stride time 
CV (%) 
3.0 ± 1.4 2.6 ± 0.9 -0.4 ± 0.7 -0.9, 0.19 
Other 
measures of 
mobility 
FSST (s) 10.4 ± 3.4 11.5 ± 2.2 -1.2 ± 1.2 -2.2, -0.23 
TUG (s) 8.9 ± 1.3 8.5 ± 1.1 0.5 ± 0.8 -1.1, 0.2 
CSST 
(number of 
repetitions) 
10.8 ± 3.2 11.3 ± 2.2 0.6 ± 2.3 -1.1, 2.2 
Functional 
performance 
in ADL 
PPT (unit) 
 
24.0 ± 2.8 23.7 ± 1.7 -0.2 ± 1.0 -0.9, 0.5 
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Table 4.16: Continued for descriptive data for test re-test reliability for outcome measures in 
pre-manifest HD  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Category 
Outcome 
measure 
Day 1 Day 2 
Difference between day 1 and 
day 2  
mean ± SD mean ± SD mean ± SD 95% CI 
Health- 
related 
quality of 
life 
PF 88.9 ± 22.6 92.2 ± 12.8  3.3 ± 10.6 -4.8, 11.5 
RP 88.9 ± 33.3 75.0 ± 43.3 -13.9 ± 33.3 -39.5, 11.7 
BP 85.2 ± 24.8 82.7 ± 23.6 -2.5 ± 13.4 -12.7, 7.8 
GH 67.3 ± 14.3 69.8 ± 14.1 2.4 ± 9.4 -4.7, 9.6 
VT 67.8 ± 14.6 66.7 ± 14.8 -1.1 ± 9.3 -8.2, 6.0 
SF 74.1 ± 21.5 74.1 ± 22.2 0 ± 14.7 -11.3, 11.3 
RE 100.0 ± 0.0 92.6 ± 22.2 -7.4 ± 22.2 -24.5, 9.7 
MH 78.6 ± 11.3 79.6 ± 12.4 1.3 ± 7.7 -4.6, 7.3 
PCS 78.6 ± 18.9 79.3 ± 12.4 0.7 ± 8.5 -5.8, 7.2 
MCS 73.8 ± 10.8 73.6 ± 11.3 -0.19 ± 4.2 -3.4, 3.0 
 rms, root mean square of postural sway movement; AP, anterior-posterior; ML, medio-
lateral;MVIC, Maximal Voluntary Isometric Contraction; FSST, Four Square Step Test; TUG, 
Timed Up and Go test; CSST, Chair Sit to Stand Test; PPT, Physical Performance Test; CV, 
coefficient of variation; PF; Physical Functioning; RF; Role limited due to physical problems; 
RE; Role limited due to emotional problems; SF; Social Functioning; MH, Mental Health; 
VT, Vitality; BP, Bodily Pain; GH, General Health Perception; PCS, Physical Component 
summary; MCS, Mental Component Summary. 
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Table 4.17:  Intra Class Correlation Coefficients (ICCs) for test re-test reliability, standard error 
of measurements (SEM) and minimal detectable changes (MDC95) for outcome measures in pre-
manifest HD  
 
Category Outcome measure 
Day 1 
ICC SEM MDC95 
Range 
Range 
(10%) 
Balance 
BBS (unit) 4.0 0.4 0.85 0.3 0.9 
Romberg test total score (s) 25.6 2.6 0.77 7.1 19.7 
rms-AP of postural sway (m) 0.006 0.0006 0.98 0.00004 0.0001 
rms-AP of postural sway (m) 0.005 0.0005 0.87 0.00007 0.0002 
Muscle 
strength 
MVIC of knee extensors 
(N.m) 
438.3 43.8 0.88 73.2 203 
MVIC of knee flexors (N.m) 269.7 26.9 0.97 28.2 78.2 
Mobility-
measures of 
gait 
Gait speed (cm/s) 42.3 4.2 0.96 3.4 9.7 
Stride time (s) 0.2 0.02 0.96 0.01 0.03 
Stride time 
CV (%) 
4.7 0.5 0.75 0.4 1.1 
Other 
measures of 
mobility 
FSST (s) 8.9 0.9 0.88 0.8 2.2 
TUG (s) 3.9 0.4 0.84 0.5 1.6 
CSST (number of 
repetitions) 
7.9 0.8 0.82 0.7 2.1 
Functional 
performance 
in ADL 
 
PPT (unit) 
 
8.0 0.8 0.69 0.7 1.9 
Health- 
related 
quality of 
life 
PF 70.0 7.0 0.83 7.5 20.8 
RP 100.0 10.0 0.63 23.6 65.4 
BP 77.8 7.8 0.85 9.4 26.1 
GH 42.0 4.2 0.78 6.6 18.3 
VT 40 4.0 0.8 6.6 18.3 
SF 55.6 5.6 0.77 10.4 28.8 
RE 0 0 0.50 15.7 43.5 
MH 36.0 3.6 0.79 5.5 15.2 
PCS 60.0 6.0 0.88 6.0 16.6 
MCS 31.0 3.1 0.91 2.9 8.0 
rms, root mean square of postural sway movement; AP, anterior-posterior; ML, medio-lateral;MVIC, 
Maximal Voluntary Isometric Contraction; FSST, Four Square Step Test; TUG, Timed Up and Go 
test; CSST, Chair Sit to Stand Test; PPT, Physical Performance Test; CV, coefficient of variation; 
PF; Physical Functioning; RF; Role limited due to physical problems; RE; Role limited due to 
emotional problems; SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, Bodily Pain; 
GH, General Health Perception; PCS, Physical Component summary; MCS, Mental Component 
Summary. 
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Figure 4.7: Distribution plots of average scores of measures of balance against difference scores (day 2minus 
day1).  Zero line indicates no difference. Positive difference (points above zero line ) in  A &B indicate better 
performance at day 2. Positive difference in C &D indicates lower performance at day 2. Blue circles indicate the 
number of cases scored on these points.
Figure 4.7: Bland and Altman plots of measures of balance in pre-manifest HD
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Figure 4.8: Bland and Altman plots of measures of muscle strength in pre-manifest HD 
Figure 4.8: Distribution plots of average scores of measures of muscle strength against difference scores (day 2 minus day1).  
Zero line indicates no difference. Positive difference (points above zero line ) in A & B indicates better performance at day2.
Negative difference (points below zero line) indicates lower performance at day 2. 
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Figure 4.9: Bland and Altman plots of measures of gait in pre-manifest HD
Figure 4.9: Distribution plots of average scores of measures of gait against difference scores (day 2 minus day1).  Zero 
line indicates no difference. Positive difference (points above zero line ) in A  (gait speed)indicates better  performance 
at day 2. Positive difference (points above zero line ) in B &C  indicates lower performance at day 2.  
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Figure 4.10: Bland and Altman plots of measures of mobility and functional performance in ADL in pre-manifest HD
Figure 4.10: Distribution plots of average scores of measures of mobility and function against difference scores (day 2 
minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in A & B  indicates lower 
performance at day 2. Positive difference (points above zero line ) in C & D  indicates better performance at day 2. Blue 
circles indicate the number of cases on these points.
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Figure 4.11: Distribution plots of average scores of measures of health related quality of life against difference scores 
(day 2 minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in A ,B , C & D 
indicates better performance at day 2. negative difference (points above zero line ) indicates lower performance at day 2.
Blue circles indicate the number of cases on these points.
Figure 4.11: Bland and Altman plots of measures of health-related quality of life
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Figure 4.11: Distribution plots of average scores of measures of health related quality of life against difference scores 
(day 2 minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in E , F, G & H 
indicates better performance at day 2. Negative difference (points above zero line ) indicates lower performance at 
day 2. Blue circles indicate the number of cases on these points.
Figure 4.11: continued Bland and Altman plots of measures of health-related quality of life in pre-manifest HD
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Figure 4.11: continued Bland and Altman plots of measures of health-related quality of life in pre-manifest HD
Figure 4.11: Distribution plots of average scores of measures of health related quality of life against difference scores (day 2 
minus day1).  Zero line indicates no difference. Positive difference (points above zero line ) in I& J indicates better 
performance at day 2. Negative difference (points above zero line ) indicates lower performance at day 2.
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4.2.3 Summary of results  
Data presented in this chapter relating to the properties of each of the outcome measures 
in participants with manifest HD and those with pre-manifest HD are summarized in 
Table 4.15 and Table 4.16. These findings on the characteristics of each of the outcomes 
in both manifest and pre-manifest HD will be discussed in detail in the sections below.  
 
The results presented in this chapter suggest that deficits in pre-manifest HD may be 
well represented by measures at the activity level of the ICF model. The PPT as well as 
the vast majority of the mobility measures which included the gait variability measure, 
the FSST, the CSST and the peak activity index were all sensitive to early changes in 
the pre-manifest HD. In addition, the gait variability, the PPT and the CSST were all 
considered to be highly repeatable. 
 
The data presented in this chapter also demonstrated that the outcomes were sensitive to 
changes in the manifest HD at each of the levels of the ICF. Taking into account the test 
re-test reliability values and the calculated SEM, balance is best assessed with the BBS, 
and activity limitations are well represented by measures of gait variability as well as 
the CSST and the PPT. The psychometric properties of these measures suggest that they 
are potentially useful outcomes to detect change over time in individuals with manifest 
HD. The test re-test reliability data and the MDC95 values presented in this chapter 
further help to explain whether changes reported for the exercise intervention (Chapter 
5) can be attributed to the intervention, rather than to natural variability or testing errors. 
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Table 4.18: Summary of the psychometric properties of outcome measures in subjects 
with manifest HD 
 
Category 
Outcome 
measure 
Discriminant 
validity 
Concurrent 
validity 
Relative 
reliability 
(ICC) 
Absolute 
reliability 
(SEM and 
Bland and 
Altman 
data)* 
Indications 
of 
directional 
bias  
Balance 
BBS Yes Yes Yes Acceptable No 
Total score of 
RT and SRT 
Yes No Yes 
Not 
acceptable 
Yes 
Root mean 
square of 
postural sway 
Yes No Yes 
Not 
acceptable 
No 
Excursion of 
postural sway 
No No NR NR NR 
Muscle 
strength 
MVIC of 
knee flexors 
and extensors 
Yes No Yes 
Not 
acceptable 
No 
Gait 
Gait speed Yes NA Yes Acceptable No 
Stride time Yes NA Yes Acceptable No 
Stride time 
CV 
Yes NA Yes Acceptable No 
Community 
walking 
Daily average 
of step count 
Yes No NR NR NR 
Percentage of 
time  at  
levels of PA 
Yes No NR NR NR 
Peak activity 
index 
Yes Yes NR NR NR 
Other 
measures of 
mobility 
FSST Yes Yes Yes 
Not 
acceptable 
Yes 
TUG Yes Yes Yes Not sure No 
CSST Yes Yes Yes Acceptable No 
NA, not applicable; NR, not reported; BBS, Berg Balance Scale; FSST, Four Square Step Test; CSST, Chair 
Sit to Stand Test; CV, coefficient of variation; PA, physical activity 
* “acceptable” means acceptable level of variability between the 2 test sessions  
* “not sure” means the variability of the test is influenced by the presence of outliers.   
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Table 4.18:  continued Summary of the psychometric properties of outcome measures 
in subjects with manifest HD 
 
Category 
Outcome 
measure 
Discriminant 
validity 
Concurrent 
validity 
Relative 
reliability 
(ICC) 
Absolute 
reliability 
(SEM and 
Bland and 
Altman 
data)* 
Indications 
of 
directional 
bias 
Functional 
performance 
in ADL 
PPT Yes Yes Yes Acceptable No 
Health-
related 
quality of 
life 
PF Yes Yes Yes 
Not 
acceptable 
No 
RP Yes No No Not sure Yes 
BP No No Yes 
Not 
acceptable 
Yes 
VT Yes No Yes 
Not 
acceptable 
Yes 
GH Yes No Yes 
Not 
acceptable 
Yes 
SF Yes No Yes Not sure No 
RE Yes No No Not sure No 
MH Yes No Yes 
Not 
acceptable 
Yes 
PCS Yes Yes Yes 
Not 
acceptable 
No 
MCS Yes No Yes 
Not 
acceptable 
Yes 
PPT, Physical Performance Test; PF; Physical Functioning; RF; Role limited due to physical problems; 
RE; Role limited due to emotional problems; SF; Social Functioning; MH, Mental Health; VT, 
Vitality; BP, Bodily Pain; GH, General Health Perception; PCS, Physical Component summary; MCS, 
Mental Component Summary. 
* “acceptable” means acceptable level of variability between the 2 test sessions.  
* “not sure” means the variability of the test is influenced by the presence of outliers.   
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Table 4.19: Summary of the psychometric properties of outcome measures in subjects with pre-
manifest HD 
Category 
Outcome 
measure 
Discriminant 
validity 
Relative 
reliability 
(ICC) 
Absolute 
reliability 
(SEM and 
Bland and 
Altman 
data)* 
Indications 
of 
directional 
bias 
Balance 
BBS No Yes Acceptable No 
Total score of 
RT and SRT 
Yes Yes Not sure No 
Root mean 
square of 
postural sway 
Yes Yes Acceptable No 
Excursion of 
postural sway 
No NR NR NR 
Muscle 
strength 
MVIC of knee 
flexors and 
extensors 
No No 
Not 
acceptable 
No 
Gait 
Gait speed Yes Yes Acceptable No 
Stride time Yes Yes Acceptable No 
Stride time CV Yes Yes Acceptable No 
Community 
walking 
Daily average 
of step count 
No NR NR NR 
Percentage of 
time at levels 
of PA 
No NR NR NR 
Peak activity 
index 
Yes NR NR NR 
Other 
measures of 
mobility 
FSST Yes Yes Acceptable Yes 
TUG No Yes 
Not 
acceptable 
Yes 
CSST Yes Yes Acceptable No 
Functional 
performance in 
ADL 
PPT Yes Yes Acceptable No 
NA, not applicable; NR, not reported; BBS, Berg Balance Scale; FSST, Four Square Step Test; 
CSST, Chair Sit to Stand Test; CV, coefficient of variation; PA, physical activity 
* “acceptable” means acceptable level of variability between the 2 test sessions  
* “not sure” means the variability of the test is influenced by the presence of outliers.   
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Table 4.19:  continued Summary of the psychometric properties of outcome measures in 
subjects with pre-manifest HD 
 
Category 
Outcome 
measure 
Discriminant 
validity 
Concurrent 
validity 
Relative 
reliability 
(ICC) 
Absolute 
reliability 
(SEM and 
Bland and 
Altman 
data)* 
Indications 
of 
directional 
bias 
Functional 
performance 
in ADL 
PPT Yes Yes Yes Acceptable No 
Health-
related 
quality of 
life 
PF Yes Yes No Not sure No 
RP Yes No No Not sure No 
BP No No No No No 
VT Yes No No No No 
GH Yes No No Not sure No 
SF Yes No No Not sure No 
RE Yes No No Not sure No 
MH Yes No Yes No No 
PCS Yes Yes Yes Not sure No 
MCS Yes No No No No 
PPT, Physical Performance Test; PF; Physical Functioning; RF; Role limited due to physical problems; 
RE; Role limited due to emotional problems; SF; Social Functioning; MH, Mental Health; VT, 
Vitality; BP, Bodily Pain; GH, General Health Perception; PCS, Physical Component summary; MCS, 
Mental Component Summary. 
* “acceptable” means acceptable level of variability between the 2 test sessions  
* “not sure” means the variability of the test is influenced by the presence of outliers.   
 
 
4.3 Discussion  
4.3.1 Measures of physical impairments in body structures and functions  
4.3.1.1 Measures of balance 
4.3.1.1.1 Berg Balance scale  
The BBS includes a number of items that test static and dynamic balance and response 
to internal perturbation. The BBS was previously used in HD and was demonstrated to 
be valid in identifying people with HD at risk of falls [45] and in differentiating 
between stages of the disease in people with manifest HD [94]. Results presented here 
provide further information about the validity and reliability of this test in people with 
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HD. Out of the 4 measures of balance evaluated in this study; the BBS has the best 
psychometric profile in the manifest HD. The test has good discriminant and 
concurrent-convergent validity in individuals with manifest HD and high test re-test 
reliability coefficient with indications of minimal variability on repeated testing 
(SEM<10% of the total range of scores as well as mean and standard deviation of 
difference scores were relatively very small). The test re-test value calculated here 
(ICC=0.95) is similar to values reported in the literature for elderly people [181] and 
people with various other disabilities [182, 185, 190, 191, 243, 244]. The MDC95 of 4 in 
this study was within the range of 2.8 to 5 reported/ or calculated from previous studies 
of subjects with stroke [185], traumatic brain injury [244] and Parkinson‟s disease (PD) 
[182, 191]. The good discriminant and concurrent-convergent validity as well the high 
test re-test reliability and the indications of minimal variability on repeated testing make 
the BBS a potentially useful test to monitor disease progression and response to 
therapeutic interventions in people who are affected with HD. 
 
Whilst the data presented here suggest that the BBS is a potentially useful test in the 
manifest HD, its use in the pre-manifest stage may be limited. The results presented 
here demonstrated that the BBS did not have good discrimination ability to detect 
changes in balance impairments in the pre-manifest HD. This suggests that the test may 
be inappropriate for measuring balance deficits in the pre-manifest stage. The test 
includes items (e.g. standing from a chair, sitting on a chair, standing still with eyes 
open) that may lack the sensitivity to detect changes in the pre-manifest stage. This is 
supported by the fact that 47% of participants in the pre-manifest HD group reached the 
ceiling score of 56 on this test, which suggests that the BBS includes tasks which are 
easy for people who do not have noticeable mobility deficits. More importantly, the 
scale is based on ordinal measures and therefore it may lack the sensitivity to capture 
mobility related deficits such as balance impairments in this population at this very 
early stage of the disease. Ratio or interval measures based on timing activities, as 
suggested based on observations from other neurological populations, are potentially 
more sensitive and specific than the ordinal measures to a wide spectrum of severity of 
impairments [245]. The observations in this study that mobility measures that were 
based on timing activities, such as the FSST and the CSST, were in contrast with the 
BBS sensitive to changes across the spectrum of the disease lend further support to this 
idea.  
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4.3.1.1.2 Romberg and Sharpened Romberg tests  
The Romberg (RT) and Sharpened Romberg (SRT) are tests of static balance that 
measure the ability to maintain balance or equilibrium with a narrowed base of support 
during standing. From the data presented here, it can be seen that performance on the 
RT and SRT decreased with increasing task complexity, from standing feet apart with 
eyes open, to tandem standing with eyes closed, across all subject groups. These results 
are in agreement with previous studies [246, 247]. It was interesting to note that many 
subjects in the healthy controls and pre-manifest groups reached the 30 second- ceiling 
on the RT with eyes open and eyes closed. In addition, there was a floor effect on the 
SRT with eyes closed in the vast majority of the subjects with manifest HD. This 
observed floor effect on this specific task has also previously been reported in people 
with Parkinson‟s disease [182] and in elderly women who were healthy [248].  
 
No hierarchical order was applied (i.e. the test was not stopped if a participant failed a 
lower level of the test). To overcome the effect of the observed ceiling and floor results 
on the individual subtasks of the RT and SRT tests, the total score of all tasks was used 
for analysis in this study. This allowed for the assessment of wide variations in ability 
levels of the included participants. This total score was sensitive to detect change 
differences between the subjects with manifest HD and healthy controls and between 
those with pre-manifest HD and healthy controls. This provided indications of the 
discriminant validity of this score along the spectrum of the disease. In particular, the 
finding that the test has good discrimination power at the pre-manifest HD is 
interesting. Noting the average values of the individual subtasks of the test, it can be 
suggested that inclusion of the SRT tasks added to the complexity of the tests and 
potentially enhanced the sensitivity of the overall test to detect balance changes at this 
very early stage of the disease.   
 
Data presented here demonstrated that although the total score of the RT and SRT had 
good discriminant validity in both manifest and pre-manifest HD, it did not obtain as 
good concurrent-convergent validity as the other measure of balance (BBS). The BBS 
correlated highly with the measure of gait variability (stride time CV), whilst the total 
score of the RT and SRT correlated only moderately with the measure of gait 
variability. The fact that the BBS involves items of dynamic balance and internal 
protrusion in addition to the items of static balance may explain this result. It seems that 
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static balance alone, specifically “standing still” as per the RT and SRT tests may be 
less important to the functional performance needed during walking, which may partly 
explain its moderate correlation with gait variability in this study. Findings from 
previous studies in elderly subjects in which measures of static balance were not strong 
predictors of measures related to gait, such as gait speed and gait variability [230, 249], 
is in agreement with results reported here and lend further support to the idea that static 
balance may be less necessary to the functional performance needed during walking.     
 
In terms of reliability, the test re-test reliability values of the total score obtained in this 
study for both the pre-manifest and manifest HD were high (ICCs; 0.88 and 0.77). 
These values fell within the range of 0.7 to 0.9 reported in the literature for the 
individual tests of Romberg and Sharpened Romberg in healthy individuals [248] and in 
people with vestibular disorders [250] and PD [182]. The absolute reliability of the 
Romberg and Sharpened Romberg in these studies was not reported. However, in this 
study and in the absolute terms of reliability, there were indications that the total score 
of the RT and SRT is subject to a high degree of variability on repeated testing in 
people with both manifest and pre-manifest HD (SEM>10% of total range of scores and 
the mean and standard deviation of difference scores were relatively large). Obtaining a 
high ICC for this measure in the presence of a high degree of variability can be 
explained by the observed wide range of scores at the test and re-test assessments, 
particularly in the manifest HD group. As indicated earlier, the ICC is strongly affected 
by the range of scores used to calculate the coefficient; ICC is high when the difference 
in scores between measurements is small in comparison with the range of scores 
between the studied participants [178], which explains in part the obtaining of high ICC 
values in this case in the presence of a potentially variable measure. Furthermore, it was 
interesting to note in Figure 4.2b that this test is susceptible to bias in the manifest HD 
as most participants (6/9) performed better on this test on day 2. This observation 
suggests that this test in the manifest HD is prone to a learning effect on repeated 
assessment. Such a bias effect may confound gains attributed to interventions and 
therefore needs to be taken into account in future clinical trials. This bias was not 
evident from the ICC result but further explains the presence of a high degree of 
variability indicated by the other tests such as the SEM.   
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High variability within subjects on repeated assessments as reflected by SEM scores has 
an impact on the MDC calculations [141]. This indicates that the MDC95 value of 39.1 
seconds in the manifest HD group for the total score, although within the range of 10 to 
39 reported from a previous study in PD for individual tasks of Romberg and Sharpened 
Romberg tests [182], would be larger than desired. The mean score of 100.4 seconds on 
the total score of RT and SRT would make a change score of 39 or better on repeated 
testing unrealistic for the majority of the group. Overall, the possibility that this score is 
prone to variability on repeated measurements may limit its applicability as a measure 
of responsiveness to change over time in individuals with HD. 
 
4.3.1.1.3 Measures of postural sway 
The results presented here demonstrated that measures related to the root mean square 
of the COP movement were sensitive to differences between people with manifest HD 
and healthy controls. This result provides indications of the discriminant validity of the 
root mean square measures in the manifest HD group. In contrast, measures related to 
excursion of the centre of pressure (COP) during quiet standing both in the anterior- 
posterior and medio-lateral directions were not sensitive to group differences between 
people with HD and healthy controls. The inability of the excursion measures to detect 
differences in balance between people with HD may be related to the force platform test 
used in this study. Force platform tests are usually done with pre-determined position of 
the feet and stance width. The required stance as such may result in excess of movement 
of the COP. In the present study, the participants themselves were allowed to determine 
the stance width. It was considered that self selected stance width better reflects actual 
performance of an individual. However, it is possible that some of the participants in 
this study compensated for their balance deficits by increasing their support base with a 
wider stance position, and thus this test was unable to capture deficits in the excursion 
measures. Indirect support for this explanation comes from the observation cited earlier 
that most of the participants in the manifest HD group were unable to complete the 
Sharpened Romberg test in which balance can be compromised by a narrow base of 
support.  
 
The ability of the root mean square measures, but not the excursion, to capture deficits 
in balance may be related to the construct of these measures and may also reflect the 
                                                                                          4. Results and discussion: part 1 
 
164 
 
standing strategy that subjects with HD adopt. Measures of root mean square provide 
indications of the variability of the movement of COP in a certain direction; whilst 
excursion represents the distance taken by the COP over the duration of the test. It can 
only be speculated that subjects with manifest HD may begin the test swaying around 
one target as a home base. As the test progresses in time, subjects may move and start to 
sway around another home base. With each different home base, the variability in the 
COP movement increases. Thus the captured changes in the root mean square may 
reflect true variability of the COP movement, and therefore balance. This in turn may 
also explain the calculated correlations between these measures and gait variability (i.e. 
stride time CV). Whilst the excursion correlated poorly with the measure of gait 
variability, the root mean square measures had correlated moderately with stride time 
CV. The correlation coefficients of the root mean square measures fell just short of the 
criterion for good concurrent convergent validity (correlation coefficients of 0.5 is 
lesser than the criterion correlation of 0.6). However, it must be noted that these 
outcomes were susceptible to outliers that seemed to have influenced their associations 
with the measure of gait variability. Therefore, further validation of these outcomes in 
future work using a larger sample is required.         
 
In terms of reliability, the test re-test reliability values of the root mean square measures 
were high. However, it should be noted that in the absolute term of reliability, there 
were indications that these measures are subject to a certain degree of variability on 
repeated testing in the manifest HD that may be more than desired  (SEM>10% of total 
range of scores). Obtaining a high ICC for this measure in the presence of a high degree 
of variability can be explained by the observed wide range of scores at the test and re-
test assessments particularly in the manifest HD group. As discussed earlier, the ICC is 
strongly affected by the range of scores used to calculate the coefficient; ICC is high 
when the difference in scores between measurements is small in comparison with the 
range of scores between the studied participants [178] which explains in part the 
obtaining of high ICC values in this case in the presence of a potentially variable 
measure. High variability within subjects on repeated assessments as reflected by SEM 
scores may be related to the protocol of testing used here. In this study the average of 
only 2 trials were used for analysis. The duration of each trial was 30 seconds. Data 
available from the literature suggests that minimal variability on measures of root mean 
square measures of COP requires averaging at least 4 trials of 2 minutes [251]. Future 
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research may need to examine the reliability of these measures using different protocols 
of testing by incorporating more trials with longer durations. Overall, the possibility that 
these measures are prone to variability on repeated testing may limit their applicability 
to measure change over time in individuals with HD. 
 
4.3.1.2 Measures of muscle strength  
The data presented here demonstrated that the MVIC measures of the knee flexors and 
extensors had good discriminant validity only in the manifest HD; significant 
differences on these measures were detected only between manifest HD and healthy 
controls but not between the pre-manifest HD and healthy controls. The discriminant 
validity of these measures in the manifest stage is consistent with data from a previous 
study in which the MVIC values of 6 muscle groups of the lower limb were able to 
distinguish between people with mid-stage HD and healthy controls [96]. The lack of 
the discriminant validity of these measures in the pre-manifest stage, however, may be 
related to the suggestion that muscular deficits are subtle in the pre-manifest stage [97, 
98] and thus are difficult to detect through clinical assessment.    
 
The MVIC measures, although showing good discriminant validity in the manifest HD, 
did not obtain good concurrent-convergent validity; these measures correlated poorly 
with the gait variability measure (stride time CV). The fact that all the subjects with 
manifest HD that were included in this study were at an early to mid stage of the 
condition may partially explain this result. In general, one may expect weaker muscles 
of lower limbs in the presence of higher gait variability. However, it should be noted 
that the relationship between these 2 variables may not be linear. Evidence available 
from other populations lends support to this idea. For example, muscle strength was 
associated with measures of gait only at the lower range of muscle strength in a group 
of older women, resulting in a curvilinear relationship between muscle strength and 
performance of gait [252]. This can be equivalent in people with HD and muscle 
weakness at an early to mid stage, such as that seen in the subjects included in this 
study, may not have a dramatic effect on the measures of gait. This may explain the lack 
of concurrent-convergent validity of the MVIC measures that were observed here. 
Further investigations to examine the validity of these measures among a sample with a 
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wider range of subjects, including subjects who are more advanced in the disease stage 
are indicated. 
 
In terms of the reliability of the MVIC measures, the test re-test reliability coefficients 
were very high in both the manifest and pre-manifest (ICC=0.94 for both groups). This 
calculated test re-test reliability fell within the range of 0.8 to 0.96 reported in previous 
studies of subjects with stroke [183], lower motor neuron disease [253] and healthy 
adults aged between 20 and 69 years [254]. None of these studies, however, assessed 
individuals with HD. Although results from this study showed high ICC values of the 
MVIC measures, these measures seemed to be subject to a high degree of variability in 
the absolute figure; the SEM values were larger than the 10% of the total range of 
scores and the mean as well as the standard deviation of the within subject‟s difference 
scores were relatively large. The wide range of scores observed at the test and re-test 
assessment of MVIC indicated that the amount of variability between participants was 
high, which may have potentially created a high test re-test reliability coefficient in the 
presence of a high degree of variability within participants on repeated testing [141]. 
Every effort was made to standardize the testing procedure to minimise variability in 
this study. The test, however, still needs good understanding of instructions, and a very 
cooperative participant. Furthermore, it is possible that participants with manifest HD in 
this study may have experienced co-activation of the knee extensor and/ or flexor 
musculature (secondary to dystonia) during performance of the test [35]. In addition, 
difficulties in movement initiation and movement execution as well as the deficits in 
force generation seen in this population may also influence the performance of this test 
[37, 255]. Any or all of these factors may have contributed to increased variability of 
the test in the present study. Thus, the susceptibility of these measures to high degree of 
variability may limit its use as a measure of responsiveness to change over time in this 
population. 
 
4.3.2 Measures of activity  
4.3.2.1 Measures of mobility  
4.3.2.1.1 Walking- measures of gait  
The present data demonstrates that measures of gait variability derived from the 
GAITRite walkway have good discriminant validity in both manifest and pre-manifest 
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HD. Participants with both manifest and pre-manifest HD had higher stride time 
coefficient of variations (CV) when compared with healthy controls. These results are 
consistent with previous studies that examined gait pattern in people with HD. Rao et al 
[40] in a study that investigated the spectrum of gait impairments in HD subjects, 
demonstrated significant differences in step time CV analogous to the data presented 
here. These results also align with those presented in a study of 17 subjects with pre-
manifest HD and 57 healthy controls by Devlal et al [107]. 
 
In contrast to the gait variability, other measures of gait which included gait speed and 
stride time demonstrated good discriminant validity in the manifest HD participants but 
not in those with pre-manifest HD. Significant differences were found in gait speed and 
stride time between the manifest HD subjects and healthy controls, but not between 
those with pre-manifest HD and healthy controls. This finding is in contrast with data 
reported in both Devlal and Rao et al studies [40, 107] in which gait speed and step time 
were found to be significantly different across all subject groups. The finding in this 
study that the gait variability, but not the parameters describing properties of average 
measures such as gait speed and stride time, was sensitive to capture change differences 
between the subjects with pre-manifest HD and healthy controls, is interesting. The fact 
that gait as a functional task is controlled by an array of physiological and 
neurophysiological systems may provide an explanation for this observation. 
Performance of gait relies on neural, motor and sensory inputs and therefore, gait 
variability can be viewed as a final integrated output of the locomotor system [104]. 
This dependence on a host of factors suggests that gait variability may act as a sensitive 
measure, perhaps revealing deficits in gait, even when the other measures of gait such 
as stride time and gait speed only show more subtle changes.  
 
Data from the present study suggests that the GAITRite walkway is a reliable 
instrument in quantifying gait measures in manifest and pre-manifest groups. The test 
re-test reliability coefficients of gait speed and stride time for both manifest and pre-
manifest groups were excellent (ICC above 0.8 for both variables). These coefficients 
were also in agreement with the values previously reported by Rao et al [140] in a 
sample of individuals with manifest HD, and fell within the range reported in previous 
studies of older adults and subjects with Alzheimer disease and Parkinson‟s disease 
(ICC range from 0.75 to 0.99) [140, 199-204]. The test re-test reliability obtained in this 
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study for the stride time coefficient of variations (CV) was also surprisingly high in 
both the manifest and pre-manifest HD groups (ICC=0.98, 0.75 respectively). The small 
SEM values relative to the range of the scores at the test re-test assessments (SEM<10% 
of the total range of scores) as well as the small mean and standard deviation of the 
within subject‟s difference score for all the gait measures included in this analysis 
suggest highly repeatable parameters. This provides indications that despite observable 
variability in motor performance, there is some underlying consistency in the pattern of 
gait deficits in HD. The MDC95 obtained in this study for the gait speed and stride time 
were lower in comparison to those calculated from a previous study by Rao et al [140], 
indicating a lesser amount of variability in the data presented in this study. One possible 
explanation for this result is that analysis of the data presented here was based on a 
larger number of trials; the average of 10 walking trials was used in this study compared 
to only 2 trials in the study by Rao et al [140]. Hence, the use of a larger number of 
trials may potentially help in providing an adequate sampling of a subject‟s motor 
performance.  
 
Overall, out of the 3 measures of gait evaluated here, gait variability as reflected by the 
stride time CV, was the most sensitive to detect changes across the broad spectrum of 
the disease. This measure as well had high test re-test reliability with indications of 
exposing minimal variability on repeated testing. This makes gait variability a 
potentially useful measure to monitor disease progression and response to therapeutic 
interventions in people with HD, even at the very early stages of the disease.  
 
4.3.2.1.2 Walking-measures of community walking   
The StepWatch Activity Monitor, which consists of an accelerometer and 
microprocessor was used in this research for the purpose of monitoring the actual 
walking in the community setting; thus providing an indication of an individual‟s 
performance of walking. The main advantage of this monitor is that it can be worn for 
extended periods and has a range of outputs available. Total step count is the most 
commonly used output, but peak activity index is also available. The peak activity index 
represents the average step rate of the fastest sustained 30 minutes. The percentage of 
time spent at high (above 40 steps/min), medium (between 15 and 40 steps/min) and 
low (below 15 steps/min) rates can also be calculated. 
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As expected, all measures derived from the activity monitor demonstrated good 
discriminant validity in the manifest HD group. Individuals with manifest HD (although 
all were able to walk independently), demonstrated significantly lower average daily 
step counts and activity levels than healthy controls. Furthermore, high correlation was 
found between the peak activity index and the stride time coefficient of variations which 
gives an indication of the good concurrent-convergent validity of this measure. This 
high correlation suggests that the associated motor deficits in HD such as increased gait 
variability may limit individuals with HD by restricting the actual number of steps that 
they are able to maintain for an extended period of time. In contrast to peak activity 
index, there were no significant correlations between the average daily step count, the 
percentages of time spent at different levels of physical activity and the stride time 
coefficient of variation. The fact that besides the physical capacity there are other 
potential influential factors on the total steps an individual with HD would take in one 
day may explain this result. It is likely that behavioural, personal, environmental and 
social factors also impact the number of steps taken in 1 day [256]. Highest step rate in 
30 minutes (peak activity index) is based on rate rather than amount of stepping or 
percentage of time and may be therefore more reflective of maximal physical 
performance in this population. This result is consistent with previous reports from 
current literature in which peak activity indices were found to best correlate with gait 
speed in individuals with stroke [257] and with the Rivermead Mobility Index in 
individuals with other neurological disorders [208]. The peak activity index was also 
found to be the most reliable compared to average daily step counts and the percentage 
of time spent at different levels of activities in stroke [186] and other neurological 
conditions [208].  
 
Interestingly, data presented here suggests that individuals with pre-manifest HD had a 
trend toward spending less time participating in medium and high activities than healthy 
controls, although these differences were not significantly different. In contrast, 
individuals with pre-manifest HD demonstrated significantly lower peak activity index 
when compared to healthy controls; providing an indication of the good discriminant 
validity of this measure in the pre-manifest HD. This finding suggests that people with 
pre-manifest HD may have reduced ability to maintain activity levels for a longer period 
of time. The origin of this is unknown and further investigations are required to 
determine factors that may potentially contribute to restricted activity levels in pre-
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manifest HD. Issues related to fatigue (if any) or the tendency toward having a 
sedentary life style as a consequence of apathy can be contributing factors. In addition, 
the possibility that subtle deficits in mobility and balance may limit individuals with HD 
at this very early stage of the disease by restricting the actual number of steps that they 
are able to maintain for an extended period of time is indicative. This warrants further 
investigation. Overall, the good concurrent-convergent and discriminant validity across 
the spectrum of the disease, as well the high test re-test reliability (based on data 
available from current literature) make the peak activity index in particular a potentially 
useful measure to monitor responsiveness to change over time in people with HD. 
 
4.3.2.1.3 Other measures of mobility  
4.3.2.1.3.1 Four Square Step Test  
Performance on the FSST was significantly different in both manifest HD participants 
and those with pre-manifest HD when compared to healthy controls. This provides 
indications of the good discriminant validity of this test in both manifest and pre-
manifest HD groups. The good discriminant validity of this test in the pre-manifest HD 
in particular is interesting and can be understood in the context of the nature of this test. 
The FSST requires the individual to comprehend, plan, organise, and incorporate the 
stepping sequence that requires combination of movement and weight shift from one 
foot to another while changing direction [210], thereby making the test more cognitively 
challenging. The fact that deficits in executive cognitive functions such as planning, 
organising and sequencing a motor task start to appear from the pre-manifest stage [22, 
23] and may therefore add to the difficulty of performing this test, explains its 
sensitivity to capture differences in the pre-manifest when compared to healthy controls.  
 
In addition to the good discriminant validity, the FSST had good concurrent-convergent 
validity with the primary measure (stride time CV). This test has not been previously 
used in HD; however data presented here are consistent with reports from the literature 
on using  the FSST in other populations such as the elderly [187], vestibular disorders 
[211] and stroke [209]. In these populations, the FSST was found to have good 
concurrent validity with walking speed [211] and other measures of balance [187, 209] 
as well as being sensitive in identifying people who are at risk of falls [187, 210, 211].  
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In terms of reliability, the test re-test reliability coefficients obtained for the FSST in 
both manifest and pre-manifest HD were high and similar to values found in previous 
studies of subjects with stroke [209], vestibular disorders [211] and older adults [187]. 
None of these studies assessed the absolute reliability of this measure. In this study, the 
calculated SEM provided indications of minimal variability of the test in the pre-
manifest HD in the absolute term. The SEM value however, suggested that this test in 
the manifest stage is prone to a high amount of variability on repeated assessments 
(SEM> 10% of the total range of scores in the manifest HD). The fact that this test 
requires the performance of a coordinated motor task that is cognitively challenging 
may partly explain the high variability in the manifest HD.  
 
Overall, data obtained from the Bland and Altman methods suggest that this test is 
prone to a learning effect (i.e. directional bias) in both manifest and pre-manifest HD; 
most manifest (7/9) and pre-manifest (8/9) individuals performed better in day 2 on this 
test compared to day 1 (Figure 4.5a and 4.10a). This bias was not evident from the ICC 
results and potentially was not big enough to produce a high value of SEM in the pre-
manifest. However, this is an interesting observation to note and it may disappear on re-
testing when more trials of the test are included; FSST score in this study was based on 
the average of 3 trials, however future studies may need to incorporate a larger number 
of trials to overcome the observed learning effect.  
 
In addition to a learning effect, data presented here revealed that there was a potential 
bias toward the larger values on this test (i.e. there was a tendency for a relationship 
between the difference score and the size of the mean). For example, in the manifest HD 
group, the 3 participants who took on average 30 seconds or more to complete the test 
were the ones who showed the largest differences in performing the test on repeated 
assessment. Taking into account the complexity of this test and its cognitive demands, 
this bias towards a larger value suggests that participants who were more impaired 
potentially both physically and cognitively may find it more difficult to perform this test 
at the baseline and this in turn may have contributed to a highly variable performance 
on repeated testing. 
 
In addition to its subjectivity to a higher degree of variability and to directional biases 
particularly in the manifest HD, the FSST has some other disadvantages that need to be 
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considered. The test requires a high level of skilled physical supervision on the part of 
the tester in order to ensure the subject‟s safety. In addition, the test can be described as 
an "all-or-nothing" test, in that a score cannot be given to a subject who does not 
complete the test, which may result in obtaining a floor effect. In this study, a floor 
effect was observed in 20% of the participants with manifest HD (i.e. 20% of the 
participants in the manifest HD group could not perform the test).  
 
In summary, the test was sensitive to early mobility changes in pre-manifest HD; 
however its susceptibility to a learning effect on repeated assessment may limits its use 
as a measure to monitor disease progression in this early stage of HD. Furthermore, its 
use in the manifest HD stage may be limited due to its susceptibility to floor effects, a 
higher degree of variability on repeated testing and directional biases.   
 
4.3.2.1.3.2 Timed Up and Go test  
The TUG evaluates mobility during transfer from sit- to stand, walking and turning. The 
TUG was also previously used in HD [93] and was demonstrated to be useful in 
identifying people with HD who are at risk of falls [45]. Results obtained from this 
study demonstrated that although the test had good discriminant as well as concurrent-
convergent validity in manifest HD, it did not obtain good discriminant validity in the 
pre-manifest HD. The test was unable to distinguish between individuals with pre-
manifest HD and healthy controls. This result is consistent with findings reported by 
Rao et al [94] in which the TUG was also found to be not sensitive in detecting mobility 
deficits in the pre-manifest HD. As indicated earlier, a likely explanation for this result 
is that mobility deficits in the pre-manifest HD are subtle and therefore tests of mobility 
that include more complex patterns of movement are required to detect such changes at 
this very early stage of the disease [92].  
 
In terms of reliability, the test re-test reliability coefficients in both the manifest and 
pre-manifest HD groups were high (ICC=0.74, 0.84 respectively). The test re-test 
reliability values obtained in this study, although relatively high, are lower than the 
values previously reporting test re-test reliability of TUG in the elderly [212], people 
with peripheral arthritis [258] and in people with Parkinson‟s disease [182, 191]. This 
can be explained in the context of the data presented here about the absolute reliability 
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of this test in HD. The calculated SEM was higher than the acceptable limit in both 
groups (SEM> 10% of the total range of scores). This indicates that the test is 
potentially susceptible to a high degree of variability between 2 test sessions in people 
with HD. Data obtained from Bland and Altman plots provided further insight into this. 
For example in the pre-manifest HD it seems that the variability between the 2 testing 
sessions occurred in one direction (i.e. bias); most individuals with pre-manifest HD 
(6/9) performed better on this test on day 2 compared to day 1. This suggests that this 
test is prone to a learning effect in the pre-manifest HD.   
 
In the manifest HD, although in most cases (7/9) differences between day 1 and day 2 
were relatively minimal (Figure 4.5b), there was an outlier. The presence of the outlier 
may have inflated the degree of variability in people with manifest HD. It was also 
interesting to note that this outlier (i.e. the case that showed the largest difference) is the 
case that had the largest average score. This suggests that the TUG in manifest HD 
stage is susceptible to the bias toward the larger value (i.e. differences between repeated 
assessments increases when average score increases). This observation needs to be 
further investigated in a larger sample with a wider range of levels of impairments. 
Overall, the high variability of the TUG in individuals with the manifest HD who are 
more impaired can be attributed to a number of factors. First, despite the fact that the 
TUG consists of basic everyday movements, its various components for individuals 
with mobility deficits can be particularly complicated; performing the test involves an 
interaction between multiple systems, such as sensory input, neuromuscular function 
and cognitive processes. For example, to be able to rise from a sitting position to a 
standing position requires both strength and technique. Walking a path for 3 meters 
includes both acceleration and deceleration as participants prepare for a turn. The 
turning sequence is challenging for people with HD. Finally, turning around to sit down 
challenges both balance and orientation in adapting the body position to the chair. 
Second, as the test requires understanding of instructions as well as an ongoing 
adaptation to tasks, anticipation, and planning, cognitive impairments as seen in HD 
may influence performance of the test [212]. This, in particular, is important to consider 
as there is some supportive evidence from other populations that cognitive impairments 
may influence the measures of the TUG assessment [212]. 
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In summary, the TUG as suggested on previous research may be useful as a screening 
tool to identify people who are at risk of fall in this population. However, its use to 
measure responsiveness to change over time may be limited as it seems to lack the 
sensitivity to early mobility changes in HD and it is susceptible to directional biases on 
repeated testing.  
 
4.3.2.1.3.3 Chair Sit to Stand Test  
The CSST is a simple and common method of assessing postural control in the 
community or in a clinic setting [188]. The test protocol has 2 versions. In the first 
version, the test measures the time the participant takes to complete a given number of  
sit- to- stand repetitions, usually either 5 or 10 [259]. While this version of the test has 
good concurrent validity relative to other measures of interest, such as walking speed 
and risk of falls [214, 260], it can result in a floor effect. As an example, a floor effect 
was observed even on a 5-stand version of the chair stand test in a study of elderly 
people, when 22% of a population of over 5,000 community individuals could not 
complete the required 5 repetitions [261]. The 30-second Chair Stand test is an 
alternative protocol that has been introduced by Jones et al [188], with the aim of 
assessing the older adult population specifically. In the 30-s Chair Stand test the 
examiner quantifies the maximum number of chair stands completed within 30 seconds 
instead of measuring the time taken to complete a specific number of repetitions. This 
allows for the assessment of a wide range of abilities and for this reason this version of 
the test was used in this study. 
 
The results in this study demonstrated that the version of the 30 seconds CSST test was 
able to distinguish between manifest HD and healthy controls as well as between pre-
manifest HD and healthy controls. This provides indications of the discriminant validity 
of this test in people with HD along the spectrum of the disease. The test also has good 
concurrent-convergent validity with gait variability measure (stride time CV). These 
results are consistent with the literature, which has shown that this test provides a valid 
indication of measures of mobility and has good discrimination power in detecting 
expected differences in age categories and physical activity level groups in community 
dwelling older adults [188, 262].  
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The finding in this study about the good discrimination validity of the CSST to capture 
changes in the mobility performance in the individuals with pre-manifest HD is 
particularly interesting. This result can be understood in light of available information 
from the literature about sit to stand performance in people with HD; subtle deficits in 
the slopes and durations of Sit to Stand transitions were previously recorded in the pre-
manifest HD group using a kinematic sensor when compared with healthy controls 
[116]. Considering these subtle deficits in sit to stand performance and taking into 
account that the 30 seconds CSST is a stress type of test in which the maximum number 
of Sit to Stand transitions is recorded in a certain amount of time, it is likely to find a 
difference in the performance of this test between the groups of pre-manifest and the 
healthy controls.  
 
In terms of reliability, the test re-test reliability coefficient obtained for the CSST in 
both manifest and pre-manifest HD was high and comparable to the value reported in a 
previous study of elderly adults [188]. The calculated SEM provided indications of 
minimal variability of the test on repeated testing in both the manifest and pre-manifest 
HD (SEM<10% of the total range of scores in both groups). The difference between the 
2 test sessions in both manifest and pre-manifest HD groups was 2 repetitions or less in 
most cases (Figure 4.5d and 4.10d) which further confirms the minimal variability of 
this test on repeated testing in this population. These results provide the suggestion of a 
highly repeatable test. Overall, the good discriminant validity as well as the high test re-
test reliability of this test in both the manifest and pre-manifest HD suggests that this 
test is potentially a useful test in monitoring disease progression and response to 
therapeutic interventions across the broad spectrum of the disease.  
 
4.3.2.2 Measures of functional performance in ADL  
The 7-item PPT was used in this study to assess the functional performance in ADL. 
The PPT was chosen because its items reflect different dimensions of function, 
specifically upper fine motor function and upper “coarse” motor function, as well as 
mobility [189, 263]. The PPT was previously demonstrated to have good concurrent 
validity with other functional performance measures, such as the Katz ADL scale and 
Tinetti gait score [189], as well as predictive validity for institutionalization or mortality 
in a sample of older adults [263]. The results of this study were consistent with these 
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previous reports and demonstrated that the PPT correlated highly with the measures of 
gait variability. This provided indications of the concurrent-convergent validity of this 
test and suggests that functional decline in HD is associated with related motor deficits 
seen in this population.  
 
In addition, results from this study demonstrated that the test was sensitive to 
distinguish between individuals with manifest HD and healthy controls. Furthermore, 
this test was able to differentiate between people with pre-manifest HD and healthy 
controls. These results provided indications of the discriminant validity of this test in 
both manifest and pre-manifest HD. The finding that the test was sensitive to early 
changes in the pre-manifest HD is important and provides the suggestion of pre-clinical 
decline in function in this population. Brach et al [206] previously used the PPT as a 
performance-based measure to identify early decline in physical functioning in 
community-dwelling older people. Similarly Landgraff et al [216] used the PPT to 
detect early changes in functional performance in a sample of individuals with 
asymptomatic carotid artery disease. These studies provide additional supporting 
evidence that the PPT is useful in identifying early decline in functional performance. 
 
Functional decline in the pre-manifest HD was not previously documented in pre-
manifest HD using the routine measure of function used to assess the functional 
performance in this population (the Total Functional Capacity scale (TFC)) [137, 139].  
This is in agreement with what is reported in this study in which all the pre-manifest 
subjects scored on the ceiling on the Total Functional Capacity scale (TFC). However, 
none of the pre-manifest HD scored on the ceiling in the PPT test. The fact that the TFC 
and the PPT use different methods to measure functional performance may explain this 
result. The TFC is a self reported measure of functional performance, whereas the PPT 
is a direct observational test that assesses individuals‟ performance based on time to 
completion of certain tasks. It is therefore likely that preclinical deficits in physical 
performance can affect function by increasing time to complete the task as indicated by 
a lower score on the PPT which have not been routinely identified clinically using the 
TFC scale, or perceived and communicated by individuals with pre-manifest HD. This 
is in agreement with available evidence which found that early deficits in physical 
function are often not reported by individuals but can be observed using performance-
based measures [206].  
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Considering the reliability, the test re-test reliability value of 0.95 obtained for the PPT 
in the group of manifest HD fell within the range of 0.8 to 0.96 reported in previous 
studies of subjects with the elderly [189] and PD [217]. The small SEM relative to the 
total score of measurements indicated that the test is highly repeatable in the absolute 
term in the manifest HD group. The calculated MDC95 value of 2.5 in this study was 
comparable to the value calculated from a previous study for subjects with PD [217]. 
Although the ICC value of 0.69 for the PPT was lower in the pre-manifest group, the 
very small SEM relative to the range of the scores indicates that the test is highly 
repeatable even in the pre-manifest HD group. The difference between the 2 testing 
sessions in the pre-manifest HD groups was 1 unit or less in the vast majority of cases 
(8/9) (Figure 4.10d) which further confirms the minimal variability of this test on 
repeated testing in this population at this very early stage. This result (obtaining low 
ICC values whilst observing minimal variability in the absolute figure), as indicated 
earlier, can be explained in light of the homogeneity of the tested sample. The ICC 
value is known to be strongly influenced by the magnitude of the observed variance 
between subjects [141, 178]. The lower the magnitude of the range or spread of the 
scores therefore, the lower the magnitude of ICC even in the presence of a highly 
repeatable measure [178]. In this study, the small range of PPT scores in the pre-
manifest group indicates the low variability of this test among the subjects being tested 
which may explain the low ICC value calculated for this test in this group. Overall, the 
good discriminant validity of this test in both manifest and pre-manifest HD as well as 
the high test re-test reliability suggests that the PPT can be useful as a measure of 
responsiveness to change in this population along the spectrum of the disease. 
 
4.3.3 Measures of participation 
4.3.3.1 Measures of health-related quality of life  
Health-related quality of life can be assessed using a generic or a disease-specific tool. 
As there is no disease-specific tool available yet for assessing health-related quality of 
life in HD, the 36-Item Short-Form Health Survey (SF-36), which is a generic tool 
commonly used in research, was used in this study. Data presented here demonstrated 
that all the subscales of the SF-36 except the bodily pain have good discriminant 
validity in individuals with manifest HD; scores obtained from all subscales except the 
bodily pain were able to distinguish between people with manifest HD and healthy 
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controls. This result is consistent with reports from previously conducted studies in 
which individuals subjects with HD had poorer health- related quality of life than 
healthy controls [117-120]. In particular, the profiles of quality of life demonstrated 
here in the manifest HD were similar to those reported in a previous study and in which 
significantly reduced health related quality of life was demonstrated on several 
dimensions of the SF-36 including physical function, role physical, social function, and 
general health perceptions [119]. Thus data presented here provides further support for 
the reduced health-related quality of life in manifest HD as identified by the SF-36.  The 
inability of the bodily pain subscale to distinguish between manifest HD and healthy 
controls in this study is also consistent with reports from a previously conducted study 
in which scores obtained from bodily pain subscales in people with manifest HD were 
not significantly different from the scores obtained from their carers [119].   
 
In addition to the good discriminant validity of the majority of the SF-36 subscales, 
some of the dimensions appeared to have good concurrent criterion validity in the 
manifest HD. In this study, the physical function subscale as well as the aggregate 
physical score (i.e. the physical component summary) correlated significantly and 
substantially with the primary measure of gait variability (stride time CV). This 
suggests that motor aspects of the disease and, in particular, walking difficulties may be 
a key factor associated with health-related quality of life in this population. This is in 
agreement with available evidence, which found that the physical dimension of the SF-
36 in HD correlates significantly with the TFC score [117], the UHDRS-motor score 
[119, 120], the disease duration and the patient‟s self-rated score on their level of 
functioning or independence level [118, 119].  
 
The test re-test reliability coefficient obtained in this study for the subscales of the SF-
36 were fair to substantial in the manifest HD and were moderate to high in the pre-
manifest HD (ICC vales ranged from 0.13 to 0.79 in the manifest HD and from 0.5 to 
0.91 in the pre-manifest HD). The lower limits of these values were lower than those 
reported in a previous study of subjects with HD [119]. The upper limits of the ICC 
values reported here, however was within the range reported in a previous study in HD 
[119] and were also similar to values reported in studies of subjects with vestibular 
disorders [264], stroke [265] and PD [182]. The absolute reliability of the SF-36 in HD 
has not been evaluated in previous studies. In this study, the calculated SEM values of 
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all the in the manifest HD were much higher than the criterion (SEM> 10% of total 
respective range of scores (Table 4.14)). Similarly in the pre-manifest HD, the SEM 
values were much higher than the criterion in the vast majority of the subscales; only 
the SEM of the physical component summary and the mental component summary just 
fell short below the criterion in the pre-manifest HD. This provides an indication that 
the SF-36 is susceptible to a high degree of variability. The data obtained from Bland 
and Altman plots provided further insights into this. It seems that reliability of the SF-
36 subscales in pre-manifest HD is affected by outliers; in some of the subscales, 
mainly the physical function, role limited due to physical problems, social functioning 
and role limited due to emotional problems, although differences in most cases were 
close to zero, there were some outliers (i.e. big differences in few cases) (Figure 4.11). 
These outliers may have inflated the degree of variability in these subscales; thus there 
is a need to confirm findings reported here with a larger sample in future studies.  
  
Data obtained from the Bland and Altman methods have also highlighted two 
interesting observations about the reliability of the SF-36 subscales in the manifest HD. 
Firstly, in some of the subscales such as the physical function and the bodily pain, there 
were a tendency toward bias to greater value. For example in the role physical subscale, 
largest differences were observed in cases where the mean is greater than 40 (Figure 
4.11). Secondly, there were indications of directional bias in at least 4 of the subscales 
(i.e. mental health, vitality, general health, mental component summary). In all of these 
subscales, most participants had a lower score on day 2 compared to day 1.  This 
observation in particular is interesting and one possible explanation of it is the 
occurrence of a response shift bias. Response shift is common in population in which 
individuals live with a chronic illness [266] and there are preliminary indications that it 
does occur in the HD population [118]. Response shift refers to the fact that subject‟s 
views, values and expectations may change over time [267]; thus influencing the 
assessment of quality of life. Spangers and Schwarts [266] suggest that coping; social 
support, goal reordering, reframing expectations, and social comparison may all be 
active mechanisms in response shift. Although it is not clear if response shift has 
occurred or not in this study, one might hypothesise that reframing expectations is an 
important factor in the observed directional bias; being a participant in a study that 
evaluate physical abilities and fitness levels may made some participants to view their 
situations at the re-test assessment (i.e. day 2) as being worse compared to what they 
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previously thought (i.e. at day 1). It should be noted however, that these are only 
speculations and further research is required to confirm of whether response shift occurs 
in HD and how it would affect the assessment of health-related quality of life. This is an 
important area of investigation as response shift bias will have implications for the 
design of future studies; subject‟s shift in rating quality of life over time may mask 
treatment gain. 
     
Although a response shift bias in HD is possible, the susceptibility of the SF-36 
subscales in general to a high degree of variability could reflect a distortion that is 
secondary to the cognitive impairments seen in this population. The majority of the 
questions in the survey are asked by inquiring if the participant is doing better, worse or 
the same. These types of questions involve implicit or explicit comparisons to the past 
and retrospective judgement of health-related quality of life; thus answering these 
questions can be cognitively demanding particularly in individuals with cognitive 
deficits as in people with HD.  
 
Overall, although the vast majority of the SF-36 subscales seem to have good 
discriminant validity and the physical function and physical summary component 
subscales in particular have a good concurrent-convergent validity in the manifest HD, 
the susceptibility of the subscales to higher degree of variability may limit their use as 
measures of responsiveness of change over time in people with HD.    
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5 Results and discussion: Part 2 
 
5.1 Overview 
This chapter presents the quantitative results of Part 2 of the study, which aimed to 
evaluate the feasibility and potential benefits of a home-based exercise programme. A 
repeated measures design was used. Twenty-five participants with early to mid-stage 
HD were randomly assigned to the exercise intervention group or to the control group 
who received delayed intervention (Figure 5.1). Participants who completed the study 
were assessed 3 times over the study duration (at baseline; at 8 weeks and at 16 weeks) 
using a battery of outcome measures whose psychometric properties were evaluated in 
the first part of the study (Chapter 4). The primary outcome was gait variability (stride 
time coefficient of variation (CV)). Secondary outcomes included other measures of 
gait as well as measures of balance, muscle strength, mobility, community walking, 
functional performance in ADL and health-related quality of life.  
 
Results in this chapter relating to the feasibility and potential benefits of the exercise 
programme are presented in 4 sections. In the first and second sections, the flow of 
participants through the study, baseline characteristics and adverse events are described. 
In the third section data related to comparison of follow- up scores at the 8-week period 
(i.e. the primary end point of the study was at 8 weeks) across groups, after adjustment 
for differences at baseline using analysis of covariance (ANCOVA), are provided. In 
addition scatter plots of individual responses for all outcomes in which scores at baseline 
were plotted against the change scores, categorized by group allocation are illustrated.  
Furthermore, effect sizes which were calculated for outcome measures at 8 weeks based 
on differences in change scores between groups are reported in this section. Descriptive 
data which was used to compare follow-up scores on the primary outcome only at 16 
weeks are provided in the fourth section of the results.  
 
The result sections will be followed by discussion of the data. Data obtained from the 
previous chapter relating to the psychometric properties of the outcome measures are 
used to aid in providing interpretations of findings from this part of the study. In 
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particular, the values of the minimal detectable change (MDC95) of each of the 
outcomes that are presented in the previous chapter are used here to determine whether 
any statistically significant changes on the outcomes in the exercise intervention are 
clinically significant. Changes in the outcomes in the intervention group that exceed the 
MDC95 are 95% likely to be admitted as a real change in the outcome rather than being 
a result of random error or natural variations in testing [141, 178] and therefore can be 
interpreted as meaningful in practice [178].  
 
5.2 Results    
5.2.1 Participants’ flow  
A flowchart detailing the flow of participants through each stage of the trial is presented 
in Figure 5.1. In accordance with the Consolidating Standards of Reporting Trials 
(CONSORT) guidelines [268, 269], this figure provides details for each group on the 
number of participants randomised, receiving treatment, completing the study and 
analysed for primary outcomes at each stage of the study. Over the study recruitment 
period, 25 participants were recruited into the study, 13 to the early intervention group 
(home-based exercise intervention) and 12 to the delayed intervention group (i.e. 
control). Of the 106 sequential subjects who attended the recruiting clinic during the 
recruitment period, 39 (36.8%) were ineligible. The reasons for ineligibility fell into 3 
main categories: 1) at an advanced stage of the disease (wheelchair dependent) (n=13); 
2) having co-morbidities that prevented participation in regular physical activity (n=8); 
or 3) having cognitive or behavioural symptoms that would have limited participants 
from co-operating with the intervention (n=18). In addition, 12 individuals (11.3%) 
were considered ineligible due to their enrolment in concurrent drug trials. Of the 55 
eligible subjects, 25 (45.5%) agreed to participate, which represents an overall 
recruitment rate of 23.6%. 
 
Of the 25 participants allocated into either exercise or control, 21 participants (84%) 
attended for the first follow-up assessment at 8 weeks. Two participants from the 
exercise intervention (early intervention group) and 2 participants from the control 
(delayed intervention group) did not attend the 8- week assessment (i.e. dropped out). 
At the 16-week review (second follow-up) 17 (68% of allocated participants) attended 
for re-assessment on the primary outcome measure, with a total of 4 participants being 
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lost from the exercise intervention group and 4 participants from the control group. Four 
of the participants who did not attend the follow-up assessments (i.e. dropped out), did 
not give a reason for non- continuing (n = 1 exercise intervention group, n = 3 control 
group). The other 4 participants who have been lost to follow-up developed concomitant 
medical issues that prevented them from continuing the study (n=4). This included 3 
participants in the exercise intervention group in which one had progressive depressive 
symptoms, one had progressive vocal spasm symptoms and one was hospitalized for an 
insertion of a percutaneous endoscopic gastrostomy tube. In addition, a participant in 
the control group had an accidental fall which was unrelated to the study. 
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Figure 5.1: Flow of participants through the study 
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5.2.2 Baseline characteristics of participants and adverse events  
The baseline characteristics of participants who enrolled in the study are shown in Table 
5.1. Nine participants (69.2%) in the early intervention exercise group and 8 participants 
(66.7%) in the delayed intervention group were prescribed medications for depression 
or mood disorders (diazepam, citalopram or olanzapine). In addition, 5 participants 
(38.5%) in the exercise intervention group and 6 participants (50%) in the control group 
were prescribed medications for managing chorea (see Appendix 6 for more details).   
 
None of the participants in either study group reported a change in their medication type 
or dose during the study period. None of the participants in the control group reported 
any changes in their usual routine related to performing physical activities in the first 8 
weeks of the study. Participants who completed the exercise programme from both arms 
of the study reported no incidences of falls, no increases in sustained fatigue levels or 
pain (there were some reports of mild muscle discomfort on initiation of the 
programme), and no other adverse events related to the exercise programme. 
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Table 5.1: Baseline characteristics for control and intervention groups (Mean ± SD) 
 
Category Outcome measure Control group 
(n=12) 
Exercise group 
(n=13) 
Age Age (years) 51.3 ± 16.9 54.2 ± 9.9 
Gender Gender: male, n (%) 5 (41.7) 7 (53.8) 
TFC TFC 6.0 ± 1.8 6.9 ± 2.8 
Medication Anti-psychotic drugs n (%) 8 (66.7) 9 (69.2) 
Anti-choreic drugs n (%) 6 (50) 5 (38.5) 
Others, n (%) 5 (41.6) 8 (61.5) 
Disease-specific motor 
scale 
mMS^ (unit) 22.9 ±  6.4 25.6 ± 9.6 
Balance BBS (unit) 44.9 ± 7.4 39.8 ± 12.1 
Total score of RT and SRT 
(s) 
104.7 ± 33.8 98.9 ± 45.4 
rms-AP (m) 0.012 ± 0.006 0.013 ± 0.004 
rms-ML (m) 0.011 ± 0.005 0.011 ± 0.004 
Muscle strength MVIC of knee extensors 
(N.m) 
235.5 ± 200.1 213.5 ± 136.4 
MVIC of knee flexors 
(N.m) 
122.3 ± 1013.3 113.6 ± 68.2 
Gait Gait speed (cm/s) 83.1 ± 21.5 63.3 ± 37.1 
Stride time (s) 1.2 ± 0.2 1.3 ± 0.5 
Stride time CV (%) 9.8 ± 10.9 11.2 ± 6.2 
Community walking Average of daily step count 3346 ± 1838 3622 ± 2034 
Percentage of time spent at 
no PA 
78.1 ± 10.2 78.2 ± 9.6 
Percentage of time spent at 
low PA 
16.0 ± 8.4 16.0 ± 6.8 
Percentage of time spent at 
moderate PA 
5.4 ± 3.1 5.3 ± 4.2 
Percentage of time spent at 
high level of PA 
0.5 ± 0.5 0.5 ± 0.09 
Peak activity index (unit) 29.7 ± 8.4 30.2 ± 10.1 
Other measures of 
mobility 
FSST (s) 30.2 ± 20.2 30.6 ± 19.8 
TUG (s) 12.7 ± 4.5 19.4 ± 11.1 
CSST (number of 
repetitions) 
8.2 ± 3.3 6.4 ± 3.5 
Functional 
performance in ADL 
PPT (unit) 13.5 ± 4.6 11.3 ± 6.1 
TFC, Total Functional Capacity scale; mMS, modified motor score of the Unified 
Huntington‟s Disease Rating Scale; BBS, Berg Balance Scale; RT, Romberg test; SRT, 
Sharpened Romberg test; rms, root mean square of postural sway movement; AP, anterior-
posterior; ML, medio-lateral;MVIC, Maximal Voluntary Isometric Contraction; FSST, Four 
Square Step Test; TUG, Timed Up and Go test; CSST, Chair Sit to Stand Test; PA, Physical 
Activity; CV, coefficient of variation. 
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Table 5.1: continued Baseline characteristics for control and intervention groups (Mean ± SD) 
Category Outcome measure 
Control group 
(n=12) 
Exercise group 
(n=13) 
Health-related quality of 
life 
PF 38.5 ± 31.5 33.3 ± 28.6 
RP 157.5 ± 48.7 129.2 ± 39.6 
BP 81.1 ± 22.9 78.7 ± 30.9 
VT 52.0 ± 14.8 47.9 ± 14.8 
GH 51.7 ± 16.9 45.3 ± 21.0 
SF 55.6 ± 31.4 59.3 ± 21.4 
RE 156.7 ± 49.8 147.2 ± 48.1 
MH 72.8 ± 15.5 62.3 ± 15.1 
PCS 58.6 ± 21.8 51.8 ± 19.5 
MCS 66.0 ± 14.0 60.2 ± 11.4 
PF; Physical Functioning; RF; Role limited due to physical problems; RE; Role limited due to 
emotional problems; SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, Bodily Pain; 
GH, General Health Perception; PCS, Physical Component summary; MCS, Mental Component 
Summary. 
 
 
5.2.3 Eight-week study outcomes 
Data analysis was carried out on complete cases; data from all participants who 
completed the first follow-up assessments (n=11 exercise intervention group, n=10 
control group) were included in the analysis. The sections below provide data from 
scatter plots of individual responses, categorized by group allocation followed by data 
obtained from statistical comparisons between study groups.   
 
5.2.3.1 Scatter plots of individual-case responses 
Figure 5.2 below shows how subjects responded to the intervention in all balance 
outcomes. The vast majority of participants in the intervention group (10/11) improved 
in the berg balance scale. However, only 5/11 subjects in the intervention group 
demonstrated improvement in the total score of Romberg and Sharpened Romberg tests. 
Similarly, only 3/11 subjects in the intervention arm of the study demonstrated some 
improvements in the measures of postural sway.  
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Figure 5.3 shows that 6/11 participants in the intervention arm demonstrated 
improvements in the modified UHDRS-motor score (mMS). In addition, only few 
participants demonstrated some improvements in measures of muscle strength.  
Most of the participants in the intervention group improved in their gait characteristics 
(9/11 subjects improved in gait speed and stride time and 8/11 subjects improved in 
stride time CV) (Figure 5.4).  Similarly most of participants in the intervention group 
(10/11) demonstrated improvements the Chair Sit to Stand Test as well as in the 
measure of functional performance in ADL (i.e. the Physical Performance Test) (Figure 
5.6). In term of community walking, Figure 5.5 shows that all participants in the 
intervention group took more daily steps after the intervention period and tended to 
spend less time being inactive and more time being active at moderate and high levels 
of physical activities.  
 
In term of health-related quality of life, most of the participants in the intervention 
group (10/11) demonstrated improvements in the physical function subscale. Similarly, 
most participants in the intervention group (6/11) demonstrated improvements in the 
general health perception subscale as well as the physical component summary (Figure 
5.7). There were lesser trends toward improvements in the intervention group in the 
other subscales of the SF-36.   
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Figure 5.2: Distribution plot of balance measures at baseline against change score, categorized by group allocation. Change score is the
difference between baseline and follow-up score (follow-up minus baseline). Zero line indicates no difference (i.e. no change from
baseline to follow-up). Positive change in A & B (i.e. change above zero) indicates improvement in these measures at follow-up. A
positive change in C & D indicates deterioration in these measures at follow-up. The score of 40 in BBS at baseline indicates those who
were at risk of falls. The 2 cases in intervention group circled in blue changed from a score below 40 to above 40. Case coded P7 (in the
intervention group; circled in red) showed the large change in in all outcomes.
Figure 5.2: Scatter plots of individual cases on measures of balance 
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Figure 5.3: Distribution plot of mMS and measures of muscle strength at baseline against change score, categorized by
group allocation. Change score is the difference between baseline and follow-up score (follow-up minus baseline). Zero
line indicates no difference (i.e. no change from baseline to follow-up). Positive change in A (i.e. change above zero)
indicates deterioration in mMS at follow-up. A positive change in B & C indicates improvements measures of muscle
strength at follow-up.
Figure 5.3: Scatter plots  of individual cases of disease-motor score (mMS) and measures of muscle strength 
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Figure 5.4: Scatter plots of individual cases of gait measures 
Figure 5.4: Distribution plot of gait measures at baseline against change score, categorized by group allocation. Change
score is the difference between baseline and follow-up score (follow-up minus baseline). Zero line indicates no difference
(i.e. no change from baseline to follow-up). Positive change in A (i.e. change above zero) indicates improvement in gait
speed at follow-up. A positive change in B & C indicates deterioration in stride time and stride time CV at follow-up.
The score of 80 cm./s is the minimum gait speed required for community mobility. The 5 cases in intervention group
circled in blue changed from a score below 80 to above 80 cm/s. Case coded P7 (in the intervention group; circled in red)
showed the large change in in all outcomes.
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Figure 5.5: Scatter plots of individual responses of community walking measures 
Figure 5.5: Distribution plot of community mobility measures at baseline against change score, categorized by group allocation.
Change score is the difference between baseline and follow-up score (follow-up minus baseline). Zero line indicates no
difference (i.e. no change from baseline to follow-up). Positive change in A, C & D (i.e. change above zero) indicates
improvement at follow-up. A positive change in B indicates deterioration at follow-up. Blue circles indicate the number of cases
scored on these points. I; Intervention group/ C; Control group.
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Figure 5.5: Distribution plot of community mobility measures at baseline against change score, categorized by group allocation.
Change score is the difference between baseline and follow-up score (follow-up minus baseline). Zero line indicates no difference
(i.e. no change from baseline to follow-up). Positive change in E & F (i.e. change above zero) indicates improvement at follow-up.
Case coded P7 (in the intervention group; circled in red) showed the large change in these outcomes. Case coded P7 (in the
intervention group; circled in red) showed the large change in in these outcomes. Blue circles indicate the number of cases scored on
these points. I; Intervention group/ C; Control group.
Figure 5.5: continued Scatter plots of individual responses of community walking measures 
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Figure 5.6: Distribution plot of mobility measures and function at baseline against change score, categorized by group
allocation. Change score is the difference between baseline and follow-up score (follow-up minus baseline). Zero line indicates
no difference (i.e. no change from baseline to follow-up). Positive change in A & B (i.e. change above zero) indicates
deterioration in FSST and TUG at follow-up. A positive change in C & D indicates improvement in CSTS and PPT at follow-
up. Case coded P7 (in the intervention group; circled in red) showed the large change in in most outcomes.
Figure 5.6: Scatter plots of individual cases of mobility measures and function 
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Figure 5.7: Distribution plot of health-related quality of life measures at baseline against change score, categorized by group
allocation. Change score is the difference between baseline and follow-up score (follow-up minus baseline). Zero line
indicates no difference (i.e. no change from baseline to follow-up). Positive change in A,B,C & D (i.e. change above zero)
indicates improvement at follow-up. Blue circles indicate the number of cases scored on these points. I; Intervention group/ C;
Control group.
Figure 5.7: Scatter plots of individual responses of measures of health-related quality of life 
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Figure 5.7: Distribution plot of health-related quality of life measures at baseline against change score, categorized by
group allocation. Change score is the difference between baseline and follow-up score (follow-up minus baseline). Zero
line indicates no difference (i.e. no change from baseline to follow-up). Positive change in E,F,G & H (i.e. change above
zero) indicates improvement at follow-up. Blue circles indicate the number of cases scored on these points. I; Intervention
group/ C; Control group.
Figure 5.7: continued Scatter plots of individual responses of measures of health-related quality of life 
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Figure 5.7: continued Scatter plots of individual responses of measures of health-related quality of life 
Figure 5.7: Distribution plot of health-related quality of life measures at baseline against change score, categorized by group
allocation. Change score is the difference between baseline and follow-up score (follow-up minus baseline). Zero line indicates
no difference (i.e. no change from baseline to follow-up). Positive change in E,F,G & H (i.e. change above zero) indicates
improvement at follow-up. Blue circles indicate the number of cases scored on these points. I; Intervention group/ C; Control
group.
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5.2.3.2 Group comparisons   
5.2.3.2.1 Primary outcome  
At the first follow-up assessment, there was a significant difference between groups on the 
mean adjusted score of stride time CV (mean difference - 6; 95% CI (-11.5, -0.6); effect 
size=1.2) (Table 5.2).  
 
Table 5.2: The primary outcome measure (stride time CV) at baseline and first follow-up for 
complete cases (n=21) 
 
 
 
5.2.3.2.2 Secondary outcomes   
5.2.3.2.2.1 Measures of physical impairments in body structures and functions  
5.2.3.2.2.1.1 The disease-specific motor scale  
Significant differences were observed between groups on the mean adjusted scores of the 
modified motor score of the UHDRS (mMS) (mean difference -4.5 units; 95% CI (-8.8, -
0.2); effect size= 1.1) (Table 5.3).  
 
Table 5.3: Disease-specific motor score at baseline and first follow-up upon complete cases  
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at 
first follow-up adjusted for 
baseline measures 
Outcome 
measure 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
Stride time 
CV (%) 
6.4 ± 2.6 11.6 ±  5.6 9.9 ± 5.8 9.7 ± 7.9 -6 (-11.5, -0.6) 0.03 1.2 
CV; coefficient of variation. 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at 
first follow-up adjusted for 
baseline measures 
Outcome 
measure 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
mMS (unit) 23.6 ± 6.5 23.8 ± 10.5 25.9 ± 7.6 21.5 ± 8.7 -4.5 (-8.8, -0.2) 0.04  1.1 
mMS; modified motor score of the Unified Huntington‟s Disease Rating Scale. 
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5.2.3.2.2.1.2  Measures of balance  
Significant differences between groups were observed on some of the measures of balance 
at the first follow-up (Table 5.4). Significant differences between groups were observed on 
the mean adjusted score of the Berg Balance Scale (BBS) (mean difference 5.4 units; 95% 
CI (1.0, 9.9); effect size= 1.4). However, there was no significant difference between 
groups on the adjusted mean scores of the total score of the Romberg and Sharpened 
Romberg (RT & SRT) tests (mean difference; -5.5 s; 95% CI (-31.7, 20.7); effect 
size=0.1), the root mean square of postural sway in the anterior-posterior direction (mean 
difference; 0.001 m; 95% CI (-0.001, 0.004); effect size=0.4) and the root mean square of 
postural sway in the medio-lateral direction (mean difference; 0.001 m; 95% CI (-0.004, 
0.005); effect size=0.3).  
 
 
Table 5.4: Measures of balance at baseline and first follow-up for complete cases (n=21) 
 
 
 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at 
first follow-up adjusted for 
baseline measures 
outcome 
measure 
Control group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
BBS 
(unit) 
45.7 ± 6.9 38.5 ± 12.4 44.7 ± 7.5 44.2 ± 10.7 5.4 (1.0, 9.9) 0.01 1.4 
Total 
score of 
RT and 
SRT (s) 
108.3 ± 35.2 89.2 ± 42.9 122.1 ± 29.2 101.5 ± 49.9 -5.5 (-31.7, 20.7) 0.7 0.1 
rms-AP 
(m) 
0.012 ± 0.006 0.013 ± 0.004 0.014 ± 0.006 0.013 ± 0.004 
0.001  
(-0.001, 0.004) 
0.3 0.4 
rms-ML 
(m) 
0.011± 0.005 0.011± 0.004 0.014 0.006 0.013 0.004 
0.001  
(-0.004, 0.005) 
0.8 0.3 
BBS, Berg Balance Scale; RT and SRT, Romberg and Sharpened Romberg tests; rms, root mean square of 
postural sway movement; AP, anterior-posterior; ML, medio-lateral. 
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5.2.3.2.2.1.3 Measures of muscle strength 
There were no significant differences between groups on the mean adjusted scores of the 
Maximal Voluntary Isometric Contraction (MVIC) of knee extensors (mean difference; 
16.1N.m; 95% CI (-179, 211.2); effect size= 0.1) and for the MVIC of knee flexors (mean 
difference; -3.1 N.m; 95% CI (-88.3, 82.2); effect size=0.3) (Table 5.5). 
 
 
Table 5.5: Measures of muscle strength at baseline and first follow-up upon complete cases 
(n=21) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at first 
follow-up adjusted for baseline 
measures 
Outcome 
measure 
Control 
group  (n=10) 
Exercise 
intervention  
group (n=11) 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
MVIC of 
knee 
extensors 
(N.m) 
245.5 ± 209.4 198.1 ± 125.7 243 ± 136.3 292.1 ± 204 16.1 (-179, 211.2) 0.8 0.1 
MVIC of 
knee 
flexors 
(N.m) 
117.8 ± 113.3 105.9 ± 70.1 94.2 ± 76.1 111.7 ± 35.5 3.1 (-88.3, 82.2) 0.9 0.3 
MVIC, Maximal Voluntary Isometric Contraction. 
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5.2.3.2.2.2 Measures of Activity 
5.2.3.2.2.2.1 Walking- other measures of gait 
Significant differences between groups were also observed on the mean adjusted scores of 
gait speed (mean difference; 26.2 cm/s; 95% CI (7.2, 45.3); effect size=1.7) (Table 5.6). 
There were no significant differences, however, between groups on the adjusted mean 
scores of stride time (mean difference; 0.05 s; 95% CI (-0.3, 0.2); effect size=0.7).  
 
 
Table 5.6: Measures of gait at baseline and first follow-up for complete cases (n=21) 
 
 
5.2.3.2.2.2.2 Walking- measures of community walking 
Significant differences were observed on all the measures of community walking at the 
first follow-up (Table 5.7). Significant differences were observed between groups on the 
mean adjusted scores of the average daily step count (mean difference1805; 95% CI (890, 
2720); effect size=1.6), and the peak activity index (mean difference 6.7; 95% CI (1.4, 
12.1); effect size=1.0). Similarly, significant differences between groups were also 
observed on the adjusted mean scores of the percentage of time spent inactive (mean 
difference -0.08; 95% CI (-0.14, -0.04); effect size=1.3) and on percentages of time spent 
at low (mean difference 0.05; 95% CI (0.01, 0.08); effect size=1.1), moderate (mean 
difference 0.02; 95% CI (0.001, 0.04); effect size=1.0) and high level of physical activities 
(mean difference 0.01; 95% CI (0.002, 0.02); effect size=0.9).  
 
 
 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at 
first follow-up adjusted for 
baseline measures 
Outcome 
measure 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
Gait 
speed 
(cm/s) 
87.8 ± 21.9 56.5 ± 30.7 86.5 ± 24.1 85.4 ± 32.5 26.2  (7.2, 45.3) 0.01 1.7 
Stride 
time (s) 
1.2 ± 0.1 1.4 ± 0.5 1.2 ± 0.1 1.3 ± 0.5 0.05 (-0.3,0.2) 0.7 0.7 
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Table 5.7: Measures of community walking at baseline and first follow-up for all complete cases 
(n=21) 
 
 
 
 
 
 
 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at 
first follow-up adjusted for 
baseline measures 
Outcome 
measure 
Control group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
Average of 
daily step 
count 
3376 ± 1758 3596 ± 2176 3249 ± 1940 5355 ± 3511 1805 (890, 2720) 0.001 1.6 
Percentage 
of time 
spent at no 
PA 
79.1 ± 11.0 79.2 ± 10.0 79.9 ± 12.0 71.8 ± 12.1 -8.0 (-14.0, -4.0) 0.001 1.3 
Percentage 
of time 
spent at low 
PA 
15.9 ± 9.0 15.8 ± 6.0 14.1 ± 9.0 2.2 ± 6.0 5.0 (1.0, 8.0) 0.007 1.1 
Percentage 
of time 
spent at 
moderate 
PA 
5.0 ± 3.0 6.0 ± 4.0 5.0 ± 3.0 8.0 ± 6.0 2.0 (1.0, 4.0) 0.04 1.0 
Percentage 
of time 
spent at 
high level 
of PA 
0.4 ± 0.5 0.6 ± 0.9 0.3 ± 0.5 2.0 ± 2.0 1.0 (0.2, 2.0) 0.03 0.9 
Peak 
activity 
index (unit) 
29.1 ± 8.0 30.3 ± 11.6 29.3 ± 10.2 37.3 ± 12.9 6.7 (1.4, 12.1) 0.02 1.2 
PA, Physical Activity. 
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5.2.3.2.2.2.3 Other measures of mobility  
Significant differences between groups were observed on the mean adjusted scores of the 
chair sit to stand test (CSST) (mean difference 3.4; 95% CI (1.0-5.7); effect size= 1.7) 
(Table 5.8). However, there were no significant differences between groups on the mean 
adjusted scores of the four square step test (FSST) (mean difference; -6.3 s; 95% CI (-14.8, 
2.2); effect size= 0.8) and the Timed Up and Go (TUG) test (mean difference; -2.6 s; 95% 
CI (-6.9, 1.7); effect size=0.9).  
 
 
Table 5.8: Other measures of mobility at baseline and first follow-up for complete cases (n=21) 
 
 
 
 
 
 
 
 
 
 
 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at 
first follow-up adjusted for 
baseline measures 
Outcome 
measure 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
FSST (s) 25.9 ± 18.9 34.8 ± 19.1 25.7 ± 18.7 27.6 ± 20.4 -6.3 (-14.8, 2.2) 0.1 0.8 
TUG (s) 12.8 ± 4.7 20.6 ± 11.6 13.7 ± 5.9 16.8 ± 9.2 -2.6 (-6.9, 1.7) 0.2 0.9 
CSST 8.8 ± 3.0 5.9 ± 3.1 7.7 ± 2.5 8.6 ± 4.2 3.4 (1.0-5.7) 0.008 1.7 
FSST; Four Square Step test; TUG, Timed Up and Go test; CSST; Chair Sit to Stand test. 
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5.2.3.2.2.2.4 Measures of functional performance in ADL 
Significant differences were observed between groups on the mean adjusted scores for the 
physical performance test (PPT) (mean difference 4.8; 95% CI (2.0, 7.7); effect size=1.8) 
(Table 5.9). 
 
 
Table 5.9: The measures of functional performance in ADL at baseline and first follow-up 
upon complete cases (n=21) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at first 
follow-up adjusted for baseline 
measures 
Outcome 
measure 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
PPT (unit) 14.8 ± 4.4 10.0 ± 6.0 14.6 ± 5.1 14.7 ± 6.6 4.8 (2.0,7.7) 0.002 1.8 
PPT, Physical Performance Test. 
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5.2.3.2.2.3 Measures of participation 
5.2.3.2.2.3.1 Measures of health-related quality of life   
No significant differences were observed in any of the subscales of the SF-36 (effect sizes 
ranged from 0.08 to 0.9) (Table 5.10). 
 
 
Table 5.10: Measures of health related quality of life at baseline and first follow-up upon complete 
cases (n=21) 
 
 
 
 
 
Baseline scores 
(Mean ± SD) 
First follow-up 
(Mean ± SD) 
Differences between groups at 
first follow-up adjusted for 
baseline measures 
Outcome 
measure 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Control 
group  
(n=10) 
Exercise 
intervention  
group (n=11) 
Mean difference 
(95% confidence 
interval) 
p-
value 
Effect 
size 
PF 40.0 ± 33.1 40.0 ± 30.3 36.9 ± 26.4 51.4 ± 33.7 21.0 (-8.9, 51.0) 0.15 0.8 
RF 63.9 ± 54.6 54.5 ± 53.4 41.7 ± 43.3 40.9 ± 45.1 9.9 (-33.7, 53.4) 0.63 0.6 
BP 53.0 ± 17.3 75.8 ± 28.0 85.2 ± 24.8 74.7 ± 29.4 -8.2 (-33.9, 17.5) 0.50 0.1 
VT 53.3 ± 15.0 48.2 ± 18.9 57.2 ± 24.3 53.2 ± 27.4 -0.9 (-26.3, 24.4) 0.90 0.1 
GH 83.9 ± 22.9 48.4 ± 19.4 51.2 ± 13.8 45.8 ± 27.5 2.4 (-15.7, 20.6) 0.70 0.3 
SF 59.0 ± 30.9 56.6 ± 30.0 56.8 ± 26.3 54.5 ± 21.9 -2.4 (-20.5, 15.6) 0.80 0.4 
RE 55.6 ± 52.7 51.5 ± 50.3 48.1 ± 41.2 54.5 ± 47.8 7.9 (-31.8, 47.7) 0.70 0.08 
MH 73.3 ± 16.4 72.0 ± 14.9 71.6 ± 17.6 65.1 ± 18.4 -1.3 (-17.7, 15.3) 0.80 0.2 
PCS 53.2 ± 22.5 49.4 ± 21.8 50.9 ± 12.6 51.5 ± 27.4 13.8 (-6.1, 32.5) 0.10 0.9 
MCS 62.1 ± 14.2 59.1 ± 14.5 61.9 ± 18.2 51.7 ± 21.4 -0.2 (-19.8, 19.3) 0.90 0.2 
PF; Physical Functioning; RF; Role limited due to physical problems; RE; Role limited due to emotional 
problems; SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, Bodily Pain; GH, General Health 
Perception; PCS, Physical Component summary; MCS, Mental Component Summary. 
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5.2.3.2.3 Summary of results of 8-week study outcome  
A summary of the adjusted mean differences between groups at the first follow-up 
assessment is presented in Table 5.11 along with the minimal detectable change (MDC95) 
values which were previously calculated in Chapter 4. Significant differences between 
groups on the BBS, stride time CV, gait speed, CSST and PPT were larger than their 
corresponding MDC95 values. This suggests that the observed differences on these 
outcomes are likely to be attributed to real changes in the outcomes rather than to 
measurement errors or natural variations in the testing.  
 
It should be noted, however, that the MDC95 values have not been calculated in this study 
for the mMS and the measures of community walking. Therefore, conclusions about 
whether changes in these outcomes are clinically significant cannot be confirmed.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                         5. Results and discussion: Part 2 
207 
 
Table 5.11: Summary of results of the adjusted mean differences at first follow-up along with the 
minimal detectable change (MDC95) values calculated in Chapter 4 
 
 
 
Domain Category Outcome measure MDC95 
Adjusted mean 
differences at 
first follow-up 
Body structure 
and function 
Disease-specific 
motor score 
mMS (unit)* NR 4.5 
Balance 
BBS (unit)* 3.9 5.4 
Total score of RT and SRT 
(s) 
39.6 5.5 
rms-AP (m) 0.008 0.001 
Rms-ML (m) 0.005 0.001 
Muscle strength 
MVIC of knee extensors 
(N.m) 
155.5 16.1 
MVIC of knee flexors (N.m) 98.8 3.1 
Activity 
Gait 
Gait speed (cm/s)* 22.5 26.2 
Stride time (s) 0.22 0.05 
Stride time 
CV (%)* 
3.6 6.0 
Community 
walking 
Average of daily step count* NR 1805 
Percentage of time spent at 
no PA* 
NR 8.0 
Percentage of time spent at 
low PA* 
NR 5.0 
Percentage of time spent at 
moderate PA* 
NR 2.0 
Percentage of time spent at 
high level of PA* 
NR 1.0 
Peak activity index (unit)* NR 6.7 
Other measures of 
mobility 
FSST (s) 19.3 6.3 
TUG (s) 16.3 2.6 
CSST (number of 
repetitions)* 
2.2 3.4 
Functional 
performance in 
ADL 
PPT (unit)* 2.2 4.8 
*Statistically significant differences between groups at follow-up adjusted for baseline differences 
(p<0.05); NR, Not Reported. 
mMS, modified motor score of the Unified Huntington‟s Disease Rating Scale; BBS, Berg Balance 
Scale; RT, Romberg test; SRT, Sharpened Romberg test; rms, root mean square of postural sway 
movement; AP, anterior-posterior; ML, medio-lateral;MVIC, Maximal Voluntary Isometric Contraction; 
FSST, Four Square Step Test; TUG, Timed Up and Go test; CSST, Chair Sit to Stand Test; PA, Physical 
Activity. 
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Table 5.11: continued Summary of results of the adjusted mean differences at first follow-up along 
with the minimal detectable change (MDC95) values calculated in Chapter 4 
Domain Category 
Outcome 
measure 
MDC95 
Adjusted mean 
differences at 
first follow-up 
Participation 
Health-related 
quality of life 
PF 52.1 21.0 
RF 66.8 9.9 
BP 62.1 -8.2 
VT 32.9 -0.9 
GH 33.5 2.4 
SF 39.5 -2.4 
RE 80.1 7.9 
MH 28.8 -1.3 
PCS 25.5 13.8 
MCS 28.8 -0.2 
PF; Physical Functioning; RF; Role limited due to physical problems; RE; Role limited due to emotional 
problems; SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, Bodily Pain; GH, General 
Health Perception; PCS, Physical Component summary; MCS, Mental Component Summary. 
 
 
5.2.4 Sixteen-week study outcomes 
Data for the primary outcome (stride time CV) were collected at the second follow-up (16-
week assessment). These data were collected from 17 of the participants (9 from the 
exercise intervention group (the early intervention group) and 8 from the control group. 
Descriptive data in the primary outcome are shown in Table 5.12.   
 
 
Table 5.12:  Mean scores of primary outcome (stride time CV) for different periods upon complete 
cases at the second follow-up assessments (n=17) 
 
 
Baseline 
(Mean ± SD) 
First follow-up 
(8-week assessment) 
(Mean ± SD) 
Second follow-up 
(16-week assessment) 
(Mean ± SD) 
Exercise intervention group 
(n=9) 
10.6 ± 5.2 6.9 ± 4.9 6.5 ± 3.4 
Control  group (n=8) 6.3 ± 2.7 8.7 ± 5.0 5.9 ± 2.9 
 
 
After the initial 8 weeks, 5 subjects out of the 9 in the exercise intervention group (i.e. the 
early intervention group) reported continuing to do the exercise programme for another 8 
weeks after the first follow-up assessment (i.e. after formal input was ceased). Descriptive 
data in the primary outcome for those who continued to exercise and those who stopped 
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the exercise programme are shown in Table 5.13. Descriptive data suggest that participants 
who continued to exercise have a greater overall reduction in the stride time CV relative to 
the participants who stopped the exercise programme.  
 
 
Table 5.13:  Within-group differences in the primary outcome (stride time CV) at the first and 
second follow-up assessments 
 
 
Mean ± SD 
 
Baseline to 8-week 
(i.e. baseline to 
first follow-up) 
8 to 16-weeks 
(i.e. first to second 
follow-up) 
 Baseline 8 weeks 16 weeks 
Difference 
(95% CI) 
Difference 
(95% CI) 
Exercise 
intervention group 
CE (n=5) 
9.7 ±  6.3 6.8 ± 3.9 4.8 ± 4.5 -2.7 (-10.9, 3.7) -1.6 (-5.8, 5.4) 
Exercise 
intervention group 
DE (n=4) 
11.5 ± 
5.7 
7.9 ± 4.5 7.0 ± 5.3 -3.6 (-8.8, 5.4) -0.9 (-3.1, 9.7) 
Control group (n=8) 6.3 ± 2.7 8.7 ± 5.0 5.9 ± 2.9 2.4 (0.08, 4.7) -2.7 (-4.9, -0.67) 
CE, Continued to exercise; DE, Discontinued exercise   
 
 
5.3 Discussion  
5.3.1 Eight-week study outcomes  
5.3.1.1 Measures of physical impairments in body structures and functions  
5.3.1.1.1 The disease-specific motor scale 
In this study, 6 /11 participants in the intervention group improved in the disease-specific 
motor score (mMS) (see Figure 5.3). The effect size was large and a significant difference 
between groups was observed on this outcome.  It should however be noted that the 
amount of deterioration in the control group in this outcome was unusually high given the 
duration of the study (i.e. 8 weeks); hence this results should be interpreted with some 
caution. Future research is required to further explore this finding.  
 
The possible improvement in the mMS reported here is consistent with the data obtained 
from a previously conducted single-case study of a home-based exercise programme in 
which there was an improvement in the total score of the UHDRS-motor (MS) [2]. Taking 
into account the progressive neurodegenerative nature of HD particularly in the motor 
domain (i.e. annual decline in the total MS is evident in HD [270, 271]), the finding of 
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possible motor improvements reflected by improvement in the mMS score in most of the 
participants in the exercise intervention group is important. This finding has implications 
and provides indications that exercise interventions may play a role in addressing motor 
impairments, maintaining independence in activity of daily living and potentially enabling 
the subjects with HD to achieve a longer period of stabilization.   
   
The possible improvement reported in the mMS in the intervention group may be better 
understood in the context of the items of the mMS and their relationship to the content of 
the exercise programme. The mMS includes items that evaluate dynamic balance, timing 
of movement, coordination and rigidity. The use of the exercise DVD provided 
demonstrations that were augmented by visual and verbal cues. These cues may have been 
useful in helping subjects to control their speed of movement[2]; thus improving muscle 
timing and coordination. The performance of the task-specific activities included in the 
exercise programme may have been useful in addressing impairments in dynamic balance 
[152]. Additionally, the range of flexibility and general strengthening exercises which were 
crucial parts of the exercise programme may have been beneficial in improving overall 
fitness level and enhancing sensory feedback from proprioceptive which may have further 
improved balance [2, 37]. The combination of the flexibility and strengthening exercises 
may also have provided a beneficial effect in reducing rigidity by producing centrally 
neural adaptations in the excitability of the α- motor neurons and the magnitude of the 
output from descending central pathways [272].  
 
Overall the reported improvements in the mMS in the intervention group provide 
indications that disease-specific motor impairments, such as deficits in timing of 
movement and balance and lack of coordination, are potentially modifiable by exercise 
interventions in people with HD. Ameliorations in any or some of these impairments may 
improve accuracy and reduce variability of movement [2, 37, 111] which in part explains 
the large observed effects in improving the gait variability, the other measures of mobility 
and some measures of balance that were reported in this study.   
  
5.3.1.1.2 Measures of balance  
Out of the 3 measures of balance evaluated in this study, the vast majority of participants 
(10/11) improved in the berg balance scale but not on the total score of Romberg and 
sharpened Romberg tests and measures of postural sway (Figure 5.2). In addition, 
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statistical analysis revealed significant differences between groups were only for the Berg 
Balance Scale (BBS).  The improvement in the BBS reported here is consistent with data 
obtained from 2 previous studies that have examined the effects of exercise on BBS in 
people with HD [2, 76]. In an individual-case control study of 12 subjects with early to mid 
stage HD, a 6-week clinic-based exercise programme resulted in significantly higher scores 
on the BBS after the exercise programme when compared to the baseline scores [76]. 
Similarly, in a single case report of an individual with mid stage HD, a 14-week home-
based exercise programme demonstrated an improvement in the BBS of 9 points [2].   
 
The reported mean change in the BBS of 5.4 in this study is larger than the Minimal 
Detectable Change (MDC95) value of 4 (Chapter 4). This suggests that the improvement 
reported on this measure of balance is more likely to be due to real change as a 
consequence of the exercise intervention, rather than to measurement error. This result is 
particularly important in that improvement in the BBS may reflect a better ability to remain 
independent and mobile in HD. The BBS has been found previously to be useful in 
predicting the probability of falls in HD, with a score of less than 40 identified as the 
threshold for risk of falls [45]. In this study, two participants in the intervention group who 
were below this threshold of risk of falls (i.e. BBS score was less than 40) increased scores 
on the BBS from below 40 to above 40 corresponding to a change from the „at risk of fall‟ 
category to that of „low risk for falls‟ (Figure 5.2). This finding highlights the potential role 
of exercise in improving some of the disease underlying impairments which could be 
linked to obtaining a better functional status despite the presence of a degenerative 
neurological disease.  
 
Although subjects in the exercise programme improved significantly in their BBS scores, 
there were no significant improvements on the other measures of balance (the total score of 
the Romberg (RT) and Sharpened Romberg (SRT) tests and the root mean square values of 
postural sway during quiet standing). The effect sizes for these outcomes (i.e. total score of 
the RT and SRT and root mean square of postural sway) were small. This was further 
reflected by the plots of individual cases particularly in the case of root mean square of 
postural sway in which only 3 subjects in the intervention group improved (Figure 5.2).  
Two factors may explain the significant improvement in the BBS but not in the other 
measures of balance (i.e. total score of RT and SRT and root man square of postural 
control during quite standing). Firstly, the smaller effect observed in the total score of the 
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RT and SRT and the measures of postural sway can be viewed in the light of their 
psychometric properties. As demonstrated previously (Chapter 4), the RT and SRT tests 
are subject to ceiling and floor effects. Furthermore both the total score of the RT and SRT 
and the measures of postural sway are susceptible to a high degree of variability on 
repeated assessments. In particular the total score of the RT and SRT is subject to a 
learning effect (Chapter 4). This learning effect in part may explain the observed 
improvement reported here on this outcome in most of the participants in the control group 
(8/10) in addition to the improvement was seen in some of the participants in the 
intervention group (6/11) on this measure (Figure 5.2).  Any or all of these factors (i.e. 
susceptibility to ceiling, floor and learning effects and high degree of variability on 
repeated assessment) may limit the ability of these outcomes to detect any improvement as 
a result of the intervention.  Secondly, whilst the BBS evaluates both dynamic and static 
balance as well as internal protrusion, RT and SRT, as well as measures of postural sway 
during quiet standing, are indicative only of static balance. Thus it can only be speculated 
that the exercise programme in this study had a marked improvement in the other aspects 
of balance but it did not affect the components of static balance. The exercise programme 
in this study was designed to improve overall function and focused on practicing task-
specific activities but it was not targeted to specifically train balance. This may have 
resulted in an improvement in balance needed to perform activities (dynamic balance) but 
not necessarily for static balance. In fact, static balance may not be the correct variable to 
examine; maintaining balance while performing functional activities such as walking may 
be more important for people with HD than simply standing still [249]. This can be viewed 
in light of the data that suggest better association between measures of walking (reflected 
by gait variability) and measures that evaluate dynamic balance (i.e. BBS) when compared 
with measures of static balance (Chapter 4). This is also supported by available evidence 
which suggests that static balance is not a strong predictor of measures related to functional 
performance of daily activities such as walking [230, 249]. Thus future research may need 
to shift the emphasis from simply improving static balance to restoring or maintaining 
functional balance needed during performing activities of daily living.    
 
5.3.1.1.3 Measures of muscle strength  
Whilst there were significant improvements in the BBS and the disease-specific motor 
score (the mMS) in the intervention group when compared to control, there were no 
significant improvements in the measures of the isometric muscle strength (the Maximal 
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Voluntary Isometric Contraction (MVIC) of the knee flexors and extensors). The lack of 
significant improvement in the isometric muscle strength can be explained by a number of 
factors. For example, the sample size in this study was small. A study with a larger sample 
may reveal significant differences. Furthermore, the MVIC outcomes as measured using 
isokinetic dynamometry are subject to a high degree of variability (Chapter 4) which limits 
their responsiveness to detect change in muscle strength over time. The isometric muscle 
strength test requires that the participant is co-operative and able to follow fairly complex 
instructions. It is also possible that the strength test is affected by co-activation of the knee 
extensor and/ or flexor musculature (potentially secondary to dystonia) [35].  In addition, 
the difficulties in movement initiation and movement execution as well as deficits in force 
generation seen in this population may also influence the performance of this test [37, 
255]. Any or all of these factors may contribute to increased variability of the output; 
hence reducing its responsiveness to measure changes over time.  
 
In addition to the factors cited above, the lack of improvement on measures of muscle 
strength can be related to the specificity and the setting of the exercise programme used in 
this study. Although the exercise programme included general strengthening exercises, it 
was designed to improve function and it did not specifically target muscle strengthening; 
progressive resistance exercise training was not included in the exercise programme. 
Progressive resistance training with high intensity has been shown to improve the muscle 
strength of people with other neurodegenerative diseases [163, 273-276]. The majority of 
these studies however, have utilised specialised strength training equipment, requiring 
participants to attend and be supervised, at a gym facility or clinic to participate [273, 274, 
276]. Other studies have shown that progressive resistance training using weighted vests in 
the participant‟s home, but with close supervision from a therapist, is a safe and effective 
alternative form of resistance training in improving muscle strength [275]. These methods 
of delivering exercise in HD may be equally beneficial in improving muscle strength in 
HD and therefore further investigations in this field are required. An exercise study with 
closer supervision where the strength of the intervention is more readily tailored and the 
dose is controlled more precisely, may enable further study to determine if and how 
exercise can affect muscle strength in people with HD. 
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5.3.1.2 Measures of activity 
5.3.1.2.1 Measures of mobility  
5.3.1.2.1.1 Walking- measures of gait and community walking  
Improvements in gait parameters including walking speed, stride time and stride time 
variability were observed in the majority of subjects in the intervention group (see Figure 
5.4 for change scores in individual cases in intervention group). The effect size for all these 
parameters was large (≥0.7) and a significant difference between the study groups was 
observed on gait speed and stride time variability.   
 
Substantial significant reduction in stride time variability was observed in the intervention 
group when compared to the control group. However, it should be noted that the amount of 
deterioration in 3 cases in the control group in this outcome was unusually high (Figure 
5.4c) given the duration of the study (i.e. 8 weeks). This may have overinflated the effect 
calculated in this study on this outcome; hence this result should be interpreted with some 
caution. Future research is required to further explore this finding. 
 
Whilst there are no previous studies in HD examining the effect of exercise on gait 
variability to compare the reported results here with, findings from this study about 
possible improvements in gait variability are consistent with data available in the literature 
on other populations such as PD and older adults. For example, participation in a 6-month 
home-based exercise programme that aimed to improve balance in the elderly 
demonstrated improvement in stride time variability [277]. Similarly, a study of a 4 week 
clinic-based exercise programme that focused on gait training and the use of rhythmic 
sound cues demonstrated improvement in gait speed and step time variability in people 
with PD [278].   
   
The finding of possible improvement in gait variability in this study is important. Gait 
variability can be considered as a key indicator of general mobility in this population [38], 
even at the very early stages of the disease [39, 40, 108], hence it being chosen as the 
primary outcome measure in this study. Critically, gait variability can be viewed as a major 
determinant of overall physical impairment and activity limitations in people with HD 
(Chapter 4) and puts them at greater risk of falls [38], thus there is a rationale to maintain 
and improve this component of gait.  
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High fall rates are the number one predictor of admission to a nursing home in people with 
HD [43]. The optimal goal of exercise interventions in HD would be to reduce the actual 
number of falls. However, fall rates were not measured directly in this study and only 
reliance on quantifying gait measures such as gait variability was used. Whilst gait 
variability serves as an objective measure in the evaluation of the risk of falls in HD [38] 
and in other populations, direct measures of falls relies on participant‟s self report. Fall 
rates can either be recorded prospectively using diaries or retrospectively using self-
reported questionnaires [279]. Both methods are subject to bias and failure to recall or 
report fall events. For these reasons, the choice of gait variability as a primary outcome 
may be more appropriate than measuring actual fall events.  
 
In addition to improvements in measures of gait variability, a significant difference 
between groups was also identified for gait speed in this study. The reported mean change 
in gait speed of 26.2 cm/s is larger than the MDC95 value of 19.4 cm/s (Chapter 4). This 
suggests that the improvement in the gait speed in the intervention group in this study is 
“clinically significant”. This finding is in agreement with data obtained from a previously 
conducted single-case study of an individual with mid stage HD in which a home-based 
exercise programme demonstrated improvement in gait speed. This result is also consistent 
with data available from exercise studies in other neurodegenerative diseases. A number of 
home based exercise programmes in people with PD and AD which aimed to improve 
mobility revealed positive effects of exercise in improving gait speed [74, 160, 163, 165, 
167].  
 
Although the exercise programme in this study revealed a significant improvement in gait 
speed, there were no significant differences between groups for stride time. Stride time 
correlates well with gait speed (Appendix 6), however, the fact that many other diverse 
factors such as balance, confidence, exercise capacity and muscle strength also contribute 
to gait speed [280-282] may further explain this result. The reliance of gait speed on a 
multiplicity of components may make it a more sensitive measure, perhaps revealing 
improvements in gait, even when the other measures of gait, such as stride time, show 
fewer changes.  The effect sizes presented in this study lend further support to this idea. 
Whilst the effect size for stride time of 0.7 is still fairly large [178], the effect size for gait 
speed of 1.7 is much larger. These effect sizes suggest that a study with a slightly larger 
                                                                                                         5. Results and discussion: Part 2 
216 
 
sample may also reveal differences in the measure of stride time. For example, using an 
effect size of 0.7,  a power of  80%, and an alpha (α) level of 0.05, a sample of 52 
participants (26 per arm) will be required to demonstrate differences in the stride time 
measure.    
 
Adding to the improvements in gait speed and gait variability, data presented here revealed 
significant differences between groups in the measures of community walking. The 
average daily step count significantly increased in the exercise group over the 8-week 
period. Additionally, the time spent doing no walking activity decreased and the time at 
low, moderate and high levels of physical activities increased. This was reflected by 
improvements on the peak activity index. The significance improvements in all measures 
of community walking were further reflected by data obtained from the change scores on 
individual cases (Figure 5.5). Whilst most participants in the control group had a fairly 
similar physical activity profile at follow-up relative to their physical activity profile at 
baseline (i.e. change score in most cases in control group was close to zero), the majority 
of participants in the intervention group improved in the various measures of community 
walking (Figure 5.5). This improvement in community walking levels was consistent with 
participants‟ perceived benefits on mobility status (see Chapter 6 for qualitative feedback 
from participants on their involvement in the programme) and further provides an objective 
measure that levels of community mobility improved in the intervention group.  
 
 Exercise training has been shown to increase overall community walking levels 
consistently in previous studies of other populations including cancer survivors and healthy 
young adults [283-285]. In this study, the changes in levels of community walking, and in 
particular in the peak activity index, in the intervention group are important as they provide 
an indication of the improvements in the participants‟ usual walking performance in the 
community rather than only capacity.  In fact these changes may reflect the carryover 
effects of the gain in subjects‟ capacity reflected by improvements in gait speed and gait 
variability into subjects‟ performance in their actual environment. In term of gait speed, a 
minimum of 80 cm/s as a walking speed is required for independent community walking 
[286]. In this study, 5 participants in the intervention group increased their walking speed 
from below 80 cm/s to above 80 cm/s corresponding to moving from the need assistance in 
community walking category into the category of no need assistance in community 
walking. In term of gait variability, stride time CV is strongly associated with the actual 
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number of steps that subjects with HD are able to maintain for an extended period of time 
(i.e. peak activity index) (Chapter 4). Thus ameliorations in gait variability, as observed 
here, may have positively influenced the ability of the subjects to sustain activities at 
higher levels for longer periods of time, which improved the peak activity measure and the 
other measures of community walking.   
 
The changes in levels of community walking also raise a number of clinical questions 
about what constitutes an optimal exercise intervention that can influence usual walking 
performance. Although performing the exercises from the exercise DVD at home in this 
study included task-oriented postural control tasks and attempted to simulate environments 
encountered outside the home (e.g. stepping, turning activities), it was nevertheless a safe 
environment, which may not adequately represent the complexity of walking in community 
settings [287]. However, the added progressive walking programme outside participants‟ 
homes might have added value in improving levels of community walking. Within this 
context, it must be noted that although the target of the walking programme was to achieve 
a 30 minute walking per week in the neighbourhood, most participants (7/11) in the 
intervention group reported walking more than once a week in their immediate 
environment (i.e. walking into shops, leisure and community centres) (see Chapter 6 for 
process evaluation). Walking in the immediate environments involves walking in different 
conditions (i.e. walking on uneven surfaces, crossing roads, negotiating obstacles as well 
as walking in different weather conditions). Thus the walking component may have added 
to the value of the programme. The potential of the added value of the walking programme 
into the benefits in mobility status reported here is consistent with evidence that suggests 
transferability of functional improvement is most noticeable in the setting in which the 
intervention is delivered [160]. Furthermore, the fact that the walking programme in this 
study was progressive with a defined goal (achieving 30 minutes of walking with minimal 
amount of breaks) may have further helped in improving the community walking. Studies 
of exercise interventions in other populations suggest that daily walking activity is likely to 
improve only when realistic goals are pre-defined [284].  
 
5.3.1.2.1.2 Other measures of mobility  
In addition to assessing benefits in measures of walking, this study evaluated the potential 
benefits of exercise in improving other aspects of mobility that are believed to be limited in 
people with HD. Out of the 3 mobility measures that were used (FSST, TUG, CSST), a 
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significant difference between groups was found only on the CSST. This was reflected by 
data obtained from change score on individual cases in which majority of the participants 
in the intervention group (10/11) improved on this test (Figure 5.6). The reported mean 
change in the CSST of 3.4 is larger than the MDC95 value of 2.2 (Chapter 4), which 
suggests that the improvement in this measure is “clinically significant”. An improvement 
in the CSST reflects a better ability to rise from a seated to standing position. This 
transitional task (the sit to stand) is one of the most common activities of daily living, it is 
a prerequisite for walking, and it is particularly important to maintain physical 
independence [131], which makes it an important activity to be improved or maintained in 
people with mobility deficits such as people with HD.      
 
Whilst a significant improvement in the exercise group was demonstrated on the CSST, 
there were no significant differences between groups on the FSST and the TUG tests. 
There are a number of factors that can provide some explanations for these findings. For 
example, the susceptibility of both the FSST and TUG to a higher degree of variability on 
repeated assessments (Chapter 4) may have influenced this result. However, based on the 
data presented here both the FSST and the TUG exerted large effects; the calculated effect 
sizes for the FSST and TUG were of 0.8 and 0.9 respectively. This was also reflected by 
data obtained from change scores on individual cases; most of the participants in the 
intervention group improved in the TUG (8/11) and FSST (6/11) (Figure 5.6). The amount 
of improvements may however not have been enough to reveal statistically significant 
differences in this small sample. Thus a study with a larger sample may also reveal some 
differences in these outcomes. Furthermore, whilst the effect size calculated for the CSST 
was larger than those calculated for the FSST and the TUG test, it should be noted that the 
CSST test as an outcome was closely aligned to what the exercise group practiced during 
the exercise programme. The exercise programme included exercises that required 
participants to specifically practice the sit to stand performance. This factor in part may 
explain the large effect size obtained from the CSST. 
 
5.3.1.2.2 Measures of functional performance in ADL  
In addition to improvement in gait speed and gait variability characteristics and some of 
the measures of mobility, improvements in the measure of functional performance in ADL 
(i.e. the PPT) were observed in the majority of participants (10/11) in the intervention 
group (Figure 5.6c). The effect size for the PPT was large (effect size=1.8) and a 
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significant difference between the study groups was observed on this measure. The PPT is 
a global measure that assesses both basic and complex ADL tasks which include writing, 
lifting, picking up a small object from the floor, dressing, simulated eating, walking and 
turning. Whilst the exercise programme in this study focused on targeting mobility aspects 
such as walking; most of the tasks included in the PPT test were not trained or practiced as 
part of this exercise programme. The significant improvement in the PPT test is therefore 
interesting and can be viewed in the light of its relationship with the measures of gait 
variability. The strong association between measures of walking performance (represented 
by gait variability) and the ability to perform ADLs (represented by the PPT test) (Chapter 
4) may reflect a common reliance of these 2 domains of activity on the same physiological 
components [230]. Therefore, interventions that have effects on 1 of these 2 domains may 
also have a parallel effect on the other. This is consistent with reports from the literature in 
which exercise interventions focusing on enhancing gait aspects have been shown to 
improve function (measured by the PPT) in older adults [288, 289]. The reported 
improvement in the PPT in this study is also consistent with a previously conducted study 
in HD in which an inpatient intensive rehabilitation programme with an exercise 
component resulted in a significant improvement in the PPT [78]. The reported mean 
change in the PPT of 4.5 in this study is larger than the Minimal Detectable Change 
(MDC95) value of 2.4 (Chapter 4). This suggests that the improvement reported on this 
measure is more likely to be due to real change as a subsequent of the exercise 
intervention, rather than due to measurement error; giving indications that this change is 
potentially clinically significant. 
 
5.3.1.3 Measures of participation  
Although the exercise programme in this study was found to significantly improve 
measures of gait, balance, levels of community walking and function, there was no 
significant improvement on health-related quality of life as measured by the SF-36. It is 
possible that the improvements of gait, postural control and physical functioning observed 
in this study were too small to carry over to perceived quality of life. However, judging by 
the magnitude of the improvements seen and the perceptions of patients and carers (see 
Chapter 6 for more details); this is unlikely to be the case. It is possible that this result is 
related to the susceptibility of the various subscales of the SF-36 to floor and ceiling 
effects as well as its susceptibility to a certain degree of variability on repeated testing 
(Chapter 4).   
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Although there were no significant differences between groups on any of the subscales of 
the SF-36, it was interesting to notice the large effect sizes on the physical function 
subscale as well as the aggregate score of the physical domain (i.e. the physical component 
summary). These large effects were reflected by data from the change score on individual 
cases in which most participants in the intervention group improved in the physical 
function subscale as well as the physical component summary (Figure 5.7). The physical 
function subscale as well as the aggregate score of the physical domain both assesses the 
perception of an individual on their ability to perform some physical activities of daily 
living such as walking, lifting an object and climbing stairs. Thus, the finding that effect 
sizes on these subscales were large is important as it suggests that the improvement on 
mobility status reported here using objective outcomes is also possibly subjectively 
perceived by participants. The large effect sizes on these subscales suggest that significant 
quality of life improvements using the SF-36 would have emerged with longer intervention 
or with a larger sample. The effect size of 0.8 that was calculated for the physical function 
subscale suggests that a sample size of 42 participants is needed to sufficiently power the 
study on this variable [178].    
   
5.3.1.4 General points for consideration of study outcome at 8-week 
In all measures of balance, gait and mobility there was one case that showed the largest 
amount of improvement relative to the other cases in the vast majority of outcomes (see the 
case circled on red in Figures 5.2-5.6). The qualitative feedback revealed that this 
participant was highly motivated to engage in the exercise programme (see Chapter 6 for 
qualitative feedback from participant coded as P7). As part of the exercise programme, 
participants were asked to undertake a progressive walk for a maximum of 30 minutes 
once a week for the 8-week period of the study. This participant, however, reported 
walking of at least an hour daily for 6 weeks of the exercise programme. Taking this into 
account, the remarkable improvement that was observed on this participant in most of the 
outcomes raises a number of questions: 1) did the data from this participant unduly 
influence the analyses conducted; 2) could this be explained by the exercise dose and 3) 
could regression towards the mean (RTM) explain the changes. In the realm of the 
influence of this case on obtained data, exploratory analyses of the dataset excluding this 
participant did not result in different outcomes. Regarding exercise dose, this observation 
raises a number of questions rated to what constitutes the optimal exercise dose and type 
that can best influence mobility status in this population. It can be argued that an exercise 
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programme with a higher frequency and intensity of walking outside home in particular is 
more beneficial in improving mobility in HD; this however needs to be further explored in 
future studies.   
 
In term of RTM, it should also be noted that this participant was rather impaired at baseline 
(i.e. the participant had a poor performance in the majority of outcomes at baseline). 
Although being more impaired at baseline suggests having a bigger window for 
improvements and this participant self report indicates a true change (see Chapter 6 for 
qualitative feedback), the possibility of RTM cannot be ruled. The RTM is a statistical 
phenomenon that happens when extremely large or small measurements tend to be 
followed at second assessment by measurements that are closer to the mean [290].  Thus in 
this case RTM may in part explain the large changes that were observed on this participant.  
 
The potential for RTM becomes clearer in two of the outcomes: the modified UHDRS-
motor score (mMS and the stride time CV. On inspecting the plots of change score of 
individual cases on these outcomes, it was apparent that subjects whose baseline scores 
were low tended to increase and those whose baseline scores were high tended to decrease. 
In both of the mMS and the stride time CV the amount of deterioration in three cases in the 
control group was unusually high given the duration of the study (i.e. 8 weeks) (Figure 
5.3a and 5.4c) which further provides indications of potential RTM. This was reflected by 
unusually high amounts of deterioration in the mean score of the control group in each of 
these outcomes. The possibility of RTM in the mMS and the stride time CV suggest that 
effects on these outcomes are potentially were overinflated; hence results obtained on these 
measures should be interpreted with some caution and further investigations are required to 
confirm these findings. Further studies needs also to accommodate for the potential of 
RTM in their design [290].     
 
5.3.2 Sixteen-week study outcomes 
The descriptive data obtained from this part of the study suggest that the stride time 
coefficient of variation (CV) decreased in the control group who then received the 
intervention following the first 8-week period (i.e. at the second follow-up) with scores 
compared to the first follow-up. This suggests that participants who received the 
intervention later in the study also improved in the primary outcome measure. In addition, 
the stride time CV continued to decrease in the early intervention group, both in subjects 
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who continued to exercise (n=5) and those who stopped exercising (n=4) after the initial 8 
week study period. The descriptive data presented here, also suggest that those who 
continued exercising had a greater overall improvement in their stride time CV. This 
observation would be in agreement with results previously reported in other 
neurodegenerative disease such as PD about the potential carry-over effects of exercise 
interventions. Lun et al [161] reported a greater improvement in the Unified Parkinson‟s 
Disease Rating Scale (UPDRS) scores in those who continued exercising at 4 months 
relative to the baseline, compared to those who stopped exercising after the initial 2 
months exercise period. Similarly Comella et al [291] reported that the UPDRS scores of 
subjects who stopped exercising after a 4-week exercise programme returned to baseline 
value after 6 months. These findings are important and emphasize the importance of 
regular engagement in physical activities and that the benefits may be short lived if not 
maintained.   
 
5.3.3 Recruitment  
In this study, recruitment difficulties acted as the main barrier to achieving the targeted 
number of participants. The initial power calculation determined that 40 participants were 
needed for the study (see Chapter 3).  However, the study was stopped before reaching this 
targeted number due to the difficulty in finding subjects who met the inclusion criteria. 
Only 25 (23.6%) were enrolled in the study out of the 106 subjects who were seen in the 
HD clinic. In particular, the concurrent drug trials made recruitment to the study more 
difficult (all subjects enrolled in concurrent clinical drug trials were excluded from this 
study). It is reasonable for people with HD who face a long-term disease to choose a 
pharmaceutical trial that has potential disease modifying properties rather than an exercise 
intervention that may influence function in the short term. However, it should also be noted 
that it is important to improve all modes of available management with a view to 
combining effective symptom management with disease modification once it is available.  
 
In general, it should be remembered that difficulties in recruitment are a common problem 
in clinical research [138]. This issue may be of even greater concern when recruiting 
individuals with HD, taking into consideration that the sample selection is limited to a 
small subset of the population. Furthermore, there are certain barriers, such as lack of 
motivation and the need to obtain support from the carer, which may limit opportunities for 
participation in clinical research in this population [292]. The difficulties encountered in 
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recruiting subjects in this study highlight the need to re-examine the best way to conduct 
clinical studies. Innovative strategies for recruiting individuals must become high priority 
in future clinical trials in HD. For example, multicenter exercise trials may be necessary in 
the future to achieve adequate statistical power. Intervention fidelity in such cases become 
extremely important part of the study conduct. However, with the use of video and 
broadband technologies, the host site could oversee an intervention at another location to 
ensure that the trial protocol is adhered to [138]. 
 
In addition to the need to consider multisite trials, Goodman et al [292] suggested a 
number of strategies that have been used in HD and found to enhance recruitment rate in 
this population. According to the authors, using web alerts for notification of new clinical 
trials, as well as providing education to individuals with HD and their families about 
clinical trials, in support group are mechanisms that have the potential to enhance 
participation in HD research. Within education in a support group strategy, community 
advocates can provide educational sessions to groups of HD individuals and their families 
about a clinical trial, its importance, rationale of the intervention, potential risks and 
benefits and inclusion and exclusion criteria. This strategy in particular seemed to boost 
recruitment rate in a previously conducted trial and therefore needs to be considered in 
future research.      
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6 Results and discussion: Process evaluation of part 2 
 
6.1 Overview 
This chapter presents the results of the process evaluation for part 2 of the study. 
Specifically an exploration was carried out to investigate: 1) if participants would 
adhere to the home-based exercise programme, 2) how the exercise programme was 
perceived by the participants and their carers, and 3) what factors impacted on the 
adherence to the home-based exercise programme. Data presented here were gathered 
from 19 participants who were offered the intervention in both arms of the study and 
were followed up on completion of the 8 week period of the exercise programme (i.e. 
early intervention group (n=11) and delayed intervention group (n=8)).   
 
Results presented in this chapter are divided into 3 sections. In the first section, 
participants‟ characteristics are provided. In the second section, data about adherence to 
the exercise programme based on participant‟s self report are illustrated. This includes 
the adherence rate of each participant which was calculated as the number of exercise 
sessions reported as a percentage of potentially expected exercise sessions prescribed 
for the 8 weeks. For the purposes of data interpretations, participants were considered to 
have good adherence if they reported performance on at least 50% of the prescribed 
sessions.  
 
Data related to adherence rate in the second section of the results are presented along 
other data related to disease-specific factors and participants‟ perceptions of the exercise 
programme. In this section, participants‟ self report about their perceptions of their 
involvement in the exercise program which was assessed using the short form of the 
Intrinsic Motivation Inventory (IMI) scale is firstly illustrated. Secondly, differences 
between those who adhered and did not adhere to the exercise programme for stride 
time coefficient of variation (CV) and UHDRS-cognitive scores and all the IMI 
subscales are provided. Thirdly, correlations between adherence rate, stride time CV, 
UHDRS-cognitive scores and IMI subscales, are presented.  
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In the third section of the results, data from semi-structured interviews which were 
conducted on completion of the exercise programme are presented. These data provide 
further explorations of factors that would have impacted on performance of the 
exercises in this study. Results presented in this section were derived from interviews 
that were conducted with participants in both arms of the study who were offered the 
exercise intervention and subsequently followed up (n=19).   
 
6.2 Results  
6.2.1 Participants  
Characteristics of those participants who were interviewed on completion of the 
exercise programme (n=19; 11 from the early intervention group and 8 from the delayed 
intervention group) are shown in Table 6.1. The data presented are coded as P1-P19; 
this adds to the transparency of the process whilst protecting the anonymity of the 
participants and allows the reader, at the same time, to gain an understanding of the 
source of the information [293]. Most of the participants (n=14) had a full time carer. 
The participants (10 females and 9 males) varied in their age, stage of the disease and 
their physical and cognitive status. The ages ranged from 25 to 69 with an average of 
52.7 years (SD ±13.3). The mean of the stride time CV was 9.2 (SD ± 4.7). One of the 
participants was at stage I (TFC 11-13), 5 participants were at stage II (TFC 7-10) and 
13 participants were at stage III (TFC 3-6). Six participants had high scores on the 
UHDRS-cognitive scores (UHDRS-cognitive >200), 6 had moderate scores (UHDRS-
cognitive ≥ 100 but less than 200) and 7 had very low scores (UHDRS-cognitive < 
100).  
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Table 6.1: Characteristics of participants who completed the intervention 
  
 
ID 
 
 
General information 
 
Carer’s 
involvement 
 
Group 
allocation 
 
Stride 
time 
CV 
 
UHDRS 
Cognitive 
scores 
 
TFC 
score 
 
Stage of 
the 
disease 
P1 
Female; aged 69 at 
interview 
Yes*^ 
Delayed 
intervention 
8.7 160 3 Stage III 
P2 
Female; aged 41 at 
interview 
Yes*^ 
Early 
intervention 
10.3 197 6 Stage III 
P3 
Male; aged 25 at 
interview 
Yes*^ 
Delayed 
intervention 
5.5 128 5 Stage III 
P4 
Female, aged 55 at 
interview 
Yes^ 
Early 
intervention 
11.3 76 5 Stage III 
P5 
Female; aged 59 at 
interview 
Yes*^ 
Delayed 
intervention 
6.2 63 5 Stage III 
P6 
Female; aged 67 at 
interview 
No 
Early 
intervention 
9.3 201 9 Stage II 
P7 
Male; aged 42 at 
interview 
Yes*^ 
Early 
intervention 
17.1 84 5 Stage III 
P8 
Male; aged 78 at 
interview 
Yes*^ 
Delayed 
intervention 
11.7 50 5 Stage III 
P9 
Female, aged 51 at 
interview 
Yes^ 
Early 
intervention 
4.1 221 11 Stage I 
P10 
Male, aged 38 at 
interview 
No 
Delayed 
intervention 
4.3 233 9 Stage II 
P11 
Female, aged 72 at 
interview 
Yes*^ 
Early 
intervention 
10.3 88 3 Stage III 
P12 
Male, aged 41 at 
interview 
Yes*^ 
Delayed 
intervention 
3.3 198 5 
Stage III 
 
P13 
Male, aged 51 at 
interview 
Yes*^ 
Early 
intervention 
17.6 57 4 
Stage III 
 
P14 
Male, aged 64 at 
interviews 
Yes*^ 
Early 
intervention 
7.4 73 5 Stage III 
P15 
Male, aged 51 at 
interview 
Yes*^ 
Delayed 
intervention 
10.1 130 6 Stage III 
P16 
Female, aged 42 at 
interview 
No 
Early 
intervention 
5.6 206 8 Stage II 
P17 
Male, aged 60 at 
interview 
No 
Early 
intervention 
7.5 200 10 Stage II 
P18 
Female, aged 41 at 
interview 
Yes*^ 
Early 
intervention 
19.8 192 6 Stage III 
P19 
Female, aged 54 at 
interview 
No 
Delayed 
intervention 
5.3 230 8 Stage II 
UHDRS, Unified Huntington‟s Disease Rating Scale; CV, coefficient of variation; TFC, Total Functional 
Capacity Scale; *, carer was involved in supporting the participant during the exercise programme; ^, carer was 
involved in the interview. 
UHDRS-cognitive >200 indicates high cognitive score, UHDRS-cognitive ≥ 100 indicates moderate cognitive 
score, UHDRS-cognitive < 100 indicates very low cognitive score. 
A categorical classification of disease severity is based on the Total Functional Capacity (TFC) score, grouped 
into 5 stages as the following: (TFC 11-13); stage II (TFC 7-10); stage III (TFC 3-6); stage IV (TFC 1-2). 
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6.2.2  Exercise adherence  
Characteristics of adherence and frequency of completion of the prescribed exercises 
from the DVD and the walking programme during the 8-week period is shown in Table 
6.2. The total expected number of exercise sessions in the 8-week period was 32 (24 
exercise sessions and 8 walking sessions). Adherence rates were high for most of the 
participants who completed the study (based on analysis of the exercise diaries): 15 of 
the 19 (78.9%) performed at least 75% of the prescribed sessions (mean adherence was 
28.4 ± 3.1 of the 32 prescribed sessions). Four participants (21.1%) (P4, P5, P8, P13) 
did not adhere well to the exercise programme and performed less than 50% of the 
prescribed sessions (mean adherence was 8.5 ± 4.7 of the 32 prescribed sessions). For 
the total 19 participants who were followed up after being offered the exercise 
programme, mean adherence was 24.2 ± 8.9 (76.5% ± 27.8%) of the 32 prescribed 
exercise sessions. The reasons for non-adherence to some of the exercise sessions in 
those who adhered well to the overall exercise programme (performed more than 50% 
of the exercise sessions; n=15) were acute illness (n=4; 26.7%), inability to walk outside 
home due to bad weather conditions (n=2; 13.3%), timing of the exercise sessions 
(overlapping with holiday or special occasions at home) (n=5; 33.3%), lack of 
motivation (n=1; 6.7%), absence of the carer (n=5; 33,3%). In all participants who did 
not adhere to the exercise programme (n=4) (i.e. performed less than 50% of the 
prescribed sessions), reasons for adherence were related to the commitment of the carer 
or carer-participant interpersonal relationship.   
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Table 6.2: Characteristics of adherence to the exercise programme 
 
ID 
 
Reported 
participation in 
the home use of 
the exercise DVD 
(Max adherence 
24 sessions) 
Reported 
participation in 
the walking 
programme 
(Max adherence   
8 sessions) 
Total reported 
participation in 
the programme 
(Max adherence 
32 sessions) 
n (%) 
Reasons for non-adherence 
(if applicable) 
P1 
 
24 4 28 (87.5%) 
Two walking sessions were missed both due 
to bad weather conditions and an additional 
2 sessions were missed due to holiday. 
P2 21 8 29 (90.6%) Three sessions were missed due to illness 
P3 22 6 28 (87.5%) 
Two sessions were missed due to the 
absence of carer and 2 walking sessions 
were missed due to bad weather conditions. 
P4 
 
2 8 10 (31.3%) 
Most of the sessions at home were missed 
due to the lack of support from the carer. 
P5 
 
6 3 9 (28.2%) Carer-participant interpersonal relationship 
P6 22 8 30 (93.8%) Two sessions were missed due to holiday 
P7 22 8 30 (93.8%) Two sessions were missed due to illness 
P8 10 3 13 (43.3%) Carer-participant interpersonal relationship 
P9 23 8 31 (96.9%) 
One session was missed as busy with a 
special occasion at home 
P10 23 7 30 (93.8%) 
One session was missed due to illness and 
one walking session was missed due to lack 
of motivation. 
P11 20 5 25 (78.1%) 
Eight sessions were missed due to the 
absence of the carer. 
P12 21 7 28 (87.5%) 
Four sessions were missed due to absence of 
the carer 
P13 2 0 2 (6.3%) 
Carer-participant interpersonal relationship 
and participants behavioural problems. 
P14 24 8 32 (100%) None 
P15 20 5 25 (78.1%) 
Seven sessions were missed due to illness 
and absence of the carer. 
P16 21 8 29 (90.6%) Three sessions were missed due to holiday 
P17 21 8 29 (90.6%) 
Three sessions were missed as busy with a 
special occasion at home 
P18 19 6 20 (75%) 
Five sessions were missed due to the 
absence of the carer 
P19 24 8 32 (100%) None 
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Table 6.3 reports the descriptive data of stride time CV and the UHDRS-cognitive 
scores as well as the scales of the IMI on both those participants who adhered to the 
programme (n=15) and those who did not (n=4). The mean score on the UHDRS-
cognitive and the tension/pressure scores were significantly different between those 
who adhered and those who did not adhere. There were no significant differences in the 
stride time CV scores as well as for all the other subscales of IMI.  
 
 
Table 6.3: Data of stride time coefficient of variation (CV), UHDRS cognitive scores and 
Intrinsic Motivation Inventory (IMI), of participants who adhered and participants who did not 
adhere to the exercise programme (mean ± SD) 
 
 
Correlation scores between adherence rates, stride time CV, UHDRS-cognitive and the 
IMI subscales are reported in Table 6.4. Adherence rate was significantly correlated 
with the stride time CV, the UHDRS-cognitive subscale, perceived competence and 
pressure/tension subscales. There were no significant correlations between adherence 
and interest/enjoyment, effort/importance and value/usefulness subscales. 
 
The stride time CV score was significantly correlated with perceived competence 
subscale; correlations with interest/enjoyment, effort/importance, pressure/tension and 
value/usefulness subscales were not significant. In addition, the UHDRS-cognitive 
Subscale 
Participants who 
adhered (n=15) 
Participants who did 
not adhere (n=4) 
p-value 
Stride time CV 8.5 ± 4.9 12.7 ± 5.7 0.09 
UHDRS cognitive score 169.4 ± 54.9 61.5 ± 11.0 0.001 
IMI-Interest/enjoyment 5.3 ± 1.5 4.7 ± 1.0 0.5 
IMI-Perceived competence 5.9 ± 1.2 3.8 ± 2.3 0.1 
IMI-Effort/importance 6.4 ± 0.8 5.8 ± 0.8 0.3 
IMI-Pressure/tension 2.5 ± 1.1 4.5 ± 1.4 0.03 
IMI-Value/usefulness 6.7 ± 0.6 6.7 ± 0.6 0.7 
For each item of IMI scale, a response on a scale of 7 points indicating how true the statement of the 
item is given (1 indicates not true at all and 7 indicates very true). Lower scores of the pressure tension 
subscale and higher scores of all the other subscales indicate positive outcome. 
Analysis for all parameters is based on using the Mann-Whitney-U test for independent samples. 
                                                                                6. Results and discussion: process evaluation 
 
230 
 
score was significantly correlated with the perceived competence and pressure/tension 
subscales.  
 
 
Table 6.4: Correlations between adherence rates, stride time coefficient of variation (CV), 
UHDRS-cognitive score and Intrinsic Motivation Inventory (IMI) subscales 
 
 
6.2.3 Semi- structured interviews  
All participants who adhered to the programme (n=15) agreed that the prescribed 
exercises were suitable for them. In particular, participants agreed that the exercise 
DVD was simple and easy to follow and was a supportive mechanism that helped them 
to perform the exercises at home without a close supervision from a therapist. Analysis 
of the interviews revealed perceived benefits as well as perceived barriers and 
facilitators to performing the exercise programme. The following sections describe 
these aspects of the interview analyses.  
 
6.2.3.1 Perceived benefits  
All participants who adhered to the programme perceived benefits from participating in 
the exercise programme. Participants perceived improvements in muscle strength (n=3), 
balance (n=5), motor control (n=4), mobility (n=8), quality of life (n=6) and a reduction 
in falls (n=2). Illustrative quotes are demonstrated in Table 6.5 below. 
 As depicted in Table 6.5, the vast majority of the participants who reported perceived 
improvements in balance, motor control and mobility demonstrated improvements on 
 
Subscale (n=19) 
 
Correlation with 
stride time CV 
 
Correlation with 
UHDRS-cognitive 
 
Correlation with 
adherence 
Adherence -0.5* 0.6** ------- 
IMI-Interest/enjoyment -0.2 0.3 0.2 
IMI-Perceived competence 0.4* 0.5* 0.5* 
IMI-Effort/importance -0.2 0.2 0.3 
IMI-Pressure/tension 0.2 -0.5* -0.6** 
IMI-Value/usefulness 0.3 -0.2 -0.2 
Correlations were calculated using the Spearman correlation coefficient 
*p<0.05 
**p<0.01 
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the corresponding objective outcome measure. These participants had higher scores on 
the Berg Balance Scale (BBS), the Chair Sit to Stand test (CSST), or lower stride time 
CV at the follow-up assessment when compared to the baseline. This suggests that there 
is an agreement between the subjective perceived improvement reported by participants 
and the objective change evaluated using the outcome measures.  
 
In addition to the above, most of the participants (n=3/4) who perceived improvements 
on quality of life had a better scores on the physical function subscale of the SF-36 at 
the follow-up, relative to what they had scored at the baseline (Table 6.6). Furthermore, 
some participants (2/4) had a better score on the aggregate score of physical domain at 
the follow-up, relative to what they had scored at the baseline. This indicates that on the 
objective outcome (i.e. SF-36), participants demonstrated improvements on some of the 
physical domains of the health related quality of life.     
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Table 6.5: Some illustrative quotes for the perceived benefits on the participation of 
the exercise programme along with the change scores on the objective outcomes of 
muscle strength, balance and mobility 
 
Perceived 
benefits 
Illustrative quotes 
Objective 
outcome 
Participant 
Change of 
scores on   
objective 
measures 
Comment 
Muscle 
strength 
P1: “The exercises with the weights are 
quite good. They strengthen the arms 
and the muscles that I have not used 
often.” 
 
MVIC of 
quadriceps 
P1 Not recorded ------- 
P2 -3.0 
Did not 
improve 
P3 Not recorded ------- 
Balance 
P3: “This programme has helped my 
balance particularly. I think it was very 
important to do this programme 
because I always thought that my 
problem is the balance. I think it 
strengthened me around the waist as 
well which is important for my 
balance.” 
BBS 
P3 Not recorded ------- 
P6 5.0 improved 
P9 3.0 improved 
P10 Not recorded ------- 
P16 5.0 improved 
Overall 
mobility 
status 
P7: “I can walk for much longer now. I 
did not used to walk for long distances 
before I started this programme but 
now I do this quite frequently. We 
went to a wedding last week and I had 
to walk for about an hour and a half, 
something that I have never done 
before.” 
Stride time 
CV 
P1 1.7 
Did not 
improve 
P2 -2.1 improved 
P3 -1.5 improved 
P7 -10.9 improved 
P16 -4.0 improved 
P17 -3.4 improved 
P18 0.85 
Did not 
improve 
P19 -2.4 improved 
Control of 
movement 
 
P11: “The sitting down is getting 
better. A lot of the time I just tended to 
lump my self down but now I am 
controlling this a bit better. I noticed 
with controlling sitting down that 
instead of lumping I now think  about it 
more and get a bit more control over 
it.” 
CSST 
P3 Not recorded ------- 
P11 5.0 improved 
P6 2.0 improved 
P15 Not recorded ------- 
Reduction 
of falls 
 
P2: “I have just noticed that I am not 
falling as many times since I‟ve been 
doing the exercises. I had falls a couple 
of times in the first couple of weeks, 
but probably in the last four or five 
weeks, I have not fallen over at all.” 
Number of 
falls 
P2 
Reported 
reduction in 
falls 
------- 
P18 
Reported 
reduction in 
falls 
------- 
 
Quality of 
life 
 
P5: “I think that doing this programme would really improve the quality of life because instead of 
sitting and watching the TV for about seven hours a day I can move and do something else; something 
that it is advantageous. So doing this programme gives more variety to life.” 
 
MVIC, Maximal Voluntary Isometric Contraction; BBS, Berg Balance Scale; CV, coefficient of variation; CSST, 
Chair Sit to Stand Test.    
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Table 6.6:  Some illustrative quotes for the perceived benefits on the participation of 
the exercise programme on quality of life along with the change scores on the 
subscales of the SF-36  
 
Quality of life quotes 
 
P5: “I think that doing this programme would really improve the quality of life because instead of 
sitting and watching the TV for about seven hours a day I can move and do something else; 
something that it is advantageous. So doing this programme gives more variety to life.” 
 
P6: „‟I think doing the exercises not only helped me physically but mentally too. I just feel much 
better when I do them.‟‟ 
 
Change scores on the subscales of SF-36 
Participant PF RF BP GH VT 
P2 10.00 0.0 -22.22 -7.00 -50.00 
P3 NR NR NR NR NR 
P6 15.00 0.0 -11.1 15.00 -5.00 
P11 0.0 0.0 -44.44 -12.00 -10.00 
P12 NR NR NR NR NR 
P14 15.00 -100. 0.0 10.00 0.0 
Participant SF RE MH PCS MCS 
P2 -22.22 0.0 -8.00 -2.59 -24.14 
P3 NR NR NR NR NR 
P6 0.0 33.3 0.0 12.96 -3.45 
P11 -22.22 -100 -4.00 -11.85 -13.79 
P12 NR NR NR NR NR 
P14 -33.33 -66.6 12.00 1.85 -3.45 
PF; Physical Functioning; RF; Role limited due to physical problems; RE; Role limited due 
to emotional problems; SF; Social Functioning; MH, Mental Health; VT, Vitality; BP, 
Bodily Pain; GH, General Health Perception; PCS, Physical Component summary; MCS, 
Mental Component Summary. 
On each subscale, a negative change indicates deterioration at follow-up and a positive 
change indicates an improvement at follow-up.  
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6.2.3.2 Perceived barriers and facilitators  
Analysis of the interviews revealed barriers and facilitators to using the exercise DVD. 
The barriers fell mainly into 3 categories: physical factors, cognitive factors and lack of 
motivation. Participants discussed strategies that they used to address these barriers, 
which improved adherence to the programme. The facilitators could be categorized as 
primarily related to the cues provided by the DVD, a person‟s self-efficacy, and their 
belief that performing the exercises would yield positive outcomes. The sections below 
describe these barriers and facilitators, and the participants‟ management strategies, 
with some illustrative quotes that are provided. A summary of the categories and 
subcategories and their relationship to each other are provided in Figure 6.1 below.  
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Figure 6.1: Summary of main areas, categories and subcategories of barriers and facilitators from interview analysis
 
Factors influencing the usability of a home based exercise DVD for people with HD
Barriers
Management
strategies
Barriers in using the exercise DVD and 
management strategies
Physical factors Cognitive factors Lack of motivation
Support from 
the carer
- Additional cues 
- Prompts
- Feedback on 
performance
- Encouragement 
by the carer 
- Exercise part of
the routine
Carer involvement 
Facilitators in using the exercise DVD and 
management strategies
Outcome expectations 
and  self efficacy 
Support provided by 
using the DVD itself 
- Education about benefits
- Demonstration how 
to use the DVD
- Phone calls
- Support provided by
the carer
Auditory  and visual 
cues with real  life
demonstration
Facilitators
Management
strategies
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6.2.3.2.1 Barriers in performing the exercise programme and management 
strategies 
6.2.3.2.1.1 Physical factors  
The majority of participants felt that HD-related physical problems limited to some 
extent their ability to perform the exercises from the DVD independently. Most of the 
participants (n=9) who completed the exercise programme felt that some of the 
exercises were difficult to perform, due to the interference of choreic movements and/or 
secondary to their perceived balance problems. Some participants at mid stage (n=5) 
needed their carers to assist with the actual exercises shown in the DVD but participants 
at earlier stages were able to do the exercises independently without the carer being 
involved. Participant 3 said:  
“I needed my husband actually to be with me. I do not think I would manage 
to do them by myself, because of the choreic movement, balance problems and 
because of the power and things like that..”.  
 
In terms of the walking programme, some of the participants at stage II and stage III 
(n=5) reported the need to have a lot of breaks due to fatigue on the initiation of the 
exercise programme. Participants, however, commented that this aspect was improved 
on continuing the exercise programme. In addition, some of the participants at stage 3 
(n=6) needed close supervision from their carers while walking to avoid tripping or 
falling over. Participant 4 said:  
“In the first couple of weeks, I was not able to walk the fifteen minutes 
without having plenty of breaks. Every three to four minutes I was stopping to 
have a little break and then continue. Simply I was feeling tired. It is 
something that I did not used to do. We were setting targets, saying for 
example; today we will walk from these chairs to the parked cars. I needed to 
hold onto the hands of my husband for the first couple of weeks as well. 
We‟ve noticed however that in the last three weeks I am walking the same 
distance without holding onto him and without taking as many breaks as I used 
to take”  
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6.2.3.2.1.2  Cognitive factors 
In addition to physical factors, cognitive problems were a main issue that had the 
potential to limit participants‟ ability to independently perform the exercise 
programme. Participants who were moderately to severely cognitively impaired were 
unable to do the exercises from the DVD on their own; this included the 4 participants 
who did not adhere to the programme. The participants believed that this was not 
necessarily due to their physical limitations, but rather because at times they were 
unable to understand what they were required to do from the DVD. Participant 4 said:  
“I watched the people - what they were doing on the DVD- but I could not 
actually see if I was doing it right.” 
 
6.2.3.2.1.3 Lack of motivation 
Participants also discussed issues related to lack of motivation as another main issue 
that impacted on their initiation to the exercise programme. The use of strategies such as 
trying to fit the programme into a daily routine also helped to maintain motivation and 
influenced adherence. Participant 6 said:   
“It was just difficult to get myself into it. Obviously people with HD do have 
difficulties to start new activity. However, making these exercises part of the 
routine would make it easier to maintain….‟‟   
 
6.2.3.2.2 Facilitators in performing the exercise programme and management 
strategies 
6.2.3.2.2.1 Cues provided by using the DVD 
All participants who completed the exercise programme felt that the DVD was a 
supportive mechanism to help them initiate and adhere to a home exercise programme. 
Participants discussed the advantages of using the DVD as an approach to demonstrate 
the exercises versus using drawings of the exercises in a paper format. They commented 
that the main advantage of using the DVD was that it provided additional visual and 
verbal cues, to ensure correct execution of the exercises. Participant 1 said:   
“The visual thing of using the DVD makes it much easier to do it because to 
do things that have to be committed to memory, particularly as in my case 
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memory is a problem, is impossible. So the visual cues of the DVD make it 
easy to do.” 
 
The DVD was used in different ways by participants to derive the support that they 
needed. The more advanced participants of those who completed the exercise 
programme (TFC<9; 15/19) needed to play the DVD at each session to do the exercises; 
the vast majority of the less advanced participants (TFC≥9; 3/19; P6, P9, P10) used the 
DVD at the beginning of the programme and then were able to integrate the exercises 
into their daily routine and refer back to the DVD or the exercise booklet only if needed.  
 
6.2.3.2.2.2 Self efficacy and outcome expectations  
Expectations of outcome and self-efficacy were 2 important concepts that emerged from 
the discussion with the participants that positively influenced their motivation and 
consequently facilitated their adherence to the exercise programme. In terms of the 
outcome expectations, most participants who adhered to the exercise programme 
(n=11/15) believed that their involvement in this programme would help them to 
manage their condition. Participant 10 said:  
“What I was just saying to myself - this is an important kind of thing and I have 
to do it. I have to do it because it can be beneficial for my balance and my 
walking.”  
 
In terms of self-efficacy, some of the participants who adhered to the programme (n= 
8/15) believed that feeling confident about how to use the DVD and how to do the 
exercises safely helped their adherence. Participant 9 said:  
“I felt that I had to do something to regain my balance but I was not sure how to 
go about it and having this programme just helped because I felt that I am doing 
the right thing in the right way.” 
 
Participants felt that the weekly telephone calls were an important component of 
maintaining adherence to the programme, positively affecting their belief in their own 
ability to affect meaningful change. Participant 9 said:  
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“The phone calls were very important to keep me on the programme. We kept 
communicating and you were answering my questions so I felt I was on the right 
track. I do not know how well motivated I would be without them.” 
 
In addition, all participants who adhered to the programme agreed that the education 
session provided at home at the beginning of the programme was important to help 
them to initiate the exercise programme and to promote their self-efficacy. Participant 3 
said:  
“The home visit was very useful because I can only see what people on the DVD 
are doing, so it is good that you saw how I was doing things. This gave me 
assurance that I was doing it right from the beginning.” 
 
While those participants who adhered to the programme thought that 1 session was 
enough to feel fully confident about how they should progress their exercises, others felt 
that providing more sessions during the first few weeks of the programme would have 
been beneficial. One participant suggested that providing feedback from a distance 
using web-based technology would be useful, rather than having a face to face session 
which would require either patient or therapist to travel.  
 
6.2.3.2.3 Master theme 
All categories of barriers and facilitators related to a master theme that emerged from 
the analysis; namely that commitment of the carer was a key to the success of the 
programme. Reasons for non-adherence were mostly attributed to the commitment of 
the carer or carer-participant interpersonal relationship. Participant 5 and her carer 
discussed how the carer-participant interpersonal relationship would affect a 
participant‟s adherence to the programme. The participant said:  
“We could not agree on how to do things.” The carer of this participant clarified by 
saying:  
“She did the exercises with you when you visited us at home but she would not 
do them with me because mentally she has authoritarian issues, she is more 
likely to do things with other people who‟ve got medical authority rather than if 
it is someone from the family.” 
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The carer of one participant (P13) commented that the participant‟s behavioural aspects 
prevented her from continuing the exercise programme after the training session at 
home with the therapist. The carer of this participant said:  
“He did the exercises very well with you when you visited us at home. I could 
not get him to do them with me though. Whenever I asked him to start doing 
them, he was getting very irritable and agitated and I could not handle his 
behaviour, so I stopped asking him to do that.”   
 
As noted earlier, some participants needed their carers to help on the actual performance 
of the exercises because of some physical limitations. In cases of cognitive 
impairments, the use of strategies such as prompts, verbal cues, and feedback on the 
participant‟s performance provided by the carer was vital to help participants 
accomplish the exercises from the exercise DVD successfully. Participant 3 said: 
“I always needed my nurse…”. The carer of this participant clarified by saying: 
“He always needed his nurse to be there to do the exercises. She was providing 
him with occasional prompts like „make sure your hands on the chair‟ when he 
was using them during standing on the balance things. It tells him put your arm 
out and touch the chair, move closer or put the chair closer.” 
 
For the majority of the participants who adhered to the programme (n=12/15), 
involvement of the carer was necessary to manage motivation by providing continuous 
encouragement. Participant 11 said:  
“Motivation was a big issue.…” The carer of this participant added some 
clarification. The carer said “If I was not there, she would think –„Do I need to 
do my exercises?‟. The problem is that she needed to be prompted to do it.” 
 
Support provided by the carer seemed also to influence self-efficacy. Participant 4 who 
did not adhere to the programme explained how the lack of support from the carer 
influenced her adherence negatively. The participant said:  
“I was panicking. I do not know why myself. I just felt that „I would be OK‟ if 
there was somebody sitting there while I was doing the exercises.” 
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6.3 Discussion 
6.3.1 Exercise adherence  
This is the first study that documents the adherence rates to unsupervised home-exercise 
programmes in people with HD. Adherence is defined as the extent to which people 
follow the prescribed components of their exercise programme [294]. In this study, 
most of the participants adhered to the exercise programme; 15 participants reported 
adherence to at least 75% of the prescribed sessions, while only 4participants reported 
adherence on a maximum of 41.7% of the prescribed sessions.  
 
Participants‟ adherence is crucial when using a home programme with self-report as 
part of a treatment intervention. In an attempt to increase adherence to the exercise 
programme, the researcher made weekly phone calls to offer encouragement, answer 
questions, and check on progress. This study‟s overall adherence rate of 76.5% is within 
the range of 70% to 95% of adherence rates reported in previous home-based exercise 
studies in other neurodegenerative diseases [161, 163, 167, 295, 296]. Furthermore, the 
reported overall adherence rate of 76.5% in this study is slightly better than rates cited 
in a recent review which concluded adherence rates to medical treatments using self-
report as 71.8% and adherence rates of 72% when exercise was the treatment choice 
[297]. A number of factors including the home visit at the beginning of the exercise 
programme, the frequent telephone contacts and attempts to involve the carer in 
supporting participants were well received by the participants and may have contributed 
to their adherence rate.   
 
Interestingly reasons for non-adherence in all those with low adherence rates were all 
attributed to the commitment of the carer or to the carer-patient relationship. It was 
evident that the successful involvement of the carer was a key to the success of the 
programme, particularly with subjects who were more advanced in the disease process. 
Participants did not adhere to the programme if they lacked the support of a carer, or if 
they had a negative relationship with their carer about the carer‟s role in supporting 
them in completing the programme. In 1 case, behavioural problems associated with 
HD, namely agitation, also acted as a main barrier and affected the carer‟s ability to 
support the participant effectively on continuing the exercise programme at home. This 
finding suggests that health-care professionals should work co-operatively with the 
carer, supporting the carers‟ self efficacy and building their confidence about the 
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important role that they can play in supporting the subject with HD to engage in an 
independent exercise programme.  
 
Data from the IMI subscales indicated positive results in terms of how participants who 
adhered perceived the participation in the exercise programme. The pressure/tension 
subscale resulted in a relatively low score, which indicates that; overall, participants did 
not experience pressure during the use of the exercise DVD or during performing the 
walking sessions. Effort/importance and value/usefulness subscales resulted in very 
high scores, which suggest that the participants felt that they produced a good amount of 
effort when doing the exercises from the DVD and/ or the walking sessions; they 
believed that it was important for them to do the exercises and they were satisfied with 
the results.   
 
Significant differences between those who adhered and those who did not adhere were 
seen on the cognitive scores and on the pressure/tension subscale of the IMI. There was 
a trend towards higher stride time CV scores in those who did not adhere to the 
programme, but this was not significant. The small sample may have influenced this 
result and further investigation on a larger sample is indicated. The significant 
correlations between the adherence rate, stride time CV, cognitive scores and perceived 
competence (and the significant differences in pressure tension and cognitive scores) 
suggest that participants who were more impaired both physically and cognitively may 
have found it more difficult to perform the exercises and felt less competent, which may 
have had a negative influence on their adherence to the programme. Furthermore, the 
significant correlation between the cognitive scores and pressure/tension subscales 
suggests that participants who were more cognitively impaired experienced more 
pressure on performing the exercises which may have also adversely influenced their 
adherence. This quantitative correlation analysis is consistent with the qualitative 
feedback obtained from the participants in which both physical and cognitive factors 
were perceived to impact on the ability to do the exercises independently.  
 
6.3.2 Perceived benefits  
Data from the interviews extend the available knowledge relating to how participants 
perceived the exercise programme. The success of an exercise programme is not only 
based on therapists‟ evaluations but also on subjects‟ personal experiences and 
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perception. It was therefore important to evaluate the perceptions of participants who 
took part in this study about their involvement in the home-based exercise programme 
in order to ensure the suitability and acceptability. 
 
All the participants who adhered to the programme perceived benefits to their 
participation in the programme. The vast majority of participants reported perceived 
improvements in mobility, balance, control of movement and a reduction in falls. This 
reported perception was consistent with data obtained from the objective measure in 
most cases and with the overall quantitative analysis that was provided in the previous 
chapter (Chapter 5). Furthermore, these reported perceptions about obtaining benefits 
from the programme exercises is in agreement with reports from the literature [80, 81]. 
In a previously conducted qualitative study, both therapists and people with HD 
believed that exercise was beneficial for managing motor symptoms related to HD [80]. 
While the research is still limited, it appears that people with HD can be effectively 
involved in a home-based exercise programme and that such an exercise programme 
may be beneficial in improving various measures of impairment, activities and 
participation. 
 
In addition to the reported improvements in balance and mobility, a number of 
participants perceived benefits from their participation in the programme on their 
quality of life. This reported perception, was consistent with data obtained from the 
objective outcome measure (i.e. SF-36) in which some participants demonstrated 
improvements on the physical function subscale as well as the aggregate score of the 
physical domain (Table 6.6). This provides further indications that that the magnitude of 
improvements on mobility status recorded in this study using objective outcomes were 
also perceived by participants.   
 
In addition to perceived improvements on mobility status, some participants reported 
improvements on other elements such as mood that may relate to other aspects of health 
related quality of life. This, however, was not captured by the other subscales of the SF-
36.  Within this context, it was interesting to note that most of the subjects who reported 
perceived improvements in their quality of life, scored lower in the vast majority of the 
other subscales of SF-36 at the follow-up (i.e. post- intervention) relative to what they 
scored at the baseline (i.e. apart from the physical function subscale, most participants 
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demonstrated deterioration on all other subscales). This response can be traced back to 
the susceptibility of the SF-36 to a certain degree of variability on repeated testing in 
general (Chapter 4) and to the possibility of response shift bias in particular. People 
with HD may change their perception about their quality of life overtime [118]. Thus, 
the negative change on the majority of SF-36 subscales suggests that these participants 
may have judged their quality of life using the SF-36 at the baseline as being better than 
was actually the case. This may reflect a coping mechanism that allowed participants to 
view their situation at that time as being better, compared to prior circumstances. 
Alternatively, this observed response on the SF-36 could reflect a distortion that is 
secondary to cognitive impairments; given that answering the SF-36 questions requires 
implicit thinking and retrospective judgment which can be cognitively challenging 
particularly in the presence of cognitive impairments, as per in the HD population [118].    
 
6.3.3 Perceived barriers and facilitators   
Although most participants used the exercise DVD successfully and managed to adhere 
to the prescribed intervention very well, a number of barriers that could impact on the 
performance of the exercises and adherence to the use of the exercise DVD were 
reported. Each of these barriers was a disease-specific factor and included physical 
impairments, cognitive impairments and lack of motivation. This is in agreement with 
what has been identified about barriers to independent exercise in people with HD [80]. 
This is also in agreement with what is known about barriers to engagement in 
independent exercise programmes in other populations. Research carried out in elderly 
individuals, and people with stroke and spinal cord injury indicated that a change in 
health status as well as impairments related to the pathology in cases of stroke and 
spinal cord injury, are the main barriers to engaging in an independent exercise 
programme [298-300].   
 
In terms of physical impairments, participants in this study, particularly those in more 
advanced stages, felt that balance deficits and choreic movements had an impact on 
their independent performance of the exercise programme. These participants needed 
their carers to help with the actual performance of the exercises from the DVD, but 
were still able to gain benefit from participation. In terms of the walking sessions, these 
participants needed close supervision from their carers to avoid tripping or falling. 
Involving the carer in supporting these participants to perform the exercise programme 
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at home minimised the risk to safety. This suggests that an independent exercise 
programme in a home setting is feasible for people with HD at a more advanced stage 
of HD who may have a good carer support.    
 
In contrast to the physical impairments, cognitive problems were reported to act as a 
main barrier to independent participation in the exercise programme, particularly at the 
more advanced stages. Cognitive symptoms are an early sign in HD in which 
difficulties in maintaining attention to a task, manipulating information and planning 
can be recognized [2]. These symptoms may progress to include disorders of memory 
retrieval and eventually global dementia [13]. Given that both the number and severity 
of cognitive impairment increases with the progression of the disease, they have greater 
impact on the ability to learn new motor tasks, including the performance of new 
exercises at the more advanced stages of the disease.  However, participants in this 
study indicated that strategies such as prompts, verbal cues, and feedback on the 
participant‟s performance provided by the carer helped to successfully support the 
accomplishment of the exercises and minimised the effect of cognitive impairment on 
the ability to perform the exercises from the DVD. Additional verbal cues and prompts 
provided by the carer were crucial in enhancing usability of the exercise DVD in the 
presence of cognitive impairment.  
 
 The DVD itself was perceived to be a supportive mechanism that helped in completion 
of the exercises, particularly in the presence of cognitive impairments. The DVD 
provided a real-life demonstration, and this was viewed by participants as being 
superior to the written instructions or printed illustrations. The DVD approach augments 
the information provided by the provision of attention-focusing verbal and visual cues. 
The literature has illustrated that such cues are important to maintain correctness of 
performance of an imitative motor task; the visual feedback is important to guide the 
imitation of the performance and the verbal description is important to assist with 
processing the visual information of the task [86, 301]. Using these cues is particularly 
important in people with HD, considering that individuals with HD often do not 
spontaneously adopt active strategies for learning but when external cues are provided, 
performance can improve [155]. One of the mechanisms underlying the potential 
improvement in motor learning in HD, using the external auditory or visual cueing, may 
stem from the conscious activation of the motor cortex overriding the loss of basal 
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ganglia function. Research has suggested that over-activity in the unaffected cerebellar 
and lateral premotor routes may signify an adaptive mechanism through which subjects 
can use sensory or attentional guidance to overcome their movement disorders [135]. 
This supports the further potential of modes of exercise that are augmented with sensory 
cues, such as an exercise DVD, in supporting people with HD to engage in 
unsupervised exercise programmes.  
 
Lack of motivation was also reported to act as another barrier to adhering to the regular 
performance of the exercises. Lack of motivation is a main feature of the disease that 
could act as a barrier to initiate a new life routine such as an exercise programme [81]. 
Particularly in the realm of exercise training, people with HD may feel helpless, 
hopeless and reluctant to participate in any exercise programme [143], considering the 
progressive and degenerative nature of the disease and the number of losses that they 
might experience as a result. 
 
Since motivation is vital to adherence [168], finding strategies to improve motivation is 
a key to the success of any provided therapy programme. In this study, outcome 
expectations and self-efficacy were the 2 main factors reported by participants that 
helped them to maintain their motivation and therefore facilitated their adherence to the 
exercise programme. There is a clear link in the literature between outcome 
expectations, self efficacy and adherence to an exercise programme [302, 303]. In a 
study that examined factors promoting adherence to a walking programme in a group of 
elderly adults, participants‟ belief in their ability to do the exercises safely (self 
efficacy) and the recognition of the benefits of the exercises (outcome expectations) 
were  key factors [304]. Outcome expectation relates to the belief that specific 
consequences will result from specific personal actions [298, 304]. In this study, this 
concept seemed to be important in the initial adoption of the exercise programme; most 
of the participants who adhered to the programme indicated that their involvement was 
because of their belief that the performance of the exercises would be beneficial to 
manage their condition. In terms of self-efficacy, people need to believe that they have 
the ability to affect their own health and that they have the tools to do that. High self-
efficacy infers that the person is capable of controlling his/her own behaviour [298, 
304].  In this study, factors that contributed to participants‟ self-efficacy and therefore to 
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their motivation to continue with the exercise programme included the belief in their 
ability to use the exercise DVD appropriately and to do the exercises safely. 
 
Carer‟s involvement and providing participants with home visit support and phone calls 
to monitor progress were factors that were perceived by participants to promote self 
efficacy and facilitate their engagement in the exercise programme, which in turn 
contributed to adherence. Factors that would promote self-efficacy in this population 
need further investigation. Behavioural motivation techniques, which have been used 
successfully in patients with PD to promote self efficacy and consequently engagement 
in physical activities can be explored to engage people with HD in exercise programmes 
[169]. Within this strategy, counselling is used to promote a behavioural change through 
working closely with participants. The strategy includes education about the benefits of 
physical activity, advice about suitable activities, identifying and overcoming any 
perceived barriers to engage in physical activity, setting goals, and recruiting social 
support. This technique can be incorporated with other strategies reported in the 
literature, such as the motivational interviewing (MI) [305] to help subjects with HD 
and their carers build their self efficacy; hence facilitating the engagement to an 
independent exercise programme. The MI has been used in a variety of client 
populations with a positive effect on exercise adherence [305]. The strategy emphasizes 
reflective listening and negotiating rather than conflict; hence supporting participant‟s 
self efficacy and building confidence so that behaviour change is made possible. Future 
studies may therefore, need to consider such a strategy to effectively support the 
subjects with HD and their carers in making a behavioural change such as the 
engagement in an independent exercise programme.   
 
The suggestion of making use of web-based technology rather than face-to-face sessions 
merits some consideration. Telemedicine has been successfully applied in other 
populations such as stroke, cerebral palsy and obstructive sleep apnoea syndrome to 
monitor the delivery of therapeutic interventions [306-309]. Although further 
investigation in this area is required, the use of telemedicine technology could be 
beneficial to people with HD to support their engagement in the independent use of the 
exercise DVD, or in any other unsupervised exercise programmes. 
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6.3.4 Trustworthiness of data 
In qualitative interviews, there is the possibility that the researchers‟ views may 
influence interpretation of the data. To avoid this and to ensure rigour of the obtained 
results and conclusions, the Krefting framework [234] for analysing qualitative data was 
used. According to Krefting [234], credible results for a study with a qualitative design 
need to focus on testing its finding in the group of people from whom the data were 
obtained (member checking) and from people who are aware of  the phenomenon being 
studied (peer checking) and testing the findings against other sources of data 
(triangulation). To ensure credible data in this study, different strategies were used as 
follows: first, full transcribing of the data from the interviews enhanced the credibility 
of the results by avoiding the selective recording of the information. Second, the 
accuracy of all the interview transcripts and their analytic categories, interpretations and 
conclusions were confirmed by the participants (member checking). Third, for accuracy, 
all the transcripts and their analytic categories were reviewed and debriefed by an 
independent researcher who was very knowledgeable about the topic of the research 
(peer checking). Fourth, data that was presented from the interviews were used to cross 
check against data obtained from the literature as well the data obtained from the 
quantitative analysis reported here (triangulation). The triangulation in particular 
provided multidimensional information in order to see a more complete and holistic 
context about how participants perceived their involvement in home-based exercise 
programme and factors that might affect participation and adherence [293].  
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7 Limitations of the current study   
 
7.1 Possible limitations of the current study  
This work is not without its limitations. A possible limitation of the first part of the 
study is the use of a single assessor who was aware of the subjects‟ diagnostic status. 
The assessor was not blinded to whether the subjects were HD gene positive or negative 
which may have been a factor in introducing bias. Knowledge of exposure status by the 
assessor can influence the scoring; thus producing biased results [310]. However, it 
should be noted that the vast majority of the outcomes were objective measures (scoring 
was based on timed tasks or automated process) and standardized procedures were used 
throughout all assessment sessions (see Appendix 4 for SOPs procedure) which may 
have helped in reducing bias.  
 
 For the second part of the study (i.e. the exercise intervention), it was not possible to 
blind participants to group allocation as person would know if they were asked to 
exercise or not. It should be further noted that a potential weakness of this study was the 
lack of formal blinding of the main assessor; follow-up assessments were undertaken by 
the same researcher who was involved in recruitment and that the same researcher also 
provided the intervention to the participants. The lack of blinded assessment may 
potentially have allowed the introduction of a systematic bias [311, 312]. Every effort 
therefore was made to overcome this limitation by strictly following the practical 
guidelines set for independent assessment in randomised clinical trials [311]. Standard 
operating procedures (SOPs) were used for all components of the assessment protocol 
(see Appendix 4 for SOPs). All tests were based on objective measures (i.e. tests were 
based on timed measures and the primary outcome involved an automated process for 
determining the primary outcome) or were self-administered (i.e. SF36). Tests that were 
potentially affected by examiner bias (i.e. BBS and mMS) were videotaped and rated by 
a blinded assessor using an established methodology [231]. The blinded assessor had no 
previous connection with the participants and acted purely as a video assessor. Practice 
and training of all assessments, including instructions and methods of scoring, was 
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undertaken before the commencement of the study which allowed the development of 
standardized data collection routines.  
 
In terms of randomization, a minimisation method was used in this study to allocate 
participants into their groups. One of the concerns regarding the use of minimisation is 
the fact that next assignment can be anticipated in some situations [227]. The 
knowledge of which allocation is more likely to occur can result in selection bias. This 
issue however, can be handled using a probability of assignment to the “optimal” 
treatment group of less than one; hence the next assignment can never be predicted with 
certainty [228]. In this study, the randomisation was carried out with the aid of MINIM 
software in which the next participant was allocated to the group that would best 
minimise imbalance with a probability of 0.7 [229].   
 
There were also some observable differences noted in the primary and secondary 
outcomes at baseline which have been accounted for in the analysis [147]. The 2 
groups, however, were well matched at baseline for age and function (TFC) and 
additionally in the level of motor impairment, as reflected by the mMS scores. In small 
studies, such as this study, perfect balance is difficult to achieve even when using a 
balanced randomisation method (namely minimisation) as has been performed in this 
study. The strategy taken in this study is in line with the CONSORT guidelines for 
reporting, and the PSI and ICH directives on statistical analysis of clinical trials [269, 
313, 314], which recommend that baseline differences should not be tested for 
significance but rather that these should be accounted for using proper statistical 
measures such as ANCOVA. Furthermore, individual responses in this study have been 
illustrated so as to aid interpretations of the data.  
 
In terms of the process evaluation, the reported rate of adherence of people with HD to 
the home-based exercise programme in this study was very good. However, it must be 
remembered that the actual exercise dose was not measured. This study relied on self-
report for the measurement of adherence. Without the use of costly accelerometers or 
cycle ergometers, it is not possible to measure frequency and intensity of home-based 
exercise interventions objectively [315, 316]. The reliance on participants‟ self report on 
recording adherence has its limitations; there is a possibility that participants might have 
over-reported their exercise activity, although the relatively large effect size of the 
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intervention and the specificity of the results suggest that participants‟ reports were 
reliable. Every effort was made by the researcher in this study to confirm the reported 
participation; reported adherence was confirmed with the carers (if applicable) and with 
participants during the weekly phone calls and at the time of the interviews.   
 
Given the cognitive issues and communication difficulties in this population, structured 
interviews were considered to be the most appropriate method to gather meaningful 
responses regarding the subjective perceptions of participants and their carers in the 
involvement in the exercise programme. Although the highly structured format of the 
interview schedule provided mostly survey type data, the interviews included some 
open questions to which qualitative analysis was applied. A limitation of this qualitative 
work of the study is that only subjects who had consented to take part in the study and 
were followed up, and who were therefore expecting to have to exercise and were 
offered the intervention, were interviewed. Therefore, findings from this study may not 
be transferable to the subjects who declined to take part in the study or who dropped 
out, who may have been less willing or less able to exercise. Although many of the 
barriers identified in the interviews for non-adherence may also apply to the non-
participants in the trial, it is likely that the non-participants had less support from their 
carers or were less motivated or less able to exercise and make lifestyle changes.      
 
Overall, findings from this study might not be transferable to the general HD population 
because of the small sample that was used. The sample was one of convenience in that 
people who were recruited came from a clinic that was actively involved in the exercise 
type of intervention research, and in which subjects were committed to research in 
general, which might influence the findings presented in this study. Furthermore, whilst 
the home exercise was found to be feasible, the recruited subjects were relatively able 
participants so the results may apply to a limited range of people with HD. The exercise 
programme in this study was designed for people at early to mid stage HD. Whilst this 
programme did have the ability to be modified based on an individual‟s level of 
impairments and functioning, it was not designed for all people with HD. The vast 
majority of the enrolled subjects had good support from their carer; however, there were 
barriers to participation which suggests that this intervention might not be appropriate 
for all people with HD, and that other systems of delivering exercise need investigation 
in this population. Future studies should include a larger number of participants with a 
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wider range of impairments and also recruit participants from different regions. The 
advantage of such trials is that by recruiting consecutive individuals from multi-regional 
centres, the sample is likely to represent the characteristics of the entire population for 
which the intervention was designed [138], hence generalising the findings would be 
more appropriate. 
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8 Clinical implications, recommendations for future work and 
conclusions 
 
 
8.1 Clinical implications  
An important finding of this study is the potential of exercise interventions in improving 
gait variability in this population. Deficits in gait variability in HD exist early in the life 
cycle of the disease; they are associated with higher risk of falls as well as more nursing 
home admissions [38, 40, 43]. Regular participation in an exercise programme that has 
the potential to influence walking ability is therefore of great importance as it may 
reduce the risk of falls and postpone the need for institutionalization in this population.  
 
Overall, given the degenerative nature of HD and the relatively short duration of the 
exercise programme (i.e. 8 weeks); positive findings reported here on multiple domains 
are clearly encouraging and have some important implications. The disease to date has 
no cure and all the current pharmacological managements remain symptomatic [31]. 
Thus, exercise interventions in HD may have a useful, adjunctive role in managing this 
condition. In view of the data presented here, exercise interventions may help in 
delaying the progression of motor deficits and improve independence by potentially 
addressing some physical impairments and limitations in activity. This in turn may have 
some economic benefits by potentially reducing the number of required medications and 
the number of visits to clinicians as well as delaying the need for nursing home 
admission. 
 
In addition to the above, the positive findings reported here about the potential benefits 
of exercise in HD has some implications on future therapeutic trials in this population. 
Firstly, in the light of data obtained from this study exercise can confound with the 
effects would be obtained from drug trials; thus future pharmacological studies need to 
control for the subject‟s level of physical activity and receipt of exercise prior and 
during the period of the study.  Secondly, future studies may need to examine the 
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combined effects of exercise training with the other potential therapeutic procedures in 
HD such as neural-transplantation; exercise training may be important to enhance 
recovery and functional gain following transplantation [317]. This is particularly 
important to be established in the HD population as evidence from animal models of 
HD [317] implies the need for task retraining following grafting.  
 
On the whole, the exercise programme in this study was perceived to be suitable. In 
particular, the exercise DVD was perceived to be a supportive mechanism in helping 
people with HD to engage in an independent home-based exercise programme. 
Although the home-based setting limits social interaction to some extent, the 
convenience of doing the exercises when one is able, not having to travel to an exercise 
facility may outweigh this limitation and possibly result in a reduction on direct costs to 
the patient [161].  It seems therefore that an innovation such as a DVD can play a 
supporting role in the provision of exercise interventions for this population, offering a 
choice in the way that exercises can be delivered outside of therapy sessions or between 
consultations. The developed DVD has the potential to provide a sustainable exercise 
intervention for people with HD, and may ultimately contribute to an integrated 
management service for people with neurodegenerative diseases, facilitating individual 
management of this disabling condition. Given that there are a number of factors that 
would impact on the adherence to an independent exercise programme in a home setting 
(Chapter 6); this study suggests that therapists should work in collaboration with 
subjects with HD and their carers, evaluating their specific considerations on delivering 
such an exercise DVD to ensure feasibility and acceptability. 
 
8.2 Recommendations and directions for future work  
8.2.1 Issues related to methods and study designs 
In the realm of outcome measures, this study additionally examined the psychometric 
properties of the core set of outcomes across the spectrum of the disease. Within this 
context, data and methods presented here revealed 3 main issues that need to be 
addressed in future research. Firstly, in this study, the stride time coefficient of variation 
was calculated based on pooled left and right strides. This method was used mainly to 
allow for adequate comparisons between data obtained from this study and data 
reported in previous HD research where which a similar method for gait variability 
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calculation was used [41, 42, 106, 107]. One of the concerns, however, regarding the 
use of this method (i.e. the use of averaged data from right and left strides) is the 
possibility that effects reported here are inflated due to the duplication of steps in 
consecutive strides. Thus, future studies needs to calculate effects on this parameter 
using data from right and left strides separately. Another approach that could be used in 
future research to calculate gait variability is to use step time CV instead of stride time 
CV. Step time CV can be calculated using the standard deviation from the residuals of 
each step around the mean of its respective limb. The advantage of such approach is that 
it allows an increased number of steps to be included in the analysis; thus providing a 
more precise measure of gait variability but at the same time ensures that there are no 
duplications of steps included in the calculation of the gait variability parameter [207].  
 
Secondly, taking into account the test re-test reliability, a number of outcomes which 
included the TUG and the total score of the RT and SRT were susceptible to outliers 
(i.e. the difference score was large in a few cases relative to the difference score 
observed in the other cases). The presence of these outliers may have influenced the 
results by inflating the magnitude of variability calculated for these outcomes. 
Interestingly, the existence of these outliers was related to an observation of bias toward 
the larger values; in these measures there was a tendency that differences increases 
when average score increased. The bias toward larger values was also observed on the 
FSST. Larger value on the TUG and the FSST indicates more impairment. The bias 
toward larger values on these measures, therefore, suggests that movement disorders in 
the more impaired individuals would be expected to result in an increased variability of 
performance; hence reducing the reliability of repeat measurements. Thus, replicating 
this part of the study (i.e. reliability study) using a larger sample of subjects and 
stratifying subjects into groups by the stage of the disease to create sample homogeneity 
is warranted. Test re-test reliability studies with larger samples by the stage of the 
disease will help further defining the Minimal Detectable Changes (MDC) of the 
outcome measures that were used in this study and in generalizing the findings into the 
HD population.  
 
Thirdly, in the realm of test-retest reliability, it should be noted that in this study all the 
subscales of the SF-36 were susceptible to a high degree of variability on repeated 
assessment. The source of variability reported here in the SF-36 subscales is not clear. 
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However, the occurrence of response shift is one possibility [118]. Response shift is 
common in populations in which individuals live with a chronic illness [266] as it is the 
case in HD. The possibility of response shift bias in HD is important in two lines of 
investigation. Observational studies of the natural course of HD may benefit from 
studying response shift explicitly. Such studies could describe whether and how quality 
of life change over time and how response shift affects these changes. Response shift 
may also be important in the design of future clinical trials in HD; the classic pre-test/ 
post-test designs may mask treatment effects if a subject‟s standard for rating of quality 
of life shifts over time.  Designs that accommodate potential response shift may need to 
be considered in this population [318]. However, the concept of response shift warrants 
particular investigation in HD in the first instance. 
       
In addition to the above, it should be noted that in the intervention study (Chapter 5), 
there were indications of regression toward the mean (RTM) in a number of outcomes. 
This included the primary outcome (i.e. gait variability) and some of the secondary 
outcomes such as the modified UHDRS-motor score (mMS); in each of these outcomes 
some subjects in the control group whose baseline performance was good tended to 
have unusual deterioration at the follow-up. Although in this study the use of ANCOVA 
accounts in part for the potential of RTM (i.e. ANCOVA has good statistical power to 
adjust subject‟s follow-up scores according to their baseline measurements) [290], it is 
important to highlight the possible impact that RTM may have on future studies.  The 
main concern regarding RTM is that natural variation in repeated data can look like a 
real change. Thus, future work needs to take the potential of RTM into account at the 
study design stage. One of the possible approaches that can be adopted in future studies 
to minimise the possible effect of RTM is to include two or more baseline 
measurements. The RTM effect is thought to decrease with multiple measurements 
[290, 319]. Thus the advantage of taking extra-baseline measurements is that it gives 
better estimates of each subject true score before the intervention as well as a better 
estimate of within subject variation [319].   
 
8.2.2 Issues related to evaluating mobility-related outcome measures 
In the realm of outcome measures, this study examined the psychometric properties of 
the core set of outcomes in a group of pre-manifest HD. The results presented here 
                                                       8. Clinical implications, recommendations &conclusions 
 
257 
 
suggest that deficits in pre-manifest HD may be well represented by measures at the 
activity level of the ICF model. The PPT as well as the vast majority of the mobility 
measures which included the gait variability measure, the FSST, the CSST and the peak 
activity index were all sensitive to early changes in the pre-manifest HD and were 
considered to be highly repeatable. These findings are important and have major 
implications for future research as these outcomes have the potential to serve as  tools to 
monitor disease progression in HD. Further validation of these outcomes using 
longitudinal design however is required. Furthermore, due to the sensitivity of these 
outcomes to early changes in HD, they have the potential to measure change in response 
to exercise interventions in the pre-manifest stage. Further validation, however is 
required in future research.  
 
Whilst the vast majority of the outcomes in this study that were sensitive to changes in 
the pre-manifest HD were at the activity level, it is still not known what optimal 
outcomes would represent impairments and participation restrictions at the pre-manifest 
stage of HD. In terms of impairments, this study focused on evaluating measures of 
physical impairments such as balance and muscle strength. There is some evidence to 
suggest that subtle changes in these categories (i.e. balance and muscle strength) are 
present in pre-manifest individuals [92, 97, 98] and therefore further investigations 
validating outcomes that reflect these constructs and their relations to function at this 
early stage of the disease are required.  Furthermore, subtle cognitive impairments that 
develop at the pre-manifest stage also need to be considered when validating functional 
outcomes in future studies. In fact, the combination of the subtle physical and cognitive 
changes is the one that may explain the early limitations on the functional abilities such 
as walking, as seen in this study. Future studies should provide in depth evaluation of 
the interaction between physical and cognitive impairments and their relationships to 
the activity and participation levels in the pre-manifest HD.    
 
The data presented in chapter 4 confirm that the outcomes were sensitive to changes in 
the manifest HD at each of the levels of the ICF. Taking into account the test re-test 
reliability values and the calculated SEM as well as the responsiveness data to the 
exercise intervention (Chapter 5), balance is best assessed with the BBS, and activity 
limitations are well represented by measures of gait speed and gait variability as well as 
the CSST and the PPT. The psychometric properties of these measures suggest that they 
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are potentially useful outcomes to detect change over time and in response to exercise 
interventions in individuals with manifest HD.  
 
Overall, from the range of outcomes evaluated here, gait variability appears to have the 
most potential to serve as a useful primary outcome in future exercise studies, both in 
manifest and pre-manifest HD. As indicated earlier, this measure is a key indicator of 
general mobility in HD [38, 93] and it is clear from the data presented here that gait 
variability has better sensitivity than the other measures of gait in capturing early 
mobility deficits in HD and in detecting responses to an exercise intervention. 
Furthermore, as gait variability seems to reflect multiple components of physical 
impairments, activity limitations and participation restrictions. Measures at each of the 3 
levels of the ICF demonstrated correlations with gait variability; measures of balance, 
the other mobility measures including the levels of community walking and the measure 
of health-related quality of life correlated highly with gait variability. Gait variability, 
therefore, can be used as a summary measure that reflects each of the 3 domains of the 
ICF. Thus its use as a primary outcome in future exercise studies in HD is 
recommended. 
 
Within the context of outcomes at the participation level (i.e. health-related quality of 
life measures), the SF-36 was the only outcome used in this study to evaluate quality of 
life. Data presented here demonstrated that SF-36 is susceptible to floor and ceiling 
effects across the spectrum of the disease. The SF-36 is a generic measure of health-
related quality of life, and possibly may not have sufficiently captured disease-specific 
aspects of quality of life.  Indeed, there is increasing recognition of the poor relevance 
of the SF-36 to quality of life recording in HD [117], and work is currently being 
undertaken to validate a more relevant disease-specific quality of life scale HDQoL 
[318]. Items of this developed scale have been generated from the perspectives of 
people with HD about disease related problems of daily living and therefore it is likely 
to be more sensitive than generic scales in capturing the true impact of HD. 
Furthermore, the scale has disease-specific physical and functional domains which 
provide the suggestion that it may allow the impact of exercise interventions that aim to 
improve function to be appropriately and holistically evaluated. Thus future research 
needs to consider using such a disease-specific health related quality of life measure in 
conjunction with a generic measure such as the SF-36.  
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8.2.3 Issues related to evaluating exercise interventions  
This study was in the exploratory phase, where the feasibility, acceptability and 
potential benefits of a home- based exercise intervention in HD were evaluated; whilst 
the small sample size does prevent generalization of the results to the HD population at 
large, the approach taken here was in line with the staged approach advocated in the 
Medical Research Council (MRC) framework for developing and evaluating complex 
interventions [69, 70]. This step is essential before conducting large-scale trials and the 
encouraging findings reported here suggest that larger studies are now indicated. 
Indeed, future studies with larger populations should replicate findings from this study 
in other contexts and explore variations in intensity, duration as well as mode and type 
of exercise as part of the exploratory phase before conducting definitive randomised 
controlled trial. Within the MRC framework [69, 70] a definitive randomized clinical 
trial should not be undertaken until a variety of doses of therapy are examined at the 
exploratory stage. This will help in fully refining and defining the variables of 
interventions that can be evaluated and compared in definitive randomised clinical 
trials. Furthermore, the best timing of applying exercise interventions as well as effects 
on both motor and non-motor symptoms in future research should also be examined 
along with mechanistic evaluations as part of this exploratory phase. A number of future 
exploratory studies are proposed below to clarify the role of exercise interventions in 
people with HD.  
 
In terms of the duration of exercise, whilst this study demonstrated that 8 weeks of 
structured exercise programme influenced mobility aspects in subjects with early to mid 
stage HD, the descriptive data from the 16 week follow up suggests that participants 
who continued exercising after the first eight weeks had a greater overall improvement 
in their gait variability. Although only descriptive data, this provides an indication that 
benefits from exercise in HD may be short lived if not maintained. Thus future studies 
exploring the long term effect of exercise interventions with variations in exercise 
duration are needed. 
   
In terms of mode of exercise delivery, this study focused on an independent home-based 
exercise programme. The advantages of such a programme are the convenience of doing 
the exercises when one is able without having to travel to an exercise facility. The 
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disadvantages, however, include loss of the social aspects of exercising in a group and 
subjects having to be self-motivated. These aspects, along with the suggestion that 
people with HD would have different preferences for the location and the way of 
exercising [80], provide indications that the feasibility of other modes of exercise in HD 
such as exercise in groups or an independent exercise programmes in a gym setting 
needs to be examined in future research. Furthermore, it should be noted that there were 
barriers to participation in an independent exercise programme that were reported here 
and that safety can be an issue when performing exercises alone if one‟s symptoms are 
more advanced. Thus some subjects with HD would benefit from an intensive, one to 
one training exercise programme that is supervised by a therapist. This may take the 
form of a supervised exercise programme carried out in the participant‟s home or at the 
clinic. In such cases individual progression specific to the individual‟s particular clinical 
and social needs can be accommodated. Such a method of service delivery where closer 
supervision is provided needs further investigation in this population.  
 
Within the realm of mode of exercise and considering the facilitators that were 
identified here, self efficacy was a main factor that influenced motivation and 
consequently the initial adoption of the exercise programme and the adherence to it. 
Strategies such as the weekly phone calls and the initial home visit were perceived to be 
important to build up participants‟ confidence and self efficacy and in turn to motivate 
them to adhere to the exercise programme in a home setting. Future research needs to 
extend these findings by exploring and examining the most effective strategies to 
improve self efficacy and other important aspects that would facilitate behavioural 
change in terms of exercise adoption and adherence in HD. For this purpose, it is 
advocated that interventions in future research be theory based. Self determination 
theory (SDT) [320] is a model that has been shown to be useful in enhancing physical 
activity motivation in healthy adults and can be used in future exercise studies in HD. 
SDT focuses on the degree to which an individual‟s behaviour is self-motivated and 
self-determined; thus behavioural change is made possible and maintained. In the 
context of exercise adherence, the SDT suggests that self efficacy and autonomy need to 
be fulfilled in order to enhance self-determined motivation [320]. This means that 
people need to feel a sense of choice with respect to their exercise goals (autonomy); 
they need to understand these goals and feel that they can be effective in carrying out 
the necessary actions to achieve these goals (self-efficacy). As per the data obtained 
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from this study, addressing barriers and facilitators and eliciting management strategies 
as well as promoting competence possibly via conducting regular contacts with subjects 
are strategies that have the potential to be used in future research to enhance autonomy 
and self-efficacy. These strategies are concordant with Motivational Interviewing (MI) 
[305], a counselling method that aims to promote behaviour change. MI involves 
avoiding controlling behaviours such as direct persuasion for change. Instead, this 
approach seeks to empower participants by eliciting personal reasons for change, 
addressing barriers, helping participants to become aware of discrepancies between 
goals and actions and supporting self efficacy. MI therefore can be seen as a method of 
promoting self determined motivation in and may offer a practical strategy for 
promoting adherence to exercise interventions in future investigations.  
 
An important finding from this study was that the successful involvement of the carer 
was a key to the successful of the programme. Participants needed their carers to 
perform their exercises and to motivate them to adhere to the exercise programme. The 
main reason cited for non-adherence was the lack of the support from the carer or the 
carer-participant relationship. Thus future research need to focus on finding strategies to 
maximize the successful engagement of the carers in supporting people with HD in 
performing their exercises particularly when an exercise programme is applied at home 
setting. In the light of results presented here and taking into account self-determination 
theory (SDT); the role of the carer in future research needs to be considered as an 
extrinsic source of motivation and an important autonomy supportive mechanism. 
According to SDT, a person will develop and maintain more self-determined motivation 
when the personal context around them is autonomy supportive [320]. The idea of 
autonomy support refers to eliciting and acknowledging individuals‟ perspectives while 
minimizing pressure and control [321]. Thus future research needs to examine effective 
strategies for how the carers can successfully support the subject with HD to engage in 
independent exercise programmes whilst at the same time minimizing conflict and 
control. For example, a behavioural management technique, which has been used 
successfully in supporting carers of people with Alzheimer's Disease (AD) to encourage 
patients‟ engagement in home-based exercise programme, could be explored in people 
with HD [74]. The concept of this technique is based on teaching carers a problem-
solving approach with the aim of motivating the patient to exercise and at the same time 
to avoid potential conflicts. Within this technique, carers are provided with skills on 
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how to identify and modify precipitants of participants‟ distress and behavioural 
problems that would impact on daily function and would adversely affect the subject-
carer interactions. Additionally, carers using this technique can be given instructions 
about how to reduce the occurrence of these problems while also gaining skills on how 
to offer choices and options, supporting the subject‟ and making the exercise experience 
fun and enjoyable. Thus more research investigating the potential role of this approach 
on helping the carer to support people with HD to engage in an independent programme 
is warranted.     
 
In terms of exercise type, this study demonstrated the benefits of a structured exercise 
programme that involved mainly the practice of task-specific activities which aimed to 
improve balance and functional activities in HD. However, it remains to be seen 
whether other types of exercises, such as aerobic as well as resistive exercises, can be 
beneficial in HD without causing undue harm. Aerobic exercises, in other neurological 
disorders, have been found to have a positive effect on motor and non-motor symptoms 
including cognitive functions [322, 323]. For example, the effect of aerobic exercise, 
compared with stretching, in participants with stroke was recorded on several measures 
of cognitive function in a study by Quaney et al [324]. In this study, participation in 
regular aerobic exercise resulted in improvement in speed of information, motor 
learning and implicit learning as measured using the serial reaction timed task (SRTT) 
and predictive grip force modulation (PGFM) with the less-affected hand. Similarly, 
significant improvements in the Mini Mental State Examination (MMSE) score were 
reported in a group of people with dementia after participation in an exercise 
programme with aerobic and resistive components over 12 months. The improvements 
in cognitive function reported in this study were also accompanied by improvements in 
the activities of daily living, cardiopulmonary function, endurance and balance. In 
another study, participation in 30 minutes of exercise training that included both aerobic 
and flexibility components significantly decreased depressive symptoms, improved 
health-related quality of life and decreased the number of hospitalisations among people 
with Alzheimer‟s disease (AD) [74]. Taking into account the available evidence from 
other populations about the benefits of aerobic exercises, their potential effects in HD 
warrant further investigation. This is particularly important considering the growing 
body of literature which suggests that exercise which is predominantly aerobic (unlike 
the intervention in this study) may have a protective effect by stimulating brain 
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perfusion and improving neurovascular integrity [325]. There is a need, therefore, for 
well designed trials to establish whether aerobic exercise is a useful intervention to 
improve or maintain motor and non-motor function in HD. This could be a vital area for 
investigation in this devastating long-term neurological condition where, to date, no 
disease-modifying treatment and very little in the way of symptomatic treatment is 
available.  
 
 Resistance training is another type of exercise that needs further investigation in people 
with HD in future studies. In this study, although the exercise programme included 
general strengthening exercises, it did not specifically target muscle strengthening. 
Progressive resistance exercise training was not included in the exercise programme 
which in part may explain the lack of significant improvements in muscle strength in 
this cohort. Progressive resistance training has generally been shown to be effective in 
the elderly and other neurodegenerative diseases such as PD in improving muscle 
strength and demonstrated a parallel effect in improving mobility [125, 326]. Resistance 
training may be equally beneficial in improving muscle strength in HD and therefore 
further investigations in this field are required.  
 
In addition to the potential role in improving function, resistive training may also 
impede the noticeable decline in bone integrity observed in individuals with HD. Recent 
investigations have reported low bone mineral density (BMD) in individuals with HD, 
from an early stage of the disease, at the hip and lumbar spine which may lead to 
osteoporosis with the progression of the disease [327]. The aetiology of the lower BMD 
status in HD is still unknown; however it is likely to be related to performing lower 
levels of physical activity as seen in the data presented here. Whilst, to the knowledge 
of the researcher, investigations are lacking in the literature regarding bone health 
outcomes and exercise in HD, there is a strong rationale for why resistive exercises in 
particular need to be considered. According to the Wolff‟s law, loads applied to the 
bone via the muscular system in addition to loading the axial skeleton, which can be 
accomplished through resistive exercise, have a direct impact on bone formation and 
remodelling [125]. Furthermore, the American College of Sports Medicine (ACSM) 
maintains the efficacy of weight bearing exercise programmes in promoting bone health 
across the life-span [328]. Such programmes are widely used in the prevention and 
treatment of osteoporosis in healthy adults and in adults with neurodegenerative disease 
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such as PD [125, 329]. People with HD may stand to derive equal benefit from resistive 
exercise; however, these potential benefits in improving bone health parameters remain 
to be determined. 
 
In term of the best time of applying exercise interventions in HD, future exercise studies 
may need to be initiated in the pre-manifest HD stage. Such studies would aim to target 
motor deficits early in the disease life cycle, before they begin to impact on a person‟s 
ability to participate in the community. This is particularly important as there is a 
growing body of evidence suggesting that exercise has a neuroprotective effect in other 
neurodegenerative disease such as AD. A meta-analysis of prospective cohort studies 
suggests that participation in regular physical activities reduces the risk of dementia and 
Alzheimer‟s disease by 28% and 45% respectively [330]. These findings along with a 
report that a passive lifestyle may potentially influence symptom onset in patients with 
HD [67] and inferences made from HD animal models suggesting that exercise may 
have direct effects on disease progression and plasticity, provides theoretical support for 
exercise interventions in the pre-manifest stage. Thus, future studies examining the 
effects of exercise in pre-manifest HD and their impact on disease onset and disease 
progression are indicated.  
 
Investigation of the potential mechanisms underlying the functional gains reported in 
this study is clearly required. A number of studies have shown that in both intact and 
brain damaged rodents, structured exercise appears to drive a set of coordinated central 
nervous system changes, including circuit reorganization [331]. Studies in animals with 
cortical lesions have shown that repetitive performance of challenging motor tasks 
promoted neuroplastic changes within the cortical and sub-cortical areas of the brain 
through increased synaptogenesis [332, 333], and suggested that this may underlie the 
reported improvements. The increased synaptogenesis, observed with the performance 
and acquisition of motor tasks, has been related in some studies to the increase of 
synthesis and release of proteins that promote neuronal survival [334]. Although the 
specific proteins required for such plasticity are yet to be fully elucidated, brain-derived 
neurotrophic factor (BDNF) increases in an activity-dependent manner making it a 
natural candidate to mediate the benefits of exercise on brain health [61]. Furthermore, 
BDNF is known to be important for the survival of striatal neurons [335]. BDNF levels 
were specifically shown to be rescued in the striatum of R6/1 HD mice housed in an 
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enriched environment, and were associated with a delayed onset of HD-like symptoms 
[64].     
 
8.3 Conclusions 
The main aim of this research was to evaluate the feasibility, acceptability and potential 
benefits of a home-based exercise programme in people with early to mid-stage HD. To 
the knowledge of the researcher, this is the first systematic controlled trial of a defined 
exercise intervention in people with HD. There was no safety concerns related to the 
exercise programme in this sample. In addition, the study demonstrated that a home-
based exercise programme was feasible, and that most individuals demonstrated 
excellent adherence to the programme. The latter is important, as reduced motivation is 
one of the core features of HD [31], and the capacity of this patient group to adhere to 
an exercise programme was previously unknown.  Furthermore, this short-term exercise 
programme also resulted in significant at the first follow-up, in a range of measures at 
the body structure and function as well as activity levels of the ICF model. This 
included the primary outcome of gait variability and secondary measures of gait speed, 
balance, mobility and community walking as well as functional performance in ADL. 
Given the degenerative nature of HD and the relatively short duration of the exercise 
intervention used in this study, this is clearly an important and highly encouraging 
finding.  
 
The significant improvement in the primary outcome (i.e. gait variability) is particularly 
important. In exercise trials, it is important that the deficits targeted by the intervention 
are not the primary outcome [138]. In this study, although a walking component was 
part of the intervention, there was no specific gait training protocol incorporated into the 
exercise programme and this leads to the suggestion that the improvements reported 
here can be considered a response to the intervention per se. 
 
Although the exercise programme in this study was found to significantly improve 
measures at the physical impairment and activity levels, there was no significant 
improvement in the used measure at the participation level. The only outcome used to 
evaluate participation was the SF-36. It is possible that this result is related to the 
susceptibility of the SF-36 subscales to a certain degree of variability on repeated 
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testing. Variability of a measure on repeated testing decreases the power of a study to 
detect differences between groups because of the random error of measurement that 
causes an increase in variance. It should be noted however, that large effect sizes were 
observed on the physical function subscale and the aggregate score of the physical 
domain (i.e. physical summary component). Taking into account the magnitude of the 
improvement on the physical functioning subscale and the physical summary 
component of the SF-36 (i.e. the large effect sizes on these subscales) and the 
perceptions of the intervention reported by participants (Chapter 6 of process 
evaluation), lack of significant improvements in these subscales is likely to be related to 
the small sample size in this study. It can also be related to the use of SF-36 as a generic 
measure of health-related quality of life. The evaluation of the impact of exercise 
interventions on health-related quality of life in this population with a larger sample and 
with the use of disease-specific quality of life measures in conjunction with the SF-36 is 
required in future studies.  
 
This work is not without limitations. The sample size was small and the main assessor 
in this study was not blinded to group allocation. However steps were taken to blind as 
far as possible and limit any assessor bias (for example by employing blinded video-
rating and further more by the use of an automated process for determining gait 
parameters). There were also some observable differences noted on some of the 
outcomes at baseline. In addition, the potential of regression toward the mean (RTM) 
was noted on some of the outcome measures. To account for these limitations (i.e. 
differences at baseline and RTM in the analyses, ANCOVA was used in line with the 
CONSORT guidelines [269] and further individual responses were illustrated to aid 
interpretations of the data. However, it is important to highlight the potential impact that 
such limitations namely baseline differences (people with different levels of 
impairments at baseline may respond differently to the applied intervention) may have 
on future trial outcomes. To account for baseline differences, future studies may need to 
consider evaluating the effects of exercise interventions according to the stage of the 
disease to ensure homogeneity of groups at the outset, and further to evaluate how 
people with HD at different stages of the disease respond to exercise interventions. In 
addition, to minimise the potential effect of  RTM, future studies may need to consider 
the involvement of multiple baseline measurements[290, 319].   
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The small sample size in this study does prevent generalization of the results to the HD 
population at large however the approach taken here is in line with the staged approach 
advocated in the Medical Research Council Framework for Developing and Evaluating 
Complex Interventions [69]. Establishing, safety and feasibility of an exercise 
intervention, estimating effects and piloting potential outcome measures are all essential 
steps before large scale definitive trials can be considered. Thus, findings from this 
study prepare the ground for future detailed exercise studies in HD. Summary of 
directions for future research based on the data presented here is provided in Figure 8.1.  
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Figure 8.1: Summary of proposed future studies in line with the Medical Research Council 
(MRC) framework for developing and evaluating complex interventions [69].  
 
 
Figure 8.1: Directions for future research includes the following: 1) modelling process to 
refine the intervention used in this study ) feasibility and piloting to additionally pilot 
outcomes and examine feasibility and effects of variations of exercise dose and type on 
motor and none motor symptoms.    
 
 
In the realm of outcome measures, findings from this study suggest that gait variability 
show the most promise to serve as a primary outcome in future exercise studies both in 
manifest and pre-manifest HD. In addition, this study suggests that outcomes that were 
sensitive to changes across the spectrum of the disease and that were highly repeatable 
on repeated assessment (i.e. Physical Performance Test and Chair Sit to Stand Test) 
have the potential to measure responsiveness to change in exercise studies and therefore 
they need to be considered in future work. Further investigations on a larger sample, 
however, are required to refine the MDC values calculated for these measures.  
 
Within the context of outcomes, all measures related to quality of life that were 
recorded in this study were highly variable on repeated assessment. Shift response is 
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one possible mechanism [118] that would explain the high variability and as this  may 
have implications on the designs of future clinical trials, future work needs to 
adequately evaluate of whether shift response occurs in HD and how it would affect the 
assessment of health-related quality of life over time in this population.  
 
In term of exercise intervention, one of the main findings of this study is that the 
successful involvement of the carer was a key to the success of the programme. Self 
efficacy and motivation were two main determinants for engagement in an independent 
exercise programme. These findings highlight the importance of further exploring 
strategies that would enhance self management and ensure behaviour-change in term of 
adherence to exercise programme as this (i.e. adherence) is very relevant to ensure 
efficacy of an intervention in future work [336]. In line with the MRC framework for 
complex interventions, the next step of the research presented here, would be to focus 
on further modelling the intervention that was used in this study for further future 
evaluation. To achieve this, a series of qualitative work in form of focus groups and 
interviews with subjects with HD and their carers needs to be conducted with the aim of 
refining the theoretical framework underpinning the intervention and determining 
contents and structures needs to be incorporated in behavioural techniques to optimize 
subject‟s self efficacy and motivation as well as the successful involvement of the carer.     
          
In conclusion, this study shows the potential of exercise as a therapeutic intervention to 
improve mobility in people with HD and justifies further work to evaluate the effects of 
exercise in this population. Given the inferences made from animal models suggesting 
that exercise may have direct effects on disease progression and plasticity [65, 66] and 
the fact that advances in HD are likely to have implications for other neurodegenerative 
conditions [337], results from this study are important and provide a landmark for future 
more extensive studies. Future work with a larger sample should replicate this study to 
confirm findings and additionally explore variations in mode, dose and type of exercise. 
Examining effects on both motor and non-motor symptoms along with mechanistic 
evaluations is now indicated. It remains to be seen whether other types of physical 
interventions, such as aerobic exercise are feasible and can be beneficial in HD without 
causing undue harm. Aerobic exercise in other neurodegenerative disease, such as 
Alzheimer‟s disease, is suggested to have a positive effect on motor and non-motor 
symptoms including cognitive functions [337] and may have a protective effect by 
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stimulating brain perfusion and improving neurovascular integrity [325]. This could be 
a vital area for investigation in this long-term neurological condition where to date no 
disease-modifying treatment is in existence. 
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10 Appendix 1: Information sheets of the study and consent forms 
 
Participant information sheet 
(Healthy group) 
 
‘’ A study of movement deficits and physiotherapy in people with Huntington’s 
disaese’’   
 
You are being invited to take part in a research study that is investigating physiotherapy 
for people with Huntington‟s disease (HD). Before you make a decision, it is important 
that you understand why the research is being done and what it will involve.  
 
Part 1 of this information sheet tells you the purpose of this study and what will happen 
if the participant takes part. Part 2 gives you more detailed information about the 
conduct of the study.  
 
Please take the time to read the following information carefully and discuss it with 
others if you wish. 
 
PART 1 
 
What is the reason for the study? 
People with Huntington‟s disease (HD) may have problems with gait and balance 
(which contribute to mobility difficulties) over the disease period. Little is known about 
when these impairments might develop and what influence their development. 
Physiotherapy is presumed to play a role in assisting people with HD to enhance their 
balance and improve their mobility, but participation in a hospital or clinic-based 
physiotherapy is sometimes difficult to coordinate as it needs frequent trips outside the 
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home. Home-based interventions may be easier for people with HD to be involved in. 
However, research into the delivery of such home-based programs is limited. A better 
understanding of the factors influencing gait impairments (across the continuum of the 
disease) as well as the factors influencing success of home based intervention may help 
us provide an improved standard of care to people with HD.  
 
What is the purpose of the study? 
The purpose of this study is to evaluate home-based physiotherapy-led interventions in 
individuals with Huntington‟s disease (HD). A further purpose of this study is to 
investigate factors that influence gait impairments in HD across the disease continuum. 
 
Why was I chosen to take part in this study? 
You have been invited to participate in the study as we are recruiting a group of 
individuals who are healthy and have not been diagnosed with HD. It is important to 
create a healthy comparison group in order to investigate the differences between 
people with HD and those without HD. 
 
Do I have to take part? 
There is no obligation to take part in the study. We will describe the study and go 
through this information sheet, which we will then give to you. We will then ask you to 
sign a consent form to show you have agreed to take part. If you do decide to take part 
you are free to withdraw at any time and without giving a reason.  
 
What will happen to me if I take part?  
If you would like to take part, we will arrange a suitable time for you to participate. This 
will be at your convenience. You will be asked to sign a written consent form indicating 
that you are happy to take part in the study and you will then be asked:  
1- To visit the Research Centre for Clinical Kinaesiology (RCCK) for assessments. The 
RCCK is based in the Heath Campus, Department of Physiotherapy, Cardiff University.  
The total duration of the assessment visit should not exceed 2 hours. During the 
assessment visit, you will be asked about your medication use, your living 
circumstances and any falls you might have had in the past 12 months. At the 
assessment visit we will record your weight, height, balance, strength level, muscle 
flexibility level, mobility level and walking characteristics.  We will ask you to wear a 
small device on your waist while you perform the following tasks:  
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a. Walk on a carpet that is embedded with sensors that will enable us to evaluate 
your walking. 
b. Perform a number of movements while measurements are being made. These 
movements include testing of strength of lower limb muscles, standing up, 
standing quietly with eyes open and closed, standing placing one foot in front of 
the other, and walking. 
c. As part of the assessment you will be asked to complete a questionnaire about 
your general physical functionality and general health perception.  
Note: A video camera will be used to video tape the assessment sessions.   
 
2- You will be requested to participate in monitoring of your general mobility.  
You will be asked to wear two activity monitors at home. You will be asked to wear the 
monitors 8 consecutive days and not to remove the sensor except for bathing and sleep. 
At the same time you will be asked to report if you have any falls and comment on the 
wearability of the monitors.  
 
Expenses: 
There will be no special payment for your involvement in this study; however we will 
refund your travel and parking costs when attending research assessments.    
 
What are the possible benefits of taking part? 
There are no specific benefits to you in taking part in this study however, the results of 
this study may help us to provide better physiotherapy treatment in the future for people 
with HD. 
 
What are the possible disadvantages and risks of taking part? 
The measurements to be taken are routinely used in people with neurological 
conditions; however any testing is not without some risk. The proposed clinical 
assessment is however unlikely to cause undue stress to you. The care and comfort will 
be ensured at all times. Before and during the study you will be given the opportunity to 
discuss any concerns with the researchers in private.  
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What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in 
part 2.  
 
What happens when the research study stops? 
After you have participated in the study you are still free to contact any of the 
researchers with any question or queries you may have regarding the study. If you are 
interested in the data collected during your participation we would be happy to send you 
a report. 
 
Confidentiality- Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
What if you would like extra information or independent advice about 
participation in research? 
You are free to contact the researchers at the contact details provided at the end of this 
letter if you would like more information. Alternatively, information on taking part in 
Clinical Research can be obtained from the UK Clinical Research Collaboration 
(UKCRC). This organisation provides independent advice and information on 
participating in clinical research. Further details, including access to a patient leaflet 
concerning clinical trial involvement, can be obtained from the UKCRN website: 
www.ukcrc.org/publications/informationbooklets or by emailing: info@ukcrn.org.uk 
 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision.  
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PART 2 
 
 
What will happen if new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, 
we will tell you and discuss whether you should continue in the study. If you decide to 
continue in the study we may ask you to sign an updated consent form.  
 
What will happen if I don’t want to carry on with the study?  
If you withdraw from the study, we will destroy all your identifiable samples, but we 
will need to use the data collected up to your withdrawal. You are free to withdraw from 
the study at any time without giving any reason.  
 
What if there is a problem? 
If you are harmed by taking part in this research study, there are no special 
compensation arrangements. If you are harmed due to someone‟s negligence, then you 
may have grounds for a legal action but you may have to pay for it. Regardless of this, 
if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the study, the normal National Health Service and 
University complaints mechanism should be available to you.  
 
Confidentiality- will my taking part in this study be kept confidential? 
We would like to reassure you that your personal details would be kept strictly 
confidential. No one, except the named investigators would have access to these details 
and no identifying details would appear in our published results.  
 
What will happen to the results of the research study? 
The results of the study may be presented at conferences and published in medical or scientific 
journals. If you would like, we can inform you of where you can obtain a copy of the published 
results. You would not be identified in any of the reports. 
 
Who is organizing and funding the research? 
The study is being organized by the Department of Physiotherapy, School of Healthcare 
Studies, Cardiff University. The study will be run by Hanan Khalil in collaboration with 
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Dr Monica Busse, Dr Robert van Derusen, Dr Lori Quinn and Professor Anne Rosser. 
Part funding for this study is provided by a grant from the Paul Jeffery Waters fund. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, whose role it is to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given favourable opinion by Research and 
Development Committee and the South East Wales Research Ethics Committee as well 
as the joint Cardiff and Vale NHS Trust and Cardiff University Risk Review 
Committee.  
 
Further information and contact details 
If you have any questions or queries please don‟t hesitate to contact Hanan Khalil  using 
the contact information addressed below. 
Hanan Khalil 
Department of Physiotherapy, Cardiff University, Ty Dewi Sant, Heath Park, CF14 
4XNTel: 0292068773 
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Participant information sheet 
(HD pre-symptomatic group) 
 
‘’A study of movement deficits and physiotherapy  in people with Huntington's 
disease’’   
 
You are being invited to take part in a research study that is investigating physiotherapy 
for people with Huntington‟s disease (HD). Before you make a decision, it is important 
that you understand why the research is being done and what it will involve.  
 
Part 1 of this information sheet tells you the purpose of this study and what will happen 
if the participant takes part. Part 2 gives you more detailed information about the 
conduct of the study.  
 
Please take the time to read the following information carefully and discuss it with 
others if you wish. 
 
PART 1 
 
What is the reason for the study? 
People with Huntington‟s disease (HD) may have problems with gait and balance 
(which contribute to mobility difficulties) over the disease period. Little is known about 
when these impairments might develop and what influence their development. 
Physiotherapy is presumed to play a role in assisting people with HD to enhance their 
balance and improve their mobility, but participation in a hospital or clinic-based 
physiotherapy is sometimes difficult to coordinate as it needs frequent trips out side the 
home. Home-based interventions may be easier for people with HD to be involved in. 
However, research into the delivery of such home-based programs is limited. A better 
understanding of the factors influencing gait impairments (across the continuum of the 
disease) as well as the factors influencing success of home based intervention may help 
us provide an improved standard of care to people with HD.  
 
What is the purpose of the study? 
The purpose of this study is to evaluate home-based physiotherapy-led interventions in 
individuals with Huntington‟s disease (HD). A further purpose of this study is to 
investigate factors that influence gait impairments in HD across the disease continuum. 
 
Why was I chosen to take part in this study? 
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You have been invited to participate in the study as we are recruiting a group of 
individuals who have tested gene positive for the disease but are without clinical 
symptoms (pre-symptomatic HD). You will take part of the study that aims to 
investigate factors associated with gait impairments according to the disease stage. It is 
important to understand this component in pre-symptomatic HD. Understanding of gait 
pattern across the disease continuum will advance our understanding of mobility 
difficulties in this population and ultimately provide insight for therapeutic 
interventions. 
 
Do I have to take part? 
There is no obligation to take part in the study. We will describe the study and go 
through this information sheet, which we will then give to you. We will then ask you to 
sign a consent form to show you have agreed to take part.  Your decision will not affect 
your future care. If you do decide to take part you are free to withdraw at any time and 
without giving a reason.  
 
What will happen to me if I take part?  
If you would like to take part, we will arrange a suitable time for you to participate. This 
will be at your convenience. You will be asked to sign a written consent form indicating 
that you are happy to take part in the study and you will then be asked:  
1- To visit the Research Centre for Clinical Kinaesiology (RCCK) for assessments up to 
2 times over the study duration. The RCCK is based in the Heath Campus, Department 
of Physiotherapy, Cardiff University.  The total duration of each visit should not exceed 
2 hours.   
During the assessment visit you will be asked about your medication use, your living 
circumstances and any falls you might have had in the past 12 months. At the 
assessment visit we will record your weight, height, balance, strength level, muscle 
flexibility level, mobility level and walking characteristics. We will ask you to wear a 
small device on your waist while you perform the following tasks:  
a. Walk on a carpet that embedded with sensors that will enable us to evaluate your 
walking. 
b. Perform a number of movements while measurements are being made. These 
movements include testing of strength of lower limb muscles, standing up, 
 296 
 
standing quietly with eyes open and closed, and standing placing one foot in 
front of the other and walking. 
c. As part of the assessment you will be asked to complete a questionnaire about 
your general physical functionality and general health perception.  
Note: A video camera will be used to video tape the assessment sessions.   
2- You will be requested to participate in monitoring of your general mobility.  In 
between assessment visits you will be asked to wear two activity monitors at home. You 
will be asked to wear the monitors 8 consecutive days and not to remove the sensor 
except for bathing and sleep. At the same time you will be asked to report if you have 
any falls and comment on the wearability of the monitors.  
Expenses: 
There will be no special payment for your involvement in this study; however we will 
refund your travel and parking costs when attending research assessments.    
 
What are the possible benefits of taking part? 
There are no specific benefits to you in taking part in this study however, the results of 
this study may help us to provide better physiotherapy treatment in the future for people 
with HD. 
 
What are the possible disadvantages and risks of taking part? 
The measurements to be taken are routinely used in with neurological conditions; 
however any testing is not without some risk. The proposed clinical assessment is 
however unlikely to cause undue stress to you. The care and comfort will be ensured at 
all times. Before and during the study you will be given the opportunity to discuss any 
concerns with the researchers in private.  
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in 
part 2.  
 
What happens when the research study stops? 
After you have participated in the study you are still free to contact any of the 
researchers with any question or queries you may have regarding the study. If you are 
interested in the data collected during your participation we would be happy to send you 
a report. 
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Confidentiality- Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
What if you would like extra information or independent advice about 
participation in research? 
You are free to contact the researchers at the contact details provided at the end of this 
letter if you would like more information. Alternatively, information on taking part in 
Clinical Research can be obtained from the UK Clinical Research Collaboration 
(UKCRC). This organisation provides independent advice and information on 
participating in clinical research. Further details, including access to a patient leaflet 
concerning clinical trial involvement, can be obtained from the UKCRN website: 
www.ukcrc.org/publications/informationbooklets or by emailing: info@ukcrn.org.uk 
 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision.  
 
 
PART 2 
 
What will happen if new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, 
we will tell you and discuss whether you should continue in the study. If you decide not 
to carry on, your clinical care will not be affected in any way. If you decide to continue 
in the study we may ask you to sign an updated consent form.  
 
What will happen if I don’t want to carry on with the study?  
If you withdraw from the study, we will destroy all your identifiable samples, but we 
will need to use the data collected up to your withdrawal. You are free to withdraw from 
the study at any time and this will not affect your continuing medical care. 
 
 
 
 298 
 
What if there is a problem? 
If you are harmed by taking part in this research study, there are no special 
compensation arrangements. If you are harmed due to someone‟s negligence, then you 
may have grounds for a legal action but you may have to pay for it. Regardless of this, 
if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the study, the normal National Health Service and 
University complaints mechanism should be available to you.  
 
Confidentiality- will my taking part in this study be kept confidential? 
We would like to reassure you that your personal details would be kept strictly 
confidential. No one, except the named investigators, would have access to these details 
and no identifying details would appear in our published results.  
 
GP notification 
We do feel that it is important that your GP is kept informed. We would like to let 
him/her know if you agree to take part in the study and we will supply him/her with a 
copy of this information sheet. However, please let us know if you would prefer that 
your GP is not informed. 
 
What will happen to the results of the research study? 
The results of the study may be presented at conferences and published in medical or scientific 
journals. If you would like, we can inform you of where you can obtain a copy of the published 
results. You would not be identified in any of the reports. 
 
Who is organizing and funding the research? 
The study is being organized by the Department of Physiotherapy, School of Healthcare 
Studies, Cardiff University. The study will be run by Hanan Khalil in collaboration with 
Dr Monica Busse, Dr Robert van Derusen, Dr Lori Quinn and Professor Anne Rosser. 
Part funding for this study is provided by a grant from the Paul Jeffery Waters fund. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has 
been reviewed and given favourable opinion by Research and Development Committee 
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and the South East Wales Research Ethics Committee as well as the joint Cardiff and 
Vale NHS Trust and Cardiff University Risk Review Committee.  
 
Further information and contact details 
If you have any questions or queries please don‟t hesitate to contact Hanan Khalil using 
the contact information addressed below. Hanan Khalil Department of Physiotherapy, 
Cardiff University, Ty Dewi Sant, Heath Park CF14 4XN Tel: 02920687739 
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Participant information sheet 
(HD symptomatic group) 
 
‘’A study of movement deficits and physiotherapy in people with Huntington’s 
disease’’   
 
You are being invited to take part in a research study that is investigating physiotherapy 
for people with Huntington‟s disease (HD). Before you make a decision, it is important 
that you understand why the research is being done and what it will involve.  
 
Part 1 of this information sheet tells you the purpose of this study and what will happen 
if the participant takes part. Part 2 gives you more detailed information about the 
conduct of the study.  
 
Please take the time to read the following information carefully and discuss it with 
others if you wish. 
 
PART 1 
What is the reason for the study? 
People with Huntington‟s disease (HD) may have problems with gait and balance 
(which contribute to mobility difficulties) over the disease period. Little is known about 
when these impairments might develop and what influence their development. 
Physiotherapy is presumed to play a role in assisting people with HD to enhance their 
balance and improve their mobility, but participation in a hospital or clinic-based 
physiotherapy is sometimes difficult to coordinate as it needs frequent trips out side the 
home. Home-based interventions may be easier for people with HD to be involved in. 
However, research into the delivery of such home-based programs is limited. A better 
understanding of the factors influencing gait impairments (across the continuum of the 
disease) as well as the factors influencing success of home based intervention may help 
us provide an improved standard of care to people with HD.  
 
What is the purpose of the study? 
The purpose of this study is to evaluate home-based physiotherapy-led interventions in 
individuals with Huntington‟s disease (HD). A further purpose of this study is to 
investigate factors that influence gait impairments in HD across the disease continuum. 
Why was I chosen to take part in this study? 
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You have been invited to participate in the study as we are recruiting a group of 
individuals who have been diagnosed with HD.  
. 
Do I have to take part? 
There is no obligation to take part in the study. We will describe the study and go 
through this information sheet, which we will then give to you. We will then ask you to 
sign a consent form to show you have agreed to take part.  Your decision will not affect 
your future care. If you do decide to take part you are free to withdraw at any time and 
without giving a reason.  
 
What will happen to me if I take part?  
If you would like to take part, we will arrange a suitable time for you to participate. This 
will be at your convenience. You will be asked to sign a written consent form indicating 
that you are happy to take part in the study and you will then be asked:  
1- To complete a home-based physiotherapy exercise program for 8 weeks at a certain 
time point during the study.  The programme will comprise a series of strength, 
flexibility, balance and endurance exercises specifically tailored for people with HD. An 
exercise DVD as well as an educational booklet will be given to you to help you with 
completing the exercise programme. You will be asked to do the exercises at least 3 
times a week. The total duration of the exercises session will not exceed one hour. In 
addition to the performing the exercises from the DVD, you will be asked to undertake 
one of the exercises of your preferences or to undergo a walking program once a week 
for 30 minutes. With assistance from your main carer, you will be asked to keep a diary, 
indicating the days that you do the exercises and also noting any problems or general 
observations. We will visit you at home when you first start to do the exercises to 
ensure that you are managing them and after the initial visits, you will be telephoned 
weekly by the researcher to discuss the exercises. You will also be provided with a 
contact telephone number to speak to the researcher if you have any specific problems 
relating to the exercise programme.  
 
At the end of the exercise programme we will ask you to complete one short 
questionnaire about the performed exercises. Additionally, we will interview you to 
obtain your opinion about the involvement in the program. We will also ask that your 
main carer is present at the interviews to be able to give any additional input, if this is 
required. The interview will not last more than 30 minutes.   
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Conversations that take place during the interview and the weekly telephone calls will 
be audio recorded. The spoken words on the audio tapes will be converted into writing 
by transcription. The taped conversations will be destroyed on completion of 
transcription of the tapes. A copy of the transcript will be made available to you for 
additional comment.  
 
2- To visit the Research Centre for Clinical Kinaesiology (RCCK) for assessments up to 
4 times over the study duration. The RCCK is based in the Heath Campus, Department 
of Physiotherapy, Cardiff University.  The total duration of each visit should not exceed 
2 hours.   
During the first visit you will be asked about your medication use, your living 
circumstances and any falls you might have had in the past 12 months.  At each visit we 
will record your weight, height, balance, strength level, muscle flexibility level, 
mobility level and walking characteristics.  We will ask you to wear a small device on 
your waist while you perform the following tasks:  
a. Walk on a carpet that embedded with sensors that will enable us to evaluate your 
walking.  
b. Perform a number of movements while measurements are being made. These 
movements include testing of strength of lower limb muscles, standing up, 
standing quietly with eyes open and closed, and standing placing one foot in 
front of the other and walking. 
c. As part of the assessment you will be asked to complete a questionnaire about 
your general physical functionality and general health perception.  
Note: A video camera will be used to video tape the assessment sessions.   
3- You will be requested to participate in monitoring of your general mobility.  In 
between assessment visits you will be asked to wear two activity monitors at home. You 
will be asked to wear the monitors 8 consecutive days and not to remove the sensor 
except for bathing and sleep. At the same time you will be asked to report if you have 
any falls and comment on the wearability of the monitors.  
 
 
Expenses: 
There will be no special payment for your involvement in this study; however we will 
refund your travel and parking costs when attending research assessments.    
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What are the possible benefits of taking part? 
There are no specific benefits to you in taking part in this study however, the results of 
this study may help us to provide better physiotherapy treatment in the future for people 
with HD . 
 
What are the possible disadvantages and risks of taking part? 
The proposed clinical assessment is however unlikely to cause undue stress to you. The 
care and comfort will be ensured at all times. The proposed exercise program is low 
intensity and does not involve any heavy load bearing exercise or high intensity 
cardiovascular intervention and therefore poses minimal risk to you. You will be 
advised on recognition of any warning signs at which to cease the execution of exercise. 
You will be provided with a contact telephone number to speak to the researcher if you 
have any specific problems relating to the exercise intervention. If necessary you will be 
seen in the HD clinic for review. Before and during the study you will also be given the 
opportunity to discuss any concerns with the researchers in private.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in 
part 2.  
 
What happens when the research study stops? 
After you have participated in the study you are still free to contact any of the 
researchers with any question or queries you may have regarding the study. If you are 
interested in the data collected during your participation we would be happy to send you 
a report. 
Confidentiality- Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
What if you would like extra information or independent advice about 
participation in research? 
You are free to contact the researchers at the contact details provided at the end of this 
letter if you would like more information. Alternatively, information on taking part in 
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Clinical Research can be obtained from the UK Clinical Research Collaboration 
(UKCRC). This organisation provides independent advice and information on 
participating in clinical research. Further details, including access to a patient leaflet 
concerning clinical trial involvement, can be obtained from the UKCRN website: 
www.ukcrc.org/publications/informationbooklets or by emailing: info@ukcrn.org.uk.  
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision.  
 
 
PART 2 
 
What will happen if new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, 
we will tell you and discuss whether you should continue in the study. If you decide not 
to carry on, your clinical care will not be affected in any way. If you decide to continue 
in the study we may ask you to sign an updated consent form.  
 
What will happen if I don’t want to carry on with the study?  
If you withdraw from the study, we will destroy all your identifiable samples, but we 
will need to use the data collected up to your withdrawal. You are free to withdraw from 
the study at any time and this will not affect your continuing medical care. 
 
What if there is a problem? 
If you are harmed by taking part in this research study, there are no special 
compensation arrangements. If you are harmed due to someone‟s negligence, then you 
may have grounds for a legal action but you may have to pay for it. Regardless of this, 
if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the study, the normal National Health Service and 
University complaints mechanism should be available to you.  
Confidentiality- will my taking part in this study be kept confidential? 
We would like to reassure you that your personal details would be kept strictly 
confidential. No one, except the named investigators, would have access to these details 
and no identifying details would appear in our published results.  
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GP notification 
We do feel that it is important that your GP is kept informed. We would like to let 
him/her know if you agree to take part in the study and we will supply him/her with a 
copy of this information sheet. However, please let us know if you would prefer that 
your GP is not informed. 
What will happen to the results of the research study? 
The results of the study may be presented at conferences and published in medical or 
scientific journals. If you would like, we can inform you of where you can obtain a copy 
of the published results. You would not be identified in any of the reports. 
 
Who is organizing and funding the research? 
The study is being organized by the Department of Physiotherapy, School of Healthcare 
Studies, Cardiff University. The study will be run by Hanan Khalil in collaboration with 
Dr Monica Busse, Dr Robert van Deursen, Dr Lori Quinn and Professor Anne Rosser. 
Part funding for this study is provided by a grant from the Paul Jeffery Waters Bequest 
fund. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has 
been reviewed and given favourable opinion by Research and Development Committee 
and the South East Wales Research Ethics Committee as well as the joint Cardiff and 
Vale NHS Trust and Cardiff University Risk Review Committee.  
 
 
Further information and contact details 
If you have any questions or queries, please don‟t hesitate to contact Hanan Khalil using 
the contact information addressed below. Hanan Khalil, Department of Physiotherapy, 
Cardiff University, Ty Dewi Sant, Heath Park, CF14 4XN, Tel: 02920687739 
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Participant consent sheet 
Title of Project: A study of movement deficits and physiotherapy in people with 
Huntington’s Disease  
 (Healthy group) 
                                                                                                              Please initial box 
 
I confirm I have read and understood the information sheet, version 3.0 dated 14/05/09, for 
the above study and have had the opportunity to consider the information to ask questions 
and to have had these answered. 
 
I understand that my participation is voluntary and that I am free to withdraw at anytime 
without giving any reason, this will not affect my legal rights being in any way. 
 
I agree for the research assessments to be video taped.  
I understand that all information about me will be kept in a secure place and in a 
confidential way and destroyed once the study is completed. 
 
I understand that data will not be used for commercial purposes.  
I confirm that data from the study can be used in the final research report and other 
academic publications. I understand that these will be used anonymously and that no 
individual respondent will be identified in such report. 
 
I agree to take part in this study.  
 
Name of subject         __________________________________            Date _______________ 
Signature                     __________________________________        
 
Name of Researcher __________________________________   Date ______________ 
Signature                                     __________________________________   
When completed, 1 for patient, 1 for researcher site file 
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Participant consent sheet 
Title of Project: A study of movement deficits and physiotherapy in people with 
Huntington’s Disease  
 (HD pre-symptomatic group) 
                                                                                                                   Please initial box 
I confirm I have read and understood the information sheet, version 3.1 dated 14/05/09, 
for the above study and have had the opportunity to consider the information to ask 
questions and to have had these answered. 
 
I understand that my participation is voluntary and that I am free to withdraw at anytime 
without giving any reason, this will not affect my medical care or legal rights being in 
any way. 
 
I agree for the research assessments to be video taped.  
I understand that all information about me will be kept in a secure place and in a 
confidential way and destroyed once the study is completed. 
 
I understand that data will not be used for commercial purposes.  
I confirm that data from the study can be used in the final research report and other 
academic publications. I understand that these will be used anonymously and that no 
individual respondent will be identified in such report. 
 
I am willing for my GP to be notified that I am taking part in this study.  
I agree to take part in this study.  
 
Name of subject         __________________________________            Date _______________ 
Signature                     __________________________________        
Name of Researcher __________________________________   Date ______________ 
Signature                                     __________________________________   
When completed, 1 for patient, 1 for researcher site file 
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Participant consent sheet  
Title of Project: A study of movement deficits and physiotherapy in people with 
Huntington’s   Disease  
(HD Symptomatic group) 
                                                                                                                 Please initial box 
I confirm I have read and understood the information sheet, version 3.2 dated 14/05/09, for 
the above study and have had the opportunity to consider the information to ask questions 
and to have had these answered. 
 
I understand that my participation is voluntary and that I am free to withdraw at anytime 
without giving any reason, this will not affect my medical care or legal rights being in any 
way. 
 
I agree for the research assessments to be video taped.  
I agree for the conversations that take place during the interview and on the telephone to be 
tape recorded. 
 
I would like to have a copy of the transcript of the conversations, in order to make 
comments. 
 
I understand that all information about me will be kept in a secure place and in a 
confidential way and destroyed once the study is completed. 
 
I understand that data will not be used for commercial purposes.  
I confirm that data from the study can be used in the final research report and other 
academic publications. I understand that these will be used anonymously and that no 
individual respondent will be identified in such report. 
 
I am willing for my GP to be notified that I am taking part in this study.  
I agree to take part in this study.  
Name of subject         __________________________________            Date _______________ 
Signature                     __________________________________        
Name of Researcher __________________________________   Date ______________ 
Signature                                     __________________________________   
When completed, 1 for patient, 1 for researcher site file 
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11 Appendix 2:  Exercise Diaries  
 
Exercise and physical activity diary (week 1) 
 
Week start date:  
Week end date: 
  
A- Please tick activities that you performed  during the week, indicating how many days you 
did the activity and how much time you spent in one of those days 
 
Activity 
 
Tick  Days/week Minutes/day 
Travelling in a motor vehicle like a train , bus or car 
 
   
Walking to go from one place to place 
 
   
Bicycling to go from one place to place 
 
   
 
 
B- Please tick activities that you performed in and around the house during the week, 
indicating how many days you did the activity and how much time you spent in one of those 
days 
 
Activity 
 
Tick  Days/week Minutes/day 
Chopping wood 
 
 
 
  
Heavy lifting 
 
 
 
  
Digging in the garden or the yard 
 
 
 
  
Carrying light loads 
 
 
 
  
Sweeping inside home 
 
   
Scrubbing floors 
 
   
Washing windows 
 
   
Raking in the garden or yard 
 
   
Others: (please describe) 
 
 
 
 
   
 
 
 
 
 
 
C- Please tick any sporting activities you performed during the week, indicating on how many 
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days you did the activity and how much time you spent doing the activity 
 
Activity 
 
Tick  Days/week Minutes/day 
Exercise bike 
 
 
 
  
Going to the gym 
 
 
 
  
Others: (please describe)  
 
 
 
 
 
  
 
 
 
D- Please record how much time you usually spent sitting (on average over the last week). This may 
include sitting at a desk, visiting friends, reading or sitting or lying down to watch television. 
 
 
 
 
 
 
 
 
 
 
E- Please record any additional activities that you have done 
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12 Appendix 3: Schedules of the home visit and weekly phone calls 
 
 
 
Agenda setting for the home visit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using the diaries 
 
Evaluating the 
home 
environment 
Working with 
the carer 
Working 
through the 
DVD 
 
 
?? 
 
?? 
 
 
?? 
Walking 
programme 
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1- Working through the DVD 
a- Revising the different sections of the exercise DVD  
b- Explaining the use of the counter and the background music 
c- Revising the correct posture  
d- Revising the list of the precautions 
e- While watching the DVD ask the following questions: 
 Where in home can you see your self doing this? 
 Which chair would you use? 
 How might this fit into your every day routine? 
 
f- Making sure that the participant has got enough space and safe environment to perform 
the exercises 
g- Picking up the exercises to start with  
h- Ensuring the correct execution of exercises; Performing the chosen exercises with the 
participant 
 
2- Walking programme 
 
 In addition to the exercises from the DVD, we would like you to  walk outside 
at least once a week, with a walking aid if required, for as long as they can, 
taking breaks if needed; the goal to achieve at 8 weeks is to walk for 30 minutes 
with minimal numbers of breaks.  
 
3- Working with the carer 
a- Talking to both the participant and the carer “so you will really have to stick together 
as a team to make this work”  
b- Ask the carer “How do you think you can help with this?” 
c- Offer options: 
 Can you be at home while the patient performing the exercises to help if there is 
a need? 
 Can you help the patient in filling out the diaries? 
 Would you both agree a time in the day for doing this? 
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Phone calls- schedule 
 
A. Performing the exercise 
Have you performed the exercises from the DVD this week?  
If yes;  
 How often? 
 What exercises have you performed? 
 Have you performed any additional exercises? 
 Do you have difficulties with performing the exercises? 
 Do you have any concerns would you like to discuss regarding the performed 
exercises? 
If never;  
 Why do you think you have not performed the exercises this week? 
 What things do you think make it difficult to you to perform the exercises? 
 How do you think things can be better for you to perform the exercises? 
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13 Appendix 4: Standard operating procedures for outcome measures 
 
 
Modified motor score of the UHDRS (mMS) 
Equipment: a video recorder, standard chair, biro pen to use as moving target. 
Requirements: Clear 9 metre walkway marked out for gait component. 
Estimated time: 5 minutes 
Testing Protocol: While the assessor is carrying out the tests, another member of the 
research team should be video recording it. Video recording will be digitized, date and 
time are removed and scoring is completed by a blinded assessor.  
1) Tongue protrusion 
Suggestion: Please ask your participants to open their mouth wide while you inspect it 
using a torch. Then ask your participants to protrude their tongue well beyond their 
front teeth while keeping their mouth wide open and to keep it out as long as it takes 
you (as the examiner) to count aloud from 1 to 10. Participants should be made aware 
that they are not allowed to prevent their tongue from slipping back into the mouth by 
biting on it. 
2) Finger taps 
Make sure participant is seated comfortably opposite you at the same level. Explain the 
test to the participant. Demonstrate the movement; tap thumb with index finger in rapid 
succession with widest amplitude possible, each hand separately. Ask participant to do 
this. 
3) Pronate/supinate-hands 
This requires the participant to alternately hit the palmar and dorsal surface of one hand 
against the palm of the opposite hand. Use the palm of the opposite hand as a target 
instead of some other surface such as the participant´s leg or the table surface. The 
participant should do this task as quickly as possible over a five-second interval. The 
task is graded according to the degree of slowing and irregularity. 
4) Luria 
             Fist-hand-palm sequencing  
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a. Say 'Can you do this?' Examiner puts hand into fist on flat surface (or in lap) 
and sequences as follows: fist, side, flat (DO NOT REPEAT THIS OUT 
LOUD).  
b. Watch to make sure that participant can mimic each step.  
c. Continue to practice Luria 3-step for 1 - 2 minutes.  
d. When participant is able to join you then say 'Very good, now keep going, I am 
going to stop.' Rest hand and start timing participant's sequences.  
e. A sequence is considered correct only if it is unaided by examiner model and in 
the correct order. Count completed sequences and score. 
f. If participant was unable to complete any sequences over a 10-second period, 
then continue as follows. 
g. Say 'Now lets try it again. Put your hands like this. FIST; SIDE; FLAT'.  
h. Watch to make sure the participant can mimic each step. Using the verbal labels, 
begin the sequences again and ask the participant to 'Do as I do, Fist, Side, Flat' 
(repeat this as you continue).  
i. Continue to perform Luria 3-step.  
j. When participant is able to join you say 'Very good, now keep going, I am going 
to stop'.  
k. Rest hand and start timing participant's sequences.  
l. A sequence is considered correct if it is unaided by examiner model and in the 
correct order.  
m. Count completed sequences and score as above. 
5) Rigidity-arms (NOTE: OBTAIN CONSENT FOR TOUCH) 
Rigidity is judged on passive movement of the arms with the participant relaxed in the 
sitting position. 
6) Bradykinesia-body 
Observe the participant during spontaneous motion such as walking, sitting down, 
arising from a chair, and executing the tasks required during the examination. This 
rating reflects the examiner's overall impression of bradykinesia. 
7) Gait 
Use cones / tape as a marker on the floor to measure 9 metres (10 yards) prior to the 
test.  Point out the markers to the participant and explain the test. Observe the 
participant walking approximately 9 meters (10 yards) at normal pace and then turning 
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and returning to the starting point. Ask them to repeat but walking as briskly as they 
can. 
Instructions to the participant: Please walk along the distance marked out as briskly 
as you can, turn safely and return to where you started, walking briskly. 
8) Tandem walking 
The participant is requested to walk ten steps in a straight line with the foot placed 
(accurately but not quickly) such that the heel touches the toe of the other foot. 
Deviations from a straight line are counted. 
9) Retropulsion pull test 
Explain the test to the participant. Ask participant to stand. The participant's response to 
a sudden posterior displacement produced by a pull on the shoulder while the 
participant is standing with eyes open and feet slightly apart is assessed. The shoulder 
pull test must be done with a quick firm tug after warning the participant. The 
participant should be relaxed with feet apart and should not be leaning forward. If the 
examiner feels pressure against his/her hands when placed on the participant's 
shoulders, the examiner should instruct the participant to stand up straight and not lean 
forward. The examiner should instruct the participant to take a step backward to avoid 
falling. Examiners must catch participants who begin to fall. 
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Berg Balance Scale 
Description:  
14-item scale designed to measure balance of the older adult in a clinical setting.  
Equipment needed:  
Ruler  
2 standard chairs (one with arm rests, one without)  
Footstool or step  
Stopwatch or wristwatch  
15 ft walkway  
Testing protocol:  While the assessor is carrying out the tests, another member of the 
research team should be video recording it. Video recording will be digitized, date and 
time will be removed and scoring will be completed by blinded assessor. 
Time: 15-20 minutes  
Scoring: A five-point ordinal scale, ranging from 0-4. “0” indicates the lowest level of 
function and “4” the highest level of function.  
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Berg Balance Scale 
 
ITEM DESCRIPTION SCORE (0-4)  
 
1. Sitting to standing ________  
 
2. Standing unsupported ________  
 
3. Sitting unsupported ________  
 
4. Standing to sitting ________  
 
5. Transfers ________  
 
6. Standing with eyes closed ________  
 
7. Standing with feet together ________  
 
8. Reaching forward with outstretched arm ________  
 
9. Retrieving object from floor ________  
 
10. Turning to look behind ________  
 
11. Turning 360 degrees ________  
 
12. Placing alternate foot on stool ________  
 
13. Standing with one foot in front ________  
 
14. Standing on one foot ________  
 
Total ________  
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General instructions  
Please document each task and/or give instructions as written. When scoring, please 
record the lowest response category that applies for each item.  
In most items, the subject is asked to maintain a given position for a specific time. 
Progressively more points are deducted if the time or distance requirements are note 
met, if the subject‟s performance warrants supervision, or if the subject touches an 
external support or receives assistance from the examiner. Subject should understand 
that they must maintain their balance while attempting the tasks. The choices of which 
leg to stand on or how far to reach are left to the subject. Poor judgment will adversely 
influence the performance and the scoring.  
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Berg Balance Scale 
 
1. SITTING TO STANDING  
INSTRUCTIONS: Please stand up. Try not to use your hand for support.  
( ) 4 able to stand without using hands and stabilize independently  
( ) 3 able to stand independently using hands  
( ) 2 able to stand using hands after several tries  
( ) 1 needs minimal aid to stand or stabilize  
( ) 0 needs moderate or maximal assist to stand  
 
 
2. STANDING UNSUPPORTED  
INSTRUCTIONS: Please stand for two minutes without holding on.  
( ) 4 able to stand safely for 2 minutes  
( ) 3 able to stand 2 minutes with supervision  
( ) 2 able to stand 30 seconds unsupported  
( ) 1 needs several tries to stand 30 seconds unsupported  
( ) 0 unable to stand 30 seconds unsupported  
 
If a subject is able to stand 2 minutes unsupported, score full points for sitting 
unsupported. Proceed to item #4.  
 
 
3. SITTING WITH BACK UNSUPPORTED BUT FEET SUPPORTED ON FLOOR 
OR ON A STOOL  
INSTRUCTIONS: Please sit with arms folded for 2 minutes.  
( ) 4 able to sit safely and securely for 2 minutes  
( ) 3 able to sit 2 minutes under supervision  
( ) 2 able to able to sit 30 seconds  
( ) 1 able to sit 10 seconds  
( ) 0 unable to sit without support 10 seconds  
 
4. STANDING TO SITTING  
INSTRUCTIONS: Please sit down.  
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( ) 4 sits safely with minimal use of hands  
( ) 3 controls descent by using hands  
( ) 2 uses back of legs against chair to control descent  
( ) 1 sits independently but has uncontrolled descent  
( ) 0 needs assist to sit  
 
5. TRANSFERS  
INSTRUCTIONS: Arrange chair(s) for pivot transfer. Ask subject to transfer one way 
toward a seat with armrests and one way toward a seat without armrests. You may use 
two chairs (one with and one without armrests) or a bed and a chair.  
( ) 4 able to transfer safely with minor use of hands  
( ) 3 able to transfer safely definite need of hands  
( ) 2 able to transfer with verbal cuing and/or supervision  
( ) 1 needs one person to assist  
( ) 0 needs two people to assist or supervise to be safe  
 
6. STANDING UNSUPPORTED WITH EYES CLOSED  
INSTRUCTIONS: Please close your eyes and stand still for 10 seconds.  
( ) 4 able to stand 10 seconds safely  
( ) 3 able to stand 10 seconds with supervision  
( ) 2 able to stand 3 seconds  
( ) 1 unable to keep eyes closed 3 seconds but stays safely  
( ) 0 needs help to keep from falling  
 
 
7. STANDING UNSUPPORTED WITH FEET TOGETHER  
INSTRUCTIONS: Place your feet together and stand without holding on.  
( ) 4 able to place feet together independently and stand 1 minute safely  
( ) 3 able to place feet together independently and stand 1 minute with supervision  
( ) 2 able to place feet together independently but unable to hold for 30 seconds  
( ) 1 needs help to attain position but able to stand 15 seconds feet together  
( ) 0 needs help to attain position and unable to hold for 15 seconds  
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8. REACHING FORWARD WITH OUTSTRETCHED ARM WHILE STANDING  
INSTRUCTIONS: Lift arm to 90 degrees. Stretch out your fingers and reach forward as 
far as you can. (Examiner places a ruler at the end of fingertips when arm is at 90 
degrees. Fingers should not touch the ruler while reaching forward. The recorded 
measure is the distance forward that the fingers reach while the subject is in the most 
forward lean position. When possible, ask subject to use both arms when reaching to 
avoid rotation of the trunk.)  
( ) 4 can reach forward confidently 25 cm (10 inches)  
( ) 3 can reach forward 12 cm (5 inches)  
( ) 2 can reach forward 5 cm (2 inches)  
( ) 1 reaches forward but needs supervision  
( ) 0 loses balance while trying/requires external support  
 
 
9. PICK UP OBJECT FROM THE FLOOR FROM A STANDING POSITION  
INSTRUCTIONS: Pick up the shoe/slipper, which is place in front of your feet.  
( ) 4 able to pick up slipper safely and easily  
( ) 3 able to pick up slipper but needs supervision  
( ) 2 unable to pick up but reaches 2-5 cm(1-2 inches) from slipper and keeps balance 
independently  
( ) 1 unable to pick up and needs supervision while trying  
( ) 0 unable to try/needs assist to keep from losing balance or falling  
 
10. TURNING TO LOOK BEHIND OVER LEFT AND RIGHT SHOULDERS 
WHILE STANDING  
INSTRUCTIONS: Turn to look directly behind you over toward the left shoulder. 
Repeat to the right. Examiner may pick an object to look at directly behind the subject 
to encourage a better twist turn.  
( ) 4 looks behind from both sides and weight shifts well  
( ) 3 looks behind one side only other side shows less weight shift  
( ) 2 turns sideways only but maintains balance  
( ) 1 needs supervision when turning  
( ) 0 needs assist to keep from losing balance or falling.  
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11. TURN 360 DEGREES  
INSTRUCTIONS: Turn completely around in a full circle. Pause. Then turn a full circle 
in the other direction.  
( ) 4 able to turn 360 degrees safely in 4 seconds or less  
( ) 3 able to turn 360 degrees safely one side only 4 seconds or less  
( ) 2 able to turn 360 degrees safely but slowly  
( ) 1 needs close supervision or verbal cuing  
( ) 0 needs assistance while turning  
 
12. PLACE ALTERNATE FOOT ON STEP OR STOOL WHILE STANDING 
UNSUPPORTED  
INSTRUCTIONS: Place each foot alternately on the step/stool. Continue until each foot 
has touch the step/stool four times.  
( ) 4 able to stand independently and safely and complete 8 steps in 20 seconds  
( ) 3 able to stand independently and complete 8 steps in > 20 seconds  
( ) 2 able to complete 4 steps without aid with supervision  
( ) 1 able to complete > 2 steps needs minimal assist  
( ) 0 needs assistance to keep from falling/ unable to try  
 
13. STANDING UNSUPPORTED ONE FOOT IN FRONT  
INSTRUCTIONS: (DEMONSTRATE TO SUBJECT) Place one foot directly in front 
of the other. If you feel that you cannot place your foot directly in front, try to step far 
enough ahead that the heel of your forward foot is ahead of the toes of the other foot. 
(To score 3 points, the length of the step should exceed the length of the other foot and 
the width of the stance should approximate the subject‟s normal stride width.)  
( ) 4 able to place foot tandem independently and hold 30 seconds  
( ) 3 able to foot ahead independently and hold 30 seconds  
( ) 2 able to take small step independently and hold 30 seconds  
( ) 1 needs help to step but can hold 15 seconds  
( ) 0 loses balance while stepping or standing  
 
14. STANDING ON ONE LEG  
INSTRUCTIONS: Stand on one leg as long as you can without holding on.  
( ) 4 able to lift leg independently and hold > 10 seconds  
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( ) 3 able to lift leg independently and hold 5-10 seconds  
( ) 2 able to lift leg independently and hold ≥ 3 seconds  
( ) 1 tries to lift leg unable to hold 3 seconds but remains standing independently.  
( ) 0 unable to try of needs assist to prevent fall  
 
 
TOTAL SCORE (Maximum = 56) 
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Romberg and Sharpened Romberg tests 
 
Romberg Tests 
1) Eyes Open 
Each subject should stand on a level surface wearing flat shoes (2 trials with his or her 
feet together, as close as they can be and 2 trials with feet apart); arms crossed over the 
chest, and the open palm of the hand falling on the opposite shoulder. Once stable, the 
subject should attempt to maintain that position for 30 seconds.  Record the time. 
 
2) Eyes Closed 
Each subject should stand on a level surface wearing flat shoes (2 trials with his or her 
feet together, as close as they can be and 2 trials with feet apart); arms crossed over the 
chest, and the open palm of the hand falling on the opposite shoulder. Once stable, the 
subject should attempt to maintain that position for 30 seconds.  Record the time. 
 
Sharpened Romberg tests 
1) Eyes open  
Each subject should stand on a level surface wearing flat shoes with his or her feet 
aligned in a strict tandem heel-to-toe position, arms crossed over the chest, and the open 
palm of the hand falling on the opposite shoulder.  
Once stable, the subject should attempt to maintain that position for 30 seconds. If the 
subject fails to maintain the position by movement of either arms or feet or by opening 
his or her eyes, the time taken to failure should be noted. Each subject is given 2 trials.  
2) Eyes closed  
Each subject should stand on a level surface wearing flat shoes with his or her feet 
aligned in a strict tandem heel-to-toe position, arms crossed over the chest, and the open 
palm of the hand falling on the opposite shoulder.  
Once stable, the subject should close his or her eyes and attempt to maintain that 
position for 30 seconds. If the subject fails to maintain the position by movement of 
either arms or feet or by opening his or her eyes, the time taken to failure should be 
noted. Each subject is given 2 trials. 
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Measures of postural sway 
 
Equipment: Kistler® force platform, 8 channel amplifier, software on a computer for 
data processing.  
  
Testing protocol: quiet standing on the force platform with eyes open for 30 seconds. 
Two trials are performed. Two examiners are included. One gives instructions and set 
the start and the end of the test from the PC. The other stands behind the participant 
during the test as a safety measure.   
 
Instructions:  
1) Stand on the force platform, placing your feet apart.  
2) Look straight ahead, with head erect while you fix your vision on the black spot 
placed on the white screen.   
3) Cross over your arms with open palm of the hand are placed over the opposite 
shoulder.  
4) Stand as still as possible for as long as you can for up to 30 seconds.   
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Isomtric muscle strength testing 
 
Equipment: Kin-com isokinetic testing chair dynamometer unit.  
Testing protocol: Participant is seated on the chair. The backrest is adjusted to 110 
degrees of posterior incline. Seat belts and pads is used The most inferior portion of the 
transducer pad is adjusted above the lateral maleolli. The axis of the lever arm is aligned 
to be at the same level of the inferior part of the lateral epicondyle of femur. The knee is 
flexed at an angle of 90 degrees. The angle of the knee is determined by using a 
universal goniometer. Participant performs 3 trials of 3 seconds for each of the right and 
left knee flexors and knee extensors. Sixty seconds of rest is given between trials. 
Participants are given verbal coaching during testing. Three progressive sub-maximal 
warm up repetitions of both knee flexors and extensors are performed prior to testing. 
Instructions:  
1) Please keep back against the backrest and fold your arm against the chest 
during the test.  
2) Once the test is started please push (or pull) as hard as you can.  
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Walking test- GAITRite  
 
Equipment: GAITRite walkway, standard chair, software on laptop. 
 
Testing Protocol: Each participant is asked to perform ten trials of walking through the 
walkway at their comfortable pace. Two familiarisation trials at the beginning of the 
testing session are performed. A two meters acceleration and deceleration distance on 
either end of the walkway was included.  
 
Instructions: Walk until the landmark placed after the end of the walkway, turn and 
walk back. Walk at a pace that is comfortable for you.  
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Stepwatch Activity Monitor (SAM)  
 
Equipment: SAM, ankle strap, appropriate packaging/ envelope for participant to send 
back SAM to research team after wearing for 8 days, software on laptop. 
 
Testing Protocol: 
1) Explain to the participant in detail what the SAM is and how it is to be used. 
2) Setup the software to establish the recording activity of the participant. 
3) Put SAM on participant to demonstrate how it should be worn. 
4) If recording activity starting straight away, check monitor is flashing with each 
step the participant takes with right leg. 
5) Participant will wear SAM for eight days and then return it in the post in the 
envelope provided. 
6) To be completed at baseline and after the first follow-up assessments.  
 
Instructions: 
1) Please wear the step watch for eight days. 
2) The SAM must be worn with the rounded end up. 
3) It is worn just above the ankle bone on either side of either leg.  
4) Adjust the Velcro for comfort and wear an extra sock if you need additional 
padding. 
5) Put the SAM on right away when you get up in the morning and wear it 
throughout the day. Take it off at night and when you shower or have a bath. 
6) Please treat the SAM with reasonable care. 
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Four Square Step Test  
Description: The FSST involves stepping over low objects (2.5cm) and movement in 4 
directions.  
Estimated time: 5 minutes 
Equipment needed: stopwatch, 4 canes, The square is formed by using 4 canes resting 
flat on the floor. Canes were 90cm long, and the direction and type of handle used is not 
important.   
 
Testing protocol: 
The subject stands in square number 1 facing square number 2. The aim is to step as fast 
as possible into each square in the following sequence. Square number 2, 3, 4, 1, 4, 3, 2, 
and 1. This sequence requires the subject to step forward, backward, and sideway to the 
right and left. The score is recorded as the time taken to complete the sequence. The 
stopwatch starts when the first foot contacts the floor in square 2 and finishes when the 
last foot comes back to touch the floor in square 1. The following instructions are given 
to the subject, “Try to complete the sequence as fast as possible without touching the 
sticks. Both feet must make contact with the floor in each square. Face forward during 
the entire sequence.” The sequence is then shown to the subject. One practice trial is 
completed to ensure the subject knows the sequence. Three FSST are completed with 
the average time taken as the score. A trial is repeated if the subject fails to complete the 
sequence successfully, loses balance, or makes contact with a cane during the sequence. 
Subjects who were unable to face forward during the entire sequence and needed to turn 
before stepping into the next square were given a score of 60 seconds. All subjects wear 
their preferred shoes. The examiner stood in a position to see all steps taken by the 
subject, and an assistant provided the subject with close supervision. The entire test, 
including giving instructions and a practice trial, took less than 5 minutes to complete. 
 
Scoring:  Time (in seconds) to complete sequence above. 
Comments: (able to stand facing front, multiple reps need) 
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Timed Up and Go test  
 
Description: For this test, subjects stand up from a chair, walk 3 meters, turn around, 
and return to the chair. 
 
Estimated time:  10 minutes 
 
Exclude subjects who:  are unable to ambulate without physical assistance.  Assistive 
devices can be used.   
 
Equipment:  standard height chair (18”) with arms (26” to arm height); firm surface; 
stopwatch 
 
Testing Protocol:  The timed “Up and Go” test measures, in seconds, the time taken by 
an individual to stand up from a standard arm chair (approximate seat height of 46 cm, 
arm height 65 cm), walk a distance of 3 meters, turn, walk back to the chair, and sit 
down. The front legs of the chair should be at the start position (0).  A cone should be 
placed at 3 meters distance, to indicate the turn around point for the subject. The subject 
wears their regular footwear and uses their customary walking aid (none, cane, walker). 
No physical assistance is given. They start with their back against the chair, their arms 
resting on the armrests, and their walking aid at hand. The subject walks through the test 
once before being timed in order to become familiar with the test. Either a stopwatch or 
a wristwatch with a second hand can be used to time the trial. The test is repeated twice.  
Turn should be anteclockwise. a demonstration of the test is provided to the subject and 
one practice trial is performed before the beginning of the test.   
 
Instructions to the patient:  “When I say „go‟ I want you to stand up and walk to the 
line, turn and then walk back to the chair and sit down again. Walk at your normal 
pace.”  
 
Scoring:  Time is recorded starting from the word “go” until the time the subjects fully 
sits in the chair. Record the time of both trials. The first trial (test trial) the time is not 
recorded.   
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30 seconds Chair Sit to Stand Test  
Equipment: standard chair without arms and with a seat height of approximately 17 
inches (43.2 cm). Place the back of the chair against a wall to prevent movement during 
the test. 
Testing Protocol:  
1) The chair should be placed against a wall to prevent it from moving during the 
test.  
2) The test begins with the participant  seated in the middle of the chair, back 
straight, feet approximately shoulder-width apart and placed on the floor at an 
angle slightly back from the knees, with one foot slightly in front of the other to 
help maintain balance when standing. While monitoring the participant‟s 
performance to assure proper form, the tester will silently count the completion 
of each correct stand.  
3) Arms will be crossed at the wrists and held against the chest.  
4) At the signal "go," the participant rise to a full stand (body erect and straight) 
and then returned back to the initial seated position.  
5) The participant will be instructed to be fully seated between each stand.  
6) Following a demonstration by the tester, a practice trial of one repetition will be 
given to check proper form, followed by the 30-s test trial.  
7) The score will be the total number of stands executed correctly within 30 s 
(more than halfway up at the end of 30-s counted as a full stand).  
8) Incorrectly executed stands will not be counted. 
9) Repeat twice. 
 
If participants are unable to stand up one time without assistance than they can use their 
hands to assist them in rising and returning to the seated position while following all 
other procedures as described above.  Make sure that if hands were used make note of 
this when recording the assessment data. 
Estimated time:  1 minute 
Instructions: 
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1) Sit in the middle of the chair, back straight, feet approximately shoulder-width 
apart and placed on the floor at an angle slightly back from the knees, with one 
foot slightly in front of the other to help maintain balance when standing. 
2) Cross your arms at the wrists and hold against your chest.  
3) On the signal “go” rise from the chair and stand fully (body erect and straight) 
and then return to the seat in the original position. 
4) You are to do this as many times as you can in 30 seconds which I will be 
timing. 
5) Between each stand make sure you are fully seated. 
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Physical Performance Test  
Description: The PPT is a compilation of items mimicking basic and complex
 
ADL 
tasks and is scored by timing the completion of a task.
 
This time then is related to a 
categorical score of 0 to 4,
 
in which 4 represents people in the fastest 20% at completing
 
the task, 1 represents those in the slowest 20%, and 0 represents
 
those who cannot 
complete the task. The maximum score on the
 
9-item PPT is 36. Subjects perform a 
series of 9 standardized tasks, which are timed. The tasks include writing a sentence, 
simulated eating, turning 360 degrees, putting on and removing a jacket, lifting a book 
and putting it on a shelf, picking up a penny from the floor, a 50-foot walk test, and 
climbing stairs (scored as two items: time for climbing one
 
flight of stairs and counting 
the number of flights of stairs
 
the subject is able to ascend) 
 
Equipment:  pen, piece of paper, 5 kidney beans, empty coffee can, teaspoon, PDR or 
similar size textbook (5.5 lbs), chair/stool height 59 cm, shelf height 118 cm, cardigan 
sweater/jacket or lab coat, 50 ft walkway, flight of stairs (12 steps), US penny or UK 1p 
coin 
 
Estimated time:  20 minutes 
 
Testing Protocol:  
Administer the test as outlined below. Subjects are given up to two chances to complete 
each item. Assistive devices are permitted for tasks 6 – 8.  
 
1) Ask the subject, when given the command to “go” to write the sentence “whales live 
in the blue ocean.” Time from the word “go” until the pen is lifted from the page at 
the end of the sentence. All words must be included and legible. Period need not be 
included for task to be considered completed.  
 
2) Five kidney beans are placed in a bowl, 5 inches from the edge of the desk in front 
of the patient. An empty coffee can is placed on the table at the patient‟s non-
dominant side. A teaspoon is place in the patient‟s dominant hand. Ask the subject 
on the command “go” to pick up the beans, one at a time and place each in the 
coffee can. Time from the command “go” until the last bean is heard hitting the 
bottom of the can.  
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3) Place a Physician‟s Desk Reference or other heavy book on a table in front of the 
patient. Ask the patient, when given the command “go” to place the book on a shelf 
above shoulder level. Time from the command “go” to the time the book is resting 
on the shelf.  
 
4) If the subject has a jacket cardigan sweater, ask them to remove it. If not, give the 
subject a lab coat. Ask the subject, on the command “go” to put the coat on 
completely such that it is straight on their shoulders and then remove the garment 
completely. Time from the command “go” until the garment has been complexly 
removed.  
 
5) Place a penny approximately1 foot from the patient‟s foot on the dominant side. Ask 
the patient, on the command “go” to pick up the penny from the floor and stand up. 
Time from the command “go” until the subject is standing erect with a penny in 
hand.  
 
6) With subject in a corridor or in and open room, ask the subject to turn 360 degrees. 
Evaluate using the scale on PPT scoring sheet.  
 
7) Bring subject to start on a 50 –foot walk test course (25 feet out and 25 feet back) 
and ask the subject, on the command “go” to walk to the 25-foot mark and back. 
Time from the command “go” until the starting line is crossed on the way back.  
 
Scoring: See scoring sheet
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PPT Scoring Sheet 
   Time Scoring Score 
1. 
 
Write a sentence. 
(Whales live in the blue ocean.) 
Seconds  ≤ 10 sec            = 4 
10.5-15 sec      = 3 
15.5 – 20 sec    = 2 
>20 sec             = 1 
unable               = 0 
 
2.  Simulated eating Seconds  ≤ 10 sec            = 4 
10.5-15 sec      = 3 
15.5 – 20 sec    = 2 
>20 sec             = 1 
unable               = 0 
 
3. Lift a book and put it on a shelf 
    Book PDR 1988: 5.5 lbs 
    Bed height 59 cm 
    Shelf height 118 cm 
    All sitting with feet on floor 
Seconds  ≤ 2 sec            = 4 
2.5- 4 sec        = 3 
4.5 – 6 sec       = 2 
> 6 sec             = 1 
Unable            = 0 
 
4. Put on and remove a jacket 
1.Standing 
2.Use of bathrobe; button down 
shirt; hospital gown. 
Seconds  ≤ 10 sec            = 4 
10.5-15 sec      = 3 
15.5 – 20 sec    = 2 
>20 sec             = 1 
unable               = 0 
 
5. Pick up a penny from floor. Seconds  ≤ 2 sec            = 4 
2.5- 4 sec        = 3 
4.5 – 6 sec       = 2 
> 6 sec             = 1 
Unable            = 0 
 
6. Turn 360 degrees  Discontinuous steps            = 0 
Continuous steps                   = 2 
 
Unsteady (grabs, staggers)  = 0 
Steady                                  = 2 
 
7. 50-foot walk test. 
  Starting sitting for instructions. 
Seconds  ≤ 15 sec            = 4 
15.5- 20 sec      = 3 
20.5 – 25 sec    = 2 
>25 sec             = 1 
unable               =  0 
 
 TOTAL SCORE (maximum 28 
for seven-item) 
 
 
 
   
 (*Round time measurements to 
nearest 0.5 seconds.) 
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Short Form 36 (SF-36)  
 
Equipment: Pencil and paper  
Testing Protocol: Ensure the participant is seated comfortably in a chair and has a 
pencil to fill in the questionnaire. Explain that the questionnaire asks for the participants 
views about their health.  Ask the participant to go through the questionnaire with the 
carer (if applicable), asking the questions as he/she goes through it. For each of the 
questions, ask the participant to tick the box that best describes the answer.  
Estimated time:  10 minutes 
Hints:  
During the past 4 weeks how much did pain interfere with your normal work; including 
both work outside the home and housework. 
Had difficulty performing the work or other activities for example it took extra effort. 
During the past 4 weeks have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems such as feeling 
depressed or anxious? 
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Intrinsic Motivation Inventory questionnaire 
 
For each of the following statements, please indicate how true it is for you, using the 
following scale: 
 
 
   1 2 3 4 5 6 7 
          not at all         somewhat            very 
            true   true            true 
 
 
 
A.  Interest/Enjoyment 
 
1. I enjoyed doing this exercise program very much 
2. This exercise program was fun to do. 
3. I thought this was a boring exercise program.       (R) 
4. This exercise program did not hold my attention at all.        (R) 
5. I would describe this exercise program as very interesting. 
6. I thought this exercise program was quite enjoyable. 
7. While I was doing this exercise program, I was thinking about how much I enjoyed 
it. 
 
B. Perceived Competence 
1. I think I am pretty good at this exercise program. 
2. I think I did pretty well at this exercise program. 
3. After working at this exercise program for awhile, I felt pretty competent. 
4. I am satisfied with my performance at this exercise program. 
5. This was an exercise program that I couldn’t do very well. (R) 
 
 
C. Effort/Importance 
1. I put a lot of effort into exercise program. 
2. I didn’t try very hard to do well at this exercise program.  (R) 
3. I tried very hard on this exercise program. 
4. It was important to me to do well at this exercise program. 
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5. I didn’t put much energy into this exercise program. (R) 
 
D. Pressure/Tension 
1. I did not feel nervous at all while doing this exercise program.  (R) 
2. I felt very tense while doing this exercise program. 
3. I was very relaxed in doing this exercise program. (R) 
4. I was anxious while working on this exercise program. 
5. I felt pressured while doing this exercise program. 
 
E. Value/Usefulness 
1. I believe this exercise program could be of some value to me. 
2. I think that doing this exercise program is useful for improving my condition. 
3. I think this exercise program is important to do.  
4. I would be willing to do this exercise program again because it has some value to 
me. 
5. I think doing this exercise program is helpful. 
6. I believe doing this exercise program could be beneficial to me. 
7. I think this is an important exercise program. 
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14 Appendix 5: Interview Schedule 
 
Closed questions:        a priori codes  
 
Was the training program suitable for you?  
What do you think about the overall structure of the  
DVD? Was it easy to navigate and follow?  
 
 
Did you have difficulty in performing the exercises?  
Can you explain?  
 
Was the home visit useful? Were the phone calls  
useful?  
 
Was the exercise programme useful?  
Open questions:  
Please state how you were using the exercises DVD? 
Prompts: If yes;  
 How often you were using the exercise DVD? 
 What exercises have you performed and how long each session was 
undertaking? 
 Can you please explain how you were performing the exercises?  
 
Prompts: If never;  
 Can you explain why do you think you have not performed the exercises?  
 
Please state how often you were doing the walking?  
Please describe what you have liked most and least about the program? 
Suitability of the exercise the 
exercise programme  
Barriers 
Facilitators 
Perceived benefits 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 6: Sample size; 
Correlations between Gait 
Measures and scatter plots of 
correlations between outcomes  
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15 Appendix 6:  Sample size; correlations between measures of gait 
and scatter plots of correlations  
 
A) Sample size calculations for reliability study 
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B) Correlations between measures of gait  
 
 mMS Stride length CV Stride 
length 
Stride time Gait 
speed  
Stride time 
CV 
0.71** 0.96** -0.63** 0.50** -0.65** 
 
 
 Stride length  Stride time  
Gait speed 0.82** -0.56** 
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C) Correlations between outcomes and stride time CV  
Data were checked for the presence of outliers using casewise diagnostic procedure 
[219]; cases where standardized residuals (differences between observed and predicted 
values divided by an estimate of their standard deviation) were greater than 1.96 or 
lesser than -1.96 were considered to be outliers (i.e. cases where standardized residuals 
were outside 2 SD of their distribution).  Analysis was carried out with and without 
outliers to estimate effects of outliers on results. Correlation coefficients after excluding 
outliers are provided in the table below.   
 
The correlation coefficient of 0.6 was used as a cut off point for the interpretation of the 
results obtained for the concurrent-convergent validity. An outcome considered to have 
a good concurrent convergent validity if the correlation coefficient with stride time CV 
was of 0.6 or more [240]. Accordingly, excluding outliers did not influence the obtained 
results. In all outcomes that had good concurrent-convergent validity, correlation 
coefficients were still of at least 0.60 even after excluding outliers. Similarly, in all 
outcomes that did not have good concurrent convergent validity (apart from the root 
mean square measures of postural sway), correlation coefficients were still lesser than 
0.6 even after excluding all outliers from analysis ( for more details see table and scatter 
plots below).      
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Summary of correlations of outcome measures with stride time coefficient of 
variations (with and without outliers) 
 Correlation 
coefficient 
Correlation coefficient 
with outliers removed 
Berg balance scale -0.72** -0.74** 
Total score of Romberg test -0.44* -0.58* 
rms-AP of postural sway 0.50* 0.58* 
rms-ML of postural sway 0.51* 0.65* 
Total excursion-AP 0.1 0.028 
Total excursion- ML 0.19 0.016 
MVIC of knee extensors  -0.14 -0.12 
MVIC of knee flexors -0.44 -0.49 
Four square step test 0.64** 0.68** 
Timed up and go test 0.6* 0.63* 
Chair sit to stand test -0.71** No outliers 
Physical performance test -0.66** No outliers 
Average of daily step count -0.32 No outliers 
Percentage of time spent at no PA 0.13 0.029 
Percentage of time spent at low PA -0.06 -0.09 
Percentage of time spent at moderate PA -0.21 No outliers 
Percentage of time spent at high PA -0.29 -0.29 
Peak activity index -0.62** 0.65** 
Physical function -0.61** 0.64** 
Role physical -0.38 No outliers 
Bodily pain -0.11 No outliers 
Vitality -0.34 0.46* 
General health -0.33 No outliers 
Social Functioning -0.16 -0.24 
Role emotional 0.15 No outliers 
Mental health -0.15 No outliers 
Physical Component Summary -0.6** -0.65** 
Mental Component Summary -0.04 0.01 
Note: an outcome measure was considered to have a good concurrent-convergent 
validity with gait variability (i.e. stride time CV %) if the correlation coefficient was of 
0.6 or more.  
 
 
 346 
 
 
One case was outside 2SD (i.e. identified by 
casewise diagnostic )
Another case was identified as an outlier by visually 
checking the scatter plot
Removing all outliers change r  (Pearson) from 0.74 to 0.76 and  r 
spearman from 0.72 to 0.74 
Berg Balance Scale 
Removing this case changes r (Pearson) from 0.47 to 0.6 and r 
(Spear man) from 0.44 to 0.5;  another case at this stage was 
identified as being outside 2SD. 
One case was outside 2 SD (i.e. identified by 
casewise diagnostic ). 
Removing the second outlier changes r (Pearson) from 0.6 to 0.7 
and r (Spearman) from 0.5 to 0.58 
Total score of Romberg and Sharpened Romberg tests
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One case  was outside 2SD (i.e. identified by 
casewise diagnostic )
Removing outlier changes r (Pearson) from 
0.5 to 0.58
rms-AP of postural sway 
rms-ML of postural sway 
One case  was outside (i.e. identified 
by casewise diagnostic )
Removing outlier changes r (Pearson) 
from 0.51 to 0.65
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R2 Linear= 0.01
Two cases were outside 2SD.
R2 Linear=4.56E-4 
After removing the first  2outlier,s, one 
more case was further indicated by 
casewise diagnostic as being outside 2SD. 
R2 Linear= 7.94E-4
Removing all outliers changes r (Pearson ) from  
0.1 to 0.028
Excursion- AP of postural sway 
Excursion-ML of postural sway
R2 Linear= 0.04
Two cases were outside 2SD .
R2 Linear= 2.00E-4
After removing the first  2outliers, 
one more case was further identified 
by casewise diagnostic as being 
outside 2SD. 
R2 Linear=2.5E-4
Removing all outliers changes r (Pearson ) 
from  0.19 to 0.016
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One case was outside 2SD (i.e. identified by casewise 
diagnostic )
•Removing  the outlier changes r (Pearson) from 
0. 46 to 0. 53 and r (Spearman) from 0.44  to 
0.49. 
•After removing the first outlier, no other 
outliers were further indicated by casewise 
diagnostic as being outside 2 SD. 
Isometric muscle strength of knee flexors
R2 Linear =0.21
R2 Linear =0.28
R2 linear=0.04
One case was identified as outside 2SD (i.e. 
identified by casewise diagnostic )
R2 Linear=0.03
•Removing outlier changes r (Pearson) from 0. 
2 to 0. 17 and r (Spearman) from 0.14  to 0.12. 
•After removing the first outlier, no other 
outliers were further indicated by casewise 
diagnostic ) as being outside 2SD. 
Isometric muscle strength of knee extensors 
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Two cases  were outside 2SD (i.e. identified by 
casewise diagnostic )
Other 3 cases (cases who were given the score of 60 
seconds when could not perform  the test ) were 
removed.
Removing all outliers changes r (Pearson)  from 0.63 to 0.74 
and r (spearman) from 0.64 to 0.68 .   
Four Square Step Test 
R2 linear=0.5
Two cases  were outside 2SD (i.e. identified by 
casewise diagnostic).
Removing outliers changes r (Pearson) 
from 0.65 to 0.70 and r (spearman) from 
0.60 to 0.63. 
R2R2 Linear =0.42
Timed Up and Go test 
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No outliers were identified
No outliers were identified
Chair Sit to Stand Test Physical Performance Test 
No outliers were identified
Average of daily step count
No outliers were identified
Percentage of time at moderate PA
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One case was outside 2SD (i.e. identified by casewise 
diagnostic)
•Removing  the outlier changes r (Pearson) 
from 0.13 to 0.029. 
•After removing the first outlier, no other 
outliers were further indicated by casewise 
diagnostic as being outside 2 SD. 
Percentage of time spent at no PA
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One case was outside 2SD
•Removing  the outlier changes r (Pearson) from 
0.06 to 0.09. 
•After removing the first outlier, no other 
outliers were further indicated by the diagnostic 
criteria as being outside 2SD. 
Percentage of time spent at low PA
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One case was outside 2SD (i.e. identified by casewise 
diagnostic )
•No change on r on removing the outlier. 
•After removing the first outlier, no other 
outliers were further indicated by casewise 
diagnostic as being outside 2SD. 
Percentage of time spent at high PA
One case was outside 2SD (i.e. identified by 
casewise diagnostic ).
•Removing  the outlier changes r (Pearson) 
from 062 to 0.65. 
•After removing the first outlier, no other 
outliers were further indicated by casewise 
diagnostic as being outside 2SD. 
Peak activity index
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No outliers were identified
No outliers were identified
Role Physical Bodily Pain
One case was outside 2SD. 
Removing this case changes r (Pearson) from 0.61 to 0.65 and 
r;  another case at this stage was identified as being outside  2 
SD. 
Removing all outliers changes  r (Pearson)  from 0.61 to 
0.64.
Physical Function
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No outliers were identified
No outliers were identified
Role Emotional Mental Health
No outliers were identified
General Health 
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R2 Linear=0.11
R2 Linear= 0.23
Three cases were outside 2SD (i.e. defined by 
casewise diagnostic )
•Removing outliers changes r from 0.33 to 0.46
•After removing the first outlier, no other 
outliers were further identified by casewise 
diagnostic as being outside 2SD. 
Vitality 
One case was outside 2SD (i.e. defined by casewise 
diagnostic )
•Removing outliers changes r from 0.16 to 
0.24
•After removing the first outlier, no other 
outliers were further identified by casewise 
diagnostic as being outside 2SD. 
Social Functioning 
R2 Linear = 0.025
R2 Linear = 0.057
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One case was outside 2SD (i.e. identified by 
casewise diagnostic )
R2 Linear= 0.37
•Removing outliers changes r from 0.61 to 
0.65
•After removing the first outlier, no other 
outliers were further identified by casewise 
diagnostic as being outside 2SD. 
Physical Summary Component 
R2 Linear= 0.42
One case was outside 2SD (i.e. identified by 
casewise diagnostic )
•Removing outliers changes r from 0.04 to 
0.01
•After removing the first outlier, no other 
outliers were further identified by casewise 
diagnostic as being outside 2SD. 
Mental Component Summary 
R2 Linear = 1.0-4
R2 Linear = 1.6-3
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16 Appendix 7: Medications 
 
Participant Group Medications Indication 
P1 Exercise 
intervention  
1. Clopiramine            
2. Diazepam               
3. Tetrapenezine 
1. Depression             
2. Depression             
3. Movement 
P2 Control 1. Oxybutanin              
2. Olanzapine 
1. Urinary frequency             
2. Movement 
P3 Exercise 
intervention 
1. Citalopram Depression 
P4 Control 1. Talopran                    
2. Olanzapine 
1. Depression             
2. Movement 
P5 Exercise 
intervention 
1. carbimazole 
2.paroxetine               
3. ramapril   
4.propranalol 
1. Hyperthyroid 
2.depression               
3. hypertension  
4.hypertension   
P6 Control  1. Olanzopine    
2.Sulpride         
3.Cocodamol 
1. Mood disorder  
2.Mood disorder   
3.Aches and pain 
P7 Control 1. MST                       
2. Olanzapine             
3. Lansoprazole          
4. Citalopram              
5. meloxican               
6. fortisip                    
7. clonazepam 
1. back pain                 
2. movement               
3. anti acid                 
4. depression                     
5. arthritis                   
6. food supplement       
7. Chorea 
P8 Exercise 
intervention  
Insuline Diabetes 
P9 Exercise 
intervention  
1. Citalopram              
2. Olanzapine 
1. Depression             
2. Movement 
P10 Control Lanzoprazotol acid (stomach) 
P11 Exercise 
intervention 
1. Quetiapine   
2.Bendrofluendhiazid 
 
Blood pressure 
P12 Control None  None 
P13 Exercise 
intervention  
1. VitB                       
2. Thiamine                
3. Mitrazapine             
4.Procyclidine              
5. Omeprazole               
6. Atorvastatine                   
7. Aspirine                  
8.Tetrabenazine 
 
P14 Control 1. Sorceral capsules  
2.Mirtazapine 
1. multivitamine  
2.depression 
P15 Exercise 
intervention  
1. Olanzopine                  
2. Citalopram 
1. Movement                 
2. depression 
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P16 Exercise 
intervention  
1. Lanzoprazole  
2.Fluxetine 
1. gastric acid             
2. depression 
P17 Control 1. Citalopram               1. depression 
P18 Control  1. Temazepam                       
2. Propranolol                
3. Tetrabinzine             
4.Cetirizine 
1. Insomina                   
2. anxity                     
3. movement             
4.nasal congestion 
P19 Exercise 
intervention 
1. Mitrazapine    
2.Chlorphinamine         
3.Pramipexole 
1. Mood disorder  
2.antihistamine       
3.HD 
P20 Control  None 
 
None 
P21 Exercise 
intervention  
1. perindopril                       
2. erbumine                
3. maxalt             
4.atrovastatin               
5. clopidognel   
all for cholestrol, 
preventing re-current 
heart attack 
P22 Exercise 
intervention  
1. Trihexyphenil                     
2. Citalopram              
3. Alanzopen   
1. Balance                 
  2. Antidepressant              
3. Antichoeric 
P23 Exercise 
intervention  
1. Nystatyin                     
2. Citalopram                
3. Tramadol          
4.Gapabentin              
5. Simvastatin 
1. Pain                      
2. Antidepressant              
3. Arthritis                  
4. Arthritis                   
5. Arthritis 
P24 Control 1. Ampladine 
2.Rampirol 
1. Blood pressure                      
2. Blood pressure 
P25 Control 1. Seroxat                   
2. Desogestnel 
1. anxity and 
depression                       
2. contraceptives 
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